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Abstract
Ventricular arrhythmias are an important cause of morbidity and mortality and come
in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the
past decade in our understanding of these arrhythmias and in our ability to diagnose
and treat them. The field of catheter ablation has progressed with the development
of new methods and tools, and with the publication of large clinical trials. Therefore,
global cardiac electrophysiology professional societies undertook to outline recommendations and best practices for these procedures in a document that will update
and replace the 2009 EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular
Arrhythmias. An expert writing group, after reviewing and discussing the literature, including a systematic review and meta-analysis published in conjunction with this document, and drawing on their own experience, drafted and voted on recommendations
and summarized current knowledge and practice in the field. Each recommendation
is presented in knowledge byte format and is accompanied by supportive text and
references. Further sections provide a practical synopsis of the various techniques and
of the specific ventricular arrhythmia sites and substrates encountered in the electrophysiology lab. The purpose of this document is to help electrophysiologists around
the world to appropriately select patients for catheter ablation, to perform procedures
in a safe and efficacious manner, and to provide follow-up and adjunctive care in order
to obtain the best possible outcomes for patients with ventricular arrhythmias.
KEYWORDS

catheter ablation, clinical document, electrical storm, electroanatomical mapping,
electrocardiogram, expert consensus statement, imaging, premature ventricular complex,
radiofrequency ablation, ventricular arrhythmia, ventricular tachycardia
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1 | I NTRO D U C TI O N
1.1 | Document scope and rationale
The field of electrophysiology has undergone rapid progress in the
last decade, with advances both in our understanding of the genesis of ventricular arrhythmias (VAs) and in the technology used to
treat them. In 2009, a joint task force of the European Heart Rhythm
Association (EHRA) and the Heart Rhythm Society (HRS), in collaboration with the American College of Cardiology (ACC) and the
American Heart Association (AHA), produced an expert consensus
document that outlined the state of the field and defined the indications, techniques, and outcome measures of VA ablation (S1.1.1).
In light of advances in the treatment of VAs in the interim, and the
growth in the number of VA ablations performed in many countries
and regions (S1.1.2, S1.1.3), an updated document is needed. This
effort represents a worldwide partnership between transnational
cardiac electrophysiology societies, namely, HRS, EHRA, the Asia
Pacific Heart Rhythm Society (APHRS), and the Latin American
Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA,
the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of
Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas
[SOBRAC]), and the Pediatric and Congenital Electrophysiology
Society (PACES). The consensus statement was also endorsed by the

CRONIN et al.

Cardiology (ACC) and the American Heart Association (AHA).
Heart Rhythm. 2009;6:886–933.
S1.1.2. 	Hosseini SM, Rozen G, Saleh A, et al. Catheter ablation for
cardiac arrhythmias: utilization and in-hospital complications,
2000 to 2013. JACC Clin Electrophysiol. 2017;3:1240–48.
S1.1.3. 	Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks
G, Heidbuchel H, Camm J. A decade of information on the use
of cardiac implantable electronic devices and interventional
electrophysiological procedures in the European Society of
Cardiology Countries: 2017 report from the European Heart
Rhythm Association. Europace. 2017;19(Suppl. 2):ii1–ii90.
S1.1.4. 	
Al-
Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017
AHA/ACC/HRS guideline for management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. Heart Rhythm.
2018;15:e73–e189.
S1.1.5. 	Priori SG, Blomström-Lundqvist C, Mazzanti A, et al; Task
Force for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death of
the European Society of Cardiology (ESC). 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the
Task Force for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death
of the European Society of Cardiology (ESC). Europace.
2015;17:1601–87.

Canadian Heart Rhythm Society (CHRS).
This clinical document is intended to supplement, not replace,
the 2017 AHA/ACC/HRS Guideline for Management of Patients with
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
(S1.1.4) and the 2015 ESC Guidelines for the Management of Patients
with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
(S1.1.5). The scope of the current document relates to ablation therapy for VAs, from premature ventricular complexes (PVCs) to monomorphic and polymorphic ventricular tachycardia (VT) and triggers of
ventricular fibrillation (VF). Due to its narrower scope, the consensus
statement delves into greater detail with regard to indications and
technical aspects of VA ablation than the above-mentioned guidelines.
Where possible, the recommendations in this document are
evidence based. It is intended to set reasonable standards that can
be applicable worldwide, while recognizing the different resources,
technological availability, disease prevalence, and health care delivery logistics in various parts of the world. In addition, parts of this
document, particularly Section 9, present a practical guide on how
to accomplish the procedures described in a manner that reflects the
current standard of care, while recognizing that some procedures
are better performed, and some disease states better managed, in
settings in which there is specific expertise.
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was required from the writing committee members (Appendix 1) and
from all peer reviewers (Appendix 2). Of the 38 committee members,
17 (45%) had no relevant RWIs. Recommendations were drafted by
the members who did not have relevant RWIs. Members of the writing group conducted comprehensive literature searches of electronic
databases, including Medline (via PubMed), Embase, and the Cochrane
Library. Evidence tables were constructed to summarize the retrieved
studies, with nonrandomized observational designs representing the
predominant form of evidence (Appendix S3). Case reports were not
used to support recommendations. Supportive text was drafted in the
“knowledge byte” format for each recommendation. The writing committee discussed all recommendations and the evidence that informed
them before voting. Initial failure to reach consensus was resolved by
subsequent discussions, revisions as needed, and re-voting. Although
the consensus threshold was set at 67%, all recommendations were
approved by at least 80% of the writing committee members. The
mean consensus over all recommendations was 95%. A quorum of
two-thirds of the writing committee was met for all votes (S1.2.1).
Each recommendation in this document was assigned a Class of
Recommendation (COR) and a Level of Evidence (LOE) according to
the system developed by ACC and AHA (Table 1) (S1.2.2). The COR
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TA B L E 1 ACC/AHA recommendation system: Applying class of recommendation and level of evidence to clinical strategies,
interventions, treatments, and diagnostic testing in patient care*

Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) (S1.2.2).

denotes the strength of the recommendation based on a careful as-

(RCTs); LOE B-R is derived from moderate-quality RCTs; LOE B-NR

sessment of the estimated benefits and risks; COR I indicates that the

is derived from well-designed nonrandomized studies; LOE C-LD is

benefit of an intervention far exceeds its risk; COR IIa indicates that

derived from randomized or nonrandomized studies with limitations of

the benefit of the intervention moderately exceeds the risk; COR IIb

design or execution; and LOE C-EO indicates that a recommendation

indicates that the benefit may not exceed the risk; and COR III indi-

was based on expert opinion (S1.2.2).

cates that the benefit is equivalent to or is exceeded by the risk. The

Unique to this consensus statement is the systematic review com-

LOE reflects the quality of the evidence that supports the recommen-

missioned specifically for this document as part of HRS's efforts to

dation. LOE A is derived from high-quality randomized controlled trials

adopt the rigorous methodology required for guideline development.
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The systematic review was performed by an experienced evidence-

the edge of the border zone, sparing only the epicardium. This

based practice committee based at the University of Connecticut, which

operation was associated with marked postoperative LV dysfunc-

examined the question of VT ablation vs control in patients with VT and

tion, likely due to interference with coronary arterial blood sup-

ischemic heart disease (IHD) (S1.2.3). The question, in PICOT format,

ply. Guiraudon et al. (S2.1.4) also attempted to disarticulate the

was as follows: In adults with history of sustained VT and IHD, what

right ventricular (RV) free wall from the rest of the ventricles in

is the effectiveness and what are the detriments of catheter ablation

patients with arrhythmogenic right ventricular cardiomyopathy

compared with other interventions? Components of the PICOT were

(ARVC). Although the surgery was successful in isolating the ar-

as follows: P = adults with history of sustained VT and IHD; I = cath-

rhythmogenic RV free wall and in producing interesting 12-lead

eter ablation; C = control (no therapy or antiarrhythmic drug [AAD]);

electrocardiogram (ECG) recordings of sinus rhythm simultaneous

O = outcomes of interest, which included (a) appropriate implantable

with persistent sustained VT in the same patient, most patients ul-

cardioverter defibrillator (ICD) therapies (ICD shock or antitachycardia

timately did poorly because of progressive RV failure. In the late

pacing [ATP]), (b) appropriate ICD shocks, (c) VT storm (defined as three

1970s, Josephson et al. (S2.1.5) developed the technique of map-

shocks within 24 hours), (d) recurrent VT/VF, (e) cardiac hospitaliza-

guided subendocardial resection. This procedure was based on the

tions, and (f) all-cause mortality; and T = no time restrictions.

observation that diastolic or presystolic electrical activation could

An industry forum was conducted to achieve a structured dialogue

be recorded during VT on the endocardium near or within the bor-

to address technical questions and to gain a better understanding of

der between the densely scarred aneurysm or infarct and more

future directions and challenges. Because of the potential for actual or

normal muscle (S2.1.6–S2.1.8). The surgical procedure thus tar-

perceived bias, HRS imposes strict parameters on information sharing

geted areas specified by mapping. As originally practiced, subendo-

to ensure that industry participates only in an advisory capacity and

cardial resection removed segments of endocardium approximately

has no role in either the writing of the document or its review.

3 mm thick and 5 cm2 (S2.1.5). These areas were almost always

The draft document underwent review by the HRS Scientific

within regions of visibly scarred endocardium, extending from the

and Clinical Documents Committee and was approved by the writ-

edge of a densely scarred aneurysm. As the procedure evolved, a

ing committee. Recommendations were subject to a period of public

more extensive area of resection was typically performed because

comment, and the entire document underwent rigorous peer review

of the ease of defining a single plane of resection with the goal

by each of the participating societies and revision by the Chairs, be-

of eliminating other arrhythmogenic areas within the visual scar.

fore endorsement.

Adjunctive cryoablation was applied to locations that were not easily resected, such as the papillary muscles or the deep myocardial
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layers beneath the removed subendocardium when VT was localized to these regions. Cryoablation targeting an isthmus of surviving myocardium between a more densely scarred inferior infarction
and the mitral annulus improved the outcome of VT ablation associated with this substrate (S2.1.9). More extensive cryoablation of
the entire visually scarred endocardial surface was also used with
some success (S2.1.10). Although success rates approached 90%
with surgery in terms of VT elimination, a mortality rate of 5%-15%
limited the procedure to a few select patients (S2.1.11).
In 1983, endocardial catheter ablation of VT using direct current
energy electrical shock delivered via the distal electrode of a standard quadripolar endocardial catheter positioned in the area to be
modified was first described by Hartzler (S2.1.12). One of the largest

2 | BAC KG RO U N D

early studies was by Fontaine et al. (S2.1.13), who referred to direct

2.1 | History of ventricular arrhythmia ablation

patients. One to 8 R-wave-synchronous shocks of preselected en-

In 1959, Couch (S2.1.1) reported the elimination of VT with the re-

patients undergoing at least one repeat procedure. Of note, a success

section of a postinfarction left ventricular (LV) aneurysm. In the

rate of 87% in preventing VT recurrence was achieved, and no deaths

early to mid-1970s, standard LV aneurysmectomy was performed

were thought to be related to the endocardial shock itself. Strategies

for patients with preoperative VT episodes in the setting of prior

for analyzing the 12-lead ECG during VT and pace mapping to mimic

infarction. Unfortunately, the operative mortality rates were high

the QRS of VT were first described in the early 1980s to help to re-

and VT recurrences were frequent (S2.1.2). Endocardial encircling

gionalize areas of interest for more detailed activation mapping for

ventriculotomy, introduced by Guiraudon et al. (S2.1.3), was de-

surgical or early catheter-based VT ablation (S2.1.14–S2.1.16).

current shock ablation as fulguration and reported their results in 43
ergy ranging from 160 to 320 J were delivered per session, with 23

signed to isolate the arrhythmogenic tissue from the remainder

Concern about barotrauma and the need for general anesthesia

of the ventricle by creating a nearly transmural incision through

with direct current shock ablation led to the use of radiofrequency
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(RF) energy for catheter ablation for all arrhythmias, including VT, by

substrate in patients with SHD. Epicardial mapping and ablation

the end of the 1980s (S2.1.17, S2.1.18). The safety and short-term

proved particularly valuable in patients with nonischemic RV and LV

effectiveness of RF catheter ablation for VT occurring either in the

cardiomyopathy, where the predominant substrate and VT circuits

absence or presence of structural heart disease (SHD) was first re-

are frequently located (S2.1.51–S2.1.56). Endocardial unipolar volt-

ported in observational reports by Klein et al (S2.1.19) and Morady

age mapping helped to identify the probable epicardial substrate

et al (S2.1.20), respectively. Activation mapping to identify diastolic

when normal endocardial bipolar voltage was demonstrated in pa-

activation coupled with entrainment mapping techniques to identify

tients with VT and nonischemic cardiomyopathy (NICM) (S2.1.57,

critical components of the VT circuit ultimately proved most useful

S2.1.58). The value of epicardial mapping and ablation in select pa-

to define a critical isthmus through which a VT circuit must pass. This

tients with postinfarction and idiopathic VT has also been demon-

isthmus identification allowed for successful targeted ablation using

strated (S2.1.59–S2.1.61).

RF ablation techniques for hemodynamically tolerated VT (S2.1.21–

In an attempt to overcome the biophysical limitations of lesion for-

S2.1.25). Using both computer simulations and catheter mapping of

mation in scar, irrigated ablation for VT was introduced with closed-

stable VT in humans, Stevenson et al (S2.1.22) elucidated a schematic

loop, internal irrigation in the late 1990s (S2.1.62). This was followed

model of the postinfarction VT circuit that endures.

by reports of even more extensive experience with open irrigated

Unfortunately, detailed activation and entrainment mapping is not

catheter ablation (S2.1.63, S2.1.64). More recently, techniques have

always feasible when VT is hemodynamically poorly tolerated (S2.1.26,

been described to further enhance lesion formation in scar and/or

S2.1.27). A successful substrate-based ablation strategy that did not

deep to the endocardium, including alcohol infusion in the coronary

require detailed mapping of VT was first described by Marchlinski et al.

arteries or coronary veins; bipolar and simultaneous unipolar ablation

(S2.1.28, S2.1.29). Linear ablation created by sequential point lesions

at both endocardial and epicardial sites; ablation with near freezing

transected the border zone, extending into the region of dense infarc-

saline; half normal saline as the irrigant; and needle electrode ablation

tion defined by detailed bipolar voltage mapping with a color-coded

(S2.1.65–S2.1.70). Simultaneously, small, multipolar electrode record-

display on a three-dimensional (3D) mapping system. The mapping sys-

ing techniques have been proven to further enhance the accuracy of

tem facilitated the ability to track lesion deployment. The location of

activation and entrainment mapping (S2.1.71–S2.1.73).

the ablation line was guided by analyzing the 12-lead QRS of VT and by

Idiopathic VT ablation with RF ablation also evolved from the ini-

pace mapping to mimic the QRS complex. Subsequent substrate-based

tial catheter ablation experience. The most common anatomical sites

VT targets, which were reported to be effective surrogates of the VT

of origin of frequent PVCs and VF triggers were described (S2.1.74).

circuit, included (a) late potentials (LPs); (b) channels defined by high

Twelve-lead ECG QRS assessment provided reasonably precise char-

voltage surrounded by lower voltage or by areas of pace capture sur-

acterization of origin for these focal arrhythmias occurring in the ab-

rounded by myocardium that could not be captured at 10 mA pacing

sence of SHD, with an emphasis on clues to identify left versus RV

output; (c) local abnormal ventricular activity (LAVA) that could demon-

outflow tract (RVOT) origin and epicardial origin (S2.1.75). New tech-

strate more abnormality with pacing; (d) paced map QRS morphologies

niques to overcome the challenges of idiopathic VT ablation associ-

that matched VT and demonstrated a long stimulus to QRS duration;

ated with the sinuses of Valsalva (SV), the coronary venous system,

and (e) regions in which pace mapping demonstrates abrupt transi-

the LV summit, and papillary muscle arrhythmias have been described

tion in paced QRS morphologies (S2.1.30–S2.1.41). More recently,

(S2.1.76–S2.1.79). The importance of PVC-induced cardiomyopathy

isolation of abnormal myocardium demonstrating critical components

has been recognized, and the potential for improvement in LV func-

of the VT circuit or extensive direct ablation of all low-voltage areas

tion with ablation has been demonstrated (S2.1.80, S2.1.81).

have been reported as successful techniques for possibly improving

Of note, this brief historical summary of VT ablation provides

substrate-based ablation outcome (S2.1.42, S2.1.43). The integration

only an overview. There have been many important contributions

of anatomical imaging of ventricular myocardial scar by computed

related to VT ablation, the details of which will be further highlighted

tomography (CT) or cardiac magnetic resonance imaging (CMR) with

elsewhere in this document.

electroanatomical mapping (EAM) has further contributed to the ability
to recognize and eliminate disrupted and potentially slowly conducting
regions of myocardium that are critical to the maintenance of VT.
The documentation of basal, perivalvular, low-
voltage scar
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nature of any underlying heart disease. Focal VTs are susceptible
to ablation with discrete RF lesions (S2.2.4.1–S2.2.4.8). Relatively
large scar substrates requiring more extensive ablation are common in VT associated with SHD; however, VT origin can appear
focal if the reentry circuit is small, or if it is due to a focal endocardial breakthrough from an epicardial or intramural reentry
circuit. Automatic VTs can also occur in some patients with SHD
and ventricular scars.
Focal VT has a point source of earliest ventricular activation with
a spread of activation away in all directions from that site. The mechanism can be automaticity, triggered activity, or microreentry. Focal
origin arrhythmias should be particularly suspected in patients without SHD who have repetitive monomorphic and nonsustained VTs
and PVCs or who have sustained VT from the outflow tract (OT) and
other more stereotypical sites of origin (S2.2.4.6–S2.2.4.8). A focal
origin is confirmed by mapping that shows spread of activation away
in all directions from the site of earliest activation relative to the QRS
onset. Unipolar unfiltered (or minimally high pass filtered at 0.5 Hz)
electrograms typically display a QS configuration at the site of origin (SOO) (S2.2.4.9, S2.2.4.10). Pacing at the origin will replicate the
VT/PVC QRS morphology if the origin is on the surface; however,
matching pace maps are frequently found within 1 cm of the site of
earliest activation. Pace mapping is particularly unreliable for VTs
originating from the aortic sinuses (S2.2.4.11).

2.2.2 | Triggered activity and automaticity
Triggered activity arises from oscillations in membrane potential during (early afterdepolarizations) or following (delayed afterdepolarizations) an action potential and can give rise to focal VA. Experimental
evidence implicates early afterdepolarizations in the initiation of polymorphic tachycardias in long QT syndromes (S2.2.4.12). However,
the mechanism of the premature ventricular beats targeted for ablation in these syndromes is unknown (S2.2.4.13).
Delayed afterdepolarizations can be caused by intracellular calcium overload, which activates the Na+/Ca2+ exchanger, resulting
in the transient inward current Iti (S2.2.4.14). Factors that increase
intracellular calcium include increases in heart rate, beta-adrenergic
stimulation, and digitalis. Beta-
adrenergic effects are mediated
through a cyclic adenosine monophosphate (cAMP)-
induced increase in intracellular calcium and are antagonized by adenosine,
which effects a decrease in cAMP. Termination of idiopathic RVOT

2.2 | Mechanisms of ventricular arrhythmia

tachycardias by an intravenous bolus of adenosine, by infusion of

2.2.1 | Mechanisms and basis for catheter
ablation of ventricular tachycardia

with triggered activity as the likely mechanism for some of these

Catheter ablation has an important role in reducing or preventing

infusion is often required. Aminophylline, calcium infusion, and atro-

VAs both in patients with heart disease and in those with idio-

pine can also be useful (S2.2.4.2).

calcium channel blockers, or by vagotonic maneuvers is consistent
tachycardias (S2.2.4.3). These tachycardias can be difficult to induce
at electrophysiology testing; rapid burst pacing and/or isoproterenol

pathic VTs not associated with SHD. The approach to ablation and

Less commonly, focal VT can be due to automaticity provoked

the efficacy are determined by the characteristics of the arrhyth-

by adrenergic stimulation that is not triggered (S2.2.4.2, S2.2.4.14).

mia and the anatomy and location of the arrhythmia substrate,

This type of VT can become incessant under stress or during iso-

which can often be anticipated from the ECG of the VT and the

proterenol administration, and it cannot be initiated or terminated
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by programmed electrical stimulation (PES); however, it can some-

has shown ongoing ion channel remodeling within scar, at least

times be suppressed by calcium channel blockers or beta blockers.

early after MI, resulting in regional reductions in ionized sodium

In contrast to its effects on triggered RVOT tachycardia, adenos-

and ionized calcium currents (S2.2.4.39), although action poten-

ine transiently suppresses, but does not terminate, the arrhythmia.

tial characteristics of surviving myocytes late after infarction can

Automaticity from damaged Purkinje fibers has been suggested as

be normal or near normal (S2.2.4.38). Coupling between myocyte

a mechanism for some catecholamine-
sensitive, focal origin VTs

bundles and myocytes is reduced by increased collagen and con-

(S2.2.4.15, S2.2.4.16). Whether these VTs are due to abnormal au-

nective tissue, diminished gap junction density, and alterations in

tomaticity, originating from partially depolarized myocytes, as has

gap junction distribution, composition, and function (S2.2.4.40).

been shown for VTs during the early phase of myocardial infarction

Surviving fibers can be connected by side to side connections in

(MI), is not clear (S2.2.4.17).

regions where the collagenous sheaths are interrupted, resulting

Although automaticity is frequently considered as a mechanism

in a “zig-z ag” pattern of transverse conduction along a pathway

of VT in the absence of overt SHD, disease processes that diminish

lengthened by branching and merging bundles of surviving myo-

cell-to-cell coupling are likely to facilitate automaticity (S2.2.4.18).

cytes (S2.2.4.41). The fibrosis pattern might be important in de-

Automatic VTs can occur in SHD, and automatic premature beats

termining the degree of conduction delay; patchy fibrosis between

can initiate reentrant VTs.

strands of surviving muscle produces greater delay than diffuse
fibrosis (S2.2.4.36). These aspects of scar remodeling contribute

2.2.3 | Scar-related reentry

to the formation of channels and regions in which conduction time
is prolonged, facilitating reentry (S2.2.4.42).

Scar-related reentry is the most common cause of sustained mono-

Unidirectional conduction block can occur after a properly timed

morphic VT in the presence of SHD (S2.2.4.19). Evidence supporting

PVC and is often functional (S2.2.4.35, S2.2.4.43, S2.2.4.44); it can

reentry includes initiation and termination by programmed stimula-

present only during tachycardia, when the refractory period of the

tion (although this does not exclude triggered activity), demonstrable

tissue exceeds the tachycardia cycle length (CL) or is maintained by

entrainment or resetting with fusion, and continuous electrical ac-

collision of excitation waves. Regions of conduction block can also

tivity that cannot be dissociated from VT by extrastimuli (S2.2.4.20,

be anatomically fixed such that they are present during tachycardia

S2.2.4.21). Prior MI is the most common cause of the substrate, but

and sinus rhythm; dense, nonexcitable fibrosis, calcifications, surgi-

scar-related VT also occurs in other myocardial diseases, including

cal scars, or valve annuli create these types of anatomical boundaries

ARVC, sarcoidosis, Chagas disease (ChD), dilated cardiomyopathy

for reentry (S2.2.4.31, S2.2.4.32, S2.2.4.45). Multiple VTs with var-

(DCM) including laminopathies, and after cardiac surgery for con-

ious QRS morphologies can be due to multiple exits from the same

genital heart disease (CHD) (particularly, tetralogy of Fallot) or valve

region of scar, or to changes in activation remote from the circuit

replacement (S2.2.4.22–S2.2.4.28).

due to functional regions of block. Ablation at one region can abolish

Regions of fibrosis with surviving myocyte bundles create fixed
and/or functional conduction block and disrupted or slow conduc-

more than one VT. Multiple reentry circuits from widely separated
areas also occur.

tion that are the substrate for reentry. Stable circuits can be modeled

It is possible that other reentry mechanisms cause some VTs.

as having an isthmus or channel comprised of a small mass of tissue

Spiral wave reentry can be induced in excitable tissue in the ab-

that does not contribute to the surface ECG. QRS onset occurs when

sence of tissue discontinuities and could cause VF or polymorphic

the excitation wave front emerges from an exit along the border of

VT (S2.2.4.46); anchoring to a discontinuity or to a region of slow

the scar and spreads across the ventricles (S2.2.4.29, S2.2.4.30).

conduction could theoretically cause monomorphic VT (S2.2.4.47).

Scars associated with VT are often close to a valve annulus and together can form the borders of the isthmus of a VT circuit (S2.2.4.31,
S2.2.4.32). The 3D structure of the reentry circuit and substrate can
be subendocardial, intramural, or subepicardial, or it can span the

2.2.4 | Reentry in the Purkinje system and
ventricular fibrillation

width of the entire ventricular wall (S2.2.4.33, S2.2.4.34). The entire

Reentry within the Purkinje fibers and the specialized conduc-

circuit or only a portion of it might be accessible to ablation.

tion system is a particular form of reentry and is covered in detail in

The substrate supporting scar-related reentry is characterized

Section 9.4. Other nonreentrant arrhythmias involving the Purkinje

by (1) regions of slow conduction; (2) unidirectional conduction

system can also occur, including VF and automatic rhythms (S2.2.4.16,

block at some point in the reentry path that allows initiation of

S2.2.4.48–S2.2.4.50). PVCs initiating VF most often originate from

reentry; and (3) areas of conduction block that often define parts

the Purkinje fiber system. Structural abnormalities in the vicinity of

of the reentry path. Some of the substrate might exhibit functional

the Purkinje fibers are frequently present and facilitate the anchor-

rather than fixed conduction block (S2.2.4.35–S2.2.4.37). VT after

ing of reentry (S2.2.4.51). However, even in the absence of detectable

MI has been extensively studied in canine models and in humans

structural alterations, VF can be initiated by PVCs from the Purkinje

(S2.2.4.35, S2.2.4.38). Reentry occurs through surviving muscle

fiber system (S2.2.4.52) and can be maintained in the complex fiber

bundles, commonly located in the subendocardium; however, this

interaction between Purkinje and myocardial fibers located in the pap-

can also occur in the midmyocardium and epicardium. Evidence

illary muscles (S2.2.4.53). The latter situation can be operative in some
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patients who have idiopathic VF, in whom no structural abnormalities
can be detected with current technology. Some structural abnormalities, however, have also recently been described in patients with
idiopathic VF, when high-density mapping is performed during sinus
rhythm revealing abnormal electrograms in a confined area located in
the epicardium (S2.2.4.54). This potential substrate, although not usually detected by imaging, was reported to colocalize with areas where
VF drivers were identified by mapping. Interestingly, in most of these
patients with idiopathic VF, VF was still triggered by PVCs originating
from the Purkinje fiber system (S2.2.4.54).
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2.3 | Definitions
The previous EHRA/HRS expert consensus on catheter ablation of VA
in 2009 proposed several definitions to standardize nomenclature in
the field (S2.3.1). The current consensus statement repeats the majority
of these recommendations for VT ablation. In the last 10 years, knowledge and experience of PVC ablations have significantly increased. In
the current report, new proposals are made to facilitate understanding of clinical characteristics and reporting of the ablation outcomes
of these arrhythmias (Table 2). Note that different cutoff rates for VT
and (accelerated) idioventricular rhythm could be appropriate for children, who have a higher resting sinus rate than adults: the mechanism,
symptoms, and clinical setting of the VA are more important than the
rate (S2.3.2).
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2.4 | Standard anatomical terminology
The following are the suggested anatomical terminology for use in the
description of catheter ablation of VA (Table 3). While these generally
represent the most commonly used terms, the writing committee recognizes that several variants or alternatives are in use and may also be
valid.
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Definitions

Clinical characteristics
Clinical ventricular tachycardia (VT): VT that has occurred spontaneously based on analysis of 12-lead ECG QRS morphology.
Hemodynamically unstable VT: causes hemodynamic compromise requiring prompt termination.
Idiopathic VT: used to indicate VT that is known to occur in the absence of clinically apparent SHD.
Idioventricular rhythm: three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of atrial or
atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of ventricular
rhythm is more important than the rate. Idioventricular rhythm can be qualified as “accelerated” when the rate exceeds 40 bpm.
Incessant VT: continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
Nonclinical VT: VT induced by PES that has not been documented previously.
Nonsustained VT: terminates spontaneously within 30 s.
PVC: premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding the
use of the terms “ventricular premature depolarization” and “premature ventricular contraction” to standardize the literature and acknowledge
that early electrical activity does not necessarily lead to mechanical contraction.
Presumptive clinical VT: similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but without
the 12-lead ECG documentation of spontaneous VT.
PVC burden: the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats over a
24-hour recording period.
Repetitive monomorphic VT: continuously repeating episodes of self-terminating nonsustained VT.
Sustained VT: continuous VT for 30 s, or which requires an intervention for termination (such as cardioversion).
VT: a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal
conduction.
VT storm: three or more separate episodes of sustained VT within 24 h, each requiring termination by an intervention.
VT Morphologies
Monomorphic VT: a similar QRS configuration from beat to beat (Figure 1A). Some variability in QRS morphology at initiation is not uncommon, followed by stabilization of the QRS morphology.
Monomorphic VT with indeterminate QRS morphology: preferred over ventricular flutter; it is a term that has been applied to rapid VT that has a sinusoidal QRS configuration that prevents identification of the QRS morphology.
Multiple monomorphic VTs: more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different times.
Pleomorphic VT: has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not continuously
changing (Figure 1B).
Polymorphic VT: has a continuously changing QRS configuration from beat to beat, indicating a changing ventricular activation sequence (Figure 1C).
Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT configurations: terms used to describe the dominant deflection in V1, with a
dominant R wave described as “RBBB-like” and a dominant S wave with a negative final component in V1 described as “LBBB-like” configurations.
Torsades de pointes: a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead in a
sinusoidal pattern. It is associated with QT prolongation.
Unmappable VT: does not allow interrogation of multiple sites to define the activation sequence or perform entrainment mapping; this could be due
to hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing-induced transition to other morphologies of VT, or
repeated termination during mapping.
Ventricular fibrillation (VF): a chaotic rhythm defined on the surface ECG by undulations that are irregular in both timing and morphology, without
discrete QRS complexes.
PVC Morphologies
Monomorphic PVC: PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the same
focus can be present.
Multiple morphologies of PVC: PVCs originating from several different focal locations.
Predominant PVC morphology: the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for ablation.
Mechanisms
Focal VT: a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be
automaticity, triggered activity, or microreentry.
Scar-related reentry: arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identified from electrogram characteristics or myocardial imaging. Large reentry circuits that can be defined over several centimeters are commonly referred to as “macroreentry.”

Abbreviations: AV, atrioventricular; ECG, electrocardiogram; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; PES, programmed
electrical stimulation; PVC, premature ventricular complex; RBBB, right bundle branch block; SHD, structural heart disease; VT, ventricular tachycardia.
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F I G U R E 1 Monomorphic (A),
pleomorphic (B), and polymorphic (C) VT.
Reproduced with permission of the Heart
Rhythm Society (S2.3.1). VT = ventricular
tachycardia
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3 | C LI N I C A L E VA LUATI O N
3.1 | Clinical presentation
Recommendation for clinical evaluation of patients with VAs
COR

LOE

Recommendation

I

C-EO

1A careful clinical evaluation including history, physical examination, review of available cardiac rhythm data,
prior imaging, and relevant laboratory workup should be performed in patients presenting with VAs

Recommendation-specific supportive text

comorbidities and family history. Available cardiac rhythm data in-

History should identify the onset, duration, frequency, and trig-

clude interrogation of cardiovascular implantable electronic devices

ger of any symptoms and should include medication use as well as

(CIEDs) to assess arrhythmia burden, morphologies, and duration as
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Anatomical terminology

Term

Definition

RV inflow

The part of the RV containing the tricuspid valve, chordae, and proximal RV

RV outflow tract
(RVOT)

The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the supraventricular crest and the
pulmonic valve

Tricuspid annulus

Area immediately adjacent to the tricuspid valve, including septal, free wall, and para-Hisian regions

Moderator band

A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular septum to the RV
free wall, supporting the anterior papillary muscle. It typically contains a subdivision of the right bundle branch (RBB)

RV papillary muscles

Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae tendineae, usually designated as septal, posterior, and anterior papillary muscles. The septal papillary muscle is closely associated with parts of
the RBB

Supraventricular
crest

Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary between the conus
arteriosus and the rest of the RV. The exact components and terminology are controversial; however, some characterize it as being composed of a parietal band that extends from the anterior RV free wall to meet the septal band, which
extends from the septal papillary muscle to meet it

Pulmonary valves

The pulmonic valve includes three cusps and associated sinus, variously named right, left, and anterior; or anterolateral
right, anterolateral left, and posterior sinuses. The posterior-right anterolateral commissure adjoins the aorta (junction
of the right and left aortic sinuses). Muscle is present in each of the sinuses, and VA can originate from muscle fibers
located within or extending beyond the pulmonary valve apparatus

Sinuses of Valsalva,
aortic cusps, aortic
commissures

The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left sinus of Valsalva (LSV)
is posterior and leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is typically the most inferior and
posterior SV, located posterior and rightward, superior to the His bundle, and anterior and superior to the paraseptal region
of the atria near the superior AV junctions, typically adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is the
most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise from muscle fibers at the commissures (connections) of the cusps, or from myocardium accessible to mapping and ablation from this location, especially from
the RSV/LSV junction

LV outflow tract
(LVOT)

The aortic vestibule, composed of an infra-valvular part, bounded by the anterior mitral valve leaflet, but otherwise not
clearly distinguishable from the rest of the LV; the aortic valve; and a supra-valvular part

LV ostium

The opening at the base of the LV to which the mitral and aortic valves attach

Aortomitral continuity (AMC);
aortomitral curtain,
or mitral-aortic intervalvular fibrosa

Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of fibrous tissue extending
from the anterior mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is connected by the left and
right fibrous trigones to ventricular myocardium, the right fibrous trigone to the membranous ventricular septum

Mitral valve annulus

Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially, either through the
coronary venous system or percutaneously

LV papillary muscles

Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and anterolateral papillary muscles. Papillary muscle anatomy is variable and can have single or multiple heads

LV false tendon (or
LV moderator band)

A fibrous or fibromuscular chord-like band that crosses the LV cavity, attaching to the septum, papillary muscles, trabeculations, or free wall of the LV. They may contain conduction tissue and may impede catheter manipulation in the LV

Posterior-superior
process

The posterior-superior process of the LV is the most inferior and posterior aspect of the basal LV, posterior to the plane
of the tricuspid valve. VAs originating from the posterior-superior process of the LV can be accessed from the right
atrium, the LV endocardium, and the coronary venous system

Endocardium

Inner lining of the heart

Purkinje network

The specialized conduction system of the ventricles, which includes the His bundle, RBB and left bundle branches (LBB),
and the ramifications of these, found in the subendocardium. The Purkinje system can generate focal or reentrant VTs,
typically manifesting Purkinje potentials preceding QRS onset

Interventricular
septum

Muscular wall between the LV and RV

Membranous ventricular septum

The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches the ventricular
myocardium

LV summit

Triangular region of the most superior part of the LV epicardial surface bounded by the left circumflex coronary artery,
the left anterior descending artery, and an approximate line from the first septal coronary artery laterally to the left AV
groove. The great cardiac vein (GCV) bisects the triangle. An area superior to the GCV is considered to be inaccessible
to catheter ablation due to proximity of the coronary arteries and overlying epicardial fat
(Continues)
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(Continued)

Term

Definition

Crux of the heart
(crux cordis)

Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the base of the heart,
approximately at the junction of the middle cardiac vein and coronary sinus (CS) and near the origin of the posterior
descending coronary artery

Epicardium

The outer layer of the heart—the visceral layer of the serous pericardium

Epicardial fat

Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free wall, left atrial
appendage, right atrial appendage, and AV and interventricular grooves

Pericardial space or
cavity

The potential space between the parietal and visceral layers of serous pericardium, which normally contains a small
amount of serous fluid. This space can be accessed for epicardial procedures

Parietal pericardium

The layer of the serous pericardium that is attached to the inner surface of the fibrous pericardium and is normally apposed to the visceral pericardium, separated by a thin layer of pericardial fluid

Fibrous pericardium

Thick membrane that forms the outer layer of the pericardium

Subxiphoid area

Area inferior to the xiphoid process; typical site for percutaneous epicardial access

Phrenic nerve

The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue. The course of the left
phrenic nerve on the fibrous pericardium can be quite variable and may run along the lateral margin of the LV near the left
obtuse marginal artery and vein; inferior, at the base of the heart; or anterior over the sternocostal surface over the L main
stem coronary artery or left anterior descending artery

Coronary sinus (CS)
and branches

The CS and its branches comprise the coronary venous system with the ostium of the CS opening into the right atrium.
Tributaries of the CS, which runs along the left AV groove, may be used for mapping. These include the anterior
interventricular vein (AIV), which arises at the apex and runs along the anterior interventricular septum, connecting to
the GCV that continues in the AV groove to the CS; the communicating vein located between aortic and pulmonary
annulus; various posterior and lateral marginal branches or perforator veins; and the middle cardiac vein that typically
runs along the posterior interventricular septum from the apex to join the CS or empty separately into the right atrium.
The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent left superior vena cava, when
present), and the valve of Vieussens (where present)

Anatomical terminology (S2.4.1–S2.4.9). See also Figures 3, 4, 7, and 8.
Abbreviations: AIV, anterior interventricular vein; AMC, aortomitral continuity; AV, atrioventricular; CS, coronary sinus; GCV, great cardiac vein; LBB,
left bundle branch; LSV, left sinus of Valsalva; LV, left ventricle; LVOT, left ventricular outflow tract; NCSV, noncoronary sinus of Valsalva; RBB, right
bundle branch; RSV, right sinus of Valsalva; RV, right ventricle; RVOT, right ventricular outflow tract; SV, sinus of Valsalva; VA, ventricular arrhythmia;
VT, ventricular tachycardia.

well as treatment. Electrogram storage may be programmed to include

can result in more severe symptoms, such as pre-syncope, syncope, or

far-and near-field electrograms to allow superior assessment of VA

even sudden cardiac death (S3.1.1, S3.1.2).

morphologies. The laboratory workup should be individualized to the

Secondary diseases caused by VA include PVC-induced cardio-

patient's presentation and may include electrolytes, troponin, brain

myopathy, which can present with typical symptoms of heart failure

natriuretic peptide, genetic testing, or drug screening as appropriate.

and reduced ejection fraction (EF) (S3.1.3, S3.1.4). If PVCs are asymptomatic, the diagnosis is commonly made by a routine physical

Synopsis

exam and is confirmed by a 12-lead ECG.
Underlying pathologies resulting in VA are numerous and include

The clinical presentations of patients with VAs encompass a wide

ischemia (S3.1.5); cardiomyopathy (S3.1.6); genetic diseases (eg, in-

spectrum, ranging from asymptomatic to VT/VF storm or sudden

herited arrhythmia syndromes) (S3.1.7); hypertrophic cardiomyopathy

cardiac death (S3.1.1).

(HCM) (S3.1.8); ARVC (S3.1.9); CHD (S3.1.10); infiltrative, inflamma-

Presenting symptoms can be classified into five groups: due to

tory, or infectious diseases (S3.1.11); and correctible causes, such

the VA itself (eg, PVCs, VT or VF); due to a secondary disease caused

as electrolyte abnormalities or medication adverse effects (S3.1.12).

by the VAs (eg, PVC-induced cardiomyopathy); due to an underlying

If VAs themselves are asymptomatic, the presenting symptoms will

pathology associated with the VAs (eg, ischemia); due to ICD ther-

mostly depend on the underlying pathology and might include chest

apy; and a combination of these causes.

pain, heart failure, dizziness, syncope, and sudden cardiac death. A

Idiopathic VA is frequently asymptomatic, especially when present-

careful history and physical exam with a review of the family history,

ing as PVCs or nonsustained VT. In those cases, VAs are commonly de-

ECG, imaging, and laboratory data (S3.1.13) will direct diagnosis and

tected coincidentally during routine exams. If symptomatic, symptoms

specific treatment (eg, immunosuppression in cardiac sarcoidosis)

can often be secondary to post-PVC augmentation of contractility or a

(S3.1.11). If inherited arrhythmia syndromes are suspected (eg, long

post-PVC compensatory pause, and commonly consist of palpitations,

QT syndrome), genetic testing should be considered (S3.1.7).

dizziness, shortness of breath, fatigue, or chest discomfort. With in-

ICD therapy including shocks is an increasingly common presenta-

creasing duration or VA rate (eg, VT or VF), hemodynamic compromise

tion of VAs in patients with CIEDs, and appropriate ICD therapy occurs

342

|

CRONIN et al.

in the first year in >50% of patients with secondary and approximately
5% of patients with primary prevention ICDs (S3.1.14, S3.1.15).
Combined presentations of those scenarios are common, such
as worsening heart failure status with increased arrhythmias burden
(S3.1.3, S3.1.4) or acute MI presenting with sudden cardiac death as
a manifestation of the VAs (S3.1.5).
Given that presenting symptoms of VA vary widely, careful documentation and correlation of the specific arrhythmia (ECG, telemetry, Holter or
event monitor, electrograms) with the presenting symptoms is important
to guide further workup and therapy. Symptoms commonly attributed to
VA (eg, palpitations, dizziness, chest pain, syncope) are nonspecific and
can either be due to other arrhythmias (S3.1.16) (eg, supraventricular
tachycardia [SVT] or bradycardia), other cardiac diseases, noncardiac conditions, anxiety, or have no clear identifiable cause (S3.1.17).
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3.2 | Diagnostic evaluation
3.2.1 | Resting 12-lead electrocardiogram
Recommendations for resting 12-lead ECG
COR

LOE

Recommendations

References

I

B-NR

1. In patients with wide complex tachycardia, a 12-lead ECG during tachycardia
should be obtained whenever possible.

S3.2.1.1–S3.2.1.15

I

B-NR

2. In patients with suspected or documented VA, a 12-lead ECG should be obtained in sinus rhythm to look for evidence of underlying heart disease.

S3.2.1.16
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Recommendation-specific supportive text
1 A 12-lead ECG during tachycardia is the first diagnostic test that
should be performed for any patient with a stable, wide, QRS
complex tachycardia to differentiate VT from SVT prior to attempts
to terminate the tachycardia. Criteria that support a diagnosis
of VT include AV dissociation, a QRS complex >0.14 seconds,
monophasic R wave in aVR, positively or negatively concordant
QRS complexes in the precordial leads, the absence of an RS
complex in all precordial leads, and an RS interval >100 ms in
at least 1 precordial lead (S3.2.1.1–S3.2.1.3). For patients with
preexisting bundle branch block, comparison of the QRS morphology during sinus rhythm with QRS morphology during wide
complex tachycardia is important. Various QRS morphologies (eg,
bundle branch block pattern) strongly support the diagnosis of
VT. An identical QRS complex during sinus rhythm and broad
QRS tachycardia, however, does not rule out the presence of
bundle branch reentry (BBR) tachycardia. Patients without SHD
can present with idiopathic VT (eg, fascicular VT) that can be
easily recognized by 12-lead ECG (S3.2.1.4). For nonsustained
VAs (PVCs or nonsustained VT), the 12-lead QRS morphology
is critical to allow for identification of the SOO. Idiopathic VAs
(eg, right and left OT VAs, PVCs from the aortic SV, papillary
muscle VAs) can be recognized, given they exhibit characteristic
ECG patterns (see Section 5.2) (S3.2.1.5–S3.2.1.10).
2 A 12-lead ECG during sinus rhythm is helpful to evaluate the presence of underlying heart disease and might be a clue for scar location and origins of related VAs, such as inferior wall or anterior
wall Q waves. An inherited arrhythmia disorder can also be identified, such as ARVC (epsilon waves and/or inverted T waves in right
precordial leads), long QT syndrome, Brugada syndrome (covedtype ST-segment elevation in the right precordial leads), and ChD
(right bundle branch block [RBBB] and/or left anterior hemiblock)
(S3.2.1.17). In patients with SHD, QRS duration and the presence
of conduction abnormalities might provide additional prognostic
information (S3.2.1.18–S3.2.1.23).

References
S3.2.1.1. 	Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new
approach to the differential diagnosis of a regular tachycardia
with a wide QRS complex. Circulation. 1991;83:1649–59.
S3.2.1.2. 	Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978;64:27–33.
S3.2.1.3. 	Vereckei A, Duray G, Szenasi G, Altemose GT, Miller JM. New
algorithm using only lead aVR for differential diagnosis of wide
QRS complex tachycardia. Heart Rhythm. 2008;5:89–98.
S3.2.1.4. 	Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left
ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1988;77:560–68.
S3.2.1.5. 	
Dixit S, Gerstenfeld EP, Callans DJ,Marchlinski FE.
Electrocardiographic patterns of superior right ventricular
outflow tract tachycardias: distinguishing septal and free-wall
sites of origin. J Cardiovasc Electrophysiol. 2003;14:1–7.
S3.2.1.6. 	Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski
FE. Repetitive monomorphic tachycardia from the left ventricular

|

343

outflow tract: electrocardiographic patterns consistent with a left
ventricular site of origin. J Am Coll Cardiol. 1997;29:1023–27.
S3.2.1.7. 	Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular
tachycardias arising from the aortic sinus of valsalva: an
under-
recognized variant of left outflow tract ventricular
tachycardia. J Am Coll Cardiol. 2001; 37:1408–14.
S3.2.1.8. 	Crawford T,Mueller G, Good E, et al. Ventricular arrhythmias
originating from papillary muscles in the right ventricle. Heart
Rhythm. 2010; 7:725–30.
S3.2.1.9. 	Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in
the left ventricle. J Cardiovasc Electrophysiol. 2009;20:866–72.
S3.2.1.10. 	Li S, Wang Z, Shan Z, et al. Surface electrocardiography characteristics and radiofrequency catheter ablation of idiopathic
ventricular arrhythmias originating from the left infero-septal
papillary muscles: differences from those originating from the
left posterior fascicle. Europace. 2018; 20:1028–34.
S3.2.1.11. 	Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada
J. Electrocardiographic recognition of the epicardial origin of
ventricular tachycardias. Circulation. 2004;109:1842–47.
S3.2.1.12. 	
Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left
ventricular tachycardia originating remote from the sinus of
Valsalva: electrophysiological characteristics, catheter ablation,
and identification from the 12-lead electrocardiogram. Circulation.
2006;113:1659–66.
S3.2.1.13. 	Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-
lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction.
Heart Rhythm. 2007;4:1403–10.
S3.2.1.14. 	Valles E, Bazan V, Marchlinski FE. ECG Criteria to identify epicardial ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3:63–71.
S3.2.1.15. 	Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features
to identify ventricular tachycardia arising from the epicardial
right ventricle. Heart Rhythm. 2006;3:1132–1139.
S3.2.1.16. 	Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al.
Prognostic value of the electrocardiogram in patients with
syncope: data from the group for syncope study in the emergency room (GESINUR). Heart Rhythm. 2014;11:2035–44.
S3.2.1.17. 	Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–41.
S3.2.1.18. 	Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch
block is associated with increased 1-year sudden and total
mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart
failure. Am Heart J. 2002;143:398–405.
S3.2.1.19. 	Desai AD, Yaw TS, Yamazaki T, Kaykha A, Chun S, Froelicher
VF. Prognostic significance of quantitative QRS duration. Am
J Med. 2006;119:600–606.
S3.2.1.20. 	Dhar R, Alsheikh-Ali AA, Estes NA 3rd, et al. Association of
prolonged QRS duration with ventricular tachyarrhythmias and
sudden cardiac death in the Multicenter Automatic Defibrillator
Implantation Trial II (MADITII). Heart Rhythm. 2008;5:807–13.
S3.2.1.21. 	Freedman RA, Alderman EL, Sheffield LT, Saporito M, Fisher
LD. Bundle branch block in patients with chronic coronary
artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol. 1987;10:73–80.
S3.2.1.22. 	Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS
duration and mortality in patients with congestive heart failure. Am Heart J. 2002; 143:1085–91.
S3.2.1.23. 	
Zimetbaum PJ, Buxton AE, Batsford W, et al.
Electrocardiographic predictors of arrhythmic death and total
mortality in the multicenter unsustained tachycardia trial.
Circulation. 2004;110:766–69.

344

|

CRONIN et al.

3.2.2 | Assessment of structural heart disease and myocardial ischemia
Recommendations for assessment of SHD and myocardial ischemia
COR

LOE

Recommendations

References

I

B-NR

1. In patients with known or suspected VA, echocardiography is recommended for evaluation
of cardiac structure and function.

S3.2.2.1–S3.2.2.2

IIa

B-NR

2. In patients presenting with VA who are suspected of having SHD, even after normal echocardiographic evaluation, advanced cardiac imaging can be useful to detect and characterize
underlying SHD.

S3.2.2.3–S3.2.2.7

IIa

C-EO

3. In patients with VA in whom myocardial ischemia is suspected, stress testing and/or
coronary angiography and subsequent revascularization can be beneficial before catheter
ablation to avoid significant ischemia during induced VT.

III: No
Benefit

B-NR

4. In patients presenting with monomorphic VT, revascularization alone is not effective to
prevent VT recurrence.

Recommendation-specific supportive text
1 Assessment of global and regional myocardial function, valvular structure and function, along with testing for adult CHD
is required in patients with or at high risk for VA or sudden
cardiac death. Echocardiography is the most readily available and
commonly used imaging technique (S3.2.2.1, S3.2.2.2). Accurate
assessment of LV ejection fraction (LVEF) using CMR is hindered
by the presence of frequent PVCs (S3.2.2.11). In these patients,
echocardiographic evaluation of LVEF may be superior to CMR.
2 Advanced cardiac imaging, such as cardiac CT, CMR, and fluorodeoxyglucose positron emission tomography (PET), is useful for
the evaluation of SHD and assessment of LV and RV function
(S3.2.2.3–S3.2.2.7). CMR with assessment of late gadolinium enhancement (LGE) is the gold standard technique for determination
of location and the extent of scarring. This information has implications for planning the ablation strategy (see Section 5.4) (S3.2.2.7,
S3.2.2.12). The use of this imaging technique is limited in some
patients with CIEDs (S3.2.2.13) (see Section 5.4). Additional myocardial inflammation or infiltrative diseases can be detected with
CMR or fluorodeoxyglucose PET (S3.2.2.14).
3 Transient myocardial ischemia is a known cause of polymorphic
rather than monomorphic sustained VT. Monomorphic VT in the
setting of prior MI is typically due to scar-related reentry and not
due to acute ischemia. For patients suspected to have myocardial
ischemia, stress testing and/or coronary angiography and subsequent revascularization should be performed when possible
before catheter ablation to avoid significant ischemia during VT
induction, mapping, and ablation.
4 Revascularization alone is unlikely to reduce the recurrence of
monomorphic VT (S3.2.2.8–S3.2.2.10). However, revascularization
might be beneficial in patients with IHD and VF, polymorphic VT, or
exercise-induced arrhythmias associated with ischemia (S3.2.2.15).
Revascularization for prognostic indications may also be indicated.
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3.2.3 | Risk stratification in the setting of frequent premature ventricular complexes
Recommendations for CMR in patients with frequent PVCs and for PES in patients with SHD and frequent PVCs
COR

LOE

Recommendations

References

IIa

B-NR

1. CMR can be useful for risk stratification for sudden cardiac death in patients with
frequent PVCs.

S3.2.3.1, S3.2.3.2

IIa

C-LD

2. PES can be useful for risk stratification for sudden cardiac death in patients with SHD
undergoing ablation of frequent PVCs.

S3.2.3.2

Recommendation-specific supportive text
1 CMR has been reported to identify patients at increased risk for
adverse outcomes in the presence of frequent PVCs (S3.2.3.1,
S3.2.3.2). One study assessed the value of CMR in an Italian patient
population with frequent LBBB PVCs (S3.2.3.1). Patients without RV
CMR abnormalities had better outcomes than patients with CMR
abnormalities. Another study assessed the benefit of CMR for risk
stratification in patients with frequent PVCs undergoing ablation
procedures for PVCs (S3.2.3.2). Except for 1 patient who had inducible idiopathic VT, 14 of 15 patients with inducible, sustained,
monomorphic VT had scarring identified by CMR. All patients with
inducible VT except the patient with idiopathic VT underwent ICD
implantation, and 50% had appropriate ICD therapy during follow-up.
2 Programmed stimulation has been reported to identify patients at
increased risk for adverse outcomes in the presence of frequent
PVCs (the PVC burden was 20 ± 13% in the cited study), but without prior documented VT, and who are undergoing PVC ablation
procedures (S3.2.3.2). All but one patient with inducible VT had
SHD prompting ICD implantation, and 50% of the patients had appropriate ICD therapy during follow-up (S3.2.3.2).

associated with an increase in all-cause mortality (hazard ratio [HR]
2.96; 95% CI 2.37-3.70; P < 0.001), cardiovascular mortality (HR 3.27;
95% CI 2.05-5.22; P < 0.001), VA and sudden cardiac death (HR 3.76;
95% CI 3.14-4.52; P < 0.001), and major adverse cardiovascular events
(HR 3.24; 95% CI 2.32-4.52; P < 0.001) (S3.2.3.6). In both studies, the
predictive value of LGE was independent of LVEF and whether the
cardiomyopathy was of ischemic or nonischemic etiology.
Patients with PVC-induced cardiomyopathy show improvement
(even normalization) of LVEF after effective PVC treatment. As opposed to patients with NICM, the absence of LGE is a common finding
in these patients; thus, absence of LGE could be used to identify patients with greater chance of LVEF recovery (S3.2.3.9). Patients with
frequent PVCs in the presence of LGE still have a possibility of LVEF
improvement (S3.2.3.10) post ablation, although the LVEF might not
completely normalize (S3.2.3.11). An RBBB morphology of the PVC
has been associated with an increased prevalence of LGE-defined
fibrosis (S3.2.3.12). This finding has prognostic implications. CMR
has been reported to identify patients at increased risk for adverse
outcomes in the presence of frequent PVCs (S3.2.3.1, S3.2.3.2). In
addition, CMR provides important information about the underlying
fibrotic substrate and facilitates ablation procedure planning. Inducible
VT can have prognostic implications in patients with frequent PVCs

Synopsis

and LGE-CMR. Over 80% of the writing committee members perform

LVEF continues to be the main prognostic clinical variable for VA. The

tion in patients without known SHD.

programmed stimulation to induce VT at the time of PVC or VT abla-

presence and extent of myocardial fibrosis, assessed by CMR-LGE,

The arrhythmogenic substrate can also be recognized by volt-

predict ventricular tachyarrhythmias in patients with ischemic and

age mapping at the time of the procedure. Low-voltage areas have

nonischemic LV dysfunction (S3.2.3.3–S3.2.3.8). In a meta-analysis

been correlated with scar tissue identified as LGE-CMR (S3.2.3.13,

including 2850 patients with IHD and nonischemic heart disease

S3.2.3.14). Although OT PVCs typically occur in patients with normal

from 19 studies, the composite arrhythmic endpoint was significantly

heart, identification of low-voltage areas and transitional zones could

higher in the patients with LGE (annualized event rate of 8.6%) than in

provide helpful information at the time of ablation (S3.2.3.15). Two-

the patients without LGE (annualized event rate of 1.7%; P < 0.0001)

thirds of the writing committee members perform voltage mapping of

(S3.2.3.8). In a larger meta-analysis including 7882 patients from 36

the relevant ventricle at the time of PVC or VT ablation in patients

studies (both ischemic cardiomyopathy [ICM] and NICM), LGE was

without known SHD.
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3.2.4 | Longitudinal follow-up in the setting of frequent premature ventricular complexes
Recommendation for longitudinal follow-up of patients with frequent PVCs
COR

LOE

Recommendation

Reference

IIa

B-NR

1Periodic monitoring of PVC burden and LV function and dimensions can be useful in patients with frequent, asymptomatic PVCs and normal LV function and dimensions.

S3.2.4.1

Recommendation-specific supportive text
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myopathy in susceptible individuals. Despite extensive study, the
predictors of future deterioration of LV function are unclear. In
one study of 249 patients, all of whom were followed for at least
4 years, none developed overt congestive heart failure, but the
LVEF decreased in 20% of patients with very frequent PVCs (>20 000
per 24 hours) (S3.2.4.1). Therefore, until the development of PVCinduced cardiomyopathy can be predicted with more precision,
periodic measurement of LVEF and LV end-diastolic dimensions,
along with quantification of PVC burden, may be useful for patients

4 | I N D I C AT I O N S F O R C AT H E T E R
A B L AT I O N

with a high PVC burden [approximately 10% or higher (S3.2.4.2)]

Following are the consensus recommendations for catheter abla-

to identify deteriorating LV function before symptoms appear.

tion of VAs organized by underlying diagnosis and substrate. These
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recommendations are each assigned a COR and an LOE according

a class 1 recommendation for ablation is present. There may also be

to the current recommendation classification system (S4.1). In draft-

scenarios not explicitly covered in this document, and on which lit-

ing each of these recommendations, the writing committee took into

tle or no published literature is available, in which the physician and

account the published literature in the specific area, including the

patient must rely solely on their own judgment.

methodological quality and size of each study, as well as the col-

In drafting these recommendations, the writing committee also

lective clinical experience of the writing group when published data

referenced several other relevant clinical documents, including

were not available. Implicit in each recommendation are several

the 2017 AHA/ACC/HRS Guideline for Management of Patients with

points: (a) the procedure is being performed by an electrophysiolo-

Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

gist with appropriate training and experience in the procedure and

(S4.2), among others. The exclusive focus of the current document on

in a facility with appropriate resources; (b) patient and procedural

VA ablation led to the opportunity to develop more detailed and nu-

complexity vary widely, and some patients or situations merit a more

anced recommendations.

experienced operator or a center with more capabilities than others,
even within the same recommendation (eg, when an epicardial procedure is indicated and the operator or institution has limited experience with this procedure, it might be preferable to refer the patient
to an operator or institution with adequate experience in performing
epicardial procedures); (c) the patient is an appropriate candidate for
the procedure (as outlined in Section 5.1), recognizing that the level
of patient suitability for a procedure will vary widely with the clinical scenario; and (d) the patient's (or designee's) informed consent,
values, and overall clinical trajectory are fundamental to a decision
to proceed (or not) with any procedure. Therefore, in some clinical
scenarios, initiation or continuation of medical therapy instead of an
ablation procedure may be the most appropriate option, even when
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4.1 | Idiopathic outflow tract ventricular arrhythmia
Recommendations for catheter ablation of idiopathic OT VA
COR

LOE

Recommendations

References

I

B-R

1. In patients with frequent and symptomatic PVCs originating from the RVOT in an otherwise
normal heart, catheter ablation is recommended in preference to metoprolol or propafenone.

S4.1.1

I

B-NR

2. In patients with symptomatic VAs from the RVOT in an otherwise normal heart for whom
antiarrhythmic medications are ineffective, not tolerated, or not the patient’s preference,
catheter ablation is useful.

S4.1.2–S4.1.12

I

B-NR

3. In patients with symptomatic idiopathic sustained monomorphic VT, catheter ablation is
useful.

S4.1.13–S4.1.17

IIa

B-NR

4. In patients with symptomatic VAs from the endocardial LVOT, including the SV, in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not
the patient’s preference, catheter ablation can be useful.

S4.1.18–S4.1.27

IIa

B-NR

5. In patients with symptomatic VAs from the epicardial OT or LV summit in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the
patient’s preference, catheter ablation can be useful.

S4.1.28–S4.1.32

Recommendation-specific supportive text
1 In symptomatic patients with frequent PVCs from the RVOT,

minimal or tolerable symptoms might prefer medical therapy
or no therapy.

catheter ablation had a higher rate of efficacy than pharmaco-

2 RVOT and LVOT are the most common SOOs for idiopathic VA

therapy with either metoprolol or propafenone in an RCT (S4.1.1).

in patients without SHD. VAs arising from these locations mostly

Ablation success rates are reported at 80%-95%, with low

present with a unique pattern on 12-lead surface ECG. The most

complication rates (S4.1.1, S4.1.12, S4.1.21, S4.1.33–S4.1.35).

common underlying pathophysiological mechanism is triggered

Catheter ablation can be considered as a preferred therapy in

activity, and RF catheter ablation is highly effective and has low

suitable, symptomatic patients. However, some patients with

complication rates (S4.1.2–S4.1.12). Multiple studies have shown
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that for RVOT VAs, catheter ablation is effective for prevention
of arrhythmia recurrences.
3 In patients with symptomatic, idiopathic, sustained monomorphic
VT, catheter ablation might be preferable to medical therapy. It is
a more definitive treatment option, given its high success and low
recurrence rates (S4.1.13–S4.1.17).
4 LVOT VA is reported to account for 12%-45% of all idiopathic
VAs (S4.1.18–S4.1.22). Compared with VAs originating from the
RVOT, ablation of LVOT VAs is more complex (S4.1.18–S4.1.22).
Rarely, LVOT VA sites require epicardial ablation via the GCV/
AIV or subxiphoid puncture. Clinically, ablation of LVOT VA can
involve greater procedural complexity as well as periprocedural
risk (stroke or coronary artery injury) compared with RVOT VA.
However, many studies report good results pertaining to the
safety, feasibility, and potential curative ability of RF catheter ablation (S4.1.18–S4.1.22).
5 Although most idiopathic VAs originate from the RVOT or
LVOT, in some cases, RF catheter ablation cannot successfully
be performed from either site. In such cases, the VAs might
originate from the LV summit (see Section 2 for definition).
VAs originating from this area can present challenges for successful RF catheter ablation, and the failure rate is high due to
epicardial fat and the proximity of coronary arteries if a subxiphoid epicardial access is used (S4.1.14–S4.1.16). Appropriate
patient selection for this approach is key, and the initial approach should focus on the endocardium and adjacent structures, including the coronary venous system, the aortic cusps,
and the RVOT.
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4.2 | Idiopathic nonoutflow tract ventricular arrhythmia
Recommendations for catheter ablation of nonoutflow tract VAs in the absence of SHD
COR

LOE

Recommendations

References

I

B-NR

1. In patients with symptomatic VAs from the RV at sites other than the OTs (tricuspid annulus,
moderator band, parietal band, or papillary muscles) in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient’s preference, catheter
ablation is useful.

S4.2.1–S4.2.14

I

B-NR

2. In patients with symptomatic VAs from the LV at sites other than the OTs (mitral annulus, papillary muscles, or AMC) in an otherwise normal heart for whom antiarrhythmic medications are
ineffective, not tolerated, or not the patient’s preference, catheter ablation is useful.

S4.2.15–S4.2.31

IIa

B-NR

3. In patients with symptomatic VAs from the epicardial coronary venous system in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the
patient’s preference, catheter ablation can be useful.

S4.2.32–S4.2.43

IIa

B-NR

4. In patients with symptomatic VAs from para-Hisian sites in an otherwise normal heart for
whom antiarrhythmic medications are ineffective, not tolerated, or not the patient’s preference,
catheter ablation can be useful.

S4.2.7, S4.2.13,
S4.2.14,
S4.2.44–S4.2.49

IIa

C-LD

5. In patients with symptomatic VAs from the posterior-superior process of the LV in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient’s preference, catheter ablation from the LV endocardium, right atrium, or CS, can be useful.

S4.2.50–S4.2.52

Recommendation-specific supportive text

sites of origin, VF triggered by PVCs arising from the moderator

1. Among idiopathic RV arrhythmias presenting for catheter abla-

band (S4.2.2) can occasionally occur. Successful catheter ablation

tion, approximately 10%-15% arise at sites other than the RVOT

is achieved in over 90% of patients with RV VAs arising outside

(S4.2.1). Sites that can be ablated with a high level of success

the RVOT, with a low risk of complications. The recurrence rate

include any of the three RV papillary muscles (S4.2.3, S4.2.6),

and need for repeat procedures are higher for VAs arising from the

the parietal band (S4.2.7, S4.2.9–S4.2.11), the tricuspid annulus

moderator, septal, and parietal bands than from other sites (S4.2.2,

(S4.2.5, S4.2.8, S4.2.12, S4.2.13), and the moderator band (S4.2.2,

S4.2.7). In addition, the probability of successful ablation is higher

S4.2.14). Although frequent PVCs, nonsustained VT, and sustained

for tricuspid annular VAs arising from the free wall than the septal

monomorphic VT are the most common idiopathic VAs at these

regions, which are closer to the conduction system (S4.2.5).
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2. Idiopathic VAs arising from the LV papillary muscles account for

coronary venous system, including the middle cardiac vein

approximately 15% of idiopathic LV arrhythmias referred for

(S4.2.40, S4.2.41, S4.2.43) and the adjacent endocardium, or

catheter ablation and are characterized by frequent PVCs or re-

might require epicardial access (S4.2.40–S4.2.42). The proximity

current monomorphic VT with a catecholamine-sensitive focal

of the coronary venous system to the posterior descending coro-

mechanism. VT can arise from either the posteromedial papillary

nary artery requires imaging to prevent arterial injury.

muscles or the anterolateral papillary muscles (S4.2.15–S4.2.23).

3. VAs arising from the RV septum near the His bundle can be

These arrhythmias often require several RF applications for suc-

successfully ablated in approximately 70%-
90% of patients,

cessful ablation. A change in QRS morphology of the VA after

with several series reporting a higher likelihood of abandoning

ablative applications to either side of the involved papillary mus-

attempts at ablation due to concerns about inducing AV block

cle is common. Due to the thickness of the papillary muscles and

(S4.2.7, S4.2.13, S4.2.14, S4.2.44–S4.2.49). The appearance of an

their vigorous contraction, catheter stability can be challenging

accelerated junctional rhythm is common during RF application

and might be improved by the use of intracardiac ultrasound and

in this region, though AV block is not (S4.2.7). Catheter stability

possibly cryoablation (S4.2.18, S4.2.22). The recurrence risk after

and the need to prevent injury to the AV node are issues that are

initial successful ablation of papillary muscle VAs is higher than

carefully considered for these VAs (S4.2.49). Pacing maneuvers

for many other idiopathic VA sites, and repeat procedures are re-

may be beneficial to prevent damage to the AV node (S4.2.53).

quired in approximately 30% of patients (S4.2.16, S4.2.18).

The careful use of cryoablation can help to prevent damage to the

The mitral annulus is the SOO for approximately 20% of idiopathic

conduction system if ablative therapy is delivered in close prox-

LV arrhythmias, with the majority being PVCs or nonsustained

imity to the conduction system.

VT rather than sustained VT (S4.2.24, S4.2.25). Mitral annular

4. The posterior-superior process of the LV is the most inferior and

VAs are based on a focal, catecholamine-sensitive mechanism. A

posterior aspect of the basal LV, posterior to the plane of the

superior-anterior mitral annular origin is more common than an

tricuspid valve (S4.2.50). Ablation of VAs in this region can be

inferior-posterior origin (S4.2.23–S4.2.26). Successful ablation is

accomplished from the LV endocardium (S4.2.51). However, VAs

achieved in approximately 90% of mitral annular VAs, with a very

arising from this region can also be successfully ablated from the

low risk of complications (S4.2.23–S4.2.29). The AMC is a com-

inferior septal surface of the right atrium, where a small atrial sig-

mon location of mitral annular VAs at the base of the LV ostium.

nal and a larger ventricular signal, earlier than the earliest site in

Most patients with VA from the AMC have frequent PVCs rather

the LV endocardium, can be recorded (S4.2.50). Reports also de-

than sustained VT (S4.2.30). Endocardial mapping demonstrates

scribe ablation from within the CS (S4.2.52). Successful ablation

a prepotential in the majority of VAs originating in this location,

can be achieved with either RF or cryoablation energies. The risk

with successful ablation in over 90% of patients with a low risk of

of complications appears to be low, although data are limited, and

complications (S4.2.30, S4.2.31).

caution is required due to the proximity to the AV node and the

VAs that can be mapped and ablated within the GCV or AIV are

AV nodal artery (S4.2.50).

relatively common SOOs near or within the LV summit (S4.2.32–
S4.2.36). Proximity to the coronary arteries needs to be assessed
(see Sections 9.3 and 11.1) prior to ablation. If the SOO is too
close (<5-10 mm) to a coronary artery, ablation from the adjacent
endocardium might be successful when within 1 cm of the SOO
(S4.2.37). These arrhythmias from the superior portion of the
coronary venous system are usually based on a focal mechanism
and typically require an irrigated-tip ablation catheter due to high
impedance within the coronary vein. Mapping and ablation from
the LSV or LV endocardium might also be successful, even if the
local ECG in the coronary venous system is earlier (S4.2.38). For
VAs with an intramural location, ablation within the perforator
veins from within the LV septum (S4.2.39), simultaneous bipolar
or simultaneous unipolar RF energy from the coronary venous
system and the LV endocardium might be required to achieve
successful ablation.
Sustained monomorphic VT arising from the crux of the heart
is typically very rapid, based on a focal catecholamine-sensitive
mechanism, and often produces syncope (S4.2.40–S4.2.43).
The QRS morphology is characterized by an abrupt transition
from negative in lead V1, to positive in lead V2, to more negative in lead V3 (S4.2.40). Ablation can be achieved within the
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4.3 | Premature ventricular complexes with or without left ventricular dysfunction
Recommendations for catheter ablation of PVCs in patients with or without LV dysfunction
COR

LOE

Recommendations

References

I

B-NR

1. In patients with cardiomyopathy suspected to be caused by frequent and predominately
monomorphic PVCs and for whom AADs are ineffective, not tolerated, or not preferred for
long-term therapy, catheter ablation is recommended.

S4.3.1–S4.3.10

IIa

B-NR

2. In patients with SHD in whom frequent PVCs are suspected to be contributing to a cardiomyopathy and for whom AADs are ineffective, not tolerated, or not preferred for long-term
therapy, catheter ablation can be useful.

S4.3.3, S4.3.11,
S4.3.12

IIa

B-NR

3. In patients with focally triggered VF refractory to AADs and triggered by a similar PVC, catheter ablation can be useful.

S4.3.13–S4.3.17

IIa

C-LD

4. In nonresponders to cardiac resynchronization therapy (CRT) with very frequent unifocal
PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation
can be useful.

S4.3.18

Recommendation-specific supportive text

of a cardiomyopathy. Several studies have demonstrated a

1 In patients with a suspected PVC-induced cardiomyopathy,

higher incidence of cardiomyopathy with PVC burdens >15%-

catheter ablation can be considered an alternative to long-

25% (S4.3.3, S4.3.5, S4.3.8, S4.3.19); however, patients with

term AAD therapy, particularly for patients with monomor-

similarly high PVC burdens can also maintain normal cardiac

phic PVCs, or PVCs of an RVOT origin (S4.3.1). PVC-induced

function. Reversible PVC-induced cardiomyopathy has also

cardiomyopathy should be suspected when cardiomyopathy

been reported in patients with PVC burdens as low as 4%–5%

and frequent PVCs are present and a comprehensive car-

(S4.3.9, S4.3.20). When PVC-induced cardiomyopathy is sus-

diac evaluation fails to identify alternate etiologies. Several

pected in these patients with relatively low PVC burdens,

studies have confirmed a correlation between a higher PVC

other etiologies for cardiomyopathy should be thoroughly

burden and development of cardiomyopathy, although no pre-

investigated and addressed, and the persistence of the PVC

cise burden of PVCs consistently predicts the development

burden established. Other risk factors for the development of
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a PVC-induced cardiomyopathy to consider include epicardial
origin of PVCs, PVCs with a longer QRS duration, longer
exposure to PVCs, asymptomatic PVCs, interpolated PVCs,
and male sex (S4.3.1, S4.3.5, S4.3.21, S4.3.22). In patients
with PVC-induced cardiomyopathy, PVC ablation has an overall
reported success rate of 65%-90%, with a low complication
rate (S4.3.1, S4.3.3–S4.3.7, S4.3.9, S4.3.10). Predictors of
ablation success include an RVOT PVC origin and a uniform
PVC morphology. Following successful ablation, the majority of patients with PVC-induced cardiomyopathy experience
significant improvement and, possibly, normalization of their
LVEF. Based on a review of current data, routine catheter
ablation of frequent PVCs in asymptomatic patients without
evidence of LV dysfunction is not presently recommended.
In some asymptomatic patients with very frequent PVCs and
preserved cardiac function who express a strong preference
for ablation, approximately half of the writing committee
members agreed that an ablation can be considered after
adequate counseling on the risks, benefits, and alternatives
to ablation, whereas half would not offer ablation. Additional
clinical features that may portend worsening LV function that
should be considered include LV dilation or a relative decrease
in EF that may still be considered in the normal range.
2 In patients with underlying SHD, the presence of frequent PVCs
can contribute to a cardiomyopathy, and successful PVC elimination by ablation can improve cardiac function (S4.3.3, S4.3.11,
S4.3.12). Detailed cardiac imaging (such as CMR to quantify
scarring) in conjunction with a comprehensive cardiac history,
including the time course of cardiomyopathy development and
onset of PVCs, can help to estimate the contribution of the PVCs
to the cardiomyopathy and guide treatment decisions targeting
the PVCs.
3 In patients with recurrent VF refractory to antiarrhythmic
medications and triggered by PVCs from a potentially identifiable site, successful ablation of the PVC can lead to VF
suppression (S4.3.13–S4.3.15). The triggering PVC is often
located in the Purkinje system and can exhibit slight variations in morphology. It is important to recognize that despite
an initially successful ablation, PVC and VF recurrences are
possible, and recurrent PVCs can arise from an alternate focus
(S4.3.14). Successful ablation, therefore, often does not eliminate the need for an ICD.
4 In patients who are clinical nonresponders to CRT, with limited biventricular pacing due to frequent PVCs despite pharmacological
therapy, successful PVC ablation has demonstrated an improvement in heart failure class and a modest improvement in LVEF. In
one prospective multicenter study in which CRT nonresponders
with frequent and primarily monomorphic PVCs were ablated,
the improvements in LV function and New York Heart Association
(NYHA) class were proportional to the preprocedural PVC burden,
and the greatest improvement was noted in patients with a preablation PVC burden >22% (S4.3.16).
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4.4 | Ventricular arrhythmia in ischemic heart disease
Recommendations for catheter ablation of VAs in patients with IHD
COR

LOE

Recommendations

References

I

B-R

1. In patients with IHD who experience recurrent monomorphic VT despite chronic amiodarone
therapy, catheter ablation is recommended in preference to escalating AAD therapy.

S4.4.1

I

B-NR

2. In patients with IHD and recurrent symptomatic monomorphic VT despite AAD therapy, or
when AAD therapy is contraindicated or not tolerated, catheter ablation is recommended to
reduce recurrent VT.

S4.4.2–S4.4.4

I

B-NR

3. In patients with IHD and VT storm refractory to AAD therapy, catheter ablation is
recommended.

S4.4.5–S4.4.9

IIa

C-EO

4. In patients with IHD and recurrent monomorphic VT, in whom AADs are not desired, catheter
ablation can be useful.

IIb

A

5. In patients with IHD and an ICD who experience a first episode of monomorphic VT, catheter ablation may be considered to reduce the risk of recurrent VT or ICD therapies.

S4.4.10–S4.4.14

IIb

C-LD

6. In patients with prior MI and recurrent episodes of symptomatic sustained VT for whom
prior endocardial catheter ablation has not been successful and who have ECG, endocardial
mapping, or imaging evidence of a subepicardial VT substrate, epicardial ablation may be
considered.

S4.4.15–S4.4.19

Recommendation-specific supportive text
1 For patients presenting with VT despite AAD therapy, which
often results in ICD therapies (shocks or ATP), therapeutic
options include escalating AAD therapy by increasing the dose,
changing the drug, adding a new drug, and catheter ablation.
The VANISH trial (S4.4.1) compared the strategies of escalating AAD therapy according to a predefined protocol versus
catheter ablation in 259 patients and followed them for a
mean (± standard deviation [SD]) of 27.9 ± 17.1 months. The
composite primary endpoint of death, VT storm, or appropriate
ICD shock was reduced by catheter ablation. Benefit was observed in the subgroup on amiodarone at baseline, for whom
escalated drug therapy was an increase in amiodarone or an
addition of mexiletine (HR 0.55; 95% CI 0.38-0.80; P = 0.001),
but not in the subgroup of patients who were on sotalol at
baseline, for whom escalation of drug therapy was initiation
of amiodarone (HR 1.14; 95% CI 0.65-2.02; P = 0.64) (S4.4.1).
Further analysis found that catheter ablation was markedly
superior to the addition of mexiletine in a small subgroup
of patients with VT refractory to high dose (≥300 mg daily)
amiodarone (S4.4.20). There were no procedure-related deaths.
2 In addition to the VANISH trial described above (S4.4.1), 3 large,
prospective, multicenter cohort studies have examined the role

of catheter ablation in reducing recurrent VT in patients with
IHD, most of whom had recurrent VT despite AAD therapy
(S4.4.2–S4.4.4). In these trials, the patient served as his/her
own control, and VT episodes were reported for the 6 months
before and the 6 months after ablation. In each study, a consistent reduction in VT episodes was observed post ablation. In the
Euro-VT study, VT recurrence occurred in 49% of the patients
(S4.4.3). A reduction in device therapies (ATP and shocks) was
observed in 79% of these patients, with the mean number of
therapies falling from 60 ± 70 in the 6 months prior to ablation
to 14 ± 15 in the same period of time after ablation (P = 0.02). In
the Multicenter Thermocool VT Ablation Trial, and the similarly
designed Post-Approval THERMOCOOL VT Trial, the number
of VT episodes in the 6 months before and after ablation was
reduced from a median of 11.5 to 0 episodes (P < 0.0001), and
from 13 to 0 episodes (P < 0.0001), respectively (S4.4.2, S4.4.4).
3 There are limited comparative data on catheter ablation vs other
therapies in the management of VT storm. AAD therapy is almost
universally used as first-line therapy for these patients; however,
catheter ablation is a particularly important therapy when VA recurs. Two small, single-center, nonrandomized studies found that
patients treated with ablation had a lower risk of recurrence than
those treated medically (S4.4.21), or they had a similar risk of recurrence but lower mortality (S4.4.22); however, these studies
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were limited by their retrospective study design and the small

endocardium in most cases, and endocardial mapping and abla-

number of patients. Several other large series (S4.4.5–S4.4.8) and

tion have been the mainstay of therapy. A number of studies have

a systematic review and meta-analysis (S4.4.9) have shown a re-

shed light on the incidence of epicardial substrate in IHD. In the

duction in ICD therapies after catheter ablation and reasonable

initial description of epicardial mapping and ablation in patients

success in controlling arrhythmia, with a nonetheless significant

with inferior wall MI, an epicardial circuit was found in 7 of 30 VTs

mortality. A common finding is that unsuccessful ablation (persis-

(S4.4.16). In another series of 11 patients with 1-4 prior unsuc-

tent VT inducibility) is associated with poor outcomes.

cessful endocardial ablation procedures, epicardial access was suc-

4 Patients who do not tolerate or are unsuitable for AAD therapy

cessful in 10, and 7 required epicardial ablation, which abolished

have not generally been included in RCTs. However, the writing

the clinical VT in all patients. However, 40% had recurrence dur-

committee felt it was reasonable to recommend catheter ablation

ing follow-up, and there was one periprocedural death (S4.4.17).

in such patients over no therapy, in view of the reduction in re-

Two larger, single-center observational studies have reported simi-

current VT demonstrated in multiple clinical trials. Examples of

lar or improved VT-free survival in patients with IHD undergoing

contraindications to AAD therapy include significant renal dys-

combined endocardial and epicardial ablation (S4.4.28, S4.4.29).

function or QT prolongation in the case of sotalol, and severe pul-

A prospective study of patients undergoing catheter ablation for

monary disease, which might be worsened by amiodarone.

electrical storm, in which epicardial access was obtained in all pa-

5 Four RCTs have examined the role of catheter ablation in patients

tients in one arm being treated with a scar homogenization tech-

who have experienced their first episode of VT (S4.4.10–S4.4.14).

nique (n = 43), found that ablation was performed in one-third.

In these studies, an ICD has been a mandatory part of the pro-

However, whether the epicardial substrate participated in clinical

tocol. Two of these trials have shown a reduction in the primary

or inducible VT was not assessed (S4.4.18). There are limited data

endpoint with catheter ablation (S4.4.10, S4.4.11). The CALYPSO

on the use of combined endocardial and epicardial ablation as a

pilot study found an increased time to first VT recurrence with

first-line approach in patients with IHD and VT (S4.4.19); an RCT is

ablation versus AADs (S4.4.12). The Substrate Modification Study

currently examining this question (S4.4.30). Preprocedural imaging

(SMS) failed to meet its primary endpoint of time to first VT/VF re-

can be useful to determine the presence of epicardial substrate,

currence; however, catheter ablation reduced the total number of

and therefore the likelihood of requiring epicardial access for com-

ICD interventions (S4.4.13). A meta-analysis of these trials, com-

plete substrate ablation (S4.4.31).

missioned to guide recommendations in this consensus document,
showed a reduction in the risk of appropriate ICD therapies with
catheter ablation (S4.4.14). However, in drafting this recommendation, the writing committee also considered that only the CALYPSO
pilot study randomized patients to either catheter ablation or AAD
therapy (S4.4.12). The other trials (S4.4.10, S4.4.11, S4.4.13) compared catheter ablation without specifying antiarrhythmic therapy
in the control group. Prospective trials have not shown that catheter
ablation reduces mortality, and the risks of the procedure must be
carefully weighed against the benefits in this population. In a large
study using the US National Inpatient Sample database, the overall rate of any in-hospital complication was 11.2% in patients with
prior MI undergoing catheter ablation, and in-hospital mortality was
1.6%, without changes over a decade (S4.4.23). The VANISH2 trial
is currently comparing these two strategies in patients with prior MI
and VT while not on AAD therapy (S4.4.24). There are limited data
exploring the feasibility of managing VT with catheter ablation without an ICD in selected patients with IHD and relatively preserved LV
function (S4.4.25–S4.4.27). Of 302 patients with IHD who underwent a catheter ablation procedure sufficiently successful to make
ICD implantation unnecessary, approximately 3% experienced sudden death during 3-4 years of follow-up (S4.4.25–S4.4.27). The
writing group did not feel there was sufficient evidence to make a
recommendation regarding ablation as a stand-alone therapy without an ICD for patients with IHD and sustained VT.
6 It has long been recognized that the epicardial surface can contain critical elements of VT circuits in patients with IHD (S4.4.15,
S4.4.16). However, the VT substrate can be accessed from the
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4.5 | Nonischemic cardiomyopathy
Recommendations for catheter ablation of VT in NICM
COR

LOE

Recommendations

References

I

B-NR

1. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic
medications are ineffective, contraindicated, or not tolerated, catheter ablation is useful for
reducing recurrent VT and ICD shocks.

S4.5.1–S4.5.6

I

B-NR

2. In patients with NICM and electrical storm refractory to AAD therapy, catheter ablation
is useful for reducing recurrent VT and ICD shocks.

S4.5.7–S4.5.9
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IIa

B-NR

3. In patients with NICM, epicardial catheter ablation of VT can be useful after failure of
endocardial ablation or as the initial ablation approach when there is a suspicion of an
epicardial substrate or circuit.

S4.5.4, S4.5.10–S4.5.13

IIa

B-NR

4. In patients with cardiac sarcoidosis and recurrent VT despite medical therapy, catheter
ablation can be useful to reduce the risk of VT recurrence and ICD shocks.

S4.5.14–S4.5.18

IIa

C-EO

5. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic
medications are not desired, catheter ablation can be useful for reducing recurrent VT and ICD
shocks.

IIb

B-NR

6. In patients with NICM related to lamin A/C (LMNA) mutations and recurrent VT, catheter
ablation may be considered as a palliative strategy for short-term arrhythmia control.

Recommendation-specific supportive text
1 Patients with NICM represent a heterogeneous population with

S4.5.19

be given to the ability to proceed to epicardial access during the
initial procedure.

diverse etiologies, including undifferentiated dilated NICM and

4 Cardiac sarcoidosis is associated with a poor prognosis. VT is

valvular, hypertensive, hypertrophic, toxic, genetic, inflammatory,

frequently resistant to AADs and immunosuppression, requiring

tachycardia-induced, peripartum, and infiltrative cardiomyopa-

ICDs. Recurrent VT is common in cardiac sarcoidosis and is associ-

thy. Several retrospective and prospective cohort studies have

ated with a poorer prognosis. Catheter ablation decreases VT re-

shown VT-free survival of 40.5%-70% at 1 year post ablation

currence and ICD shocks in cardiac sarcoidosis (S4.5.14–S4.5.18).

(S4.5.1–S4.5.6). VTs in the context of NICM are more often

5 AADs are not as effective as the ICD at decreasing mortality in

pleomorphic and polymorphic; they are less hemodynamically

patients with SHD and sustained VAs. Even if successful at acutely

tolerated, are more difficult to induce, and are faster com-

terminating VT or VF, ICD shocks have been associated with in-

pared with postinfarction VT (S4.5.20, S4.5.21). Differences in

creased heart failure and mortality in NICM (S4.5.26, S4.5.27).

the results of VT catheter ablation between NICM and ICM

To date, there has been no RCT comparing catheter ablation with

could be due to a substrate that is less favorable to ablation

AADs for preventing VT recurrences in NICM. Indirect comparisons

with NICM (S4.5.22). The substrate is often intramurally located

have found similar reductions in VT recurrences with catheter ab-

and can involve the epicardium; it is typically located at the

lation or amiodarone in patients with SHD (S4.5.28). Amiodarone

basal perivalvular regions and at the interventricular septum.

might increase mortality in patients with cardiomyopathy (S4.5.28,

The intramural substrate makes the arrhythmogenic substrate

S4.5.29) and can cause serious long-term adverse effects. Catheter

less accessible for identification of optimal ablation target sites

ablation of VT appears to be safe and effective in NICM, achiev-

based on pace mapping and identification of abnormal electro-

ing long-term arrhythmia control in 50%-70% (S4.5.1, S4.5.6,

grams. Although sustained VT occurs in only 5% of patients

S4.5.23, S4.5.30) (with AADs in one-third), with a survival rate of

with NICM, it is an important cause of sudden cardiac death

70% (S4.5.1, S4.5.6). Retrospective series show that acute success

(S4.5.23). Recurrent VT is associated with significantly increased

of catheter ablation and freedom from recurrent VT after catheter

mortality in NICM (S4.5.24).

ablation are associated with a significant reduction in mortality and

2 Electrical storm with recurrent VT/VF episodes in patients with

heart transplantation in NICM (S4.5.1, S4.5.6, S4.5.31, S4.5.32).

NICM and ICD can adversely affect hospitalization rates and long-

6 Mutations in the lamin A/C (LMNA) gene are an important cause

term survival (S4.5.24, S4.5.25). Catheter ablation of patients with

of NICM, with a disease course more aggressive than other forms

NICM and electrical storm refractory to, or intolerant of, AADs

of idiopathic NICM in terms of progression to end-stage heart

eliminates recurrent VT in most cases (S4.5.7–S4.5.9). Whether

failure or the tendency toward malignant VAs (S4.5.33, S4.5.34).

ablation reduces mortality in this population is unclear at present.

Catheter ablation can be beneficial as a palliative strategy to allow

3 In multicenter registries, 30% of epicardial VT catheter abla-

transient arrhythmia control in patients with NICM related to

tions were performed on patients with NICM (S4.5.12, S4.5.13).

LMNA mutations before aggressive heart failure management is

Epicardial mapping and catheter ablation can significantly reduce

proposed (S4.5.19). However, acute and chronic success are low,

VT recurrence in patients with NICM (S4.5.3, S4.5.4) and long-

due to frequent intramural substrate, and complication rates are

term success rates reach 55% to 70% after epicardial ablation

high in the published literature (S4.5.19). Disease progression to

(S4.5.11, S4.5.13). However, due to an increased risk of compli-

end-stage heart failure requiring mechanical support or transplant

cations or late adhesions preventing future pericardial accesses,

is also common, and VT ablation might be best targeted toward

epicardial ablation may be reserved to first-line endocardial ap-

those with relatively earlier stage disease, rather than being a

proach failures (S4.5.1), except when ECG or imaging suggests a

means to delay progression in those approaching end-stage heart

predominant epicardial substrate (S4.5.1). Consideration should

failure.
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4.6 | Ventricular arrhythmia involving the His-Purkinje system, bundle branch reentrant ventricular
tachycardia, and fascicular ventricular tachycardia
Recommendations for catheter ablation of bundle branch reentrant VT and for catheter ablation of fascicular VT
COR

LOE

Recommendations

References

I

B-NR

1. In patients with bundle branch reentrant VT, catheter ablation is useful for reducing
the risk of recurrent VT.

S4.6.1–S4.6.9

I

B-NR

2. In patients with idiopathic left fascicular reentrant VT for whom medications are
ineffective, not tolerated, or not the patient’s preference, catheter ablation is useful.

S4.6.10–S4.6.22

I

B-NR

3. In larger pediatric patients (≥15 kg) with idiopathic left fascicular reentrant VT in
whom medical treatment is ineffective or not tolerated, catheter ablation is useful.

S4.6.23–S4.6.26

I

B-NR

4. In patients with focal fascicular VT with or without SHD, catheter ablation is useful.

S4.6.11, S4.6.27–S4.6.29

I

B-NR

5. In patients with postinfarction reentrant Purkinje fiber-mediated VT, catheter ablation is useful.

S4.6.30–S4.6.32

Recommendation-specific supportive text
1 Bundle branch reentrant VT (BBRVT) is curable by catheter ablation, which is successful in almost all patients (S4.6.1–S4.6.4).
However, for patients with SHD or conduction system disease,
long-term outcome depends on the type of underlying cardiac
disease. Despite successful BBRVT ablation, many patients remain at risk of sudden death due to concomitant scar-related
VTs and/or LV dysfunction. An ICD with or without cardiac
resynchronization should be considered (S4.6.4–S4.6.6). On the
other hand, for patients with BBRVT who have unacceptably
frequent shocks from their ICD, catheter ablation can be helpful
in preventing or reducing the shocks (S4.6.3). Even for patients
with terminal heart failure and incessant BBRVT, catheter ablation can function as a bridge to cardiac transplantation (S4.6.3).
BBRVT can be cured by catheter ablation for patients with normal heart structure and function (S4.6.3–S4.6.5, S4.6.7, S4.6.8).
Although data are limited, some reports suggest that patients
with preserved LV systolic function and no other inducible VT
might not further benefit from ICD insertion after successful
ablation. This subgroup had excellent long-term outcomes for
VT-free survival without deterioration of conduction properties
during follow-up. However, further study is required before a
specific recommendation can be formulated (S4.6.4). For patients with BBRVT who have a normal HV interval, catheter
ablation is also a curative approach. Approximately 22%-46%
of patients with BBRVT had a normal baseline HV interval, and
significant prolongation of the HV interval only developed during

tachycardia. This result suggests that either a functional or fixed
conduction block in the His-Purkinje system could be sufficient
to maintain a BBRVT mechanism. Long-term outcome depends
on the underlying cardiac disease (S4.6.4, S4.6.6). Patients with
normal LV systolic function and HV interval have excellent longterm outcomes after ablation (S4.6.4). Myocardial VT is the
most common type of inducible sustained monomorphic VT
in patients with valvular heart disease. The majority of these
patients have underlying coronary artery disease and significant
LV dysfunction. However, in almost one-third of the patients,
sustained BBRVT is the only type of inducible VT. This type
of VT is facilitated by the valve procedure occurring within
4 weeks after surgery in most patients. In these patients, LV
function is relatively well preserved, and the RBBB-type of BBRVT
is frequently induced. Because a curative intervention can be
offered to these patients (eg, bundle branch ablation), BBRVT
should be seriously considered as the VT mechanism in patients
with valvular heart disease, particularly if the arrhythmia occurs
soon after valve surgery (S4.6.5). Catheter ablation of the RBB
or LBB interrupts the circuit and is usually curative. However,
severely impaired antegrade conduction in the remaining bundle
is often present, requiring permanent pacing, which can have
hemodynamic consequences. Consideration should be given to
future CIED requirements when selecting the ablation target. In
patients with baseline complete or incomplete LBBB, anterograde
slow conduction over the LBB is present, and ablation of the
LBB might leave adequate residual anterograde conduction over
the right bundle. Ablation targeting the portion of the distal LBB
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(left posterior or anterior fascicle) that has slow conduction can

5 The Purkinje system might be part of the reentry circuit in pa-

potentially preserve the residual AV conduction. Close follow-up

tients with postinfarction monomorphic VT, resulting in a type of

for recurrent arrhythmias, progressive conduction deterioration,

VT with a relatively narrow QRS complex that mimics fascicular

or LBBB-induced ventricular dysfunction is important (S4.6.9).

VT. Catheter ablation is effective (S4.6.31, S4.6.33).

2 In the published literature, the overall success rate of ablation for
idiopathic left fascicular reentrant VT is >95%. Although complications related to left heart catheterization might be encountered,
no serious complications were reported. Left posterior hemiblock
was observed when a line of RF lesions was applied through the
posterior septal region (S4.6.10–S4.6.22). Left upper septal fascicular VT often presents as narrow QRS complex tachycardia,
but some left upper septal fascicular VTs occur after catheter ablation targeting left posterior fascicular VT. Such VTs can be managed successfully by focal ablation at the left upper septum with
some risk of fascicular injury (S4.6.22).
3 In pediatric patients with fascicular reentrant VT (age 10.0 ± 5.1 years,
62% males), nondihydropyridine calcium channel blockers were effective at terminating and preventing VT in 80% of the patients;
however, 21% of the patients experienced recurrence during chronic
oral therapy. Catheter ablation was successful in 71% of fascicular
VTs. After a follow-up period of 2 years (1 day to 15 years), 72% of
all patients with fascicular VT were off medications, with no tachycardia recurrence (S4.6.23). Two small series reported an acute success rate for catheter ablation for fascicular VT of 100%. However,
the overall recurrence rate was 0%-50% over 2-3 years’ follow-up.
Major complications included 1 case of complete AV block and 1
case of LBBB (S4.6.24, S4.6.25). In smaller patients (less than 15 kg)
with fascicular reentrant VT that either is controlled medically or is
hemodynamically well tolerated without ventricular dysfunction,
ablation is generally not pursued (S4.6.26, S4.6.33). As with many
other forms of arrhythmia, infants with this VT frequently experience resolution of the VT with time; such resolution is much less
common in older children and adolescents. Idiopathic VAs are often
well tolerated, minimally symptomatic, and are not associated with a
risk of sudden death (S4.6.33). A case series of two patients showed
that oral verapamil suppressed VTs in newborns. Following discontinuation of verapamil at 1 year of age, both children remained free
of tachycardia recurrence at 3 and 4 years of age (S4.6.34).
4 Among idiopathic VT cases referred for ablation, 2.8% were focal
nonreentrant fascicular tachycardia, which had distinct clinical characteristics and usually originated from the left posterior
fascicle (LPF), and less commonly from the left anterior fascicle
(LAF) and RV Purkinje network. Catheter ablation guided by activation mapping is effective, whereas a pace map–guided approach is less effective. VT recurrence was observed in 27% of
patients, and among them, pace mapping was used to target VT
during the initial ablation attempt (S4.6.27). Another small series
reported two focal Purkinje VT cases with IHD in whom complete AV block occurred after the successful ablation of the VT.
This outcome suggests that ablation often is not sufficient as the
sole therapy due to other induced VTs and conduction abnormalities, requiring pacemaker and/or defibrillator implantation
for these VT patients with SHD (S4.6.28).
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4.7 | Congenital heart disease
Recommendations for catheter ablation of VA in patients with CHD
COR

LOE

Recommendations

References

I

B-NR

1. In patients with CHD presenting with sustained VAs, evaluation for potential residual anatomical or coronary abnormalities should be performed.

S4.7.1–S4.7.6

I

B-NR

2. In patients with CHD presenting with sustained VT in the presence of important
hemodynamic lesions, treatment of hemodynamic abnormalities as feasible should be
performed in conjunction with consideration for ablation.

S4.7.2, S4.7.7–S4.7.16

I

B-NR

3. In patients with repaired tetralogy of Fallot and sustained monomorphic VT or recurrent
appropriate ICD therapy for VAs, catheter ablation is effective.

S4.7.17–S4.7.24

IIa

B-NR

4. In select patients with CHD and clinical episodes of sustained VT who are undergoing
surgical repair of residual hemodynamic abnormalities, surgical ablation of VT guided by
preoperative or intraoperative EAM can be beneficial.

S4.7.2, S4.7.8, S4.7.9,
S4.7.11, S4.7.25

Recommendation-specific supportive text
1 The substrate for VAs in patients with repaired CHD is typically
reentry related to ventricular hypertrophy and areas of scar from
prior incisions, patches, and conduit placement. The development

of VAs in patients with CHD can be a manifestation of hemodynamic abnormalities, including valvar obstruction or regurgitation,
ventricular dysfunction, or coronary abnormalities. Identification of
the underlying abnormality contributing to ischemia, ventricular
dysfunction, and VAs is important to therapeutic planning, given
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to catheter and surgical ablation and/or ICD therapy as indicated
(Figure 2).
3 The majority of reports of successful VT ablation in adults with
repaired CHD include patients with tetralogy of Fallot, with small
numbers of patients with transposition of the great arteries, ventricular septal defects (VSDs), and other lesions (S4.7.17, S4.7.18,
S4.7.26, S4.7.27). VT circuits tend to be multiple and related to prior
ventriculotomies and VSD patches in patients with complex CHD
(S4.7.19–S4.7.22, S4.7.24, S4.7.26, S4.7.28). In patients with tetralogy of Fallot, anatomical isthmuses (AIs) critical to the reentrant
circuit have been identified between the septal defect patch or
ventriculotomy and the pulmonary valve, and between the tricuspid
annulus and the OT patch or septal defect patch (S4.7.19, S4.7.22,
S4.7.24). EAM to identify and ablate reentrant channels, with verification of conduction block and occasionally ablation from the left
side of the ventricular septum, have procedural success rates of
approximately 80% (S4.7.21, S4.7.24, S4.7.28). Patients with procedural success from catheter ablation and with preserved biventricular ventricular function have not experienced recurrent VT or
sudden cardiac death in up to 10-year follow-up (S4.7.22, S4.7.28).
4 Several small studies have demonstrated the effectiveness of
map-guided surgical ablation of VT during concomitant repair
of SHD, with recurrent VT reported in 15%-20% of patients
(S4.7.2, S4.7.8, S4.7.9, S4.7.11). To date, in patients with tetralogy of Fallot empiric surgical cryoablation lesions for sustained
VT without electrophysiological mapping of the tachycardia circuit have shown recurrent VT in 18%–45% of patients (S4.7.25,
S4.7.29). The role of prophylactic empiric cryoablation of the OT
in selected high-risk patients with tetralogy of Fallot is evolving
(S4.7.16, S4.7.25).
F I G U R E 2 Congenital heart disease and sustained VT. For
further discussion of ICD candidacy, please see PACES/HRS
Expert Consensus Statement on the Recognition and Management
of Arrhythmias in Adult Congenital Heart Disease (S4.7.14) and
2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines
for Device-Based Therapy of Cardiac Rhythm Abnormalities
(S4.7.30). ACA = aborted cardiac arrest; CHD = congenital heart
disease; DORV = double outlet right ventricle; ICD = implantable
cardioverter defibrillator; TOF = tetralogy of Fallot; VT = ventricular
tachycardia

that interventions for the substrate may reduce the frequency
of recurrent VAs and/or improve the hemodynamic status.
2 Most data regarding reoperation for patients with CHD and sustained VAs are from patients with tetralogy of Fallot. Treatment of
underlying hemodynamic abnormalities may reduce the incidence
of recurrent VAs and allow for ventricular remodeling or improvement in ventricular function. In studies of patients with tetralogy
of Fallot and sustained VT undergoing reoperation for hemodynamic abnormalities without specific arrhythmia intervention,
late postoperative VT was reduced to 11%-33% during mid-term
follow-up (S4.7.2, S4.7.7–S4.7.9, S4.7.13). Given the incomplete
protection from recurrent VA, consideration should also be given
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4.8 | Inherited arrhythmia syndromes
Recommendations for catheter ablation of VA in inherited primary arrhythmia disorders
COR

LOE

Recommendations

References

I

B-NR

1. In patients with ARVC who experience recurrent sustained VT or frequent appropriate ICD interventions for VT in whom AAD therapy is ineffective or not tolerated,
catheter ablation, at a center with specific expertise, is recommended.

S4.8.1–S4.8.11

I

B-NR

2. In patients with ARVC who have failed one or more attempts of endocardial VT catheter ablation, an epicardial approach for VT ablation is recommended.

S4.8.3–S4.8.7, S4.8.12,
S4.8.13

IIa

B-NR

3. In patients with ARVC who experience recurrent sustained VT or frequent appropriate ICD interventions for VT in whom AAD therapy is not desired or preferred, catheter
ablation, at a center with specific expertise, is reasonable.

S4.8.1, S4.8.3–S4.8.6,
S4.8.8
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COR

LOE

Recommendations

References

IIa

B-NR

4. In patients with Brugada syndrome who experience recurrent sustained VAs or frequent appropriate ICD interventions, catheter ablation can be useful.

S4.8.14–S4.8.17

IIa

C-LD

5. In patients with ARVC, a first-line combined endocardial/epicardial approach for VT
ablation is reasonable.

S4.8.1, S4.8.6, S4.8.12,
S4.8.18

Recommendation-specific supportive text

undergoing repeat ablation, was observed in 2 of 11 patients

1 In patients with ARVC, recurrent VT or frequent appropriate

over a mean follow-up of approximately 6 years (S4.8.21). In

ICD interventions for VT can be seen despite the use of

the second, similar progression occurred in 2 of 7 patients

multiple AAD therapies, including amiodarone and sotalol.

over a 30-month follow-up, and recurrent VTs were ablated

Catheter ablation has demonstrated an acceptable acute suc-

within the previously documented scar, suggesting incom-

cess rate and over time with development of different tech-

plete ablation at the index procedure (S4.8.22). This outcome

niques (substrate vs. conventional mapping) and approaches

suggests that with a comprehensive initial procedure that

(endocardial, epicardial, or combined endo-epicardial) has

achieves noninducibility, substrate progression and recurrent

reduced recurrence rates and appropriate ICD interventions

VA are not inevitable, at least over the medium term. Strong

(S4.8.1–S4.8.11). The writing committee felt that earlier con-

consideration should be given to performing such a procedure

sideration could be given to ablation, as opposed to further

in a center that can proceed to an epicardial ablation during

AAD therapy, in centers with specific expertise in VA ablation

the same procedure should an endocardial ablation be insuf-

in ARVC, including epicardial access. Reference should also

ficient to eliminate VT. However, to achieve long-term free-

be made to the 2019 HRS Expert Consensus Statement on

dom from AADs, patients might require repeated ablation

Evaluation, Risk Stratification, and Management of Arrhythmogenic

procedures and rely on ICD interventions for treatment of

Cardiomyopathy (S4.8.19).

hemodynamically unstable VT. The writing committee felt that

2 In patients with ARVC, scar location is heterogeneous based on the

stronger consideration could be given to catheter ablation as

chamber (mainly RV dominant but can involve the LV), the num-

a first-line approach without preceding AAD therapy by ex-

ber of foci, and depth (epicardial and/or endocardial) (S4.8.7). Over

perienced operators and centers, and with fully informed pa-

time, the need for repeat catheter ablation is common and due to

tients. Reference should also be made to the 2019 HRS Expert

the scar location, and an epicardial approach is often necessary.

Consensus Statement on Evaluation, Risk Stratification, and

Long-term freedom from VA is achieved in approximately one-third

Management of Arrhythmogenic Cardiomyopathy (S4.8.19). The

of patients with an endocardial approach (S4.8.4). An endocardial

role of catheter ablation in new-onset single morphology VT

followed by an epicardial ablation approach if the patient remains

without ICD therapy prior to or after ablation was examined

inducible for VT may avoid unnecessary epicardial access and as-

only in a small number of patients (S4.8.20). Catheter ablation

sociated procedural risk. However, strong consideration should be

has not been shown to reduce sudden cardiac death in patients

given to performing the procedure in a setting where it is possible

with ARVC; thus, ICD therapy remains the mainstay for sudden

to proceed to epicardial ablation during the same procedure, if endocardial ablation fails to terminate the clinical VA, or if the patient
remains inducible.

cardiac death prevention (S4.8.20, S4.8.23–S4.8.25).
4 Patients with Brugada syndrome and a type I Brugada ECG pattern (spontaneous or drug induced) have an arrhythmogenic

3 In patients with ARVC, recurrent VT or frequent appropri-

substrate located in the anterior epicardial RVOT that can be

ate ICD interventions for VT can be seen despite the use of

further unmasked with provocative drug testing (S4.8.16).

multiple AAD therapies (S4.8.20). The majority of patients

Targeted catheter ablation can normalize the electrographic

undergoing catheter ablation are on antiarrhythmic therapy,

abnormalities and reduce VA inducibility during programmed

including beta blockade before and after ablation. However,

stimulation (S4.8.14–S4.8.17). Use of ablation with substrate

some patients in the published series were not on AAD ther-

modification in the most symptomatic patients (recurrent VF/

apy at the time of ablation (S4.8.1, S4.8.3–S4.8.6, S4.8.8). The

VT, VF storm, or frequent ICD interventions) with Brugada syn-

overall acute success rates are acceptable, especially when an

drome and a type I Brugada ECG pattern (spontaneous or drug

epicardial approach is used, and indeed are superior to that

induced) has demonstrated a reduction in arrhythmic events

reported for other substrates like NICM (S4.8.2). Patients are

(S4.8.14–S4.8.17). Long-term follow-up has been limited, and

often younger and might not be on other medications, which

generalizability is unknown, given that procedures have been

could influence the choice between AAD therapy and ablation.

performed at highly specialized centers with expertise in

Two studies have assessed whether the substrate underly-

Brugada syndrome and epicardial ablations (S4.8.14–S4.8.17).

ing VAs in ARVC progressed over time. In the first, scar pro-

Drug therapy with quinidine should be considered as a first-line

gression, as assessed by bipolar voltage mapping in patients

alternative (S4.8.26).

CRONIN et al.

5 In patients with ARVC, combined endocardial and epicardial substrate catheter ablation has improved acute success and lowered
recurrence rates compared with endocardial-only catheter ablation. A combined endocardial-epicardial approach might be a
reasonable first-line approach, although not all patients require
epicardial catheter ablation for elimination of VT. Risks associated with epicardial access and ablation should be considered,
and these procedures should be performed at centers with expertise (S4.8.27, S4.8.28).

References
S4.8.1. 	Berruezo A, Acosta J, Fernández-Armenta J, et al. Safety,
long-term outcomes and predictors of recurrence after first-
line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact
of arrhythmic substrate distribution pattern. A prospective
multicentre study. Europace. 2017;19:607–16.
S4.8.2. 	Jiang H, Zhang X, Yang Q, et al. Catheter ablation for ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: a systematic review and
meta-analysis. Acta Cardiol 2016;71:639–49.
S4.8.3. 	Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic
right ventricular dysplasia/cardiomyopathy. Heart Rhythm.
2015;12:716–25.
S4.8.4. 	
Santangeli P,ZadoES, SuppleGE, et al.Long-
termoutcome
with catheter ablation of ventricular tachycardia in patients
with arrhythmogenic right ventricular cardiomyopathy. Circ
Arrhythm Electrophysiol. 2015;8:1413–21.
S4.8.5. 	Philips B,Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic
right ventricular dysplasia/cardiomyopathy. Circ Arrhythm
Electrophysiol. 2012;5:499–505.
S4.8.6. 	Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmiafree survival after endo-epicardial
substrate based mapping and ablation. Circ Arrhythm
Electrophysiol. 2011;4:478–85.
S4.8.7. 	Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial
substrate and outcome with epicardial ablation of ventricular
tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009; 120:366–75.
S4.8.8. 	Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter
ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll
Cardiol. 2007;50:432–40.
S4.8.9. 	Verma A, Kilicaslan F, Schweikert RA, et al. Short-and long-
term success of substrate-
based mapping and ablation of
ventricular tachycardia in arrhythmogenic right ventricular
dysplasia. Circulation. 2005;111:3209–16.
S4.8.10. 	Marchlinski FE, Zado E, Dixit S, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy.
Circulation. 2004;110:2293–98.
S4.8.11. 	Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated delayed component as an endpoint of catheter ablation in arrhythmogenic right ventricular cardiomyopathy:
predictor for long-term success. J Cardiovasc Electrophysiol.
2008;19:681–8.

|

365

S4.8.12. 	Müssigbrodt A, Efimova E, Knopp H, et al. Should all patients
with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? J Interv Card
Electrophysiol. 2017;48:193–9.
S4.8.13. 	Pokushalov E, Romanov A, Turov A, Artyomenko S, Shirokova
N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the
pediatric population with arrhythmogenic right ventricular
dysplasia. Heart Rhythm. 2010;7:1406–10.
S4.8.14. 	Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada
syndrome. Circ Arrhythm Electrophysiol. 2017;10:e005053.
S4.8.15. 	Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome
phenotype elimination by epicardial substrate ablation. Circ
Arrhythm Electrophysiol. 2015;8:1373–81.
S4.8.16. 	Zhang P, TungR,Zhang Z, et al.Characterization of the epicardial substrate for catheter ablation of Brugada syndrome.
Heart Rhythm. 2016;13:2151–58.
S4.8.17. 	
Nademanee K,Veerakul G, Chandanamattha P, et al.
Prevention of ventricular fibrillation episodes inBrugada syndrome by catheter ablation over the anterior right ventricular
outflow tract epicardium. Circulation. 2011;123:1270–79.
S4.8.18. 	Berruezo A, Fernández-Armenta J, Mont L, et al. Combined
endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5:111–21.
S4.8.19. 	Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification,
and management of arrhythmogenic cardiomyopathy. Heart
Rhythm. 2019 May 9 [Epub ahead of print].
S4.8.20. 	
Orgeron GM, James CA, Te Riele A, et al. Implantable
cardioverter-d efibrillator therapy in arrhythmogenic right
ventricular dysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complications. J Am
Heart Assoc. 2017;6:e006242.
S4.8.21. 	Riley MP, Zado E, Bala R, et al. Lack of uniform progression of
endocardial scar in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and ventricular tachycardia. Circ Arrhythm Electrophysiol. 2010;3:332–8.
S4.8.22. 	Berte B, Sacher F, Venlet J, et al. VT Recurrence after ablation:
incomplete ablation or disease progression? a multicentric
European study. J Cardiovasc Electrophysiol. 2016;27:80–7.
S4.8.23. 	Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC:
predictors, characteristics, and treatment. J Am Coll Cardiol.
2014;64:119–25.
S4.8.24. 	Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-
defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/
dysplasia. Circulation. 2003;108:3084–91.
S4.8.25. 	
Corrado D, Calkins H, LinkMS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular
fibrillation or sustained ventricular tachycardia. Circulation.
2010;122:1144–52.
S4.8.26. 	
Belhassen B, Glick A, Viskin S. Efficacy of quinidine in
high-
risk patients with Brugada syndrome. Circulation.
2004;110:1731–37.
S4.8.27. 	Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter
study. Circ Arrhythm Electrophysiol. 2011;4:653–59.
S4.8.28. 	Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am
Coll Cardiol. 2010; 55:2366–72.

366

|

CRONIN et al.

4.9 | Ventricular arrhythmia in hypertrophic cardiomyopathy
Recommendation for VA ablation in HCM
COR

LOE

Recommendation

References

IIa

B-NR

1. In patients with HCM and recurrent monomorphic VT in whom AAD therapy is
ineffective or not tolerated, catheter ablation can be useful.

S4.9.1–S4.9.5

Recommendation-specific supportive text

procedures performed for high-risk and complex patient subsets
(S5.1.3.1–S5.1.3.4). In these cases, the competing risks associated

1 Although a less common arrhythmia in HCM, the reported
ablation experience is largely limited to monomorphic VT
(S4.9.1–S4.9.5). Most patients in these series had already
failed AAD therapy. Ablation can be challenging due to the
thickness of the myocardium, and epicardial access has been
required in the majority of patients (S4.9.1–S4.9.4), along
with adjunctive techniques such as intracoronary ethanol

with the concomitant presence of advanced heart failure syndromes and high burden of associated comorbidities pose substantial periprocedural and postprocedural management challenges. A
proper preprocedural risk stratification is crucial to minimize the risk
of adverse periprocedural outcomes such as acute hemodynamic
decompensation (AHD), which can have devastating consequences
(S5.1.3.2, S5.1.3.5, S5.1.3.6).

ablation and surgical epicardial cryoablation (S4.9.3, S4.9.4).
Satisfactory results have been reported, although multiple
procedures were required in some patients (S4.9.1–S4.9.5).
VAs associated with apical aneurysms are mostly ablated from
the LV endocardium.

5.1.1 | The PAAINESD Risk Score
The PAAINESD risk score (chronic obstructive Pulmonary disease
[5 points], Age >60 years [3 points], General anesthesia [4 points],
Ischemic cardiomyopathy [6 points], New York Heart Association class
III or IV [6 points], Ejection fraction <25% [3 points], presentation with
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VT Storm [5 points], Diabetes mellitus [3 points]) has been demonstrated to be helpful to identify patients undergoing scar-related VT
ablation who are at increased risk of adverse periprocedural outcomes,
and represents the most studied risk stratification tool in this context
(Table 4) (S5.1.3.2, S5.1.3.3, S5.1.3.5–S5.1.3.8). In a single center, the
risk of acute hemodynamic deterioration increased across tertiles
of the score, with values ≥ 17 (or ≥ 15 when “general anesthesia” is
excluded) being associated with a risk of 24%. Another single-center
report found that, when excluding general anesthesia, a score between 9 and 14 points was associated with a 6% risk of acute hemodynamic collapse, and that risk increased to 24% in patients with a
score ≥ 15 (S5.1.3.6). A multicenter cohort found the score (excluding
general anesthesia) was higher in those who died early post procedure
versus those who survived to the end of follow-up (16 ± 7 vs 9 ± 6;
P < 0.001), although chronic obstructive pulmonary disease was not
included in the calculation (S5.1.3.3). These findings were mirrored in
another single-center cohort, which found a higher score (excluding
general anesthesia) in those who died early post ablation (17.4 ± 6.3 vs
11.6 ± 7.6; P = 0.012) and in patients who experienced complications
(16.4 ± 6.7 vs 11.6 ± 7.6; P < 0.001) (S5.1.3.7). Of note, intraprocedural

5 | PRO C E D U R A L PL A N N I N G

mechanical hemodynamic support (HS) was commonly used in two of

5.1 | Patient selection and preprocedural risk
assessment

(S5.1.3.6, S5.1.3.7).

RF catheter ablation is an important therapeutic option in patients

variable “general anesthesia” is included in the risk score calculation

with different forms of VA. Over the last decade, significant im-

or not) identifies patients with SHD and VT at particularly high risk

provements in the techniques and technologies available for cath-

of adverse periprocedural and postprocedural outcomes (S5.1.3.2,

eter ablation have been paralleled by an increasing number of

S5.1.3.3, S5.1.3.6, S5.1.3.8). Careful consideration of the optimal

these series, which could limit the generalizability of these findings
The cumulative evidence arising from published studies suggests that a PAAINESD score ≥ 15-17 (depending on whether the
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The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation

Variable

Points

Pulmonary disease (COPD)

5

Age > 60

3

General anesthesia

4

Ischemic cardiomyopathy

6

NYHA class III/IV

6

EF < 25%

3

VT storm

5

Diabetes mellitus

3

The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has values that range from 0 to 35 points (or 0
to 31 [PAINESD] when the modifiable intraprocedural variable “general anesthesia” is excluded) (S5.1.3.2).
Abbreviations: COPD, chronic obstructive pulmonary disease; EF, ejection fraction; NYHA, New York Heart Association; VT, ventricular tachycardia.

sedation or anesthesia strategy could further help to prevent AHD

of the management of such patients both immediately after VA ablation

in patients with multiple other risk factors.

and in the longer term.

5.1.2 | The Seattle Heart Failure Model
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Failure Model (SHFM), given its established role in predicting mortality in patients with heart failure. The major limitation of the SHFM is
that it has been developed from cohorts of patients with heart failure
without recurrent VAs, and it remains a complex risk score to calculate due to the number of variables included. Evidence from a single
observational study has shown that the SHFM may help to identify
patients with scar-related VT undergoing catheter ablation at high
risk of midterm (ie, 6 months) postprocedural mortality (S5.1.3.9).
Other institutional risk assessment protocols combining variables included in the PAAINESD and SHFM with other risk features, such as
hemodynamic status during recurrent VT episodes, have also been
proposed to determine which patients are best managed in the setting of dedicated intensive care units or with the aid of HS devices,
and whether prolonged postablation surveillance may be helpful
(S5.1.3.1, S5.1.3.10).

5.1.3 | Multidisciplinary involvement
The optimal management of high-risk patients extends well beyond
the treatment of recurrent VAs and typically involves shared treatment
plans and close collaboration between multiple disciplines, including
interventional electrophysiologists, cardiologists, heart failure specialists, cardiac anesthesiologists, cardiothoracic surgeons, and pediatric
electrophysiologists or those with expertise in CHD (especially in young
patients <16 years of age or those with moderate/complex CHD) as appropriate. As such, it is preferable that high-risk patients with recurrent
VAs for whom a catheter ablation procedure is planned are managed
in centers with proficiency in these procedures, and that they receive
prompt access to advanced therapies, including percutaneous HS devices, permanent ventricular assist devices (VADs), and/or heart transplantation. Ongoing heart failure management is a critical component
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5.2 | 12-lead electrocardiogram and body surface
mapping before ventricular tachycardia ablation
5.2.1 | Standard 12-lead electrocardiogram
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S5.2.8.8). In contradistinction to papillary muscle origins, a fascicular
origin has a much narrower QRS complex (S5.2.8.6).
Despite the range of heart positions in the chest and body habitus, and variations of ECG lead positions, these ECG features can
be remarkably accurate at indicating the SOO to within a 1-to 2-cm

The standard 12-lead ECG has been shown to be a valuable tool

radius. Refinement of the exact site of impulse formation using ac-

in planning catheter ablation procedures for treatment of VAs, in-

tivation or pace mapping is still needed prior to ablation (S5.2.8.9–

cluding VT and PVC, and in the case of hemodynamically toler-

S5.2.8.13). Examples of PVC morphologies from several common

ated VAs, every effort should be taken to record the 12-lead ECG.

SOOs in the RV and LV are shown in Figures 3 and 4.

In cases of focal VA in the absence of SHD, the 12-lead ECG is
a relatively accurate indicator of the source location, whereas in
the presence of myocardial scarring from whatever cause (in which

5.2.3 | Postinfarction ventricular tachycardia

reentry is the predominant mechanism of arrhythmia), the ECG re-

Several algorithms have been devised to predict the exit site in post-

flects the exit site from the reentrant circuit, rather than the di-

MI VT. As noted above, these all have the important limitation that

astolic corridor that typically represents the best ablation target.

(to the degree they can reveal localizing information about the ar-

In some cases, the distance between these two locations can be

rhythmia) they indicate the exit site of the circuit, not the location

several centimeters.

of the midportion of the diastolic corridor (S5.2.8.14–S5.2.8.17).
Although the distance from the exit site to a vulnerable portion of

5.2.2 | Ventricular tachycardia and premature
ventricular complex in the absence of structural
heart disease
Features of the 12-lead ECG during VT or PVC occurring in the

the diastolic corridor can be 1 cm or less, it could be more. In addition, the existing algorithms are not applicable in all cases, and in
those cases in which they are, only approximately 75% of VTs can be
regionalized to a 2-to 5-cm2 area. In general, correlation of exit sites
with VT morphology conforms to rather intuitive principles:

absence of SHD have been reported, which suggest endocardial
catheter-accessible origins in the RV vs LV outflow regions (includ-

1 The majority of post-MI VT exit sites are LV endocardial.

ing the aortic SV), idiopathic fascicular (verapamil-
sensitive) VT

2 LBBB VTs tend to have exit sites on, or within 1 cm of, the intra-

related to the LV Purkinje system, and other LV sources, including

ventricular septum.

anterior and posterior papillary muscle VT, para-Hisian VT, mitral an-

3 Patients with inferior infarctions often have Q waves in the infe-

nular VT, AMC VT, and GCV/AIV VT; and other RV sources, including

rior leads, indicating inferior wall scarring and an inferior wall exit

tricuspid annular VT, moderator band VT, and papillary muscle VT.

site, which tend to be located on the inferobasal septum or the

Certain ECG patterns can indicate these regions of origin. An LBBB

inferolateral free wall, with a common diastolic corridor on the

inferior axis morphology with late transition (>lead V3) indicates an
origin in the RVOT. Lead I indicates whether the origin is anteriorly (negative) or posteriorly (positive) located (S5.2.8.1). Notching
in the inferior leads indicates a lateral (free wall) position in the OT
(S5.2.8.1). A Q wave in lead V1, combined with an R wave in lead aVL
and an R wave in lead I, together with smaller R waves in the inferior
leads, has been found for VAs originating from close to the conduction system (S5.2.8.2). An early transition (≤lead V3) in the presence
of an LBBB pattern could indicate a left-sided origin (S5.2.8.3), and
a broader and taller R wave in V1 or V2 could indicate an origin from
the SV (S5.2.8.4).

inferobasal free wall along the mitral annulus.
4 VTs with a predominant inferior axis tend to have exit sites on the
anterior wall (cranial half of the LV).
5 VTs with a predominant superior axis tend to have exit sites on
the inferior half of the LV.
6 VTs with a leftward axis tend to have exit sites on or within 1 cm
of the septum.
7 VTs with concordant positive precordial QRS complexes tend to
have basal exit sites.
8 VTs with concordant negative precordial QRS complexes tend to
have apical exit sites.

Epicardial origins from the LVOT, in addition to displaying a broad
QRS complex with a pseudodelta wave (see below), often have a Q

There can sometimes be disagreement among observers about spe-

wave in lead I. An epicardial origin close to the AIV, however, can

cific features of ECGs, such as whether an axis is leftward or rightward

closely resemble the ECG pattern of an origin from the RVOT. An RBBB

(ie, discordance between vector of leads I and aVL/lateral precordial

and inferior axis pattern with positive concordance is the hallmark for

leads). Automated algorithms can remove some of the subjectivity of

VAs originating from the anterior mitral annulus (S5.2.8.5). A transition

VT ECG analysis (S5.2.8.18–S5.2.8.20).

to a precordial rS pattern, usually in lead V3–V4, has been observed
for origins from the papillary muscles with a leftward axis, indicating
an origin from the posteromedial, or with a rightward axis, indicating

5.2.4 | Epicardial sources

an origin from the anterolateral papillary muscle (S5.2.8.6). Papillary

Several ECG criteria have been proposed that indicate an epicardial

muscle sources often produce a small Q wave in lead V1 (S5.2.8.7,

source of VT in patients without SHD or with NICM. These include
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F I G U R E 3 Examples of 12-lead ECGs of premature ventricular
complexes from different LV sites, as corroborated by successful
focal ablation. A, shows 12-lead ECG patterns of common
ventricular arrhythmia origins in patients without SHD [1-9] from
the left ventricle. All leads are displayed at the same amplification
and sweep speed. These locations are illustrated in (B) based on 3D
reconstruction of a cardiac computed tomography using the MUSIC
software that was developed at the University of Bordeaux. The
reconstruction shows an anterolateral view of the left ventricle,
aorta, and left atrium. Also shown are the coronary arteries (red),
the coronary venous system (blue), and the phrenic nerve (green).
AIV = anterior interventricular vein; AL PAP = anterolateral papillary
muscle; AMC = aortomitral continuity; GCV = great cardiac vein;
ant. MA = anterior mitral valve annulus; PM PAP = posteromedial
papillary muscle; R/L = right-left; SHD = structural heart disease;
SoV = sinus of Valsalva.
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FIGURE 4 Examples of 12-lead ECGs of premature ventricular
complexes from different right ventricular sites, as corroborated
by successful focal ablation. All leads are displayed at the same
amplification and sweep speed. A, shows the 12-lead ECG pattern
of common origins of right ventricular arrhythmias in patients
without SHD [1-6]. The locations are detailed in a 3D reconstruction
of the computed tomography using the MUSIC software that was
developed at the University of Bordeaux. The reconstruction shown
in (B) illustrates the septal view of the right ventricle. Indicated are
the pulmonary artery, the tricuspid valve annulus, and the right
ventricular apex. ECGs = electrocardiograms; PA = pulmonary artery;
RVOT= right ventricular outflow tract; SHD = structural heart
disease; TVA = tricuspid valve annulus

several interval measurements that reflect slow, muscle-to-muscle
propagation at the beginning of the QRS complex, the maximum deflection index in precordial leads, and presence of Q waves where

AADs or hyperkalemia as well as by CL (less accurate with faster VTs)

they would not ordinarily be expected (indicating propagation away

(S5.2.8.25). The maximum deflection index (time to earliest peak in

from the epicardial surface of the ventricular wall recorded by that

any precordial lead divided by the total QRS duration (S5.2.8.26), at

chest lead) (S5.2.8.21–S5.2.8.24). Of these, the raw interval meas-

least in principle, prevents this problem by indexing the intrinsicoid

urements are subject to false-positive errors in that they can be

deflection to the total QRS duration, which will be subject to the

nonspecifically prolonged by sodium-
channel blocking effects of

same effects.
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5.2.5 | Ventricular tachycardia in nonischemic
cardiomyopathy
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poorer for reentrant VTs (many of which have septal diastolic corridors
with variable epicardial breakthrough sites that can be detected by
ECGI), and with origin from sites close to scar (S5.2.8.33).

The 12-lead ECG of a VT could be less helpful in NICM to direct ablation; however, target areas can be estimated in a fashion comparable
to post-MI VT. In many cases of NICM, successful ablation sites are
on the epicardial surface; however, NICM VTs originating from anteroseptal scar typically have an LBBB inferior axis morphology, and
these patients (who might also present with AV conduction disturbances due to septal scarring in the region of the bundle branches)
might not benefit from an epicardial approach for ablation (S5.2.8.27).

5.2.6 | Bundle branch reentrant ventricular
tachycardia
Patients with BBRVT typically have some form of SHD (nonischemic
more than ICM), with an LBBB pattern in the baseline conducted
rhythm (sinus or atrial fibrillation [AF]), although RBBB or nonspecific
interventricular conduction delay can also occur. During BBRVT, the
QRS generally closely resembles the baseline QRS, with characteristically rapid initial forces (in contrast to the delayed upstrokes in
most other myocardial VTs). This is an important entity to recognize
because of its prevalence as well as its curability with a rather simple
ablation procedure (targeting RBBs or LBBs).
Many patients with SHD have an ICD in place that terminates
the majority of VT episodes with pacing or shock, thus precluding
recording of a full 12-lead ECG of the arrhythmia. Only when the
device is disabled, or when the VT rate or episode duration is below
the device's programmed detection levels, is it possible to record
the ECG during VT. In patients with SHD, having the 12-lead ECG of
all spontaneously occurring VTs is especially important during procedures in which multiple morphologies of VT are induced and the
operator must decide which morphology (or morphologies) are most
important to target for ablation. In the absence of a 12-lead ECG,
ICD electrograms of the recorded VT episodes have been particularly helpful to identify the clinical VT when multiple VTs are induced
during an ablation procedure (S5.2.8.28).

5.2.7 | Body surface mapping
Body surface mapping has been used for many years as a predictor of
VA exit site, starting with skin surface potential minima and more recently as electrocardiographic imaging (ECGI). The latter integrates unipolar electrograms obtained during the arrhythmia while the patient is
wearing a 256-electrode vest, with ventricular anatomy derived from
a CT or CMR scan with the vest in place. An activation map during the
arrhythmia is then mathematically derived using the inverse solution
and is plotted on the epicardial surface as designated by the CT or
CMR scan. Although experience with this modality in VAs is limited,
ECGI maps have shown good correlations with endo-and epicardial
mapping results in a variety of settings, in patients with and without
SHD (S5.2.8.29–S5.2.8.32). Correlations appear to be very good for
OT arrhythmias (right vs left) and for those with epicardial sources, and

5.2.8 | Summary
In most settings, ECG tracings provide important insights regarding
location of either the source of focal arrhythmias or the exit site for
reentrant VTs; when possible, a 12-lead ECG should be obtained of
the target VA(s) (PVC or VT) and be used as a guide for where to concentrate mapping efforts based on published algorithms. However, no
matter how specific the ECG algorithm or ECGI map is, it remains as
a guide to where mapping efforts should begin or focus, rather than
pinpointing an actual site at which ablation will be certain to eliminate
the arrhythmia. Careful mapping is still needed in all situations.

References
S5.2.8.1. 	
Dixit S, Gerstenfeld EP, Callans DJ, Marchlinski FE.
Electrocardiographic patterns of superior right ventricular outflow tract tachycardias: distinguishing septal and free-wall sites
of origin. J Cardiovasc Electrophysiol. 2003;14:1–7.
S5.2.8.2. 	Yamauchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic
characteristics of repetitive monomorphic right ventricular tachycardia originating near the His-bundle. J Cardiovasc
Electrophysiol. 2005;16:1041–48.
S5.2.8.3. 	Tanner H, Hindricks G, Schirdewahn P, et al. Outflow tract
tachycardia with R/S transition in lead V3: six different anatomic approaches for successful ablation. J Am Coll Cardiol.
2005;45:418–23.
S5.2.8.4. 	Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic
ventricular tachycardia originating from the aortic sinus cusp:
electrocardiographic characterization for guiding catheter
ablation. J Am Coll Cardiol. 2002; 39:500–8.
S5.2.8.5. 	Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup
of idiopathic ventricular arrhythmias. J Am Coll Cardiol.
2005;45:877–86.
S5.2.8.6. 	Good E, Desjardins B, Jongnarangsin K, et al. Ventricular arrhythmias originating from a papillary muscle in patients without prior infarction: a comparison with fascicular arrhythmias.
Heart Rhythm. 2008; 5:1530–37.
S5.2.8.7. 	Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the papillary muscles in
the left ventricle: prevalence, electrocardiographic and electrophysiological characteristics, and results of the radiofrequency
catheter ablation. J Cardiovasc Electrophysiol. 2010;21:62–9.
S5.2.8.8. 	Al'Aref SJ, Ip JE,Markowitz SM, et al. Differentiation of papillary muscle from fascicular and mitral annular ventricular
arrhythmias in patients with and without structural heart disease. Circ Arrhythm Electrophysiol. 2015; 8:616–24.
S5.2.8.9. 	Kamakura S, Shimizu W, Matsuo K, et al. Localization of optimal ablation site of idiopathic ventricular tachycardia from
right and left ventricular outflow tract by body surface ECG.
Circulation. 1998;98:1525–33.
S5.2.8.10. 	Betensky BP, Park RE, Marchlinski FE, et al. The V(2) transition ratio: a new electrocardiographic criterion for distinguishing left from right ventricular outflow tract tachycardia
origin. J Am Coll Cardiol. 2011; 57:2255–62.
S5.2.8.11. 	Kumagai K. Idiopathic ventricular arrhythmias arising from
the left ventricular outflow tract: Tips and tricks. J Arrhythmia.
2014;30:211–21.

|

CRONIN et al.

S5.2.8.12. 	L arroussi L, Badhwar N. Ventricular tachycardia arising from
cardiac crux: electrocardiogram recognition and site of ablation. Card Electrophysiol Clin. 2016;8:109–13.
S5.2.8.13. 	Enriquez A, Pathak RK, Santangeli P, et al. Inferior lead discordance
in ventricular arrhythmias: a specific marker for certain arrhythmia locations. J Cardiovasc Electrophysiol. 2017;28:1179–86.
S5.2.8.14. 	
Miller JM, Marchlinski FE, Buxton AE, Josephson ME.
Relationship between the 12-lead electrocardiogram during
ventricular tachycardia and endocardial site of origin in patients
with coronary artery disease. Circulation. 1988;77:759–66.
S5.2.8.15. 	
Kuchar DL, Ruskin JN, Garan H. Electrocardiographic localization of the site of origin of ventricular tachycardia in
patients with prior myocardial infarction. J Am Coll Cardiol.
1989;13:893–3.
S5.2.8.16. 	Segal OR, Chow AW, Wong T, et al. A novel algorithm for determining endocardial VT exit site from 12-lead surface ECG
characteristics in human, infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2007;18:161–8.
S5.2.8.17. 	de Riva M, Watanabe M, Zeppenfeld K. Twelve-lead ECG
of ventricular tachycardia in structural heart disease. Circ
Arrhythm Electrophysiol. 2015;8:951–62.
S5.2.8.18. 	
YokokawaM, Liu TY, Yoshida K, et al. Automated analysis
of the 12-
lead electrocardiogram to identify the exit site
of postinfarction ventricular tachycardia. Heart Rhythm.
2012;9:330–4.
S5.2.8.19. 	Yokokawa M, Jung DY, Joseph KK, Hero AO 3rd, Morady F,
Bogun F. Computerized analysis of the 12-lead electrocardiogram to identify epicardial ventricular tachycardia exit sites.
Heart Rhythm. 2014;11:1966–73.
S5.2.8.20. 	Sapp JL, Bar-Tal M, Howes AJ, et al. Real-time localization of
ventricular tachycardia origin from the 12-lead electrocardiogram. JACC Clin Electrophysiol. 2017;3:687–99.
S5.2.8.21. 	Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada
J. Electrocardiographic recognition of the epicardial origin of
ventricular tachycardias. Circulation. 2004;109:1842–47.
S5.2.8.22. 	Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features
to identify ventricular tachycardia arising from the epicardial
right ventricle. Heart Rhythm. 2006;3:1132–39.
S5.2.8.23. 	Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-
lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction.
Heart Rhythm. 2007;4:1403–10.
S5.2.8.24. 	Valles E, Bazan V, Marchlinski FE. ECG criteria to identify epicardial ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3:63–71.
S5.2.8.25. 	Piers SR, de Riva Silva M, Kapel GF, Trines SA, Schalij MJ,
Zeppenfeld K. Endocardial or epicardial ventricular tachycardia in nonischemic cardiomyopathy? The role of 12-lead ECG
criteria in clinical practice. Heart Rhythm. 2014;11:1031–39.
S5.2.8.26. 	Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left
ventricular tachycardia originating remote from the sinus of
Valsalva: electrophysiological characteristics, catheter ablation, and identification from the 12-lead electrocardiogram.
Circulation. 2006;113:1659–66.
S5.2.8.27. 	Oloriz T, Silberbauer J, Maccabelli G, et al. Catheter ablation
of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus inferolateral scar sub-t ypes. Circ Arrhythm
Electrophysiol. 2014;7:414–23.
S5.2.8.28. 	Yoshida K, Liu TY, Scott C, et al. The value of defibrillator
electrograms for recognition of clinical ventricular tachycardias and for pace mapping of post-infarction ventricular
tachycardia. J Am Coll Cardiol. 2010;56:969–79.
S5.2.8.29. 	Wang Y, Cuculich PS, Zhang J, et al. Nonninvasive electroanatomic mapping of human ventricular arrhythmias with electrocardiographic imaging. Sci Transl Med. 2011;3:98ra84.

371

S5.2.8.30. 	
Rudy Y. Noninvasive electrocardiographic imaging
(ECGI) of arrhythmogenic substrates in humans. Circ Res.
2013;112:863–74.
S5.2.8.31. 	
Varma N, Strom M, Chung MK. Noninvasive voltage and
activation mapping of ARVD/C using ECG imaging. JACC
Cardiovasc Imaging. 2013;6:1346–7.
S5.2.8.32. 	Zhang J, Cooper DH, Desouza KA, et al. Electrophysiologic scar
substrate in relation to VT: noninvasive high-resolution mapping and risk assessment with ECGI. Pacing Clin Electrophysiol.
2016;39:781–91.
S5.2.8.33. 	Sapp JL, Dawoud F, Clements JC, Horácek BM. Inverse solution mapping of epicardial potentials: quantitative comparison
with epicardial contact mapping. Circ Arrhythm Electrophysiol.
2012;5:1001–9.

5.3 | Facilities for the procedure
5.3.1 | Facilities
VT ablation can be a complex electrophysiological procedure, especially in patients suffering from deterioration of LV function or from
cardiogenic shock. In addition, many patients with scar-related VT have
comorbidities that impact on procedural planning. Adequate preprocedural planning and standardization of procedural steps are crucial in
this population with advanced heart disease. Preprocedural planning
should involve communication with other subspecialties, including cardiothoracic surgeons and physicians with expertise in heart failure management, to optimize patient safety. In general, VT ablation in patients
with advanced heart disease should only be performed by experienced
operators in centers with expertise for complex electrophysiological
procedures with onsite cardiosurgical backup and expertise in HS.
All personnel and equipment should meet institutional requirements and training requirements for treating patients with complex
cardiac pathologies. Integrity and functionality of the equipment
should be regularly maintained as required by institutional standards.

5.3.2 | Laboratory equipment
The electrophysiology laboratory for VT ablation should meet standard requirements for any type of catheter ablation procedure, with
availability of emergent echocardiography to rule out cardiac tamponade. Laboratory specifications include a dedicated work space
and fluoroscopy system (mono-or biplane, capability of cinefluoroscopy or angiography), a programmed stimulator, an electrophysiology recording system with EAM ability, as well as the possibility
to perform cardiac catheterization procedures with hemodynamic
monitoring capabilities. Institutional and societal requirements for
electrophysiology laboratories should be met, and regular maintenance is imperative (S5.3.4.1). The electrophysiology lab should be
equipped with a biphasic defibrillator and an ECG monitor, and a
backup defibrillator should be immediately accessible. Continuous
connection of the defibrillator to the patient (eg, using attached defibrillator pads) is used in many labs for fast and easy defibrillation. A
code cart with standard advanced cardiac life support medications is
mandatory. For surgical access, such as epicardial surgical windows,
institutional hygienic standards should be maintained.
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Programming devices for the patient's specific ICDs should be avail-

Operators performing VT ablation procedures should be certi-

able in the electrophysiology lab to allow pre-and intraprocedural pro-

fied interventional electrophysiologists with expertise for RV and LV

gramming and device interrogation as well as emergency internal shock

mapping and ablation. Coronary angiography by the operator him-or

delivery if required. For patients with implanted left or right VADs, the

herself or by another physician might be needed during epicardial or

appropriate equipment and personnel should be available as required.

aortic SV ablation procedures to delineate anatomy of the coronary

Epicardial access for mapping and ablation might be needed in a sub-

arteries. In addition, physicians capable of inserting percutaneous HS

group of patients with VT. Epicardial instrumentation is a complex part

devices should be available in case of prolonged hemodynamic com-

of VT ablation and requires high expertise and experience with epicar-

promise. A cardiac surgeon should be available in case cardiopulmo-

dial puncture or surgical access. Continuous availability of an ICD pro-

nary bypass, surgical HS, or sternotomy is required.

grammer and the capability of delivering internal shocks can be crucial

Epicardial VT procedures can be more complex than endocar-

to terminate VAs in case of external defibrillation failure due to pericar-

dial VT ablation procedures; these are discussed in more detail in

dial fluid and/or air and in cases of suboptimal defibrillator pad location.

Section 6.3. For adequate treatment of possible complications and

Patient monitoring is crucial for safety during ablation of VT, in-

also for surgical epicardial access, cardiac surgical backup is warranted.

dependent of the underlying cardiac disease. A physiological recorder
capable of monitoring pulse oximetry, noninvasive and invasive arterial blood pressure, and ECG is recommended. Vital signs in addition

5.3.4 | Patient safety

to oxygen saturation should be displayed for the operator and assist-

Due to procedural complexity and risks, catheter ablation for VAs

ing staff throughout the procedure. For longer procedures involving

should have appropriate patient safety and pertinent laboratory pro-

patients with SHD, invasive intra-
arterial blood pressure monitor-

tocols in place. Electrophysiology laboratory equipment should un-

ing might be superior to noninvasive noncontinuous measurement.

dergo routine maintenance by a biomedical engineering department

Noninvasive monitoring of cerebral tissue oxygen saturation has been

to ensure appropriate functionality and should be available for trou-

used to reflect end organ perfusion when longer episodes of VT were

bleshooting. In particular, routine assessment for external defibrillator

required, to allow for adequate mapping (S5.3.4.2, S5.3.4.3).

functionality should be performed according to regulatory, manufacturer, and institutional policies. Radiation exposure should be mini-

5.3.3 | Personnel
Credentialing of personnel involved in VT ablation procedures is
specific to institutions and can vary by country. The personnel in the
electrophysiology lab typically consist of a nurse and a technician
involved in patient care and monitoring; possibly a person handling
the ICD programmer (approximately 15% of the writing committee
have a representative from the device company assisting with intraprocedural management of the ICD) during the ablation; an expert operator for manipulation and placement of catheters; and one
or two operators managing the electrophysiology recording system,
the stimulator, and the mapping system. When a 3D EAM system is
used, as is the case in most VA ablation procedures, a highly trained
professional (eg, a manufacturer's representative, a technician, or a
physician) is usually present to operate this system and assist with
acquisition, editing, and interpretation of data. With respect to sedation, different requirements exist in different countries and societies.
An anesthesiologist, a nurse anesthetist, or an equivalent person experienced with sedation and intubation should be present if deeper
sedation is required. In this regard, sedation during VT ablation by
trained cardiologists has been shown to be safe (S5.3.4.4–S5.3.4.6).
Personnel involved in VT ablations should be trained for complex
electrophysiology maneuvers and mapping maneuvers for monitoring
severely impaired patients under sedation and administration of antiarrhythmic as well as inotropic drugs (S5.3.4.4–S5.3.4.6). Recognizing
any potential complication or prolonged hemodynamic compromise
is a key feature to patient safety. Personnel involved in VT ablation
should be proficient in using cardiac defibrillators and in performing
advanced life support and cardiopulmonary resuscitation.

mized to the operator and patient with the use of digital-pulsed, low
pulse rate fluoroscopy if feasible, and implementation of ALARA (as
low as reasonably achievable) principles. Safety protocols should be
in place for management of emergent complications, with a focus on
those pertaining to higher-risk VA ablation (eg, epicardial access with
surgical backup, hemodynamically unstable VAs requiring HS, acute
coronary injury requiring coronary intervention).
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5.4 | Preprocedural imaging
Recommendations for preprocedural imaging for VA catheter ablation
COR

LOE

Recommendations

References

I

B-NR

1. In patients with LV dysfunction undergoing catheter ablation of VA, preprocedural or intraprocedural imaging is recommended to rule out cardiac thrombi.

S5.4.1–S5.4.6

IIa

B-NR

2. In patients with NICM or ICM undergoing catheter ablation of VT, preprocedural CMR can be
useful to reduce VT recurrence.

S5.4.7–S5.4.9

IIa

B-NR

3. In patients with NICM or ICM undergoing catheter ablation of VA, preprocedural imaging can be
useful for procedural planning.

S5.4.10–S5.4.26

IIa

C-EO

4. In patients with NICM, CMR can be useful prior to ICD implantation to allow imaging without
device-related artifact for diagnostic purposes and identification of potential arrhythmogenic
substrate.

IIb

C-EO

5. In patients with ICM, CMR may be considered prior to ICD implantation to allow imaging without
device-related artifact for identification of the potential arrhythmogenic substrate.

Recommendation-specific supportive text

periprocedural planning regarding the need for obtaining epicardial

1 In patients with LV dysfunction, recent preprocedural imaging

access. Other imaging modalities, such as CT and nuclear imaging,

should be performed if LV catheter manipulation is anticipated

have been correlated with electroanatomical voltage mapping data

to assess for LV thrombi to prevent thromboembolic events.

to identify scarring by detecting areas of delayed enhancement

Typically, a transthoracic echocardiogram is performed to as-

(S5.4.10–S5.4.17, S5.4.19), wall thinning (S5.4.21), hypoperfu-

sess for intracardiac thrombi (S5.4.27, S5.4.28), and contrast

sion (S5.4.20), and lack of metabolic activity (S5.4.24). Contrary to

echocardiography has further been shown to improve the yield

CMR, CT and nuclear imaging do not provide specific information

of echocardiography to detect cardiac thrombi, especially in

about the precise extent of scarring within the myocardial wall;

high-risk patients (S5.4.4, S5.4.29) and in patients with poor

these imaging techniques might be preferable for preprocedural

echocardiographic windows. CMR has been shown to be su-

imaging in case of contraindications to CMR.

perior to transthoracic echocardiography for the detection of

4 Prior to implantation of a cardioverter defibrillator, performing a

intracardiac thrombi (S5.4.5, S5.4.6, S5.4.30), especially in the

CMR might be beneficial in patients with NICM and ICM. Especially

presence of small and mural thrombi. To further minimize the

for patients with NICM, the writing committee felt that in addition to

possibility of thromboembolic events, for patients with concom-

localizing scar in the event of future VT development, a CMR will be

itant AF, it might be prudent to also obtain a preprocedural

beneficial for diagnostic reasons to clarify the etiology of NICM. In

transesophageal echocardiogram to rule out left atrial thrombi

the 2013 ACC/AHA Guideline for Management of Heart Failure, CMR is

if defibrillation or cardioversion might be required during the

considered a class IIa recommendation to assess for infiltrative dis-

ablation procedure (S5.4.27). An intracardiac echocardiogra-

orders (S5.4.35). In general, it was felt that the higher the odds that

phy (ICE) can alternatively be performed prior to LV catheter

patients might have recurrent VTs, the stronger the indication for a

manipulation if no recent imaging is available to rule out LV

CMR prior to ICD implantation (for example, in patients with a sec-

thrombi.

ondary prevention indication for ICD implantation). Concerns about

2 Preprocedural imaging with CMR and use of CMR for targeting the
arrhythmogenic substrate has resulted in reduced VT recurrence

cost implications were the main reason why the writing committee
issued a class IIb recommendation for patients with ICM.

and reduced mortality in a few observational studies (S5.4.7–
S5.4.9). Patients with contraindications to CMR were excluded,
and in one study, only patients with good image quality benefited

Synopsis

from the preprocedural CMR (S5.4.9). CIEDs have long been con-

Although randomized studies that demonstrate that the use of im-

sidered as being contraindicated for magnetic resonance imaging

aging results in improved procedural outcomes are lacking, pre-,

(MRI). However, provided that appropriate precautions are taken,

intra-and postprocedural imaging is routinely used for VA ablation

MRIs in patients with CIEDs have been demonstrated to be safe in

procedures.

multiple studies and registries (S5.4.31–S5.4.33), and a recent HRS

Advances in imaging technology, image integration, and image

expert consensus statement details specific recommendations for

analysis have paved the way for CMR and CT to take the lead as im-

MRIs in patients with CIEDs (S5.4.34).

aging modalities to define the presence and extent of SHD as well as

3 By demonstrating location (S5.4.12, S5.4.25, S5.4.26) and extent

to refine the characteristics of the arrhythmogenic substrate.

(S5.4.26) of delayed enhancement, CMR helps to identify the loca-

Due to the high spatial resolution of ex vivo MRI, myocardial

tion of the arrhythmogenic substrate and therefore is beneficial in

scarring can be characterized with an almost histological precision

374

|

CRONIN et al.

(S5.4.36, S5.4.37). Therefore, LGE-CMR is often referred to as the

improved outcomes have been described in patients who underwent

gold standard for scar assessment. Unfortunately, a clinical CMR

CMR prior to VT ablation procedures (S5.4.7–S5.4.9).

study obtained for a patient has a much lower spatial resolution due

The advantage of multidetector cardiac CT (MDCT) over LGE-

to the motion of the beating heart compared with an ex vivo MRI.

CMR is the higher spatial resolution that is in the submillimeter

Several studies have reported on the accuracy of CMR-defined scar

range. Various MDCT characteristics indicative of scarring have

by correlating CMR-defined scar with areas of low voltage from EAM

been described, including a degree of wall thinning with a cutoff

data (S5.4.10–S5.4.17). Although differences exist between these

wall thickness of <5 mm (S5.4.22), hypoattenuation (S5.4.20), and

studies, there is general agreement between imaging defined scar

delayed enhancement (S5.4.19). More recently, thanks to the higher

and the abnormal substrate defined by EAM. Important limitations of

spatial resolution of MDCT, thicker ridges of tissue separating

the EAM-defined substrate, however, need to be kept in mind, and

areas of thinning have been described within the myocardial scar

there is mounting evidence for improved procedural outcomes with

harboring the majority of VT target sites in patients post infarction

an imaging-guided ablation compared with an EAM-guided ablation

(S5.4.18). Hence, MDCT imaging has been found to be beneficial

approach (S5.4.7–S5.4.9). EAM-derived data reflect the 3D surface of

as an alternative to CMR to indicate the location of myocardial

the myocardium and lack information about the 3D anatomical and

scarring, especially in the presence of contraindications for CMR.

pathological integrity of the heart. Hence, CMR offers a more com-

Although assessment of wall thickness in MDCT imaging has been

prehensive assessment of the entire heart, especially of the intramural

used successfully in patients with prior infarctions, the ability to

and epicardial myocardium, which is difficult, if not impossible, to as-

identify scarring based on wall thickness alone has been less suc-

sess with endocardial voltage mapping alone. Lack of adequate cath-

cessful (S5.4.21, S5.4.44) in patients with NICM, and might require

eter contact with the myocardium can further impact on accuracy of

a different approach (S5.4.19). MDCT is the imaging technique of

EAM. These limitations can be overcome by integrating the CMR data

choice for preprocedural imaging of the coronary arteries, the coro-

into the EAM. Accurate registration of the CMR with the electroana-

nary veins, and the phrenic nerve. The ability to image the coronary

tomical map is of critical importance to have reliable information about

arteries in conjunction with the ability to image epicardial fat thick-

location and extent of myocardial scarring. The information about scar

ness has been especially valuable for epicardial ablation procedures

location has been supplemented by further characterization of the tis-

to enhance safety and to quantify epicardial fat thickness covering

sue heterogeneity within the scar that contains the surviving myofiber

potential epicardial VT target sites (S5.4.45, S5.4.46).

bundles as the arrhythmogenic substrate (S5.4.38–S5.4.40).

Nuclear imaging for the purpose of facilitating VT ablation

Two methods have been described to characterize tissue hetero-

procedures has been described for PET and single-p hoton emis-

geneity: the SD method, which uses the remote, unenhanced myo-

sion computerized tomography (SPECT) scanning, using CT for

cardium as a reference, defining scar if the signal intensity is above

image integration. Although there is a correlation between PET/

normal myocardium (usually >2–3 SD) (S5.4.11, S5.4.12, S5.4.41); and

CT defined scar and EAM (S5.4.23, S5.4.24), the correlation

the signal intensity method (full-width at half maximum technique),

of SPECT perfusion imaging with low-voltage areas on EAM is

which uses >50% of the maximal signal intensity within a region of

lower (S5.4.47). It is intriguing that metabolically active areas

interest to define scar. Various cutoff values have been used to dis-

corresponding to critical VT sites have been identified; however,

tinguish the border zone from the scar core and have been correlated

they might not correspond to areas of low voltage on the EAM

with outcomes (S5.4.38–S5.4.40). Controversy exists, however, about

(S5.4.23). Furthermore, sympathetic denervation can be imaged

which of the methods and which of the cutoff values is preferable for

using tracers, such as 11C-m eta-hydroxyepinephrine and iodine-

assessment of tissue heterogeneity. It is important to note that quanti-

123-
m etaiodobenzylguanidine. Regional sympathetic denerva-

fication of the border zone still awaits histologic validation. Limitations

tion has been recognized as an imaging marker for an increased

of LGE-CMR include the limited spatial resolution that is in the 1-to

risk of sudden cardiac death (S5.4.48). Viable but denervated

2-mm range, making it difficult to characterize tissue heterogeneity

myocardium has been shown to be particularly sensitive to de-

if the wall thickness is in this range. This, among others, is one of the

velopment of arrhythmias (S5.4.49, S5.4.50). Klein et al (S5.4.51)

reasons why the assessment for LGE in the thinner RV is challenging

have demonstrated that critical VT ablation sites were located

when using standard LGE-CMR techniques. In the past, CIEDs have

in denervated areas, some of which were located in areas with

been considered to be contraindications for CMR. This is no longer

preserved bipolar voltage.

the case, and provided that certain precautions are followed, CMR

Finally, echocardiography is typically used to rule out the presence

has been shown to be safe in several studies (S5.4.33) and registries

of cardiac thrombi (S5.4.27, S5.4.28) prior to an ablation in patients

(S5.4.31, S5.4.32). However, in the presence of a CIED, artifacts from

with SHD in whom catheter manipulation in the LV is anticipated.

the device generator, especially from ICDs, can obscure the myocar-

Although transthoracic echocardiography has been beneficial in iden-

dium and render a CMR study completely or partially nondiagnostic

tifying intracardiac thrombi (S5.4.1–S5.4.3), the use of contrast has

(S5.4.42). It is therefore recommended to perform CMRs prior to

been shown to further increase the yield of cardiac thrombi (S5.4.4,

ICD implantation. The prevalence and extent of artifact can be min-

S5.4.29) and should be used if the LV endocardium is not well visual-

imized by wideband CMR sequences (S5.4.43). CMR in patients with

ized. Although ablation procedures might be safe in the presence of

NICM has been particularly helpful despite the presence of ICDs, and

laminated thrombi (S5.4.52), it would be prudent in the absence of

CRONIN et al.

an urgent indication for VT ablation, and especially in the presence
of a mobile thrombus, to anticoagulate the patient for a period of
time and reassess for LV thrombus prior to the ablation procedure.
Not every patient has optimal echocardiographic windows that allow
for comprehensive assessment of the entire endocardium to rule out
LV thrombi, even if sonographic contrast is used. LGE-CMR and Cine-
CMR are alternative imaging techniques that have a higher accuracy in
identifying myocardial thrombi (S5.4.5, S5.4.6, S5.4.30), which should
be kept in mind, particularly in patients for whom transthoracic echocardiography is considered insufficient to rule out an LV thrombus. The
sensitivity of ICE for detection of LV thrombus has not been systematically studied, but it can provide real-time assessment immediately
before catheter placement. To minimize the risk of thromboembolic
events for patients with concomitant AF, a preprocedural transesophageal echocardiogram will be helpful to exclude a left atrial thrombus
if a cardioversion is required during the ablation procedure (S5.4.27).
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5.5 | Patient preparation
Heart failure, electrolyte abnormalities, and myocardial ischemia should
be adequately treated and controlled, if possible, before the patient is
subjected to an invasive electrophysiology study. Similarly, associated
SHDs should be clearly defined, given that patients with conditions
such as severe LV systolic dysfunction, severe coronary artery disease,
critical aortic stenosis, and advanced renal impairment might not tolerate induction of arrhythmia, prolonged procedures, or fluid overload
resulting from the use of saline-irrigated catheters. Although some of
these conditions can be optimized prior to an elective procedure, this
is often not possible for more emergent procedures. In these cases,
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a substrate-based ablation approach without repeated VT inductions

of thromboembolic events (S5.5.1). Approximately half of the writing

might be preferable.

committee do not use bridging in similar patients, and a further 20%

AADs, with the exception of amiodarone, should, if at all possible,

do not use bridging in patients taking direct oral anticoagulants.

be discontinued for at least 5 half-lives prior to the ablation procedure.

Informed consent needs to be obtained from the patient or his or

This is almost mandatory for cases in which the primary strategy of

her surrogate after discussing the risks and benefits involved in the

mapping is not substrate-based, but it might not be possible for emer-

procedure, as well as alternatives. The patient should fast overnight

gency cases. Oral anticoagulants are generally discontinued prior to

or for at least for 6 hours prior to the procedure (S5.5.2, S5.5.3).

the ablation to achieve an international normalized ratio < 1.5 at the
time of the study. Direct oral anticoagulants should be withheld for
24-48 hours before the procedure, depending on anticipated access,
and bridging with heparin can be used for patients with mechanical
heart valves or other features that place them at high risk of thrombosis. The majority of the writing committee (60%) usually use bridging
in patients with mechanical valves, where possible, but many distinguish between mechanical aortic valves, in which transseptal access
with continued anticoagulation can be used, and mechanical mitral
valves, in which retrograde access is used. For elective procedures,
imaging with ultrasound can help to define the feasibility of an arterial closure device, and therefore continued anticoagulation. Routine
perioperative bridging in patients with AF who interrupted warfarin
for procedures, including percutaneous transvascular procedures, was
noninferior to no bridging in a large RCT with respect to the occurrence
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6 | I NTR A PRO C E D U R A L PATI E NT C A R E
6.1 | Anesthesia
Recommendations for anesthesia during catheter ablation of VA
COR

LOE

Recommendations

References

I

C-EO

1. Provision of variable depth of sedation, analgesia, and anesthesia during mapping and ablation of VA is
recommended.

I

C-EO

2. In patients undergoing VA ablation, careful preprocedural assessment is indicated to define the ideal
strategy for sedation and analgesia.

IIa

C-LD

3. It is reasonable to avoid general anesthesia and deeper levels of sedation in patients with idiopathic VA,
particularly if the arrhythmia is suspected to be catecholamine-sensitive or was not inducible at a prior
procedure.

S6.1.1

IIb

B-NR

4. Moderate to deep sedation under close hemodynamic and respiratory monitoring might be considered
for VA ablation in stable patients with idiopathic or scar-related VAs expected to have a longer procedure
or undergo a painful technique, such as epicardial access.

S6.1.1–
S6.1.3

Recommendation-specific supportive text

anesthesia is its potential suppression of VA. Elimination of mental

1. The American Society of Anesthesiologists defines levels of sedation

stress and the related changes in the autonomic tone during general

in a continuum, varying from minimal sedation (anxiolysis), to moderate sedation or analgesia (conscious sedation), to deep sedation
or analgesia, to general anesthesia (S6.1.4). Careful preprocedural
assessment is indicated to define the ideal strategy for sedation
and analgesia based on age and comorbidities, targeted arrhythmia,
planned procedure, risk for airway obstruction, and patient wishes.
General anesthesia ensures patient comfort that facilitates vascular
and especially epicardial access, and also ensures immobility during
catheter manipulation for mapping and ablation, especially for procedures of long duration. However, a major disadvantage of general

anesthesia or deep sedation can potentially decrease the spontaneous manifestation of catecholamine-sensitive VA and the induction/
maintenance of reentrant VT (S6.1.5–S6.1.8). Inhaled anesthetics
that prolong action-potential duration and ventricular refractoriness
(sevoflurane and isoflurane) and intravenous anesthetics that reduce
sympathetic tone (dexmedetomidine) are commonly avoided for ablation procedures (S6.1.5, S6.1.6). Additionally, most of the anesthetic
agents used for sedation and analgesia reduce myocardial contractility
and systemic vascular resistance, causing hypotension that could be
exacerbated during VT, requiring pharmacological or mechanical HS.
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Those cardiovascular effects are more intense at the anesthetic doses

2. The selection of sedation strategy for patients undergoing ablation

needed for general anesthesia, which additionally produce higher at-

of VAs requires a balance between the desire of assuring a comfort-

tenuation of sympathetic tone. General anesthesia or the use of car-

able and safe procedure and the need to induce the targeted ar-

diodepressive medications, such as propofol for anesthesia in patients

rhythmia (S6.1.9). Proactive communication between the operator

with severely compromised LV function, can result in acute hemody-

and the anesthesia team and with the patient about the patient's

namic compromise during the ablation procedure, and its use needs to

needs and desires, as well as the electrophysiological requirements,

be carefully considered for these patients. If general anesthesia is used

helps to select a sedation strategy that is in the best interest of the

during epicardial ablation procedures, the concomitant use of muscle

patient.

relaxants could preclude identification of the phrenic nerve during

3. In the prospective arm of a large observational study, in which pa-

epicardial ablation. Use of a short-acting muscle relaxant during induc-

tients with sustained, monomorphic VT and SHD underwent noninva-

tion of anesthesia is acceptable, without redosing; however, it could

sive programmed stimulation (NIPS) under minimal sedation, followed

necessitate a deeper level of anesthesia with resultant exaggeration of

by invasive programmed stimulation under general anesthesia using

the above-mentioned hypotensive effects. Nevertheless, the effects

propofol or isoflurane, >90% remained inducible under general anes-

of propofol on cardiac electrophysiological proprieties are diverse and

thesia, although in half, a different VT was induced (S6.1.10). General

could include arrhythmia suppression. In fact, propofol has been as-

anesthesia was associated, however, with less hemodynamic stability

sociated with suppression of VT and VT storm (S6.1.7).

and greater use of vasopressor support with phenylephrine, without

The need for sedation and analgesia varies throughout the proce-

an adverse effect on procedural outcomes. More aggressive stimula-

dure, being higher during vascular and epicardial access and car-

tion was often required with general anesthesia than with conscious

dioversion or defibrillation. On the other hand, a more superficial

sedation (S6.1.10). In another cohort of 25 patients referred for epicar-

level of sedation (or any) is desirable to prevent VA suppression

dial ablation in the setting of NICM, a strategy of initial programmed

and to assure VT induction and maintenance for mapping. Short-

stimulation under sedation with midazolam, fentanyl, or remifentanil

acting agents are considered more suitable to provide those rapid

led to induction of tolerated VT in 15 patients, and avoidance of epi-

changes in the requirements of sedation level during mapping and

cardial access (which was performed under general anesthesia) alto-

ablation of VAs (S6.1.9). Intravenous boli of midazolam and fen-

gether occurred in 10 (40%) (S6.1.3).

tanyl at repeated doses as needed was reported by a single-center

On the basis of the cited single-
center observational studies

observational study as a feasible and safe strategy for minimal se-

(S6.1.1–S6.1.3, S6.1.5–S6.1.11) about the various sedative and

dation in patients with idiopathic PVC or VT planned for shorter

analgesic strategies for ablation of VAs, it is reasonable to avoid

procedures (S6.1.1). However, even shorter-acting sedatives such

general anesthesia and deeper levels of sedation in patients with

as midazolam have the potential for suppressing idiopathic VA

idiopathic VAs (PVC or VT) planned for shorter procedures, par-

for prolonged periods of time and need to be used with caution

ticularly when the arrhythmia is suspected to be catecholamine-

during procedures targeting idiopathic VAs, such as frequent PVCs.

sensitive (typically, automatic and triggered arrhythmias) or was

A strategy to use shorter-acting sedatives such as propofol for al-

not inducible during a prior procedure. In these patients, a minimal

lowing temporary deeper sedation is frequently used initially, and

sedation strategy with short-acting sedatives and analgesics, with

if VAs are suppressed, sedation can be reduced or discontinued to

repeated doses as needed, can be useful to ensure adequate seda-

allow for arrhythmias to reappear as necessary. For patients with

tion without VA suppression.

scar-related VTs, sedatives such as midazolam, which has the ad-

4. Epicardial scar-related VT mapping and ablation under deep seda-

ditional benefit of amnesia, do not impact on inducibility of VT

tion with sufentanil or remifentanil and intermittent boli of midaz-

and can be used in conjunction with analgesics and/or other sed-

olam was reported as a feasible and safe strategy in a single-center

atives such as propofol to achieve the desired level of sedation.

prospective series and a case report (S6.1.9, S6.1.11). Interestingly,

Continuous infusion of propofol, alone or complemented with re-

no respiratory failure resulting in endotracheal intubation or pro-

peated boli of fentanyl (as needed), has been proposed for deep

longed periods of hypotension requiring HS were observed (except

sedation of stable patients during ablation of idiopathic or scar-

during periods of unstable VT) in these cases (combined 79 proce-

related VT that are expected to have a longer duration or that re-

dures in 73 patients). Importantly, this strategy allowed epicardial

quire more painful and challenging techniques, such as epicardial

access with comfort, preventing the need for general anesthesia

access. Two single-center observational studies reported that this

and muscle relaxants (facilitating the identification of the phrenic

strategy can be safely performed in this subset of patients under

nerve during epicardial ablation), and providing rapid recuperation

close hemodynamic monitoring (S6.1.1, S6.1.2). Propofol had to be

of consciousness with no recall of punctures or cardioversions.

discontinued (switched to midazolam) in 11.7% of the procedures,

Remifentanil is an opioid with an analgosedative effect that can

predominantly due to hypotension presenting in elderly patients

have advantages for ablation of VAs, including a lack of negative

and prolonged procedural duration (S6.1.2). Respiratory depression

inotropic effect, comparatively little effect on arrhythmogenicity,

resulting in sustained oxygen saturation of <90% requiring reduc-

time-to-peak effect of approximately 90 seconds and a half-life of

tion of propofol and transitory mechanical maneuvers to assist ven-

3-4 minutes (S6.1.9). This agent is also associated with hypoten-

tilation was present in 1.5% of the patients in the same study.

sion likely secondary to vasodilatation and bradycardia.
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Moderate to deep sedation with continuous infusion of propofol
and repeated boli of fentanyl under close hemodynamic and respiratory monitoring might be considered for stable patients with
ablation of idiopathic or scar-related VA with no indication for
general anesthesia who are expected to undergo a procedure of
longer duration or for patients who require more painful techniques, such as epicardial access. Another short-action anesthetic,
such as remifentanil or sufentanil, could also be considered. Of
note, patients with severe hemodynamic compromise, severe life-
threatening comorbidities or acute illness, respiratory failure, high
risk for airway obstruction, or who were intubated before the procedure for arrhythmia storm or cardiogenic shock were excluded in
the cited studies and are also traditionally considered candidates
for general anesthesia. Hospital and regulatory guidance varies
widely on the training and specialization required for different levels of sedation and administration of various drugs (see Section 11).
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6.2 | Vascular access
Recommendation for vascular access during catheter ablation of VA
COR

LOE

Recommendation

References

I

B-NR

1Ultrasound-guided femoral arterial and venous access is recommended to reduce the incidence of vascular access complications during VA ablation.

S6.2.1–S6.2.5

Recommendation-specific supportive text

a meta-analysis of nonrandomized controlled trials of ultrasound-vs

1. Significant vascular complications occur in approximately 2% of VT

fluoroscopy-or palpation-guided femoral arterial access found it was

ablation procedures (S6.2.6), which are further detailed in Section 10.

associated with a reduction in the number of attempts and vascular

Ultrasound-
guided femoral arterial and venous access has been

complications (S6.2.4). An RCT of ultrasound-vs fluoroscopic-guided

widely implemented in electrophysiological procedures in an effort

retrograde femoral arterial access in patients undergoing angiogra-

to reduce vascular complications. Several observational studies of

phy or interventional procedures found that ultrasound guidance re-

electrophysiological procedures, mostly examining AF ablation, one

duced the number of attempts, time to access, risk of venipuncture,

RCT, and a meta-analysis have shown an association of ultrasound

and vascular complications (S6.2.5).

guidance with a reduction in major and minor vascular access complications and bleeding (S6.2.1–S6.2.4). One observational study reported the rate of major complications in the subgroup undergoing

Synopsis

VA ablation, which was 8.9% in the conventional group and 0% in

For VA ablation, standard percutaneous vascular access techniques

the ultrasound-guided group (S6.2.1). In a single RCT in patients un-

are used. The choice of peripheral vascular access depends upon

dergoing AF ablation, ultrasound guidance reduced time, additional

several factors, including the arrhythmia's SOO, the location of

punctures, arterial puncture, and unsuccessful access. Although it

any substrate identified on pre-or intraprocedural imaging, the pa-

increased first pass success, however, it was underpowered for the

tient's anatomy, and the presence of peripheral vascular disease or

primary endpoint of major vascular access complications due to a

venous occlusion or agenesis. LV access can be achieved through

lower than expected observed complication rate (S6.2.3). Similarly,

either retrograde transaortic or antegrade transseptal approaches,
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depending on patient specifics and operator preference, the latter
especially in the presence of mechanical aortic valve replacement
or severe aortic or peripheral vascular disease. Although most areas
of the endocardial LV can be accessed by either approach, the degree of contact force can vary (eg, contact force was significantly
higher transseptally in the mid-anteroseptum, mid-lateral, and apical segments, and significantly higher with a retrograde approach in
the basal-anteroseptum, basal-inferoseptum, basal-inferior, and the
basal-lateral segments) (S6.2.7). If a retrograde access to the LV endocardium has been chosen, the use of long sheaths can be helpful
in the presence of tortuosity of the iliac arteries or the distal aorta.
Once vascular access has been obtained, heparin can be administered to prevent clotting of the sheaths.
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6.3 | Epicardial access
Recommendations for epicardial access for catheter ablation
COR

LOE

Recommendations

I

C-EO

1. In patients undergoing epicardial VT ablation, imaging of the epicardial coronary arteries by
coronary arteriography or coronary CT angiogram prior to ablation is recommended to reduce
the risk of arterial injury.

I

C-EO

2. In patients undergoing epicardial VT ablation via a percutaneous approach, provision for
immediate echocardiography, blood transfusion, and onsite cardiothoracic surgical backup is
recommended.

I

C-EO

3. In patients with prior cardiac surgery or pericardial adhesions for whom epicardial VT ablation
via a percutaneous approach is considered, careful assessment of the risk/benefit ratio and
alternative therapies such as surgical dissection are recommended.

I

C-EO

4. In patients undergoing epicardial VT ablation, pacing with high stimulus intensity from the
ablation electrode to rule out diaphragmatic stimulation is recommended to avoid phrenic nerve
injury.

Recommendation-specific supportive text
1 Inadvertent injury to an epicardial coronary artery can occur
by puncture or laceration with a needle and is recognized by
aspiration of arterial blood from the pericardial space. Arterial
injury can require arterial stenting or surgical repair. In addition, application of RF current within 5 mm of an epicardial
coronary artery can result in stenosis, spasm, or occlusion of
the vessel (S6.3.4.1–S6.3.4.3). Because of the risk of arterial
injury, imaging of the coronary arteries with arteriography is
essential. The use of other coronary artery imaging techniques
assumes that an adequate registration of imaging data has been
accomplished. Hence, coronary angiography is the preferred
technique.

2 Epicardial ablation requires considerable preparation prior to the
procedure. Major complications occur in approximately 5% of epicardial ablation procedures (S6.3.4.4). Unintended puncture of the
RV can occur in up to 17% of cases (S6.3.4.4), although bleeding is
usually self-limited provided that a sheath has not been introduced
through the RV free wall. The patient's blood should be typed and
cross-matched for immediate transfusion should significant bleeding occur. Because bleeding within the pericardial space is common,
intracardiac or transthoracic echocardiography should be immediately available. In addition, cardiothoracic surgical backup should
be readily available. A potentially serious complication of percutaneous subxiphoid transpericardial puncture is laceration of the
liver or intra-abdominal arteries. Thus, unexplained hypotension
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should prompt imaging of these structures to evaluate possible
intra-abdominal bleeding that could necessitate surgical repair.
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6.3.2 | Criteria suggesting epicardial substrate

3 The presence of pericardial adhesions can severely restrict the

Several factors suggest an epicardial substrate for VT, including

ability to maneuver a guidewire or catheter within the pericardial

the anatomical location of scar on CMR or CT imaging (S6.3.4.12,

space. Thus, patients with prior cardiac surgery or a history of

S6.3.4.45, S6.3.4.46), unipolar voltage mapping from the endocar-

pericarditis can present significant challenges for epicardial abla-

dium (S6.3.4.14), and the lack of identifiable scarring or regions

tion. Although dissection of pericardial adhesions using a guide-

of slow conduction with endocardial mapping. The presence of a

wire, deflectable catheter, or deflectable sheath can be useful to

subepicardial or midmyocardial scar with contrast-e nhanced CT or

allow epicardial mapping (S6.3.4.5–S6.3.4.7), access to the entire

CMR is a valuable tool to identify potential epicardial substrates

epicardial surface might not be possible, and loculated pericar-

for VT and correlates with voltage mapping (S6.3.4.45, S6.3.4.46).

dial effusions that are challenging to drain percutaneously can

Preprocedural imaging is therefore useful to select patients for

occur in this setting. A planned surgical dissection of pericardial

epicardial mapping and ablation and to guide the operator to the

adhesions can allow dense adhesions to be safely lysed and allow

regions of interest. The surface ECG (S6.3.4.47–S6.3.4.51) dur-

epicardial ablation in selected cases (S6.3.4.8, S6.3.4.9).

ing VT provides important clues to an epicardial origin, including

4 Damage to the phrenic nerves can occur if the ablation electrode

the presence of a pseudo-d elta wave (≥34 ms in duration) in the

lies adjacent to these structures (S6.3.4.10) and can be minimized

precordial leads, an intrinsicoid deflection to the peak of the R

by pacing from the ablation electrode using high stimulus inten-

wave in lead V2 ≥ 85 ms, and an RS duration of ≥ 121 ms, although

sity to identify phrenic nerve stimulation. If phrenic nerve stimu-

with limited specificity in patients with ICM (S6.3.4.47, S6.3.4.48).

lation is observed during pacing, mechanical means to protect the

An ECG algorithm to identify epicardial VT in patients with NICM

phrenic nerve might be required, such as inflation of an intraperi-

includes the absence of Q waves in the inferior leads with either

cardial balloon (S6.3.4.11).

pseudo-d elta waves (≥75 ms), a maximum deflection index ≥ 0.59,
or a Q wave in lead I (S6.3.4.51). The reported sensitivity and spec-

6.3.1 | Background

ificity of these criteria to predict successful epicardial ablation in
NICM can exceed 90% (S6.3.4.51). ICE has also been shown to

VA can originate from the endocardium, the midmyocardium, or

be useful for identifying epicardial scar as VT substrate with in-

might involve the epicardium. The latter is particularly true for pa-

creased echogenicity strongly correlating with the results of EAM

tients with NICMs, including idiopathic DCM (S6.3.4.12–S6.3.4.14),

(S6.3.4.52). Although the origin of epicardial VTs in patients with

ARVC (S6.3.4.15–S6.3.4.19), myocarditis (S6.3.4.20), sarcoidosis

SHD depends on scar location, in patients without SHD, the SOO

(S6.3.4.21, S6.3.4.22), and ChD (S6.3.4.23–S6.3.4.26), as well as

is often in close proximity to the mitral annulus and the LV sum-

Brugada syndrome (S6.3.4.27–S6.3.4.30). Also, for patients with

mit. This area can be reached and mapped via the coronary ve-

VT following MI, the arrhythmogenic substrate can be located

nous system. Scar-related VTs are often beyond the reach of the

in the midmyocardium or in the subepicardial region (S6.3.4.31–

coronary venous system and hence require different access to the

S6.3.4.36). Finally, idiopathic VA can originate from the LV epi-

pericardial space.

cardium (S6.3.4.37–S6.3.4.40). The percutaneous technique for
epicardial mapping and ablation in patients with Chagas cardiomyopathy (CCM) was described by Sosa et al in 1996 (S6.3.4.23). Since
that initial description, epicardial ablation has become an important

6.3.3 | Epicardial access technique
Access to the epicardium is most often achieved with a subxiphoid,

technique to effectively treat VA in a variety of diseases. Despite

transpericardial puncture using either a 17–18-gauge, 6-inch Tuohy

mapping data implicating an epicardial origin of postinfarction VT in

or similar needle with a beveled tip (S6.3.4.23), a thinner 21-gauge

up to one-third of cases (S6.3.4.31, S6.3.4.32, S6.3.4.41), epicardial

needle (S6.3.4.53), or a needle-
in-
needle technique (S6.3.4.53,

ablation procedures are typically performed in only a small minority

S6.3.4.54). Three-quarters of the writing committee who perform

of patients post infarction. This is most likely due to the predominant

epicardial access use a Tuohy needle, whereas the rest use the

endocardial involvement of postinfarction scarring and the three-

needle-in-needle technique. The latter approach uses a 7-cm, 18-

dimensionality of reentry circuits that can include the endocardium.

gauge needle for support while puncturing the skin and subcuta-

The anatomical distribution of post-MI epicardial VTs is highly as-

neous tissues, while a longer (15–20-cm) 21-gauge micropuncture

sociated with infarctions in the distribution of the left circumflex or

needle is inserted through the 18-gauge needle to puncture the pa-

right coronary arteries (S6.3.4.42). The prevalence of epicardial VT

rietal pericardium (S6.3.4.54). With either approach, small amounts

in patients with NICMs appears to be significantly higher than for

of radiographic contrast are injected to confirm that the needle is

VT following MI (S6.3.4.13, S6.3.4.43, S6.3.4.44). The site of scarring

within the pericardial space and that contrast moves freely within

and slowed conduction supporting VT in NICM is most often located

this space. A long guidewire is then advanced through the needle,

on the epicardial surface of the basal lateral LV (S6.3.4.43, S6.3.4.44).

with care taken to ensure that it moves freely to surround the car-

Thus, epicardial ablation is an important technique to address VT in a

diac silhouette. The angle of entry into the pericardial space can be

variety of SHDs, particularly in those with NICM.

either anterior, in which case the guidewire travels superiorly over
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the free wall of the RV, or posterior (inferior approach), in which the

Avoidance of dual antiplatelet therapy can reduce periprocedural bleed-

guidewire travels beneath the LV inferior wall before traveling su-

ing during epicardial ablation. Inadvertent puncture of the RV can be

periorly toward the posterobasal LV. Transpericardial access should

recognized if a guidewire can be advanced into the pulmonary artery.

be guided by fluoroscopy, including a steep left anterior oblique or

This is managed by withdrawing the guidewire from the RV, withdraw-

lateral view; the latter being useful for an anterior access. Once

ing the needle, and readvancing the wire until the pericardial space is

successful entry within the pericardial space is achieved, a sheath

accessed. If the needle enters and then exits the RV before pericardial

is advanced over the guidewire, allowing the mapping and ablation

access is obtained, a “through and through” puncture of the RV can re-

catheter to be moved across the epicardial surface. Percutaneous

sult. In this case, hemodynamic collapse might occur only on removal

subxiphoid access to the pericardial space might not be feasible in

of the sheath at the end of the procedure. This complication can be de-

patients with dense pericardial adhesions, including patients with

tected when bleeding occurs after withdrawal of the pericardial sheath

prior cardiac surgery, previous pericarditis, or prior epicardial abla-

with the guide wire still in place. It is recommended to advance a guide

tion procedures (S6.3.4.5–S6.3.4.7). For these patients, a limited

wire into the pericardial space prior to sheath removal and to observe

thoracotomy with a small subxiphoid or larger left lateral thora-

the puncture site for bleeding before removing the guide wire. Other

cotomy might be required that allows for manual lysis of adhesions

complications of percutaneous, subxiphoid pericardial access include

and control of bleeding (S6.3.4.8, S6.3.4.9). Thus, a collaborative

laceration or puncture of an epicardial coronary artery or vein (which

approach with a cardiothoracic surgeon and an electrophysiologist

could necessitate coronary stenting or surgical repair), RV pseudoaneu-

might be required for patients in whom a percutaneous approach

rysm, and coronary spasm (S6.3.4.71). RF current that is applied within

is not feasible because of pericardial adhesions. The presence of

5 mm of an epicardial coronary artery can produce occlusion, spasm, or

less extensive pericardial adhesions can be approached percutane-

stenosis of the artery (S6.3.4.1–S6.3.4.3). Because of this risk, imaging

ously, using a deflectable catheter and sheath for adhesion lysis.

of the coronary arteries with arteriography or preprocedural CT angi-

Insufflation of carbon dioxide or contrast via intentional exit into

ography is essential to accurately localize the ablation electrode rela-

the pericardial space from the right atrium (S6.3.4.55) or coronary

tive to the position of the coronary arteries. The left phrenic nerve has

venous system (S6.3.4.56) could have a role in determining the ex-

a variable course and can be damaged by RF or cryoablation energy

tent of adhesions in patients with prior cardiac surgery (S6.3.4.55)

(S6.3.4.10, S6.3.4.11). Preprocedural imaging (see Section 5) has been

and can facilitate epicardial access; however, further study is

particularly helpful to display the anatomical course of the coronary ar-

required.

teries and the phrenic nerve, thereby preventing damage to these struc-

Catheter ablation on the epicardial surface is usually performed

tures. Reliance on imaging only, however, might cause damage to these

with irrigated RF current, though cryoablation has also been re-

structures in case of imperfect image registration. Also, pacing from the

ported (S6.3.4.57–S6.3.4.61). Use of a low irrigation flow rate

ablation electrode with high stimulus intensity prior to ablation should

(5-7 mL/min) appears to result in a similar lesion size as the higher

be performed to exclude phrenic nerve stimulation. In some cases in

flows used in endocardial ablation while limiting intrapericardial fluid

which the ablation target is in close proximity to the phrenic nerve, a

accumulation, which reduces lesion size (S6.3.4.58). Frequent aspi-

balloon or steerable catheter can be advanced into the pericardial space

ration of irrigant is also important to prevent hemodynamic com-

to shield the nerve from ablation-related injury (S6.3.4.10, S6.3.4.72);

promise. The use of contact force-sensing catheters can improve

the use of air and fluid in the pericardial space has also been reported

orientation of the ablation electrode so that current is directed to-

to reduce the risk of phrenic nerve damage (S6.3.4.11). Of note, the

ward the epicardial surface rather than toward the parietal pericar-

presence of air in the pericardial space can increase the defibrillation

dium (S6.3.4.62–S6.3.4.64). Epicardial fat >5 mm in thickness results

threshold, requiring emergent decompression or internal defibrillation if

in reduced electrogram voltage and increased stimulation thresh-

defibrillation is required (S6.3.4.73).

old, and could limit the depth of RF lesions (S6.3.4.41, S6.3.4.65–

Esophageal injury can also occur if ablation is performed in the

S6.3.4.70). Epicardial fat is typically clustered along the course of

posterior LV (S6.3.4.74–S6.3.4.76). Although the exact mechanism

epicardial coronary arteries, within the AV grooves, and along the

and risk factors are unclear, esophageal temperature monitoring

free wall of the RV.

might be warranted before ablating near the esophagus. A significant
complication of subxiphoid transpericardial access is bleeding within

6.3.4 | Epicardial access complications

the abdomen from laceration of the liver or an intra-abdominal artery
(S6.3.4.71). Unexplained hypotension during or after epicardial abla-

The complications of epicardial ablation are important to consider.

tion should lead to prompt investigation of possible intra-abdominal

Major complications have been reported in approximately 5% of pa-

bleeding, which could require surgical repair.

tients (S6.3.4.4, S6.3.4.44). The most common complication of epicar-

Because of the many important complications that can occur

dial mapping and ablation is pericarditis, which can occur in over 20%

with epicardial ablation, extensive experience with this procedure

of patients (S6.3.4.44). The use of systemic or intrapericardial steroids

is required. Careful preprocedural planning is essential, including

can decrease the risk and severity of pericarditis (see Section 10.1).

immediate access to echocardiography, imaging of the coronary ar-

Inadvertent puncture of the RV can occur in up to 17% of cases and

teries, provision for immediate blood transfusion of cross-matched

usually results in self-limited bleeding of < 80 cc venous blood (S6.3.4.4).

blood, and backup cardiothoracic and general surgical support.
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6.4 | Intraprocedural hemodynamic support
Recommendations for catheter ablation of VA with mechanical HS
COR

LOE

Recommendations

I

C-EO

1. In select patients at risk of requiring HS, a decision to proceed
with catheter ablation of VA should be made in collaboration
with specialists in advanced heart failure management.

IIa

B-NR

2. In select patients, HS with a percutaneous VAD and extracorporeal membrane oxygenation during VT ablation can be useful
to avoid acute hemodynamic deterioration.

S6.4.1–S6.4.7

IIb

B-NR

3. Mechanical HS may be considered in select cases to allow mapping and ablation of unstable VTs.

S6.4.1–S6.4.6

Recommendation-specific supportive text
1 In patients with VAs and severe comorbidities, incessant or
recurrent VTs treated by multiple ICD shocks might cause end
organ hypoperfusion and further deterioration in cardiac function (S6.4.8, S6.4.9). Planning for a VA ablation procedure, in
which there is a significant risk that it will be complicated by
hemodynamic deterioration, should involve specialists in heart
failure. The patient's values regarding the various temporary and
permanent HS options and their feasibility should be considered.
2 Data about strategies for HS during VT ablation are available
from single and multicenter, nonrandomized, retrospective,
and observational trials, which have demonstrated feasibility
and safety (S6.4.1–S6.4.6). Mapping of nontolerated VTs can
be performed for longer periods of time when HS with either
percutaneous left ventricular assist device (pLVAD) (Tandem
Heart, CardiacAssist, Pittsburgh, PA; and Impella, Abiomed,
Danvers, MA) or extracorporeal membrane oxygenation is performed as opposed to no support or intra-aortic balloon pump
(IABP) (S6.4.1, S6.4.2). A large retrospective multicenter report,
however, has demonstrated that the use of HS was associated
with higher acute ablation failure rates, increased periprocedural complications, higher mortality, and a higher rate of VT

References

recurrence (S6.4.6). It is possible that HS was used in patients
with more severe disease in this study, and outcome data were
similar between the HS and no HS groups compared with patients with severely compromised EF (≤20%) and advanced heart
failure (NYHA class III and IV). Hence, the use of HS in these patients needs to be carefully considered. Of note, data supporting
HS as a bailout strategy during or right after VT ablation are poor
and do not demonstrate a benefit for procedural outcomes and
survival (S6.4.3, S6.4.5, S6.4.7).
3 The benefit of HS to allow mapping of unstable VTs needs to be
weighed against the potential detrimental effects of HS, depending on the type of support that is used, including vascular damage
due to large-bore venous and arterial access sites, among others
(S6.4.1). Prevention of hemodynamic deterioration during the ablation procedure by cautious use of cardiodepressive medications
such as propofol could obviate the necessity for HS; also, the use
of general anesthesia has been identified as a factor associated
with hemodynamic deterioration and needs to be carefully considered in patients with severely impaired myocardial function.
Adequate patient selection using risk assessment algorithms (see
Section 5) could help to identify patients for whom HS might be
beneficial.
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6.5 | Intraprocedural anticoagulation
Recommendations for intraprocedural anticoagulation
COR

LOE

Recommendations

References

I

B-NR

1. In patients undergoing endocardial LV catheter mapping and/or ablation, intraprocedural
systemic anticoagulation with intravenous heparin is recommended.

S6.5.1–S6.5.6

I

C-EO

2. In patients undergoing RV endocardial mapping and/or ablation who are considered high risk
for thromboembolism, intraprocedural systemic anticoagulation with intravenous heparin is
recommended.

IIa

C-LD

3. In patients undergoing epicardial access after systemic heparinization, reversal of heparin with
protamine is reasonable.

S6.5.7, S6.5.8

Recommendation-specific supportive text

infusion to maintain a target activated clotting time (ACT) longer

1 Catheter ablation of VA can be associated with risk of thrombus

than 250-350 seconds (S6.5.4, S6.5.6–S6.5.8, S6.5.10, S6.5.11).

formation and thromboembolism. Although the individual risk

In a survey regarding intraprocedural anticoagulation among the

varies with type and site of ablation and patient factors, the

writing committee members, for idiopathic VA, 48% of the re-

risk of clinically apparent stroke or thromboembolism in patients

sponders use ACT levels longer than 250 seconds, 39% longer

with SHD undergoing VT ablation in RCTs has ranged from

than 300 seconds, and 13% longer than 350 seconds. For patients

0% to 1.9% (S6.5.1–S6.5.5) and is lower in patients without

with SHD, 25% of the committee members use an ACT target

SHD (S6.5.9). A small study with diffusion-weighted magnetic

of 250 seconds, 58% use a target longer than 300 seconds,

resonance brain imaging demonstrated the presence of a new

and 17% use a target longer than 350 seconds. The ACT level

brain lesion in 58% of patients undergoing LV endocardial ab-

should be checked at 15-minute intervals until therapeutic anti-

lation (S6.5.10). These lesions were detected in the absence

coagulation is achieved, and then at 15- to 30-minute intervals

of clinically apparent stroke; no brain lesion was identified in

for the duration of the procedure. Approximately 90% of the

patients undergoing RV ablation. Although systemic heparinization

surveyed committee members routinely check for ACT during VT

has been routine for LV endocardial ablation since the earliest

ablation procedures. Most members use either a Hemochron ACT

large-scale investigations, few studies have compared different

(Instrumentation Laboratory, Bedford, MA) or an i-STAT (Abbott

approaches to anticoagulation before, during, or after the VT

Point of Care Inc., Princeton, NJ) device for ACT monitoring. For

ablation procedure (S6.5.6, S6.5.7) (Table 9). Systemic anticoag-

transseptal access, heparin should be administered prior to or

ulation with heparin is recommended for all procedures that last

immediately following the transseptal puncture. More than 70%

more than several minutes involving left heart catheterization.

of the writing committee members surveyed routinely administer

Intraprocedural anticoagulation schemes differ between centers.

heparin before the transseptal puncture, and approximately 20%

Unfractionated heparin is commonly administered after sheath

use a higher target ACT when a transseptal approach is used.

insertion as an initial bolus (empirical dose 5000–10,000 IU or

Among the writing committee members, 85% use continuous

50–100 IU/kg) followed by intermittent boli and/or continuous

flushing for sheaths, especially if a transseptal approach is used.
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Heparin infusion can be discontinued once all catheters are removed from left sided chambers. In the event of significant
persistent bleeding or cardiac tamponade, protamine should be
administered to reverse heparin. In patients with a history of
heparin-induced thrombocytopenia or allergy, a direct thrombin
inhibitor, such as bivalirudin or argatroban, can be considered as
an alternative for intraprocedural anticoagulation; however, limited
experience exists in patients undergoing VA ablation (S6.5.11).
2 During RV endocardial mapping, systemic anticoagulation with
heparin is not necessary unless other factors are present that increase the thromboembolic risk. The use of heparin can, however,
prevent deep venous thrombosis or pulmonary embolism, especially when a prolonged procedure with multiple venous catheters
and extensive ablation is anticipated. Similarly, patients with a
history of deep venous thrombosis, pulmonary embolism, hypercoagulable state (eg, factor V Leiden), right-to-left cardiac shunt,
severe RV dilatation, and advanced heart failure should undergo
systemic anticoagulation. Among the writing committee members, 65% reported routine use of heparin for VT ablation procedures even in the absence of risk factors for thromboembolism.
3 Anticoagulation is not required solely for epicardial mapping and/
or ablation. If LV mapping is planned, epicardial access can be obtained prior to LV instrumentation and systemic anticoagulation
(see Section 6.3). When epicardial access is required after therapeutic heparinization, reversal of heparin anticoagulation with
protamine is typically performed (S6.5.12, S6.5.13). Two small
studies reported epicardial access in fully anticoagulated patients
without a major increase in risk of bleeding complications (S6.5.14,
S6.5.15). When the writing committee was surveyed about epicardial access after full heparinization, half of the writing committee
would administer protamine for heparin reversal even when extensive endocardial ablation had been performed, 20% would administer protamine only after limited LV endocardial ablation, and
another 20% of the writing committee members would terminate
the procedure and schedule an epicardial ablation as a separate
procedure.
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6.6 | Antibiotic prophylaxis
Prophylactic antibiotics are not generally indicated for sterile
procedures such as VA ablation (S6.6.1). However, patients with
ICDs undergoing VA ablation, in which catheters might be in direct contact with the intravascular leads, could present a special
circumstance. No data exist to support this practice, nor is a specific antibiotic preferred over another. Approximately 40% of the
writing committee members administer prophylactic antibiotics to
patients with a pacemaker or ICD undergoing VA ablation, whereas
a quarter never do, and the remaining do in select patients based
on potential risk factors for device infection, such as a prosthetic
valve or use of a Foley catheter. Thirty percent of the writing committee use antibiotic prophylaxis for patients undergoing epicardial
access.
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6.7 | Fluid balance
Careful monitoring of fluid balance is essential in patients undergoing VA ablation, especially given that many have impaired ventricular
function, putting them at risk of volume overload, and they might
have renal impairment. Various irrigated catheters are currently in
use, allowing for different flow rates, and hence, different volume
loads. A urinary catheter might not be required for cases performed
under sedation when the anticipated procedure duration is short,
but for longer ablation procedures, it should be considered. This permits more precise assessment of the fluid balance, which becomes
particularly important for patients in whom irrigated-tip RF catheters are used. However, urinary catheters can cause urinary tract
infection and bleeding; thus, a sterile technique is essential during
insertion and after-care. After measurement of volume infused and
eliminated (“ins and outs”), an intravenous loop diuretic should be
considered, especially with a large infused volume, a significantly
positive procedural fluid balance, and impaired LV function.
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sequences during programmed stimulation has been particularly
helpful to induce BBRVT that can easily be addressed with an ablation procedure.
The most important objective of the ablation procedure is to
identify and eliminate the clinical VT. Prior studies have demonstrated that programmed stimulation results in VT induction in
93%–95% of patients with healed MI and a history of sustained
VT (S7.4, S7.5). Importantly, these studies were concerned with
induction of any VT, but not necessarily the clinical VTs. Limited
data are available to address the question of how reliable PES
is in reproducing all clinically pertinent VT morphologies. Given
that 12-lead ECGs of the clinical VT are frequently not available, ICD electrograms have been described to reliably identify
the clinical VT when induced in the electrophysiology lab (S7.6).
Unfortunately, the clinical VT is not always inducible: 7%-24%
of patients are completely noninducible (S7.7–S7.9), and the
clinical VT cannot be induced in another 13%-3 0% of patients
(S7.6, S7.7, S7.10). Furthermore, induction of VTs that have not
been previously documented occurs frequently, depending on
whether the PES protocol is completed, until all extrastimuli
are delivered from multiple sites and refractoriness has been
reached. Elimination of all inducible VTs has been found to result in improved outcomes (S7.11, S7.12); hence, this is the ideal
objective of the ablation procedure. Inducibility of nonclinical
VTs post ablation has been found to be associated with a high
VT recurrence rate (S7.13). Risks and benefits will need to be
weighed, however, given it might take performance of longer
procedures to reach this objective. A major concern about the
reliability of PES is that VTs often recur even when patients
have been rendered completely noninducible post ablation
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(S7.12). Edema formation in a critical area can render a targeted

PES is a key component of the VT ablation procedure, allowing for

also form a new or modified substrate, generating new VTs. The

mapping of induced arrhythmias. In addition, a baseline assessment
of arrhythmia induction can be useful by comparison for the eventual assessment of procedural outcome (see Section 9.17). Given the
majority of idiopathic VAs are caused by cAMP-mediated delayed
afterdepolarizations, they can be provoked with catecholamine infusion and burst pacing (S7.1, S7.2). Although purely substrate-based
ablation (without arrhythmia induction) can be performed, many
laboratories perform programmed stimulation in select patients
with reentrant scar-related VT for several reasons: 1) to perform activation and entrainment mapping in tolerated VT; 2) to identify the
clinical VT morphologies to better focus substrate-based ablation;
and 3) to limit the extent of ablation delivery. Although “legacy” protocols for programmed stimulation have been proposed (S7.3, S7.4),
most laboratories that perform programmed stimulation would hold
to a minimal standard of at least 1 site and 2 drive CLs, with the
delivery of 1-4 ventricular extrastimuli at coupling intervals limited
by local refractoriness or a minimum of 180-200 ms. Given known
site dependence for induction of reentrant VT, additional sites of
stimulation (particularly the LV) can be useful. The use of long-short

VT temporarily noninducible; however, incomplete lesions can
former can be addressed with NIPS a few days after the ablation
procedure, which has been found to predict VT recurrence in
patients who were noninducible at the conclusion of the ablation procedure (S7.14). PES is typically performed at the onset
of the procedure, but it might need to be deferred to the conclusion of the procedure if there is concern about the patient's
hemodynamic status.
Despite there being less complete characterization of the effectiveness of PES to guide ablation of VT in nonischemic substrates,
noninducibility has also been demonstrated to result in superior outcomes post ablation (S7.15). Only limited data and anecdotal reports
exist on the use of other agents (aminophylline, epinephrine, calcium, dobutamine, caffeine) to induce idiopathic arrhythmias when
isoproterenol and burst pacing fail (S7.16).
A survey of the writing committee is summarized here to give
some perspective. For induction of VT in SHD, all the members
routinely stimulate from the RV apex, 66% from the RVOT and
59% from the LV if LV access has already been obtained. Up to 3
extrastimuli are routinely performed in 76%, and up to 4 in 24%. For
induction of idiopathic arrhythmias, the majority of the committee
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uses isoproterenol frequently (93%), followed by epinephrine (21%),
phenylephrine (14%), atropine (11%), and calcium (7%). In addition,
some members of the committee at least considered dobutamine
and caffeine.
At this point, PES remains a key tool of the mapping and ablation procedure. The use of PES, however, often needs to be complemented by alternative strategies, given its many limitations.
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8 | M A PPI N G A N D I M AG I N G TEC H N I Q U E S
8.1 | Mapping catheters
8.1.1 | Multielectrode mapping
The use of multielectrode mapping catheters has gained popularity
over the past several years with the introduction of mapping systems capable of acquiring data from multiple sites for each beat.
These catheters offer several advantages, particularly in respect to
mapping density, resolution, and speed. The ability to record electrograms from multiple sites at each beat increases the number of
data points and can shorten the duration of mapping.
Multielectrode catheters often use small electrodes with
short interelectrode spacing, thereby increasing mapping resolution, which can be advantageous for substrate mapping (S8.1.1.1–
S8.1.1.3), facilitating identification of surviving myocardial bundles
within heterogeneous scar tissue that may escape detection when
mapping with standard ablation catheters with larger electrodes
and spacing is performed (S8.1.1.3–S8.1.1.5). Multielectrode catheters allow pacing from multiple electrodes positioned in and around
areas of scar. The increased current density during pacing from
smaller electrodes can achieve capture at relatively low pacing stimulus strength (S8.1.1.1). In addition, pacing from one site while recording from surrounding sites allows investigation of propagation
in multiple directions that can identify anisotropy and areas prone to
slow conduction and/or block (S8.1.1.6, S8.1.1.7). These catheters
can also be useful for activation mapping during VT, given they allow
rapid acquisition of multiple sites at high spatial resolution that can
facilitate identification of a reentry isthmus or VT focus (S8.1.1.5).
Currently, several multielectrode catheters are available. The
Pentaray catheter (Biosense Webster, Diamond Bar, CA) is shaped
like a flower and has 5 splines, each with 4 electrodes (a total of 20
electrodes), which can be used with the CARTO EAM system. This
catheter frequently causes ectopic beats in areas of contracting myocardium, and spatial sampling is nonuniform due to variable spread
of the splines and limited contact with the myocardium. A linear
catheter with 20 electrodes is also available for use with this mapping system. This catheter has uniform spatial spread of electrodes
and a relatively large area of contact, although during endocardial
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mapping the proximal electrodes are often not in contact. It is well
suited for mapping of the epicardial surface. A duodecapolar catheter with tighter interelectrode spacing (Livewire, Abbott Laboratories,
Abbott Park, IL) has been used to map endocardial and epicardial ventricular surfaces in vivo and has been validated against histology in
an animal model (S8.1.1.8, S8.1.1.9). The Advisor HD Grid catheter
(Abbott Laboratories, Abbott Park, IL) is a novel 4-by-4 unipolar electrode array with 1-mm (diameter) electrodes, equidistantly spaced 3
mm apart from each other, which can be used in conjunction with
the EnSite Precision system (S8.1.1.10). A potential advantage is the
uniform spatial sampling; however, collection of ventricular mapping
data in humans in vivo is currently not available. The fourth catheter
is a small basket catheter with 64 very small electrodes arranged on
8 splines that can be used with the Rhythmia EAM system (Orion,
Boston Scientific, Marlborough, MA) (S8.1.1.5, S8.1.1.11). This cath-
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Electrophysiol. 2011;22:49–56.
S8.1.1.9. 	Tung R, Nakahara S, Ramirez R, et al. Accuracy of combined endocardial and epicardial electroanatomic mapping of a reperfused
porcine infarct model: a comparison of electrofield and magnetic systems with histopathologic correlation. Heart Rhythm.
2011;8:439–47.
S8.1.1.10. 	Magtibay K, Massé S, Asta J, et al. Physiological assessment
of ventricular myocardial voltage using omnipolar electrograms. J Am Heart Assoc. 2017;6:e006447.
S8.1.1.11. 	V iswanathan K, Mantziari L, Butcher C, et al. Evaluation of a
novel high-resolutionmapping system for catheter ablation of
ventricular arrhythmias. Heart Rhythm. 2017;14:176–83.

eter has a low noise level, facilitating recording of low amplitude signals. However, the basket is not well suited for mapping the papillary
muscles, the RV, or the epicardium.
Common limitations of multielectrode mapping catheters include
mechanical trauma with frequent ectopy, transient injury of the superficial conduction bundles, limited maneuverability, lack of tissue
contact information, and the potential for thrombus formation with
the need for careful anticoagulation. In addition, the potential benefit
of mapping with smaller electrodes in patients with NICM and high
prevalence of intramyocardial substrate is unclear. Currently, ablation
is performed with a second catheter, necessitating integration of the
anatomy and physiology acquired with the multielectrode catheter in
a mapping system that can also support data acquisition with an ablation catheter. Newer catheter designs integrating very small electrodes
positioned at the circumference of a standard ablation catheter could
allow combining high-resolution mapping with ablation on a single
catheter (S8.1.1.2).
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8.2 | Activation mapping
Mapping of the electrical activation sequence during VT is a valuable
mapping strategy for patients with hemodynamically stable monomorphic tachycardia (S8.2.1). It can localize the origin for focal tachycardias and potentially reentry circuits, depending on their anatomy
(S8.2.2).
Activation mapping is performed by recording of local electrograms from multiple sites during VT and is facilitated by the use of 3D
mapping systems, allowing display of the position and relative timing
on the EAM system. For focal VTs, the earliest site of activation identifies the SOO and is the target of ablation. At this site, the local bipolar electrogram precedes the QRS onset, and the unipolar signal (with
high-pass filter setting <1 Hz) demonstrates a QS configuration, consistent with a centrifugal spread of activation away from the SOO. In
intramural focal tachycardias, the bipolar electrogram often inscribes
with or after the onset of the QRS and the unipolar electrogram
demonstrates an rS configuration, consistent with an initial activation
propagating toward the recording electrode. In a true intramyocardial
origin, mapping from all opposing surfaces demonstrate relatively late
bipolar activations with rS unipolar configurations.
The most common VT mechanism in patients with SHD is scar-
related reentry with continuous excitation of the circuit throughout
the tachycardia CL (S8.2.1). The QRS onset typically occurs when
the impulse reaches the exit from the scar to activate the contractile
myocardium (S8.2.3). In “exit sites,” electrograms can be fractionated
and immediately precede the onset of the QRS complex. Ablation at
exit sites can terminate the tachycardia; however, it can also result
in a change of the tachycardia configuration and/or CL in which the
diastolic pathway exits at different locations from the scar (S8.2.4).
Ablation of the diastolic pathway “isthmus” is therefore a more desirable target, given it can eliminate the machinery required for reentry.
Electrograms at isthmus sites occur earlier during diastole, are typically of very low-voltage amplitude (<0.5 mV), and can have multiple potentials. Mapping of these circuits with multielectrode mapping
catheters can be helpful for identifying low amplitude signals, for differentiating near-field from far-field potentials, and for shortening the
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time required for mapping (see Section8.1). It should be noted that
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technique is used to identify critical sites of the arrhythmia circuit,

the mere presence of diastolic potentials does not suggest an isth-

through the analysis of the QRS morphology, the measured inter-

mus location. These can also be recorded in dead-end pathways and

vals, and the recorded electrograms (S8.3.2.1) (Figures 5 and 6):

adjacent bystanders unrelated to the circuit. It is therefore important
to carefully review and interpret the activation map in order to under-

1 The QRS configuration during entrainment provides information

stand the location and complexity of the circuit. In principle, an activa-

about whether the pacing site is within or outside the pro-

tion map of a macroreentrant VT circuit should demonstrate distinct

tected zone of the reentry circuit. With the pacing site being

entrance, isthmus, and exit sites that all serve as obligatory parts of

located outside the reentry circuit, during entrainment, the

the circuit, such that it cannot continue without all of these elements.

stimulated wavefronts that propagate out from the pacing site

However, scar-related circuits (particularly in patients with a nonisch-

collide with the orthodromically propagating wavefront of the

emic substrate) can have intramural component(s) that might not be

reentry circuit and fuse; therefore, the QRS complex is due to

recorded on the surface. These usually exhibit a “gap” in the activation

the fusion of wavefronts propagating directly away from the

sequence, such that part of the circuit is “concealed” from the surface

pacing site with those emerging from the tachycardia circuit

map, residing deep in the myocardium or on the opposing surface.

(classic entrainment). During pacing from within a protected

Activation mapping of scar-related VTs can be highly valuable

region in or near the reentry circuit, pacing entrains VT with-

for identifying the isthmus. However, it is often limited to patients

out changing the QRS configuration (concealed entrainment or

with hemodynamically stable VT. In patients with less tolerated VTs,

entrainment with concealed fusion) (S8.3.2.2–S8.3.2.4).

limited activation mapping can be performed in conjunction with

2 The stimulus-QRS interval during entrainment with concealed fu-

substrate, entrainment, and/or pace mapping. The utility of HS to

sion: Entrainment with concealed fusion indicates that the pacing

allow extended mapping during VT can improve the acute proce-

site is within a protected region of the reentry circuit, and can be

dural end-point of noninducibility; however, it has limited impact on

located in the common pathway of the reentry circuit (also re-

the long-term outcome (see Section 6.4) and has not reduced VT

ferred to as a critical isthmus or channel), or in a bystander site

recurrence (S8.2.5, S8.2.6).

that communicates with a critical isthmus. If pacing is performed
from a site in the circuit, the stimulus-QRS interval should be
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equal to the electrogram-QRS interval during VT. On the other
hand, if stimulation is performed from a bystander site, the stimulus-QRS interval is longer than the electrogram-QRS interval during tachycardia (S8.3.2.5, S8.3.2.6). A difference in stimulus-QRS
and electrogram-QRS up to 30 ms was superior to other criteria
for distinguishing bystander sites from critical sites in one study
(S8.3.2.7). The stimulus-QRS interval indicates the conduction
time from the pacing site to the VT exit site (S8.3.2.8). Similarly,
the stimulus-QRS/VT CL ratio is a reflection of the pacing site
location within the critical zone of the reentry circuit. The exit site
is defined as a stimulus-QRS/VT CL ratio <0.3, the common pathway and entry sites have a stimulus-QRS/VT CL ratio 0.3-0.7, and
the inner loop sites have a stimulus-QRS/VT CL ratio >0.7. There
is, however, an important exception to keep in mind: a longer
stimulus-QRS/VT CL ratio of >0.7 can occur at critical sites within
the reentry circuit. Discrete potentials located in electrical systole
rather than diastole that match with the stimulus-QRS interval are
present in these situations and reflect that the catheter is within
the VT entrance zone (S8.3.2.9).
3 The postpacing interval (PPI): The PPI is also an indication of the

8.3 | Entrainment mapping

proximity of the pacing site to the reentry circuit (S8.3.2.6); the PPI

8.3.1 | Entrainment mapping: overview

nonstimulated depolarization recorded at the pacing site. The PPI

Entrainment is a pacing maneuver that helps to distinguish reentrant

within the circuit or is in a bystander area. At a site with concealed

from nonreentrant arrhythmias and can be used as a mapping tool

entrainment, a PPI that matches the VT CL (±30 ms) is consistent

to target ablation to critical parts of the reentry circuit. Entrainment

with a site where delivery of RF energy is likely to terminate VT; a

involves the continuous resetting of a reentry circuit during pac-

PPI >30 ms is often an adjacent bystander (S8.3.2.1) when ablation

ing at sites that are either within or outside the reentry circuit. This

fails to terminate VT. The PPI includes the conduction time for a

measures the interval from the pacing stimulus to the following
can be used during entrainment to verify whether the pacing site is
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Entrainment responses from components of reentrant VT circuit. CL = cycle length; PPI = postpacing interval; VT = ventricular

F I G U R E 6 Pacing from the protected
isthmus of a VT circuit. Entrainment
mapping during VT. The VT CL is 620 ms,
and pacing is performed at a CL of
580 ms. A low-voltage electrogram is
located in diastole on the recordings of
the ablation catheter (Map). The stimulus-
QRS interval is 230 ms and matches
with the electrogram-QRS interval. The
postpacing interval (PPI) is equal to the VT
CL. The stimulus-QRS/VT CL ratio is 0.37,
indicating that the catheter is located in
the common pathway. CL = cycle length;
PPI = postpacing interval; VT = ventricular
tachycardia

full revolution of the propagating wavefront through the reentry

The measurement of the PPI assumes that the recorded electro-

circuit. Several factors can impact PPI accuracy. A faster pacing

gram indicates a depolarization at the pacing site. Electrograms

rate can result in slower conduction and a prolongation of the PPI.

generated by remote tissue represent far-field electrograms and
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can result in erroneous measurements of the PPI. Distinction of

The advantage of entrainment mapping over a substrate mapping ap-

local electrograms from far-field electrograms is hence key to ac-

proach is that individual VTs can be reliably and permanently elimi-

curately measuring the PPI (S8.3.2.10).

nated with few RF ablation lesions when reentry circuit targets are
identified (S8.3.2.7, S8.3.2.13). An approach targeting only VT exit

Both the PPI and the comparison of the stimulus-QRS interval

sites in the border zone based on QRS morphology and presystolic

to the electrogram intervals are methods to differentiate bystander

activity in VT, for example, can fail to eliminate VT if the exit site is

sites from critical ablation sites. The method using stimulus-QRS

deep to the endocardium. Entrainment mapping can potentially iden-

and electrogram-QRS interval assesses a smaller part of the reen-

tify critical components of the reentry circuit other than the exit site

try circuit (pacing site to exit site); thus, it could be less susceptible

that might be within the reach of the ablation catheter. Unfortunately,

to error than the PPI that assesses a full revolution of the reentry

most patients with heart disease have multiple VTs that are not he-

circuit.

modynamically tolerated; hence, entrainment mapping as the only

Entrainment mapping is most easily used to select ablation sites

mapping technique is insufficient to eliminate most of the VTs en-

during mapping of hemodynamically tolerated VTs and is particularly

countered in a given patient. In the modern era of VT ablation in the

useful in patients with incessant VTs (S8.3.2.4). Unfortunately, the

setting of complex VAs and multiple etiologies with different sub-

majority of inducible VTs in patients with SHD are not hemodynam-

strates, in which 3D mapping is routinely adopted, entrainment map-

ically tolerated, and entrainment mapping can only be used for short

ping is only one component of the ablation strategy. Ablation guided

time periods to confirm that a particular site is critical.

by entrainment and activation mapping of hemodynamically tolerated
VT has not been shown to be superior to substrate-based ablation

8.3.2 | How to perform entrainment mapping

(S8.3.2.14). Therefore, entrainment mapping is typically combined

Ideally, the VT is hemodynamically tolerated in order to perform entrain-

SHD.

with substrate mapping in patients with VT associated with scars and

ment mapping. Furthermore, the VT must have regular RR intervals to
prevent erroneous PPI measurements. Pacing is performed at a CL faster
than the VT, with care taken to ensure that all QRS complexes and electrograms are accelerated to the pacing rate. Pacing at faster rates can facilitate detection of QRS fusion; however, it can further slow conduction
in the circuit, resulting in termination of VT or resulting in acceleration
to a different VT. A pacing interval 10–50 ms shorter than the VT CL is
frequently used for pacing. Pacing can be performed either in a unipolar
manner from the tip electrode or in a bipolar manner from the two distal electrodes. Theoretically, the optimal pacing output is slightly above
threshold to limit capture to the tissue immediately beneath the distal
electrode, which is also the source of the near-field signal. Determining
threshold at each site is not practical, however, and some centers use
an initial output of 10 mA and a pulse width of 2 ms, which can increase
until capture is achieved or which can decrease if capture of a large area
is suspected (S8.3.2.11). Pacing for a sufficient duration to be certain
that reliable capture is achieved is important.
Limitations of entrainment mapping are as follows:
1 Inducibility of sustained and stable VT is required if pacing
maneuvers are to be attempted.
2 Pacing during VT can either interrupt, accelerate, or modify the
ongoing VT.
3 AADs can decrease conduction velocity during pacing, increasing
the postpacing and stimulus-QRS intervals (S8.3.2.5).
4 Electrograms indicating local depolarization need to be distinguished from far-field signals, and this is subject to error in regions of fractionated, complex electrograms (S8.3.2.1, S8.3.2.2,
S8.3.2.6, S8.3.2.12).
5 Incomplete ablation can create areas where conduction slows or
blocks during pacing, creating misleading, increased postpacing
and stimulus-QRS intervals.
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Within scar, the spatial resolution of pace mapping is heterogeneous and can indicate a region of interest that measures up to
18 cm2 (S8.4.13). Even in patients without SHD, a perfect pace map
can be observed at sites up to 2 cm away from the VT origin (S8.4.5,
S8.4.14). Most electrophysiologists of the writing committee perform pacing in a bipolar manner, starting with an output of 10 mA
at 2 ms pulse width. Limitations to bipolar pacing, including anodal
capture, and the limitations to pacing with a minimal fixed output,
including generation of a virtual electrode that captures more tissue with higher stimulus strength, need to be recognized (S8.4.15).
Pacing at stimulus strengths only slightly greater than threshold is
desirable to avoid capture over a large area, which can reduce accuracy; however, checking the threshold at each mapping point is time
consuming and might not be practical.
Smaller interelectrode spacing, smaller electrode size, and unipolar pacing could increase the accuracy of pace mapping (see

8.4 | Pace mapping
Pace mapping is a technique used to locate the origin of a PVC or
VT by stimulating the myocardium to reproduce the clinical 12-
lead morphology in the absence of VT; it is particularly useful if
the targeted arrhythmia is difficult to induce or is hemodynamically unstable. The optimal site should exactly match the tachycardia QRS, including individual notches as well as major deflections.
Comparison of the 12-lead ECG during pace mapping and VT is usually expressed with a scale from 0 to 12; however, computer-assisted
comparison allows its quantification (S8.4.1). Manufacturer-specific
algorithms (Labsystem Pro, Boston Scientific, Arden Hills, MN [formerly Bard]; PaSo CARTO module, Biosense Webster, Diamond
Bar, CA; Rhythmia, Boston Scientific, Marlborough, MA; and EnSite
Precision, Abbott Laboratories, Abbott Park, IL) exist that use
template-matching algorithms to generate a correlation coefficient
between VT morphology and pace maps (S8.4.2, S8.4.3). These algorithms allow computational comparisons between pace maps; however, careful external validation is currently lacking.
Pace mapping indicates the location of the origin of focal VAs
(S8.4.4), although activation sequence mapping is more accurate
(S8.4.5). Furthermore, pace mapping is used to identify the exit of
the VT in reentrant VTs (S8.4.6–S8.4.8). Critical sites of the reentry circuit and regions of slow conduction can be identified based
on pace mapping and electrogram characteristics (S8.4.9). Pacing in
noncritical areas adjacent to the exit can generate an adequate pace
match that is similar in morphology to a pace map from the VT exit.
On the other hand, pacing at sites close to the entrance of the reentry circuit during sinus rhythm often generates markedly different
QRS complexes, given the stimulated wavefront propagates away
from the pacing site via paths that are blocked during VT (S8.4.7,
S8.4.10, S8.4.11). Thus, sites without matching pace maps could still
be critical for the reentry circuit, and identification of a transition
from an adequate to a poor matching pace map might indicate the
isthmus orientation (S8.4.3). Importantly, the pacing rate has been
reported to alter the QRS morphology; therefore, a pacing rate close
to the VT rate should be used (S8.4.12).

Section 8.1) (S8.4.16).
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8.5 | Sinus rhythm substrate mapping
8.5.1 | Substrate mapping in sinus rhythm
Recommendations for substrate mapping in sinus rhythm
COR

LOE

Recommendations

References

I

B-NR

1. In patients with scar-related VT, substrate-guided ablation is useful for prevention of arrhythmia recurrences.

S8.5.2.1–S8.5.2.11

IIa

B-NR

2. High-density multielectrode mapping to obtain a more comprehensive characterization of the
arrhythmogenic tissue during catheter ablation of scar-related VT can be useful.

S8.5.2.12–S8.5.2.14

IIa

B-NR

3. In patients with no or minimal endocardial bipolar electrogram abnormalities, reduced unipolar
voltage can be useful for detection of epicardial or intramural scar.

S8.5.2.15–S8.5.2.19

Recommendation-specific supportive text
1 Substrate-guided mapping and ablation during sinus rhythm are
intended to overcome the limitations of conventional mapping
and ablation. They allow ablation of multiple VT morphologies
irrespective of inducibility or hemodynamic tolerance. Multiple
studies have shown that substrate-guided ablation is effective for prevention of arrhythmia recurrences in scar-related
unmappable VT (S8.5.2.1–S8.5.2.11).
2 Multielectrode mapping has been shown to increase mapping
density and to shorten mapping and RF delivery time (S8.5.2.12–
S8.5.2.14). Although in retrospective studies the use of multielectrode mapping has been associated with better outcome, no effect
on acute and long-term outcome has yet been prospectively demonstrated (S8.5.2.12, S8.5.2.14).
3 Bipolar electrograms have a limited field of view to detect epicardially or intramurally located scar. Unipolar voltage mapping can
be used to extend field of view of endocardial mapping, and low
unipolar voltages can indicate regions of epicardial or intramural
involvement in patients with no or minimal endocardial abnormalities evident on bipolar electrogram analysis; however, there is substantial overlap of unipolar low voltage between scar zones and
regions without scar (S8.5.2.15–S8.5.2.19).

8.5.2 | Summary
The majority of patients with SHD presenting for catheter ablation have hemodynamically unstable VTs that prevent accurate

delineation of the critical part of the reentrant circuit with activation or entrainment mapping (S8.5.2.20). Substrate mapping is an
approach to characterize areas likely to support reentry based on
electrophysiological characteristics that can be determined during
stable sinus or paced rhythm. It allows for elimination of VT, irrespective of inducibility or hemodynamic tolerance. Even for hemodynamically stable VTs, substrate mapping is often used to limit
activation mapping or entrainment to a region of interest (S8.5.2.7,
S8.5.2.10, S8.5.2.11).
The concept of substrate mapping has developed from the success of surgical subendocardial resection for postinfarction VT,
which has established the physical link between the VT circuit and
the infarction scar (S8.5.2.21). Current criteria to define the abnormal arrhythmogenic substrate rely on a combination of lower
bipolar or unipolar voltage and abnormal electrogram characteristics (eg, fragmented, split, and late electrograms). These abnormal
electrogram features can represent slow or delayed activation that
constitute surrogate markers for potential VT circuits (S8.5.2.22,
S8.5.2.23).

Voltage criteria for scar identification
Scar tissue can be identified based on bipolar electrogram amplitude. Using a 4-mm tip mapping catheter and 1-mm ring interelectrode spacing with a 2-mm ring filtered at 10-4 00 Hz, 95% of
normal LV endocardial electrograms have a peak-to-peak amplitude
>1.55 mV (S8.5.2.24). Conversely, bipolar voltage <0.5 mV has been
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designated as “dense scar,” but it is important to recognize that these

Importantly, the lines of block delimiting the channels responsible

regions can still contain viable myocytes (S8.5.2.25) that can be cap-

for arrhythmias can be both fixed and functional (S8.5.2.34), and the

tured by pacing. Use of cutoff values has important limitations as

participation of functional barriers in VT circuits challenges the iden-

shown by recent work integrating voltage mapping and full human

tification of potential VT circuits during substrate mapping. Abnormal

heart histology (S8.5.2.26). This is particularly relevant in patients

local electrograms can be hidden in far-field signals, preventing their

with NICM with patchy scar, in whom larger bundles of surviving

recognition during sinus rhythm or RV pacing. Identification of such

myocytes are mixed with fibrotic tissue. Bipolar voltage and elec-

electrograms might require pacing maneuvers to demonstrate their

trogram characteristics can be further affected by different elec-

poorly coupled nature (S8.5.2.35–S8.5.2.37). This could be relevant

trode size and/or interelectrode distance of the mapping catheter

in the presence of smaller, nontransmural scars, in which subepicardial

(S8.5.2.13), direction of activation wavefront (S8.5.2.27), and wall

viable myocardium can overlay the subendocardial scar, creating far-

thickness (S8.5.2.26).

field obscuration of the local signal (S8.5.2.38).

Bipolar voltage mapping can have a limited field of view to de-

Some abnormal electrograms can be disclosed only by catheters

tect epicardially or intramurally located scar, typically observed in

with small electrodes and shorter interelectrode distance, which

patients with NICM. Under these circumstances, unipolar voltage

allow for higher near-field resolution (S8.5.2.39) (see Section 8.1).

mapping can be used to extend the field of view of endocardial

Most of the studies concerning substrate mapping were per-

mapping (S8.5.2.15, S8.5.2.16, S8.5.2.19). Endocardial low uni-

formed on patients after MI, and significant differences exist with

polar voltages could indicate regions of epicardial or intramural

respect to the arrhythmogenic substrate characteristics between

involvement in patients with no or minimal endocardial abnormal-

patients with ICM and NICM (see Section 9).

ities evident on bipolar electrogram analysis. Although various

There is currently no standardized approach for substrate-guided

studies have reported different cutoff values to identify deeper

ablation. A number of substrate-based ablation approaches have been

scar tissue, validation studies with CMR-d efined scar have demon-

developed, with the main purpose of targeting and eliminating areas

strated that there is a substantial overlap of unipolar low voltage

of slow conduction within the abnormal substrate defined during

between scar zones and regions without scar. CMR-d efined scar

sinus rhythm (S8.5.2.24, S8.5.2.29, S8.5.2.30, S8.5.2.35, S8.5.2.40–

remains the gold standard for precise demarcation of scar and

S8.5.2.44) or evoked by pacing (S8.5.2.36–S8.5.2.38) (see Section 9.5).

is preferable over unipolar voltage mapping for defining scar.
Furthermore, cutoff values are impacted by electrode size, wall
thickness, surrounding anatomical structures, and ventricular hypertrophy, or are region specific (S8.5.2.16, S8.5.2.18, S8.5.2.26,
S8.5.2.28).

Other electrogram characteristics as ablation targets
Low-voltage areas in patients with SHD are often large, and not all
are related to VT. To limit the extent of ablation, several other electrogram features obtained during spontaneous rhythm or elicited
by pacing maneuvers have been studied to identify areas within the
scar potentially related to VT. In the seminal study of de Bakker et al
(S8.5.2.22), the authors have demonstrated the presence of inhomogeneous “zig-zag” conduction within the infarcted area, which was
related to the presence of poor cell-to-cell coupling of surviving myocyte bundles interspersed among fibrous tissue. In these regions,
abnormal fractioned and LPs were recorded. Although fragmented
electrograms can be typically recorded throughout the whole scar,
isolated and LPs have been demonstrated to be a more specific
marker of the VT circuit (S8.5.2.29–S8.5.2.33). However, clinical
studies have adopted heterogeneous definitions of abnormal electrograms, with nonuniform use of terms such as “fragmented,” “split,”
and “late,” and the relationship between these surrogate markers and
the VT circuits remains to be thoroughly explored (S8.5.2.34). In this
respect, LAVA has been proposed as a global term that incorporates
all abnormal ventricular signals that represent near-field signals from
poorly coupled fibers within scar, representing potential VT isthmus
sites (S8.5.2.35).

References
S8.5.2.1. 	Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter
ablation for the prevention of defibrillator therapy. N Engl J
Med. 2007; 357:2657–65.
S8.5.2.2. 	Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol.
2015;66:2872–82.
S8.5.2.3. 	Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease
using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators
Group. J Am Coll Cardiol. 2000;35:1905–14.
S8.5.2.4. 	Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping
for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–82.
S8.5.2.5. 	Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia
ablation versus escalation of antiarrhythmic drugs. N Engl J
Med. 2016; 375:111–21.
S8.5.2.6. 	Kuck K-H, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-
defibrillator interventions in patients with unstable ventricular
arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification
Study). Circ Arrhythm Electrophysiol. 2017;10:e004422.
S8.5.2.7. 	Volkmer M, Ouyang F, Deger F, et al. Substrate mapping vs.
tachycardia mapping using CARTO in patients with coronary
artery disease and ventricular tachycardia: impact on outcome of catheter ablation. Europace. 2006;8:968–76.
S8.5.2.8. 	Makimoto H, Nakajima I, Miyamoto K, et al. Clinical impact of
mapping strategies for treatment of ventricular tachycardias in

CRONIN et al.

patients with structural heart disease. Pacing Clin Electrophysiol.
2015;38:630–40.
S8.5.2.9. 	Carbucicchio C, Ahmad Raja N, Di Biase L, et al. High-density
substrateguided ventricular tachycardia ablation: role of activation mapping in an attempt to improve procedural effectiveness. Heart Rhythm. 2013; 10:1850–8.
S8.5.2.10. 	Briceño DF, Romero J, Villablanca PA, et al. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic
review and meta-analysis. Europace. 2018;20:104–15.
S8.5.2.11. 	Kumar S, Baldinger SH, Romero J, et al. Substrate-based ablation versus ablation guided by activation and entrainment
mapping for ventricular tachycardia: a systematic review and
meta-analysis. J Cardiovasc Electrophysiol. 2016;27:1437–47.
S8.5.2.12. 	Acosta J, Penela D, Andreu D, et al. Multielectrode vs. point-
by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace. 2018;20:512–9.
S8.5.2.13. 	Berte B, Relan J, Sacher F, et al. Impact of electrode type
on mapping of scar-related VT. J Cardiovasc Electrophysiol.
2015;26:1213–23.
S8.5.2.14. 	Yamashita S, Cochet H, Sacher F, et al. Impact of new technologies and approaches for post-myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circ
Arrhythm Electrophysiol. 2016; 9:e003901.
S8.5.2.15. 	Hutchinson MD, Gerstenfeld EP, Desjardins B, et al. Endocardial
unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular
cardiomyopathy. Circ Arrhythmia Electrophysiol. 2011;4:49–55.
S8.5.2.16. 	Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar
voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart
Rhythm. 2011;8:76–83.
S8.5.2.17. 	Chopra N, Tokuda M, Ng J, et al. Relation of the unipolar low-
voltage penumbra surrounding the endocardial low-
voltage
scar to ventricular tachycardia circuit sites and ablation outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol.
2014;25:602–8.
S8.5.2.18. 	
Soto-
Becerra R, Bazan V, Bautista W, et al. Ventricular
tachycardia in the setting of Chagasic cardiomyopathy. Circ
Arrhythm Electrophysiol. 2017;10:e004950.
S8.5.2.19. 	Desjardins B, Yokokawa M, Good E, et al. Characteristics of
intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ
Arrhythm Electrophysiol. 2013; 6:891–7.
S8.5.2.20. 	Stevenson WG, Friedman PL, Kocovic D, Sager PT, Saxon
LA, Pavri B. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation.
1998;98:308–14.
S8.5.2.21. 	
Miller JM, Kienzle MG, Harken AH, Josephson ME.
Subendocardial resection for ventricular tachycardia: predictors of surgical success. Circulation. 1984;70:624–31.
S8.5.2.22. 	de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation. 1993;88:915–26.
S8.5.2.23. 	
Callans DJ, Ren JF, Michele J, Marchlinski FE, Dillon SM.
Electroanatomic left ventricular mapping in the porcine
model of healed anterior myocardial infarction: correlation
with intracardiac echocardiography and pathological analysis.
Circulation. 1999;100:1744–50.
S8.5.2.24. 	Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia
in patients with ischemic and nonischemic cardiomyopathy.
Circulation. 2000;101:1288–96.
S8.5.2.25. 	
Soejima K, Stevenson WG, Maisel WH, Sapp JL, Epstein
LM. Electrically unexcitable scar mapping based on pacing

|

397

threshold for identification of the reentry circuit isthmus: feasibility for guiding ventricular tachycardia ablation. Circulation.
2002;106:1678–83.
S8.5.2.26. 	Glashan CA, Androulakis AFA, Tao Q, et al. Whole human
heart histology to validate electroanatomical voltage mapping in patients with nonischaemic cardiomyopathy and ventricular tachycardia. Eur Heart J. 2018;39:2867–75.
S8.5.2.27. 	Tung R, Josephson ME, Bradfield JS, Shivkumar K. Directional
influences of ventricular activation on myocardial scar characterization: voltage mapping with multiple wavefronts during
ventricular tachycardia ablation. Circ Arrhythm Electrophysiol.
2016;9:e004155.
S8.5.2.28. 	Santangeli P, Marchlinski FE. Substrate mapping for unstable
ventricular tachycardia. Heart Rhythm. 2016;13:569–83.
S8.5.2.29. 	Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an isolated, delayed component as treatment
of unmappable monomorphic ventricular tachycardias in
patients with structural heart disease. J Am Coll Cardiol.
2003;41:81–92.
S8.5.2.30. 	Bogun F, Good E, Reich S, et al. Isolated potentials during sinus
rhythm and pace-mapping within scars as guides for ablation
of post-
infarction ventricular tachycardia. J Am Coll Cardiol.
2006;47:2013–9.
S8.5.2.31. 	Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated
delayed component as an endpoint of catheter ablation in arrhythmogenic right ventricular cardiomyopathy: predictor for
long-term success. J Cardiovasc Electrophysiol. 2008;19:681–8.
S8.5.2.32. 	Vergara P, Trevisi N, Ricco A, et al. Late potentials abolition
as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation. J
Cardiovasc Electrophysiol. 2012;23:621–7.
S8.5.2.33. 	Mountantonakis SE, Park RE, Frankel DS, et al. Relationship between voltage map “channels” and the location of critical isthmus sites in patients with post-infarction cardiomyopathy and
ventricular tachycardia. J Am Coll Cardiol. 2013;61:2088–95.
S8.5.2.34. 	
Josephson ME, Anter E. Substrate mapping for ventricular tachycardia assumptions and misconceptions. JACC Clin
Electrophysiol. 2015;1:341–52.
S8.5.2.35. 	Jaïs P, Maury P, Khairy P, et al. Elimination of local abnormal
ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia.
Circulation. 2012;125:2184–96.
S8.5.2.36. 	Acosta J, Andreu D, Penela D, et al. Elucidation of hidden
slow conduction by double ventricular extrastimuli: a method
for further arrhythmic substrate identification in ventricular
tachycardia ablation procedures. Europace. 2018;20:337–46.
S8.5.2.37. 	Porta-Sánchez A, Jackson N, Lukac P, et al. Multicenter study
of ischemic ventricular tachycardia ablation with decrement-
evoked potential (DEEP) mapping with extra stimulus. JACC
Clin Electrophysiol. 2018;4:307–15.
S8.5.2.38. 	de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden
substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol. 2018;4:316–27.
S8.5.2.39. 	Nakahara S, Tung R, Ramirez RJ, et al. Distribution of late
potentials within infarct scars assessed by ultra high-density
mapping. Heart Rhythm. 2010;7:1817–24.
S8.5.2.40. 	Irie T, Yu R, Bradfield JS, et al. Relationship between sinus
rhythm late activation zones and critical sites for scar-related
ventricular tachycardia: systematic analysis of isochronal late
activation mapping. Circ Arrhythm Electrophysiol. 2015;8:390–9.
S8.5.2.41. 	
Berruezo A, Fernández-
Armenta J, Andreu D, et al. Scar
dechanneling: new method for scar-related left ventricular
tachycardia substrate ablation. Circ Arrhythm Electrophysiol.
2015;8:326–36.

398

|

CRONIN et al.

S8.5.2.42. 	Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy
for unmappable ventricular tachycardias—feasibility and clinical outcome. Europace. 2014; 16:1040–52.
S8.5.2.43. 	Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based

ventricular tachycardias. Circ Arrhythm Electrophysiol.
2015;8:353–61.
S8.5.2.44. 	Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial
homogenization of the scar versus limited substrate ablation
for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:132–41.

8.6 | Intraprocedural imaging: Intracardiac echocardiography, fluoroscopy, cardiac magnetic resonance imaging
8.6.1 | Intraprocedural imaging during catheter ablation of ventricular arrhythmias
Recommendations for intraprocedural imaging during catheter ablation of VAs
COR

LOE

Recommendations

References

I

B-NR

1. Coronary angiography or ICE is recommended to localize the ostia of the coronary
arteries prior to ablation within the SV.

S8.6.2.1–S8.6.2.4

I

B-NR

2. Coronary angiography is recommended to identify the course of the coronary arteries
when ablation is performed in the coronary venous system or in the epicardium.

S8.6.2.5–S8.6.2.8

I

B-NR

3. ICE is beneficial to identify and target the papillary muscles with ablation and to assess
for catheter stability.

S8.6.2.9–S8.6.2.20

I

B-NR

4. ICE or transthoracic echocardiography is useful to assess for pericardial effusion in case
of hemodynamic deterioration of the patient.

S8.6.2.21–S8.6.2.23

I

C-LD

5. ICE is useful for early recognition of complications, including pericardial effusion.

S8.6.2.21–S8.6.2.23

IIb

B-NR

6. ICE may be useful as an adjuvant technique to identify wall segments with wall thinning, wall motion abnormalities, and segments with increased echogenicity, and also to
identify intracardiac thrombi.

S8.6.2.24, S8.6.2.25

Recommendation-specific supportive text

8.6.2 | Summary

1 For the coronary ostia, a distance of ≥1 cm of the cathe-

For intraprocedural imaging during catheter ablation of VAs, several

ter tip from a coronary ostium is considered a safe distance

technologies have been used: fluoroscopy (including coronary angiog-

(S8.6.2.3), although ablations have been reported to be as

raphy), echocardiography (intracardiac, transthoracic, or transesoph-

close as 7.3 mm (S8.6.2.1) and 7.5 mm (S8.6.2.4) from the

ageal), and real-time CMR. Although no randomized studies have

coronary ostium, without resulting complications.

demonstrated the benefit of intraprocedural imaging, there are data

2 In the epicardial space, coronary angiography should be consid-

supporting the use of coronary angiography or ICE to enhance pro-

ered prior to ablation to ensure that there is no coronary artery

cedural safety for selected cases, allowing for real-time imaging while

in the proximity of the ablation catheter (S8.6.2.7, S8.6.2.8); a

mapping and ablation are performed (S8.6.2.1–S8.6.2.20).

minimal distance of >5 mm from the ablation catheter tip to an

Fluoroscopy is routinely used for catheter placement and cath-

epicardial coronary artery has been considered safe (S8.6.2.7).

eter manipulations during mapping and ablation procedures. With

3 No randomized studies have shown improved outcomes if ICE

the development and improvement of EAM systems, the need for

is used to target papillary muscle arrhythmias. Several case

fluoroscopy can be minimized (S8.6.2.28, S8.6.2.29).

series, however, have demonstrated that ICE is useful for tar-

Integration of fluoroscopic cine loops into electroanatom-

geting papillary muscle arrhythmias with real-time localization

ical maps has further helped to shorten fluoroscopy times

of the papillary muscle apparatus and the ablation catheter tip

(S8.6.2.30–S8.6.2.32).

(S8.6.2.9–S8.6.2.20). Catheter stability on the papillary mus-

With respect to the coronary arteries, the use of coronary angi-

cles or other parts of the myocardium can be assessed with ICE.

ography or ICE to localize the ostia of the coronary arteries has been

4 ICE further can help to identify complications such as pericardial

found useful when ablation is directed toward the SV (S8.6.2.1–

effusions, allowing for early intervention (S8.6.2.21–S8.6.2.23).

S8.6.2.3). Although data are limited, a minimal distance of ≥10 mm

It also can be used to assess intracardiac structures, including

from the coronary ostia has been considered to be safe for RF abla-

wall thickness, wall motion abnormalities, increased echogenic-

tion (S8.6.2.9). The coronary ostia can also be identified by ICE and

ity to identify scarring, and intracardiac thrombi (S8.6.2.24–

can be marked in the electroanatomical map. This could obviate the

S8.6.2.26). Furthermore, ICE is beneficial in monitoring catheter

need for coronary angiography. Coronary angiography is the preferred

contact during ablation for arrhythmias not related to papillary

technique to identify the course of the coronary arteries when abla-

muscles and could be useful to assess for tissue changes preced-

tion is performed in the coronary venous system or the epicardium. A

ing steam pops (S8.6.2.27).

distance of >5 mm of the ablation catheter to an epicardial coronary
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artery is considered safe (S8.6.2.3). A coronary angiogram is often repeated at the conclusion of the procedure to document patency of the
coronary arteries.
ICE is beneficial to identify and target VAs originating from the
papillary muscles (S8.6.2.10–S8.6.2.21). No randomized studies, however, have shown improved outcomes when ICE was used. Several
case series, however, have demonstrated that ICE is useful for targeting papillary muscle arrhythmias. The main benefit is the real-time
localization of the papillary muscle apparatus in conjunction with the
ablation catheter tip being visualized in the EAM system. Integration
of ICE images into the EAM system together with the mapping or
ablation catheter is particularly helpful (S8.6.2.16). ICE helps to define the level of the pulmonary valve when arrhythmias are targeted
in the RVOT or in the pulmonary artery. This is of importance when
ablation needs to be performed in the pulmonary artery, which can
be in close proximity to the coronary arteries. Furthermore, ICE can
be used as an adjuvant technique to identify scarring by identifying
wall segments with wall thinning, wall motion abnormalities, excessive trabeculations (S8.6.2.23), segments with increased echogenicity (S8.6.2.24, S8.6.2.26), and also to identify intracardiac thrombi
(S8.6.2.25). Furthermore, predictors for steam pops can be identified
with ICE (S8.6.2.27), which might help to prevent complications.
ICE further can help to identify complications such as pericardial effusions, allowing for early intervention (S8.6.2.21–S8.6.2.23).
Transthoracic echocardiography, as well as ICE, can be useful to
assess for pericardial effusion in case of intraprocedural hemodynamic deterioration of the patient (S8.6.2.33).
Real-time CMR can enable visualization of lesion formation. It
has the advantage of avoiding ionizing radiation and of imaging the
whole heart in real time, and it has been used to target typical atrial
flutter (S8.6.2.34, S8.6.2.35). However, real-time imaging during
VT ablation in humans has not yet been reported and has thus far
been limited to postablation image acquisition (S8.6.2.36). A laboratory with real-time CMR capabilities requires a major financial investment, adaptation, and commitment to a work flow that is very
different from that of a standard electrophysiology laboratory. At
this time, real-time CMR is used only in a few centers on an investigational basis. Other investigational imaging techniques include
the use of endoscopy in the epicardial space for visualization of
catheters, epicardial structures, and ablation lesions (S8.6.2.37).
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8.7 | Electroanatomical mapping systems and robotic navigation
Recommendations for the use of EAM systems and remote navigation in ablation procedures for VAs
COR

LOE

Recommendations

References

I

B-NR

1. In patients with VA due to SHD undergoing an ablation procedure, EAM is useful.

S8.7.1–S8.7.9

IIa

B-NR

2. In patients with idiopathic VA undergoing an ablation procedure, EAM can be useful.

S8.7.4, S8.7.6

IIa

B-NR

3. In patients undergoing an ablation procedure for VA, magnetic catheter navigation can be
useful to reduce fluoroscopy use.

S8.7.10–S8.7.14

Recommendation-specific supportive text

EnSite NavX, St. Jude Medical, St. Paul, MN) uses voltage and imped-

EAM systems combine cardiac electrical information obtained from
catheter-mounted electrodes and 3D spatial location information
to reconstruct an image that represents the targeted cardiac chamber (S8.7.15). Several EAM systems are commonly used in clinical
practice. The CARTO mapping system (current version CARTO 3,
Biosense-Webster, Diamond Bar, CA) makes use of magnetic field
differences for accurate localization of proprietary mapping and
ablation catheters. This system also uses an impedance-based algorithm to visualize the electrodes and shafts of various diagnostic
catheters. A proprietary intracardiac ultrasound cathe

ter can in-

terface with the mapping system to further define cardiac geometry within the mapping field (S8.7.1). The EnSite Precision system
(Abbott Laboratories, Abbott Park, IL; formerly EnSite Velocity and

ance measurements to localize diagnostic and ablation catheters.
With the use of proprietary catheters, the EnSite Precision system
can now also provide magnetic-based navigation. The Rhythmia HDx
mapping system (Boston Scientific, Marlborough, MA) uses both
magnetic-and impedance-based methods for catheter tracking. A
prominent feature of this system is the proprietary 64-pole mini
basket catheter with closely spaced electrodes. The Topera mapping
system (Abbott Laboratories, Abbott Park, IL) combines unipolar
electrogram data from an intracavitary basket catheter with proprietary electrogram analysis software algorithms to identify focal
and rotational activity during cardiac fibrillation. Though it is marketed for atrial mapping, it has been used in cases of idiopathic VF
(S8.7.16). Access to EAM systems worldwide is limited, largely due
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to the high cost of systems, necessary peripherals, and proprietary
catheters.
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Catheter-based ablation of VA requires significant demands on the
skill and experience of the operator. The concept of remote or robotic

Regardless of the type of EAM available, knowledge of the first

catheter navigation is appealing to reduce the physical demands of

principles of cardiac electrophysiology remains essential to create

the procedure while developing more advanced abilities to achieve

maps that accurately represent the physiology and anatomy. Maps

stable and precise catheter location than traditional catheters can

created using EAM systems are subject to considerable variability

afford. Several technologies have been developed to achieve these

depending on a number of factors, including (but not limited to)

goals. The Niobe magnetic navigation system (Stereotaxis, St. Louis,

accurate annotation of electrogram qualities, consistent catheter

MO) remotely controls the tip of a proprietary ablation catheter using

contact with tissue, distributed sampling of the entire structure

changes in magnetic field direction from large rotating earth magnets

of interest, density of location “points” in the map, type of rhythm

(S8.7.27). This system can be combined with robotic catheter manipu-

being mapped, direction of activation wavefront propagation, and

lation components (Vdrive system) to control various diagnostic cathe-

the size and spacing of the electrodes used to acquire the data.

ters remotely as well. Previous technologies include a second magnetic

Numerous technologies have been developed or are in development

navigation system, the Catheter Guidance Control and Imaging system

to improve mapping quality and user experience. These include au-

(Magnetecs, Inglewood, CA), which used 8 electromagnets to guide a

tomated chamber segmentation, imported scar delineation from

proprietary magnetically tipped catheter. The Sensei robotic system

alternative cardiac imaging, such as CMR, CT, and echocardiogra-

(Hansen Medical, Mountain View, CA) robotically steered a deflectable

phy, and automated electrogram analysis tools. Ultra high-density

sheath. A stand-alone robotic catheter manipulation system (Amigo,

mapping catheters have significantly changed the resolution of scar

Catheter Precision, Ledgewood, NJ), interacted with a wide range of

features and, as a result, our understanding of VT circuit physiology.

diagnostic and ablation catheter handles via a handheld remote con-

EAM has proven to be a versatile technology to guide treatment

trol. Use of such technologies is a matter of operator preference: the

of a wide range of arrhythmias. Prospective randomized trials with

potential advantages are offset by additional costs for the navigation

and without EAM in patients with SVT demonstrate similar acute

systems, disposables, and maintenance contracts.

procedural success rates and substantial reduction in fluoroscopy

For patients undergoing ablation for VA, the use of an approved

use (S8.7.2, S8.7.3). No such randomized trials with and without

magnetic navigation system can be useful to reduce fluoroscopy ex-

EAM exist for VAs, and no prospective trial has demonstrated su-

posure. One small prospective randomized trial comparing magnetic

perior outcomes with the use of EAM. It is generally accepted that

navigation to manual ablation demonstrated reduced use of fluoros-

the use of EAM can reduce fluoroscopy time and allow for more pre-

copy without clear differences in procedure outcome (S8.7.13). A

cise mapping, with comparative analyses of nearby locations during

retrospective case series supported similar conclusions, with a low

VA ablation procedures. Particularly for more complex strategies of

rate for procedural complication (S8.7.28). A multicenter, single-arm

mapping ventricular scar, EAM enables the user to perform the nec-

study using remote navigation for patients with ischemic VT has

essary mapping to achieve a successful result, which would other-

demonstrated favorable procedural outcomes of VT noninducibility

wise be impossible without EAM (S8.7.4).

and longer-term VT freedom rates that are comparable to published

In patients with SHD undergoing catheter ablation for VA, EAM

results for manual catheter ablation (S8.7.29). Several retrospective

is particularly helpful. EAM is especially versatile in this setting, of-

comparison studies and single-arm series in patients with SHD con-

fering the operator the possibility of using various mapping strat-

sistently support reduced fluoroscopy times during the procedure

egies, including activation maps, entrainment maps, pace maps,

and low rates of procedural complication (S8.7.14, S8.7.30–S8.7.36).

electrogram amplitude (voltage) maps, and tagging location of spe-

None of the remote navigation systems are specifically indicated to

cific electrograms of interest. A prospective multicenter trial for VA

facilitate the catheter ablation procedure for VAs, though a prospec-

ablation in patients with IHD has used EAM (S8.7.6). Several retro-

tive clinical trial using the Niobe remote magnetic navigation system

spective reports have used EAM for a wide range of SHDs and loca-

is underway (S8.7.37).

tions within the heart (S8.7.7, S8.7.8, S8.7.17–S8.7.25).
In patients with idiopathic VA undergoing catheter ablation, EAM
can be useful. It is technically feasible to perform successful ablation
for idiopathic VA without EAM, using 12-lead ECG, fluoroscopy, and
careful analysis of intracardiac electrograms. Common examples include ablation of BBRVT and idiopathic VT originating from RVOT
or LV fascicular system locations. For most centers, when EAM is
available, it has become a mainstay in the procedure workflow for
VA ablation procedures. EAM systems allow activation mapping of
idiopathic VA to support catheter ablation in the RV, LV, aortic sinuses, and coronary venous system (S8.7.4, S8.7.5, S8.7.26). Reasons
to not choose EAM for ablation of idiopathic VA include increased
cost and limited access.
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2017;48:237–45.
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9.1.2 | Unipolar radiofrequency catheter ablation
Unipolar RF energy has been the mainstay of catheter ablation technologies since the early 1990s. This technology was refined with the
addition of temperature sensing and larger tip catheters and further
with catheter tip cooling. Lesion depth is limited by the amount of
power that can be safely delivered: too much power will result in
overheating at the tip-tissue interface and consequent protein denaturation with thrombus formation (S9.1.9.6, S9.1.9.7). Irrigation of
the ablation electrode reduces temperature at this interface and allows greater power delivery and thus the creation of larger lesions
(S9.1.9.8–S9.1.9.10). Several catheter tip designs and irrigation rates
have been made available, each of which generates similar myocardial lesion depth and volume (S9.1.9.11). Some degree of surface
sparing is observed with irrigation, more so at higher flow rates and

9 | M A PPI N G A N D A B L ATI O N

with tip designs that direct more irrigant at the surface (S9.1.9.11,

9.1 | Ablation power sources and techniques

deep tissue overheating and steam pops (S9.1.9.9). Catheter tip de-

S9.1.9.12). Power delivery, however, remains limited by the risk of
signs with greater irrigant dispersion might permit lower irrigation
flow rates and less volume load for patients with reduced ventricular
function. Ablation lesion size increases with the duration of current

Key Points

application (S9.1.9.13), and although short duration applications are

• An impedance drop ≥10 Ω or a contact force ≥10 g is

sufficient for ablation in thin structures, 60-90 seconds or longer

commonly used as a target for RF energy delivery.
• The use of half normal saline generates larger ablation
lesions but can result in steam pops.
• Simultaneous bipolar or unipolar ablation can result in
larger ablation lesions.
• Cryoablation can be beneficial for achieving more stable
contact on the papillary muscles.

applications are usually employed for VT. The optimal duration has
not yet been defined.
Steam pops can occur when excessive heating of myocardial tissue occurs and can occasionally result in harmful tissue disruption
(S9.1.9.14). However, the methods for avoiding steam pops are limited. Catheter tip irrigation partially attenuates the correlation between tip temperature and tissue temperature. Steam pops can still

• Ethanol ablation can generate lesions in areas where the

occur when tip temperatures rise excessively, although higher flow

arrhythmogenic substrate cannot be otherwise reached,

catheters with more irrigation ports could reduce the incidence of

provided that suitable target vessels are present.

steam pops (S9.1.9.15). Monitoring the impedance could be useful

• Stereotactic radiotherapy is an emerging alternative to

in preventing steam pops, most of which occur when the impedance

ablation, requiring identification of a region of interest

decreases more than 18 ohms from baseline or when greater power

that can be targeted prior to the radiation treatment.

is delivered for longer durations (S9.1.9.16). A typical initial power
setting for ablation with an open irrigated catheter in the LV is 30
watts and can be adjusted up to 50 watts to achieve an impedance

9.1.1 | Introduction
Successful ablation requires the creation of durable lesions of
adequate size (S9.1.9.1). When successful ablation cannot be

drop of 10 Ω.

9.1.3 | Contact force sensing

achieved from the endocardium, percutaneous access of the peri-

Lesion size is critically dependent on the contact of the ablating elec-

cardial space (discussed in Section 6.3) that permits contact map-

trode with the tissue (S9.1.9.17). Catheters with contact force sen-

ping and ablation of the arrhythmogenic substrate, which is close

sors have become common and can help to ensure lesion creation

to the epicardial surface, can be effective but is limited when

at intended sites (S9.1.9.18). Although a clear improvement in clini-

there are pericardial adhesions, overlying fat (S9.1.9.2), or criti-

cal outcomes for catheter ablation for VA is difficult to demonstrate

cal structures nearby (S9.1.9.3, S9.1.9.4), or when the substrate

(S9.1.9.19), RF applications with a mean contact force >10 g are more

is located deeper within the myocardium (S9.1.9.5). Innovative

likely to result in electrical unexcitability in scar areas (S9.1.9.20), and

techniques intended to reach deeper arrhythmogenic substrates

contact force sensing has become an integral part of RF catheter

have been developed.

ablation (S9.1.9.21).
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9.1.4 | Hypotonic external irrigation

9.1.6 | Needle ablation

Most ablation catheter tips are 3.5–4 mm in length and are typically

Infusion needle ablation has been reported as a means to achieve

irrigated with 0.9% sodium chloride solution. The efficiency of deliv-

intramural ablation lesions. A catheter with an extendable/retract-

ering current to myocardial tissue can be increased by using smaller

able needle at the tip can function as an intramural electrode for

electrode tip sizes (S9.1.9.22) and less conductive irrigant, such as

the temperature-controlled delivery of RF energy (S9.1.9.32), which

0.45% sodium chloride (S9.1.9.23, S9.1.9.24). These techniques de-

can create large, deep lesions during saline irrigation (S9.1.9.33,

liver greater current to myocardial tissue for any given applied power

S9.1.9.34). This approach has been demonstrated to be effective

but remain limited by the potential for tissue steam pops. The ef-

for select patients with treatment-
refractory VA in small series

fectiveness and safety of using a higher impedance irrigant has been

(S9.1.9.35). The efficacy and procedural risks of this technique have

supported by a multicenter, prospective, observational human study;

not been fully characterized. Investigational systems are under eval-

however, direct clinical comparisons are still pending (S9.1.9.25). The

uation (S9.1.9.36).

use of hypotonic saline irrigant can have the additional advantage
of a reduced salt load for patients with compromised ventricular
function.

9.1.7 | Cryoablation
Catheter cryoablation has been infrequently employed for treating VA.

9.1.5 | Simultaneous unipolar or simultaneous
bipolar radiofrequency delivery

Compared with RF ablation, focal cryoablation lesions are smaller and
take longer to develop. Larger lesions can be created with larger tip
cryoablation catheters (S9.1.9.37), but the clinical effectiveness and

Conventional unipolar RF catheter ablation delivers current be-

recurrence rates are less favorable than those achieved with RF ab-

tween the catheter tip and a dispersive skin electrode. Two

lation (S9.1.9.38, S9.1.9.39), likely because of the smaller lesion size.

catheters placed on either side of the target tissue, delivering si-

Cryoablation catheters become adherent to the tissue during lesion

multaneous unipolar RF energy (using two RF generators), have

creation, which enhances catheter stability and can provide additional

been employed to reach deeper myocardial substrates, which

utility in the catheter ablation for VA arising from highly mobile papil-

could create larger lesions than sequential ablations at each of

lary muscles, which can be difficult to ablate using RF ablation cath-

these sites by raising the temperature of tissue deep to either abla-

eters (S9.1.9.40). Although surgical cryoablation for VA has been used

tion site, limiting its heat sink effect, and increasing the conduc-

for decades (S9.1.9.41, S9.1.9.42), currently available technology will

tive heating zone (S9.1.9.26). This method provides independent

likely be limited to specialized circumstances unless further innova-

control and monitoring of RF delivery from each ablating catheter

tion enables larger cryoablation lesion delivery from catheter platforms

but can pose technical challenges with device interactions. The

(S9.1.9.43).

efficacy and risks of this procedure have not been completely
characterized.
Bipolar ablation is performed by replacing the dispersive skin

9.1.8 | Transvascular ethanol ablation

electrode with a second catheter that is closely apposed to tissue

Creating an arterial occlusion and controlled infarction has long

with culprit substrate between the catheters. This technique con-

been used to create ventricular ablation lesions (S9.1.9.44). Early

centrates current density between the catheters. Lesion creation

experiences had moderate success but with a higher risk of

extends from both catheters, and lesions are larger and more likely

complications (S9.1.9.45). The refinement of mapping strategies

to be confluent than those achieved with sequential unipolar en-

and percutaneous coronary interventional technology encour-

ergy delivery (S9.1.9.27). The efficacy of this technique has been

aged further development, and several series have reported on

demonstrated in both preclinical models (S9.1.9.28, S9.1.9.29) and

treatment-
refractory patients who underwent transcoronary

in humans (S9.1.9.30, S9.1.9.31). Bipolar ablation can be delivered

ethanol ablation (S9.1.9.46, S9.1.9.47). Larger series have demon-

between catheters that are positioned across the interventricular

strated that this technique's efficacy can be limited by the avail-

septum from one another, on either side of a papillary muscle, or with

ability of suitable target vessels, its procedural risk, and the risk

catheters in the endocardial and epicardial spaces. Bipolar ablation is

of collateral injury (S9.1.9.2). Heart block is a frequent risk when a

limited by the requirement for custom cabling and the technical chal-

septal substrate is targeted (S9.1.9.48).

lenges of visualizing and placing two catheters sufficiently close with

Although experience is limited, ventricular ablation can be per-

target tissue between them. The catheter tip temperature cannot be

formed by injecting alcohol in a retrograde manner into the coronary

monitored simultaneously for both catheters, and impedance will be

venous system, which can lead to a lower risk than in the coronary

influenced by both tip-tissue interfaces. Optimal power and current

arterial system. Reports from small series have been promising, al-

settings have not yet been defined, and the risk of coagulation has

though collateral myocardial injury and recurrence are still a con-

not yet been fully characterized. An investigational system is under

cern (S9.1.9.49–S9.1.9.51). Further study could help to refine the

evaluation.

technique.

CRONIN et al.

9.1.9 | Stereotactic radiotherapy
The use of stereotactic motion-gated external beam radiation for ablation has been explored in animal models (S9.1.9.52), and its feasibility
has been demonstrated in humans (S9.1.9.53–S9.1.9.56). Tissue injury
is likely the result of a combination of cell nuclear damage and vascular damage, the results of which can manifest within days or weeks
(S9.1.9.53). This method requires the accurate preprocedure identification of the culprit arrhythmogenic substrate, using either intracardiac
mapping, imaging, or noninvasive ECGI (S9.1.9.53). Limiting the radiation
to the target is complicated by cardiac and respiratory motion. Further
study is required to quantify the risk of injury to nontarget myocardial
and adjacent structures and to further define the methods and efficacy.
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9.2 | Idiopathic outflow tract ventricular arrhythmia

Key Points
• The RVOT, pulmonary arteries, SVs, LV epicardium and endocardium contain most of the OT arrhythmias.
• Activation mapping and pace mapping can be used to guide
ablation in the RVOT.
• Imaging of coronary artery ostia is essential before ablation
in the aortic SVs.
• The LV summit is a challenging SOO, often requiring mapping and/or ablation from the RVOT, LVOT, SVs, coronary
venous system, and sometimes the epicardial space.
• Deep intraseptal VA origins can be challenging to reach.
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9.2.1 | Introduction
Approximately two-thirds of idiopathic VAs originate from the ven-
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CS provides useful information prior to left heart catheterization.
Mapping can then include the AIV and its septal branches followed
by the SV and endocardial LVOT.

tricular OTs, accounting for 10% of all patients referred for VA ablation (S9.2.7.1). OT VAs comprise a wide spectrum of VAs, ranging
from premature ventricular beats to sustained monomorphic VT.
Approximately three-quarters originate from the RVOT, with the

9.2.3 | Right ventricular outflow tract and
pulmonary artery

remaining from the LVOT and adjacent structures, including the

VAs ablated at the RVOT typically display LBBB morphology

pulmonary artery, the area surrounding the His bundle, the aor-

and transition at or >V3, without broad initial r waves in the right

tic SVs, the epicardium and GCV region, LV summit, AMC, and the

precordial leads. Most VAs arise from the septal anterior aspect of

superior mitral and tricuspid valve annuli (S9.2.7.1–S9.2.7.11). OT

the RVOT. ECG algorithms can help to suggest the specific region

VAs usually exhibit either an RBBB or LBBB morphology with an

(S9.2.7.18) and identify those with this morphology that can arise

inferior axis. OTs and adjacent areas have a broad and complex 3D

outside the RVOT or in the pulmonary artery (S9.2.7.17, S9.2.7.19,

anatomical structure, accounting for some of the unique challenges

S9.2.7.20). Given that the posterior RVOT abuts the RSV, mapping

in arrhythmia localization and ablation (S9.2.7.2, S9.2.7.4–S9.2.7.6).

of this structure is useful when ablation in the RVOT fails (S9.2.7.5).

Most idiopathic OT VAs have a focal origin and are thought to

Some RVOT VAs originate from a conus papillary muscle that can be

be due to adenosine-sensitive, cAMP-mediated triggered activity
(S9.2.7.12, S9.2.7.13).

identified by ICE (S9.2.7.21).
Myocardial fibers extend along the pulmonary artery and can
give rise to VAs that can be ablated from within the pulmonary ar-

9.2.2 | General approach

tery. ECG and electrophysiological characteristics of pulmonary

The success of ablation depends largely on the presence of VA

nary artery should be considered while performing catheter ablation

at the time of the procedure. All AADs should be discontinued

at the RVOT. ICE or angiography is required to know with certainty

for at least 5 half-lives before the procedure. Sedation with long-

whether the catheter is above or below the valve.

artery VAs are not well delineated (S9.2.7.3). Mapping at the pulmo-

acting sedatives can decrease spontaneous or inducible VA and

Acute procedural success is in the range of 90% (S9.2.7.14,

should be avoided if possible. If spontaneous VA is absent, limited

S9.2.7.22, S9.2.7.23), with more than 80% free of recurrent VA

physical activities, including hand grip and leg-rising exercises,

during follow-up. Serious complications occur in approximately 1%

programmed stimulation, burst pacing, and the administration of

of patients and are usually related to cardiac perforation (S9.2.7.14).

isoproterenol, epinephrine, or phenylephrine, can be helpful in

The left main coronary artery is directly posterior to the distal RVOT

eliciting the arrhythmia (Section 7).

and is at risk of injury when ablating in the distal posterior RVOT

Ablation is based on activation mapping and pace mapping

(S9.2.7.24) or the pulmonary artery. The left anterior descending ar-

(S9.2.7.4, S9.2.7.14), the latter of which is helpful when the VA is in-

tery can be damaged when ablation is performed at the insertion of

frequent. Activation mapping is, however, more accurate (S9.2.7.15),

the anterior free wall to the septum of the RVOT, especially when

given a similar paced QRS morphology can be observed over a rela-

high power (>30 W) is used for ablation.

tively large area (S9.2.7.14) and can be misleading in the SV (S9.2.7.14,
S9.2.7.16).
The most frequent SOO remains the RVOT (S9.2.7.1), but failure

9.2.4 | Aortic sinuses of valsalva

of catheter ablation at the earliest RVOT site should raise concerns

The aortic root lies posterior and rightward of the RVOT and is com-

that the RVOT breakthrough is not sufficiently close to the focus,

prised of the SVs and commissures. Both the RSV and the anterior

warranting further mapping, including adjacent structures. A step-

part of the LSV are connected to the adjacent LVOT, while both the

wise approach to the detailed and careful mapping of the region of

posterior LSV and the NCSV are in fibrous continuity with the mitral

interest, avoiding futile ablation at inappropriate sites, shortens the

annulus at the AMC (S9.2.7.5, S9.2.7.6, S9.2.7.25). Although this is

procedure and enhances success (S9.2.7.4, S9.2.7.17).

a fibrous structure, rare VAs can arise from this region. Myocardial

Detailed knowledge of OT anatomy is required, and the use of

sleeves can cross the aortic valve plane and extend a few millimeters

fluoroscopy alone is often sufficient for guiding catheter position.

above the basal valvular attachment, most commonly adjacent to the

However, preprocedure CT or CMR can help to exclude myocar-

RSV and sometimes at the LSV. Myocardial sleeves are rarely ob-

dial disease and define the anatomy that can be registered in the

served adjacent to the NCSV (S9.2.7.5, S9.2.7.6, S9.2.7.25).

mapping system. ICE can help to precisely determine the catheter

The ECG characteristics of VAs from the SV vary, but relatively

location in relation to the valves and the adjacent coronary arter-

common features that are not usually encountered in RVOT VAs

ies at risk of injury from ablation in the SV or pulmonary artery.

include a QRS transition <V3, prominent tall or broad R waves in

For VA with LBBB morphology, mapping should start at the

V1 or V2 (S9.2.7.4, S9.2.7.8, S9.2.7.25–S9.2.7.28), qrS or notched

RVOT and pulmonary artery. When mapping indicates a focus out-

complexes in V1–V2 (S9.2.7.29, S9.2.7.30), and a large R wave in

side the RVOT and pulmonary artery, mapping of the GCV via the

lead I (S9.2.7.31). A single focus can result in VAs with different QRS
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morphologies (RBBB and LBBB), suggesting a fiber with multiple OT

of the coronary arteries and overlying epicardial fat (S9.2.7.38). One

connections (S9.2.7.32).

group has reported success in mapping and identifying origins of VA

Initial mapping should include the LVOT and SVs (S9.2.7.33).

from the summit region within communicating veins between the

ICE is useful for confirming the catheter position and the relation

aortic cusp and the pulmonary artery in half of the patients allowing

to adjacent structures. Local electrograms are helpful indications of

for anatomic targeting of these VAs (S9.2.7.39). Ablation in the ad-

catheter location: in NCSV, the atrial electrograms are larger than

jacent endocardium is occasionally successful even when activation

the ventricular electrogram, whereas the ventricular electrogram is

is later than 10 ms prior to the QRS onset at that site (S9.2.7.40–

larger in the other SVs, particularly in the RSV (S9.2.7.5, S9.2.7.25,

S9.2.7.42). VAs originating from the apical summit are rightward of

S9.2.7.34, S9.2.7.35). SV foci are typically characterized by a small

those in the basal part and tend to have a longer QRS duration, more

pre-
QRS fragmented electrogram that precedes a large far-
field

rightward axis, and more often an RBBB configuration compared

ventricular electrogram during the VA and follows the QRS and far-

with those from the basal part of the summit (S9.2.7.41). Ablation

field ventricular potential during sinus rhythm (S9.2.7.5, S9.2.7.25,

from within the GCV or epicardium can be successful for VAs arising

S9.2.7.30).

from the inferior part of the summit.

Prior to ablation, ICE imaging or coronary angiography is re-

Epicardial VAs often cluster at perivascular sites, with the major-

quired to ensure that the distance between the ablation catheter

ity at the junction of the GCV/AIV or at the proximal AIV (S9.2.7.26,

and the nearest coronary ostia exceeds 10 mm (S9.2.7.25, S9.2.7.26,

S9.2.7.28, S9.2.7.43, S9.2.7.44). ECG characteristics can be similar to

S9.2.7.36). Coronary angiography can be repeated after the ablation

those of VAs originating from the SVs. Mapping within the GCV/AIV

to confirm the absence of injury or spasm. Injury to the aortic valve

can be performed using standard RF catheters or small-diameter (2-

is theoretically possible. An RF power of 25-35 W and a duration of

Fr) multipolar electrode catheters (S9.2.7.26, S9.2.7.28). RF ablation

30-60 seconds for each RF energy application are commonly em-

in the coronary veins has a risk of perforation or injury to adjacent

ployed for irrigated or nonirrigated RF ablation catheters (S9.2.7.25).

coronary arteries, or, in some patients, injury to the left phrenic nerve.

The compact AV node and His bundle are potentially at risk

Some physicians perform ablation in the GCV only after failure of RF

during ablation from the NCSV or commissure between the NCSV

energy application at the adjacent LVOT endocardium and SV, even if

and RSV and can be identified by the presence of a His potential

activation at these sites occurs later. Coronary angiography prior to

(S9.2.7.6, S9.2.7.25). AV conduction should be monitored during

ablation in the vein is essential, and a distance of 5 mm from the adja-

ablation, which might necessitate the delivery of RF energy during

cent artery is recommended for ablation to be considered (S9.2.7.26,

sinus rhythm rather than during tachycardia, as well as gradually in-

S9.2.7.44). An irrigated catheter is needed due to the low flow in the

creasing power (S9.2.7.25).

vein, and the impedance cutoff is usually disabled given that imped-

Ablation for VAs at the aortic root is usually successful (S9.2.7.8,

ance in the vein might exceed the set parameters. Some physicians

S9.2.7.15, S9.2.7.35). In rare cases, earliest activation is identified at

limit the maximum power to 20 W, the maximum temperature to

a coronary artery ostium or even within the proximal coronary ar-

43°C, and the RF duration to 60 seconds (S9.2.7.26). Cryoablation has

tery, precluding ablation directly on the focus (S9.2.7.26, S9.2.7.35).

been considered when the target site is very close to the artery, but ar-

Potential complications include aortic valve injury, coronary artery

terial injury is also possible with cryoablation (S9.2.7.26, S9.2.7.42). To

injury and thromboemboli; with appropriate precautions, however,

avoid phrenic nerve injury, ablation should not be attempted if there is

these complications appear to be rare.

diaphragmatic capture while pacing at the site at 20 mA.
In some cases, VAs in the apical portion of the LV summit are

9.2.5 | Left ventricular outflow tract and left
ventricular summit

sufficiently leftward to be accessible from the pericardial space
(S9.2.7.26, S9.2.7.38, S9.2.7.41). Proximity to major coronary arteries and overlying epicardial fat can limit ablation (S9.2.7.38).

Endocardial left OT VAs can originate from the superior basal re-

When proximity to the epicardial coronary artery precludes

gions of the interventricular septum or the LV free wall, near the

catheter ablation, a direct surgical approach can be an option

aortic annulus, including the area adjacent to the His-bundle region

(S9.2.7.45–S9.2.7.47).

where ablation carries a risk of AV block. The QRS typically has an
LBBB inferior axis configuration, with R waves in V1, V2 and dominant R waves in these leads for those originating in the more leftward aspect of the LVOT near the AMC.

9.2.6 | Para-Hisian ventricular arrhythmias
The His bundle is located at the most proximal and rightward

The epicardial area bounded by the left anterior descending

part of the RVOT in the region of the perimembranous septum.

and circumflex coronary arteries has been termed the LV summit

VAs originating from this area often have distinctive ECG char-

(Figure 7) (S9.2.7.4). Ablation for VAs in this region can be challeng-

acteristics, including a QS in V1-V2, relatively narrow QRS, and

ing and less successful than other OT VAs. The GCV divides the LV

tall R waves in the lateral leads (S9.2.7.10). Ablation risks include

summit into two parts: the inferior part can be accessible to epicar-

damage to the His bundle or RBB and the possibility of complete

dial catheter ablation, while the superior one—the triangle of Brocq

AV block. When earliest activation is recorded near the His bun-

and Mouchet (S9.2.7.37)—is inaccessible due to the close proximity

dle, mapping at the RSV and NCSV should be performed, given
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that earlier activation can be identified at these sites (S9.2.7.34,
S9.2.7.35, S9.2.7.48). Ablation with careful monitoring of AV conduction can be successful. Cryoablation can be an option to avoid
AV block (S9.2.7.49).

9.2.7 | Deep intraseptal sites
Often, idiopathic OT VAs can arise from deep intraseptal sites and
share LBBB morphology with inferior axis (S9.2.7.50); however, no
specific ECG pattern has been described indicating an intramural origin. Identification of the SOO is often only possible in retrospect after
several structures (including the RVOT, LVOT, cusps, and coronary venous system) have been carefully mapped, and timing has been found
to be equally early in several anatomical structures without matching pace maps. Activation mapping from within a vascular perforator
branch within the interventricular septum can be helpful in identifying the SOO that can be targeted from an adjacent endocardial site
(S9.2.7.50). Temporary suppression of VAs by cold saline infused into
the distal coronary venous system and perforator veins can also suggest an intramural septal focus (S9.2.7.51). Body surface mapping and
multisite pacing have been found to help in indicating a deep septal
origin (S9.2.7.52, S9.2.7.53). Ablation is attempted by RF application
at the earliest endocardial breakthrough sites or as close as possible
to the site identified by intraseptal mapping. If this is ineffective, simultaneous unipolar (S9.2.7.54) or simultaneous bipolar RF ablation
(investigational) between two RF catheters positioned at both breakthrough sites (S9.2.7.26), or between RVOT and SV (S9.2.7.55), or RF
ablation directly within a septal perforator vein (S9.2.7.50) have been
reported. Intracoronary ethanol infusion (S9.2.7.4) and the use of an
investigation needle ablation catheter have been reported (S9.2.7.56).

F I G U R E 7 Anatomical boundaries of the LV summit, with the
inaccessible [1] and accessible [2] parts. Shown are the left anterior
descending artery (LAD), the circumflex artery (Cx), the great
cardiac vein (GCV), the anterior interventricular vein (AIV) and the
first and second diagonal branch of the LAD (D1, D2).
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9.3 | Idiopathic nonoutflow tract
ventricular arrhythmia

Key Points
• VAs originating from the papillary muscles can be challenging due to multiple morphologies of the VA and the difficulty in achieving and maintaining sufficient contact during
ablation.
• VAs originate in LV papillary muscles more often than in
RV papillary muscles; they more often originate from the
posteromedial than the anterolateral papillary muscle and
occur more often at the tip than at the base.
• Pace mapping is less accurate than in other focal VAs.
• ICE is particularly useful for assessing contact and stability.
• Cryoablation can also aid in catheter stability during lesion
delivery.

9.3.1 | Ventricular arrhythmias from the
tricuspid and mitral annuli
Arrhythmias arising from the mitral annulus occur in approximately
5% of patients presenting for ablation for idiopathic VAs and can
arise from anywhere around the mitral annulus, with a slight pre-
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morphology, positive polarity in leads I, V5, and V6, and a QS
or rS pattern in aVR. Compared with RVOT arrhythmias, lead I
has a taller R wave. A precordial R wave transition >V3 favors a
free wall location, and a QS pattern in V1 favors a septal location
(S9.3.1.5, S9.3.1.6).
Outcomes from ablation for VAs from the free wall of the tricuspid annulus are favorable, with success rates of approximately
90% (S9.3.1.5, S9.3.1.6). Ablation for VAs from the septal side of
the tricuspid annulus are more challenging due to difficult catheter contact, proximity to the conduction system, and a possible intramural origin for the arrhythmias (S9.3.1.6). Use of a deflectable
sheath can help to improve catheter contact, and exploration of
the LV or SV and the coronary venous system should be considered when ablation at the RV septum is unsuccessful (S9.3.1.7). The
risk of AV block should be considered, and careful mapping of the
conduction system prior to ablation at the septal tricuspid annulus
is warranted.
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dilection for the superior aspect (S9.3.1.1–S9.3.1.3). In the surface
ECG, VAs from the mitral annulus have an RBBB morphology, with
dominant R waves from V1 to V5, and can have an S wave in V6
(S9.3.1.2–S9.3.1.4). Successful ablation has been reported in 80%-

9.3.2 | Mapping and ablation of ventricular
arrhythmia from the papillary muscles

100% of cases (S9.3.1.1–S9.3.1.3). Some cases have an epicardial

Ablation of papillary muscle arrhythmias presents unique anatomical

origin and can be approached from the CS or GCV, in which case the

challenges that can result in long procedural, fluoroscopy, and RF times

use of coronary angiography to verify a sufficient distance from the

(S9.3.2.1). Idiopathic VAs from the papillary muscles comprise up to 5%

adjacent coronary arteries is warranted.

of patients presenting for PVC ablation (S9.3.2.1), typically have a focal

VAs from the tricuspid annulus are encountered in 8%–10%

origin consistent with triggered activity or abnormal automaticity as

(S9.3.1.5) of patients with idiopathic VA referred for abla-

the mechanism, and are more likely to be provoked by catecholamine

tion (S9.3.1.6). VAs from the tricuspid annulus have an LBBB

administration than by programmed stimulation (S9.3.2.2–S9.3.2.4).
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F I G U R E 8 Intraprocedural imaging during ablation of papillary muscle arrhythmias. A, Anatomical map of the left ventricle (CARTO,
Biosense Webster) showing contact of the ablation catheter (Abl) with the posteromedial papillary muscle (PMPAP). B, Intracardiac
echocardiogram showing real-time visualization of the ablation catheter during ablation on the anterolateral papillary muscle (ALPAP)

Postinfarction VAs from the papillary muscle can arise from an area of

originate in a deep intramural location, and the electrograms with

scar tissue and can have a reentrant mechanism (S9.3.2.5). Preprocedural

the earliest activation time can have a far-field appearance or be dif-

imaging including CMR is helpful for identifying areas of scar tissue or

ficult to define. In these patients, ablation at sites with a matching

fibrosis that are potential sources of arrhythmia.

pace map and prolonged S-QRS might be successful, although longer

Although most idiopathic PVCs from the papillary muscles are

and higher-powered RF application might be necessary (S9.3.2.16).

benign, they have the potential to cause cardiomyopathy (S9.3.2.6,

Defining the anatomy and maintaining consistent catheter con-

S9.3.2.7), and rarely they are triggers for VF (S9.3.2.8). Patients with

tact and stability during ablation delivery are significant challenges.

frequent papillary muscle arrhythmias are also more likely to have mi-

The use of ICE integrated with EAM systems can help to identify

tral valve prolapse (S9.3.2.7, S9.3.2.9). While the large majority of these

papillary muscle surfaces within the ventricle and provide real-time

patients have benign outcomes, sudden death can occasionally occur,

visualization of catheter contact on the papillary muscle during ab-

and this condition has been associated with the female sex, bileaflet

lation (Figure 8) (S9.3.2.4, S9.3.2.12, S9.3.2.17). Catheter instability

prolapse, complex VAs, inverted or biphasic T waves in the inferior ECG

often induces PVCs that complicate mapping. Steerable sheaths can

leads of sinus beats, and LGE-CMR, typically in the inferior LV (S9.3.2.10,

be useful when a transseptal approach is employed, although there

S9.3.2.11). Further studies on risk stratification are therefore needed.

is a lack of comparative data. Cryoablation has the advantage of

Papillary muscle arrhythmias can arise from either ventricle, but
the LV is the most common origin, with the posteromedial papillary

achieving stable contact with the papillary muscle during freezing
and can be effective; however, data are limited (S9.3.2.18).

muscle being the most frequent (S9.3.2.12). Papillary muscle ar-

Lower success rates and higher recurrence rates have been re-

rhythmias originate more frequently toward the tip of the muscle,

ported for the catheter ablation of papillary muscle arrhythmias,

in its distal third (S9.3.2.13). QRS morphology can suggest the origin,

compared with other idiopathic VAs, with one study citing a 60%

but variable papillary muscle anatomy and exit sites into the myo-

long-term success rate for ablation in patients with idiopathic papil-

cardium limit ECG accuracy. PVCs from the posteromedial papillary

lary muscle PVCs (S9.3.2.1). Although worsening mitral regurgitation

muscles have RBBB QRS morphology with a superior axis and a tran-

following ablation of the papillary muscles has been reported, this is

sition in leads V3-V5. PVCs from the anterolateral papillary muscles

a rare occurrence, and complications from ablation of papillary mus-

have RBBB QRS morphology, a rightward axis, and inferior leads,

cle arrhythmias are generally not significantly different from abla-

demonstrating an inferior or discordant axis (S9.3.2.4, S9.3.2.14). A

tion at other LV locations (S9.3.2.4, S9.3.2.19, S9.3.2.20).

small initial q wave in V1 is common. Papillary muscle PVCs have a
longer QRS duration compared with fascicular PVCs (153 ± 27 ms
vs 127 ± 25 ms, P < 0.05) (S9.3.2.14), and fascicular PVCs frequently
exhibit an rsR′ morphology in V1, which is more consistent with a
typical RBBB morphology.
Papillary muscle VAs in the same patient often exhibit variability
in QRS morphology, which can be due to variable exits from the same
origin (S9.3.2.15). Pacing can produce the same QRS over a relatively
large area on the papillary muscle, and ablation at a site with a pace
map identical to the VA might not eliminate the arrhythmia, leading
to ablation over larger areas (S9.3.2.15). In some patients, the VA can
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9.4 | Bundle branch reentrant ventricular
tachycardia and fascicular ventricular tachycardia

Key Points
• BBR can occur in a variety of patients in whom the conduction system can be affected, including patients with DCM,
valvular heart disease, MI, myotonic dystrophy, Brugada
syndrome, and ARVC, among others.
• Ablation of either the RBB or LBB eliminates BBRVT but
does not eliminate other arrhythmic substrates.
• A correct diagnosis of BBRVT is crucial and should employ
established criteria prior to ablation of either of the bundle
branches.
• Ablation of the AV node does not cure BBRVT.
• Ablation of either bundle branch does not cure interfascicular
VT.
• For posterior fascicular VTs, the P1 potential is targeted
during VT; if P1 cannot be identified or VT is not tolerated,
an anatomical approach can be used.
• Purkinje fibers can extend to the papillary muscles, and
these can be part of the VT circuit.
• For anterior fascicular VTs, the P1 potential is targeted with
ablation.
• Focal nonreentrant fascicular VT is infrequent and can
occur in patients with IHD; however, it cannot be induced
with programmed stimulation, and the target is the earliest
Purkinje potential during VT.

9.4.1 | Introduction
There are 4 distinct groups of Purkinje-related monomorphic VTs:
(a) BBR including interfascicular reentry VTs; (b) idiopathic fascicular
reentrant VT; (c) fascicular reentrant VT post infarction; and (d) focal
nonreentrant fascicular VT. The mechanism of focal nonreentrant
fascicular VT is abnormal automaticity from the distal Purkinje system, and the ablation target is the earliest Purkinje activation during
the VT. The other VTs are caused by macroreentry and usually occur
in specific locations with specific QRS morphologies.

9.4.2 | Bundle branch reentrant ventricular
tachycardia
Recognition
BBRVT is a unique, typically fast (200-3 00 bpm), monomorphic
tachycardia, which is usually associated with hemodynamic collapse, syncope, and/or cardiac arrest (S9.4.2.4.1). BBRVT is
caused by a macroreentry circuit involving the RBB and LBB, and
septal ventricular muscle (S9.4.2.4.1–S9.4.2.4.5). BBR is often associated with advanced heart disease and has been observed in
DCM (S9.4.2.4.3), coronary artery disease (S9.4.2.4.3), valvular
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Type A

Type B (Interfascicular
tachycardia)

Type C

ECG morphology

LBBB pattern

RBBB pattern

RBBB pattern

Anterograde limb

RBB

LAF or LPF

LBB

Retrograde limb

LBB

LPF or LAF

RBB

TA B L E 5 Types of bundle branch
reentrant tachycardia

Abbreviations: LAF, left anterior fascicle; LBB, left bundle branch; LBBB, left bundle branch block;
LPF, left posterior fascicle; RBB, right bundle branch; RBBB, right bundle branch block.

heart disease (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.7), muscular dys-

in patients undergoing PES and has been called a V3 phenomenon

trophy (S9.4.2.4.8–S9.4.2.4.10), CHD (S9.4.2.4.11), LV noncom-

(S9.4.2.4.2, S9.4.2.4.29).

paction (LVNC) (S9.4.2.4.12), ARVC (S9.4.2.4.13), and Brugada

In the electrophysiology laboratory, ventricular extrastimuli

syndrome (S9.4.2.4.14). BBRVT can also occur in association with

delivered with short–long–short coupling intervals (pacing train of

His-P urkinje system disease in the absence of SHD (S9.4.2.4.15–

400 ms with a delay of 600 or 800 ms before the short-coupled

S9.4.2.4.17). Although classically associated with DCM, BBRVT

premature coupling intervals are introduced) tend to cause unidirec-

can also occur in the setting of isolated, unexplained conduction

tional block in the bundle branches facilitating the initiation of BBR

system disease (S9.4.2.4.15, S9.4.2.4.18, S9.4.2.4.19). Recently, 6

(S9.4.2.4.30). Atrial pacing and/or isoproterenol might be required

cases of idiopathic BBRVT were identified in patients with nor-

(S9.4.2.4.18).

mal biventricular size and function. All patients were noted to
have His-P urkinje system disease, with prolonged HV at base-

Specific considerations

line (mean 69.2 ms), and underwent successful ablation targeting

Several criteria help in diagnosing BBRVT:

the RBB. Mutations were identified in 3 of the 6 patients: 2 in
the SCN5A gene and 1 in the LMNA gene (S9.4.2.4.19). Idiopathic
BBRVT can be a genetic conduction disease, manifested by
isolated conduction system disease and curable with catheter
ablation.

1 The typical 12-lead ECG morphology during tachycardia is LBBB
or RBBB.
2 A critical delay in His-Purkinje system conduction is needed to
initiate tachycardia.

The reported incidence of BBRVT is 3.5%, representing 6% of

3 Although AV dissociation can be present, there is usually per-

VTs in separate series and 20% in a series of patients with NICM

sistent 1:1 His-bundle or QRS activation, with the H-V interval

alone undergoing evaluation for ablation (S9.4.2.4.20–S9.4.2.4.22).

during the tachycardia equal to or longer than the H-V interval in

The incidence of BBRVT is likely underestimated.
BBRVT can have a typical LBBB (S9.4.2.4.23) or RBBB pattern,
depending on which bundle forms the anterograde limb (Table 5);

sinus rhythm (and no H-V dissociation) (S9.4.2.4.31).
4 Tachycardia stops and cannot be reinitiated if conduction in one
of the bundle branches is interrupted.

however, both morphologies can occur in the same patient

5 During BBR, the His-bundle, RBB, and LBB activation sequences

(S9.4.2.4.24). Tchou and Mehdirad (S9.4.2.4.25) described three

during an LBBB morphology tachycardia (or the His-bundle, LBB,

categories of BBRVT (Table 5). Type A and type C are the clas-

and RBB activation sequences during an RBBB morphology tach-

sic counterclockwise and clockwise BBRVT circuits, respectively.
Type B is reentry within the LBB fascicles (interfascicular reentry).
Counterclockwise BBR (type A) accounts for 98% of BBRVTs and

ycardia) remain stable.
6 If the CL fluctuates, then the H-H interval oscillations precede the
V-V interval oscillations. The H-V timing remains constant.

has a typical LBBB pattern with an R-wave transition between

7 Entrainment with constant fusion (manifest entrainment) is pre-

leads V4 and V5 (S9.4.2.4.26). Alternatively, activation can pro-

sent during pacing from the RV apex (S9.4.2.4.32). However, it

ceed in an anterograde manner via the LBB and then through the

results in a PPI within 30 ms of the tachycardia cycle (S9.4.2.4.33).

septum, with retrograde activation via the RBB, creating an RBBB

8 Entrainment with concealed fusion is present during atrial pacing

morphology (“clockwise” reentry, type C) (S9.4.2.4.20, S9.4.2.4.27).

faster than the tachycardia, provided that AV nodal conduction

Interfascicular reentry tachycardia often has an RBBB and left he-

allows 1:1 conduction.

miblock QRS pattern.
Patients with BBR generally have a prolonged PR interval, QRS

In type A and C BBRVTs, the onset of ventricular depolarization is

duration, and H-V interval. LBBB, or less commonly RBBB, on the

preceded by His-bundle, RBB, or LBB potentials with an appropriate

sinus rhythm ECG, is due to conduction slowing in the bundle rather

sequence of His-bundle>RBB>LBB activation. Spontaneous variations

than complete block.
Single BBR beats can occur in patients who have apparently
normal His-Purkinje conduction during sinus rhythm but who have

in V-V intervals are preceded by similar changes in H-H/RBB-RBB/
LBB-LBB intervals. Recording from both sides of the septum can help
to identify the BBR mechanism.

functional conduction impairment (S9.4.2.4.28). This condition is ob-

Interfascicular tachycardia is an uncommon type (S9.4.2.4.3,

served as a normal response to premature ventricular extrastimuli

S9.4.2.4.18, S9.4.2.4.34–S9.4.2.4.37) in which one of the fascicles
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serves as the anterograde limb while the other serves as the retro-

LBB would not be expected to terminate the tachycardia because

grade circuit. The distal link between fascicles occurs through the

the circuit is distal to this point. Catheter ablation of the LAF or LPF

ventricular myocardium. The LAF is usually the anterograde limb

will result in termination of the tachycardia (S9.4.2.4.35, S9.4.2.4.37,

and the LPF is the retrograde limb (S9.4.2.4.16, S9.4.2.4.37). BBRVT

S9.4.2.4.38). A change of electrical axis might be the only manifesta-

and interfascicular tachycardia can be present in the same patient

tion during sinus rhythm after fascicular ablation.

(S9.4.2.4.2, S9.4.2.4.34, S9.4.2.4.38). In contrast to BBR, the H-V
interval during interfascicular tachycardia is usually shorter by more

Outcomes and risks

than 40 ms than that recorded in sinus rhythm (S9.4.2.4.39). This

In the 2 largest reported series, acute success rates for BBRVT and

condition occurs because the upper turnaround point of the circuit

interfascicular reentry were 100% (S9.4.2.4.3, S9.4.2.4.51). After

(the LBB point) is relatively far from the His bundle activated in the

ablation, BBRVT recurrence is uncommon but has not been thor-

retrograde direction.

oughly assessed with follow-
up testing (S9.4.2.4.3, S9.4.2.4.37,

It is important to recognize BBRVT and interfascicular tachycar-

S9.4.2.4.51).

dia because they can be cured with catheter ablation. The differen-

The reported incidence of clinically significant conduction

tial diagnosis for BBR includes (a) VT due to myocardial reentry, (b)

system impairment requiring implantation of a permanent pace-

idiopathic left intrafascicular VT, (c) SVT with aberrant conduction,

maker varies from 0% to 30% (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.8,

and (d) atriofascicular reentry.

S9.4.2.4.29–S9.4.2.4.31, S9.4.2.4.39).

With myocardial reentry, the His potential usually does not

Despite the success of BBRVT ablation, patients with cardiomyopa-

precede the QRS complex, and variations in the H-H interval fol-

thy and heart failure continue to have a high mortality rate. Despite the

low changes in the V-V interval because there is retrograde passive

impressive success of ablation for BBRVT, progressive heart failure is a

activation of the His-Purkinje system. The PPI after entrainment of

common cause of death (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.20, S9.4.2.4.26,

tachycardia from the RV apex will usually be long, unless the myo-

S9.4.2.4.28, S9.4.2.4.38, S9.4.2.4.48, S9.4.2.4.49). Therefore, a CRT

cardial reentrant VT involves the apex (S9.4.2.4.3, S9.4.2.4.33).

defibrillator should be considered after ablation based on the status of

The possibilities of other Purkinje-
related VTs (S9.4.2.4.40),

the residual conduction system and the severity of the underlying SHD.

such as idiopathic fascicular VT (S9.4.2.4.41), fascicular VT post-MI

Furthermore, VT of myocardial origin can be induced in 36% to 60%

(S9.4.2.4.42–S9.4.2.4.44), automatic His-Purkinje VT, focal Purkinje

of patients after successful ablation for BBR (S9.4.2.4.26, S9.4.2.4.37).

VT (S9.4.2.4.45, S9.4.2.4.46), and AV node/His-
Purkinje reentry
(S9.4.2.4.47), should also be considered (see below).

Catheter ablation
Pharmacological antiarrhythmic therapy is usually ineffective; however, RF catheter ablation of a bundle branch can cure BBRVTs and
is currently regarded as first-line therapy (S9.4.2.4.3, S9.4.2.4.20,
S9.4.2.4.48). Given that significant underlying structural disease is
usually present, concomitant placement of an ICD should be strongly
considered.
The technique of choice is ablation of the RBB (S9.4.2.4.3,
S9.4.2.4.38, S9.4.2.4.49). BBRVT can be prevented by ablating the
right or left main bundle branch (S9.4.2.4.16, S9.4.2.4.25). Although
most patients demonstrate conduction system disease in the LBB,
the RBB is typically the target for ablation because of the technical
ease and desire to avoid complete LBBB. In patients with a complete LBBB pattern during sinus rhythm, anterograde ventricular
activation occurs solely via the RBB due to slow anterograde conduction over the LBB, potentially with retrograde LBB activation
due to transseptal concealed conduction (S9.4.2.4.16, S9.4.2.4.50).
Complete AV block can develop with RBB ablation, and the LBB may
be targeted in such patients (S9.4.2.4.16, S9.4.2.4.50).
Complete RBB or LBB develops with successful ablation, although QRS changes can be subtle in patients with preexisting conduction abnormalities. Elimination of retrograde V-H conduction has
been used as a marker of successful ablation.
In interfascicular reentry, RBB ablation will not cure the tachycardia because the RBB is a bystander. Similarly, ablation of the main
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Nogami (S9.4.4.3.4) and Talib et al (S9.4.4.3.5) subsequently reported
on upper septal fascicular tachycardia. According to the QRS morphology, verapamil-sensitive left fascicular reentrant VT can be divided
into 3 subgroups (S9.4.4.3.4): (a) left posterior fascicular reentrant
VT, in which the QRS morphology exhibits a RBBB configuration and
a superior axis; (b) left anterior fascicular reentrant VT, in which the
QRS morphology exhibits an RBBB configuration and inferior axis;
and (c) upper septal fascicular VT, in which the QRS morphology exhibits a narrow QRS configuration and normal or right-axis deviation
(S9.4.4.3.4–S9.4.4.3.6). The left posterior type is most common, the
left anterior type is uncommon, and left upper fascicular VT is very
rare but sometimes occurs after catheter ablation of other fascicular
reentrant VTs.
The reentrant circuit of verapamil-sensitive fascicular reentrant VT can involve the Purkinje network around the papillary
muscles (S9.4.4.3.7). In addition to the current classification with
3 subtypes, papillary muscle fascicular VT is another identifiable
verapamil-
s ensitive fascicular reentrant VT. Finally, verapamil-
sensitive left fascicular reentrant VT can be classified into 5
subgroups (Table 6). Papillary muscle VTs originating from the
Purkinje fiber system and VT originating from myocardial tissue of
the papillary muscle appear to be different entities, although there
can be some overlap.

Specific considerations
The anatomical basis of this tachycardia has provoked considerable
interest, with data suggesting that the tachycardia can originate

9.4.3 | Idiopathic fascicular reentrant ventricular
tachycardia

from a false tendon or fibromuscular band in the LV (S9.4.4.3.8–
S9.4.4.3.11). Using ICE and 3D mapping systems, the successful
ablation site appears to be at the connection of a false tendon and

Recognition

ventricular wall in some cases. The Purkinje networks in these small

Verapamil-sensitive fascicular reentrant VT is the most common form

anatomical structures can be important parts of the circuit. In papil-

of idiopathic left-sided VT and was first recognized as an electrocar-

lary muscle fascicular VTs, fibromuscular bands near papillary mus-

diographic entity in 1979 by Zipes et al. (S9.4.4.3.1), who identified the

cles can potentially be the substrate of the circuit.

following characteristic diagnostic triad: (a) induction with atrial pac-

During tachycardia, two distinct groups of potentials, P1 and

ing, (b) RBBB and left-axis configuration, and (c) manifestation in pa-

P2, are typically recorded from a catheter lying along the midsep-

tients without SHD. In 1981, Belhassen et al (S9.4.4.3.2) were the first

tum (S9.4.4.3.12–S9.4.4.3.14). The mid-
diastolic potentials (P1)

to demonstrate the verapamil sensitivity of the tachycardia, a fourth

show proximal to distal activation along the septum, and the fused

identifying feature. In 1988, Ohe et al (S9.4.4.3.3) reported another

presystolic Purkinje potential (P2) shows distal to proximal acti-

type of this tachycardia, with RBBB and a right-axis configuration.

vation. During sinus rhythm, the P2 potentials are later than the

TA B L E 6

Fascicular ventricular tachycardias

I. Verapamil-sensitive fascicular reentrant VT
1. Left posterior type
i. Left posterior septal fascicular reentrant VT
ii. Left posterior papillary muscle fascicular reentrant VT
2. Left anterior type
i. Left anterior septal fascicular reentrant VT
ii. Left anterior papillary muscle fascicular reentrant VT
3. Upper septal type
II. Nonreentrant fascicular VT
Abbreviations: VT, ventricular tachycardia.
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His-b undle potential and earlier than the onset of the QRS, which

Outcomes and risks

is consistent with an origin in the LPF. P1 represents the activation

In the largest series of reentrant fascicular VTs, which included 160

from tissue that has decremental properties and verapamil sensi-

patients with left posterior septal fascicular VT, 30 patients with left

tivity that constitutes the anterograde limb of the circuit in VT. P2

anterior septal fascicular VT, and 8 patients with left upper septal

represents the activation of the LPF or a Purkinje fiber near the

fascicular VT (S9.4.4.3.15), the success and recurrence rates were

LPF and is a bystander during VT. The LV septal muscle is likely the

97% and 4%, respectively, for left posterior septal fascicular VT; 90%

retrograde limb.

and 11%, respectively, for left anterior septal fascicular VT; and 100%
and 2.5%, respectively, for left upper septal fascicular VT. Recurrence

Catheter ablation

of papillary muscle fascicular VT after ablation was high (S9.4.4.3.7),

VT can be initiated with atrial extrastimuli or burst pacing, or ventric-

with 3 of 8 patients (38%) with posterior papillary muscle fascicular

ular extrastimuli or burst pacing, facilitated by an isoproterenol infu-

VT and 1 of 5 patients (20%) with anterior papillary muscle fascicular

sion, if necessary. When evaluating these tachycardias, a multipolar

VT requiring a second ablation session for VT recurrences.

catheter placed along the left septum can be helpful in delineating
parts of the reentry circuits (S9.4.4.3.12–S9.4.4.3.14).

Aside from the complications that can result from any LV electrophysiological procedure, the only complications specifically as-

Left posterior septal fascicular reentrant VT mapping along the

sociated with catheter ablation of idiopathic left fascicular VT have

LV septum identifies 2 distinct groups of potentials (P1 and P2)

been LBBB and AV block. Tsuchiya et al (S9.4.4.3.16) have reported

during the VT (S9.4.4.3.4, S9.4.4.3.12). The apical third of the septum

that two patients in their series of 16 patients (12.5%) had transient

with a P1 potential is usually targeted to avoid creating LBBB or AV

LBBB after ablation. The authors targeted the left basal septum, and

block. If the VT or ventricular echo beats are not inducible, an empir-

the LBBB disappeared within 10 minutes without VT recurrence. In a

ical anatomical approach can be effective (S9.4.4.3.14). First, the VT

larger series (S9.4.4.3.15), 1 (0.5%) of 198 patients had a transient AV

exit site is determined by pace mapping during sinus rhythm, and RF

block. This patient presented with left posterior fascicular VT, and

energy is delivered to that site. Second, a linear lesion is placed at the

the diastolic potential (P1) at the midseptum was targeted for abla-

midseptum, perpendicular to the long axis of the LV, approximately

tion. Before the ablation, the patient had catheter-induced RBBB.

10-15 mm proximal to the VT exit. This anatomical approach is also

The AV block disappeared immediately after discontinuing the RF

useful in patients in whom diastolic Purkinje potentials cannot be

energy delivery.

recorded during VT.
Reported cases of left posterior papillary muscle fascicular VT presented an RBBB configuration and right-axis deviation QRS configuration. A diastolic Purkinje potential (P1) is recorded at the papillary

9.4.4 | Focal nonreentrant fascicular ventricular
tachycardia and premature ventricular complex

muscle with the location confirmed by ICE imaging. Ablation at this

Recognition

site is highly effective for suppressing this VT (S9.4.4.3.7).

Focal nonreentrant fascicular VT is classified as propranolol-sensitive

Left anterior septal fascicular VT exhibits an RBBB QRS mor-

automatic VT (S9.4.4.3.17, S9.4.4.3.18) and is usually observed in pa-

phology with Rs pattern in V5–V6. A Purkinje potential is recorded

tients with IHD (S9.4.4.3.19), although it has been observed in pa-

in the diastolic phase during the VT at the midanterior LV septum

tients with structurally normal hearts (S9.4.4.3.20, S9.4.4.3.21). VT

(S9.4.4.3.13). In this circuit, P1 potentials represent activation in the

can be induced by exercise and catecholamines (eg, isoproterenol

proximal portion of the specialized Purkinje tissue, which has dec-

and phenylephrine); however, it cannot be induced or terminated

remental conduction properties. During VT, the anterograde limb is

by PES (S9.4.4.3.17). VT is transiently suppressed by adenosine and

the Purkinje tissue exhibiting P1, and the retrograde limb is the LV

with overdrive pacing. Although this VT is responsive to lidocaine

muscle. The circuits of the left anterior and posterior fascicular reen-

and beta blockers, it is usually not responsive to verapamil. These

trant VTs are mirror images.

features can be employed to distinguish it from reentrant fascicu-

Left anterior papillary muscle fascicular VTs have RBBB with

lar VT. The clinical and electrophysiological characteristics of this

deep S waves in V5-V6. LV endocardial mapping during left anterior

VT have not yet been well defined. Gonzalez et al (S9.4.4.3.20) have

fascicular reentrant VT identifies the earliest ventricular activation

reported the electrophysiological spectrum of Purkinje-
related

in the anterolateral wall of the LV, where ablation suppresses VT

monomorphic VT in 8 patients and have shown the mechanism to be

(S9.4.4.3.7, S9.4.4.3.13).

consistent with abnormal automaticity or triggered activity in five

Upper septal fascicular VT has a narrow QRS and inferiorly di-

patients. Talib et al (S9.4.4.3.17) have reported on 11 patients (2.8%)

rected frontal plane axis. P1 represents the activation potential of the

with idiopathic nonreentrant fascicular VT among 530 patients with

specialized Purkinje tissue at the LV septum (S9.4.4.3.5). P2 represents

idiopathic VT without SHD. All patients had monomorphic VT with

the activation of the left anterior and posterior fascicles. Both the left

a relatively narrow QRS (123 ± 12 ms) and did not respond to vera-

anterior and posterior fascicles are the anterograde limbs of the reen-

pamil. The VT exhibited RBBB and superior-axis configuration in 11

trant circuit in VT, producing the narrow QRS configuration and infe-

patients (73%), inferior axis in 3 (20%), and LBBB and superior-axis

rior axis. This VT is successfully ablated at the LV midseptum.

configuration in 1 (7%). The VT could not be entrained.
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Catheter ablation
The ablation target of nonreentrant fascicular VT is the earliest
Purkinje activation during VT. If the VT was not induced by ventricular stimulation and catecholamines, isolated PVCs with a similar QRS
morphology to that observed during the VT can be targeted. At the
earliest Purkinje activation during VT/PVC, a Purkinje potential is
also recorded during sinus rhythm (S9.4.4.3.17).

Outcomes and risks
Although VT and PVC had been suppressed by catheter ablation in
one series, the acute success rate is unclear because this VT is difficult to induce (S9.4.4.3.17). VT recurrence was observed in four
patients (27%), 3 of whom underwent pace map–guided ablation
during the first session. A second ablation with activation mapping
guidance eliminated the VT during the 88 ± 8–month follow-up.
Catheter ablation guided by activation mapping appears effective,
whereas the pace map–guided approach is less efficacious.
LBBB and AV block have been associated with catheter ablation of
nonreentrant fascicular VT. In verapamil-sensitive reentrant fascicular VTs,
the creation of LBBB or AV block is rare because the ablation target is the
diastolic abnormal Purkinje potential (P1) during VT, and the abolition of
the normal Purkinje or fascicle potential (P2) is not needed to suppress
the VT. By contrast, abolition of a portion of the Purkinje network is usually necessary to suppress the nonreentrant fascicular VT. After successful
ablation, the amplitude of the local myocardium is diminished, and the
Purkinje potential appears after the myocardial potential. When the ablation site is located at the distal portion of the left fascicle, there is no
change in the surface QRS morphology or H-V interval after ablation. If
the VT arises from a more proximal portion of the fascicle, there is a potential risk for causing LBBB or AV block by the ablation. Rodriguez et al.
(S9.4.4.3.21) have reported cases of nonreentrant fascicular VT with an
RBBB configuration and right-axis deviation in patients who presented
left anterior fascicular block after the ablation. Lopera et al (S9.4.4.3.19)
have reported on two patients with nonreentrant fascicular VT and IHD in
whom complete AV block occurred after successful ablation for VT.
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CL of both spontaneous and induced VTs can vary, and CL alone is
often insufficient for recognizing clinical VT (S9.5.5.14). Adding to
the challenge of determining the area of interest and the endpoint

Key Points

for ablation is the lack of up-front inducibility of any VT in 7%–24%

• In cases of multiple inducible VTs, the clinical VT should be

of patients (S9.5.5.12, S9.5.5.15, S9.5.5.16) and specifically that of

preferentially targeted.
• Elimination of all inducible VTs reduces VT recurrence and
is associated with prolonged arrhythmia-free survival.
• For tolerated VTs, entrainment mapping allows for focal ablation of the critical isthmus.

clinical VT in 13%–30% of patients (S9.5.5.12, S9.5.5.14, S9.5.5.17).
It is important to note that most patients are inducible for multiple
previously undocumented VTs, with separate circuits and variable
exit sites from the scar (S9.5.5.12, S9.5.5.18–S9.5.5.20). The clinical
relevance of VTs induced in the electrophysiology laboratory with-

• For nontolerated VTs, various ablation strategies have been

out prior documentation is unclear; numerous laboratories have only

described, including targeting abnormal potentials, match-

targeted induced VTs with CL equal to or longer than that of clini-

ing pace mapping sites, areas of slow conduction, linear le-

cally observed VT(s) but not those with comparatively shorter CLs

sions, and scar homogenization.

(S9.5.5.18, S9.5.5.20). In these multicenter trials, the VT rate could

• Imaging can be beneficial in identifying the arrhythmogenic
substrate.
• Epicardial ablation is infrequently required, but epicardial
substrate is an important reason for VT recurrence after VT
ablation in patients with prior infarcts.

be markedly reduced in a substantial number of patients; however,
approximately 50% of patients experienced VT recurrence within
6 months (S9.5.5.18–S9.5.5.20).
The association between noninducibility following ablation for
any VT, including nonclinical VTs and the subsequent greater freedom from VT recurrence, supports the clinical relevance of non-

9.5.1 | General considerations

clinical VTs. However, as many as 41% of the patients who remain
inducible for nonclinical VT do not present with recurrence during

The mechanism for most VTs after MI is macroreentry involving

short-term follow-up (see Section 9.17) (S9.5.5.12, S9.5.5.21). A po-

ventricular scar areas, and initial events commonly occur several

tentially useful electrophysiological characteristic in distinguishing

years after the acute MI (S9.5.5.1–S9.5.5.4). Focal nonreentrant

relevant from nonrelevant induced VTs is the similarity between

mechanisms have been described in up to 9% of cases (S9.5.5.5). The

VT CL and the baseline ventricular refractory period, given that

chronic scar pattern observed after coronary occlusion has been

VTs with a CL within 30 ms of the ventricular refractory period CL

most widely described as compact in architecture, extending from

(fast VT based on the individual ventricular refractory period) rarely

the subendocardium to the epicardium, with increasing ischemia

occur spontaneously (S9.5.5.22). The presence of only the latter VTs

duration, typically sparing the endocardial rim close to the cavity.

has been associated with low VT recurrence, comparable to that of

Along the border of the scar, viable myocardium is interspersed with

patients who were rendered noninducible by ablation (S9.5.5.22).

fibrous tissue, providing the substrate for slow conduction (S9.5.5.1,
S9.5.5.2, S9.5.5.6, S9.5.5.7). Although most reentry circuits appear
to involve the subendocardium, intraoperative mapping studies have

9.5.3 | Mapping and ablation strategy

demonstrated that a substantial number of VT circuits involve or are

Mapping and ablation strategies are determined by the type of VT

confined to the subepicardial layer (S9.5.5.3).

and substrate. After MI, a minority of patients have only mappable

Early reperfusion therapy, which has been increasingly ad-

VTs (hemodynamically tolerated, reproducibly inducible, with stable

opted for effective management of acute MI, has not only resulted

morphology) that allow for extended activation and entrainment

in myocardial salvage but also less LV aneurysm formation, scar

mapping (S9.5.5.12, S9.5.5.18, S9.5.5.20). Hence, for most patients,

transmurality, and wall thinning. Less confluent histological and

additional mapping methods need to be employed in conjunction

electroanatomical scars (S9.5.5.8) are associated with the induction

with entrainment mapping to identify critical components of the

of faster VTs (S9.5.5.8, S9.5.5.9) and pose additional challenges for

reentry circuit. Although there is no single gold standard approach, a

mapping and ablation for post-MI VT.

reasonable workflow is presented in Figure 9.
Voltage mapping facilitated by 3D EAM systems (Section 8) is con-

9.5.2 | Clinical, unknown clinical, and nonclinical
ventricular tachycardia

sidered the standard for invasive identification of scar tissue during sinus
rhythm and has been validated by histology in postinfarct animal models
(S9.5.5.23–S9.5.5.26). For electroanatomically confluent and dense scars

The first goal of VT ablation is to abolish the clinical VT, which can

typical of nonreperfused infarcts (S9.5.5.8), VT-related sites are often

be accomplished in 90%–100% of patients inducible at baseline

but not exclusively located in low-voltage areas (S9.5.5.27, S9.5.5.28). To

(S9.5.5.10–S9.5.5.13). However, determining which VT is clinical

provide additional guidance in identifying putative isthmus sites in low-

can often be challenging. Although a 12-lead VT ECG is not avail-

voltage areas, especially for unmappable VTs, several additional strate-

able for most patients, the stored ICD electrograms, if available,

gies have been suggested focusing on electrogram characteristics (split,

can act as an accurate surrogate for the 12-lead ECG (S9.5.5.14).

late, fractionated potentials) and pace mapping (S9.5.5.18, S9.5.5.20,
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and in patients with recurrent VT despite AAD therapy (S9.5.5.18,
S9.5.5.29, S9.5.5.30, S9.5.5.40).
After substrate modification guided by clinical and induced nonclinical VT, a significant number of patients experience recurrence of
symptomatic VT, including 30% of patients who have been rendered
noninducible after ablation (S9.5.5.21). The number of induced VTs is
a potential surrogate for a larger and complex substrate (S9.5.5.12,
S9.5.5.18), and larger scars have been associated with VT recurrence
(S9.5.5.12). Recurrent VT can be due to lesion recovery or incomplete
lesions with local modification of the substrate (S9.5.5.16, S9.5.5.41).
Although some of these VTs originate from a previously targeted area,
they can have a different morphology based on 12-lead ECGs or ICD
electrograms (S9.5.5.16, S9.5.5.41). However, recurrent VT can also
originate from unmapped areas or from those areas not considered
relevant during the index ablation (S9.5.5.41).
F I G U R E 9 Overview of the workflow for catheter ablation of
VT in patients with IHD. Not all of these steps might be required,
and steps can be performed in a different sequence. For instance,
repeat VT induction can be deferred in patients with hemodynamic
instability. In addition, the operator might have to adapt to events
that arise during the case, for instance, to take advantage of
spontaneous initiation of stable VT during substrate mapping
and switch to activation mapping. IHD = ischemic heart disease;
PES = programmed electrical stimulation; SR = sinus rhythm;
VT = ventricular tachycardia

9.5.4 | Substrate-based ablation strategies without
upfront ventricular tachycardia induction
Substrate-based approaches that target some or all abnormal electrograms, irrespective of clinical and/or induced VTs, have been
suggested (Table 7), which can also be performed if VT is not inducible or if VT induction is not desired because of safety concerns
(S9.5.5.13, S9.5.5.15, S9.5.5.31, S9.5.5.37). These strategies have
targeted sites with abnormal electrograms, either of the entire scar
in the endocardium and epicardium (S9.5.5.13) or, more selectively,

S9.5.5.23, S9.5.5.24, S9.5.5.29, S9.5.5.30). Mapping within regions of low

target sites with LPs (S9.5.5.15) anywhere within the scar or sites

voltage while pacing with extrastimuli at sites remote from low-voltage

with fractionated potentials predominantly located in the border

regions has also been demonstrated to be useful for exposing abnormal

zone, which are markers for conducting channels (S9.5.5.37), or that

conduction regions that can be critical for VT (S9.5.5.31–S9.5.5.34).

have targeted sites with abnormal potentials that are poorly coupled

Various RF lesion delivery strategies have been described, rang-

to the myocardium (ie, LAVA) (S9.5.5.31). These techniques have

ing from focal ablations guided by entrainment mapping to ablation

been demonstrated to be superior to those employed in the control

of the entire scar (S9.5.5.13, S9.5.5.18). Suggested strategies include

groups in the previously cited studies. There is, however, no gener-

short linear lesions from the putative VT exit sites toward the center

ally accepted control group, and it is therefore difficult to compare

of the substrate, across the presumed critical isthmus and/or along the

the benefit of the various approaches with each other.

scar border zone (S9.5.5.23, S9.5.5.24, S9.5.5.30). However, the end-

There is currently no standardized approach for substrate-

point for these short linear lesions is often arbitrary. Circumferential

guided ablation, and definitive comparisons between different tech-

isolation of the identified scar (bipolar voltage <1.5 mV) (S9.5.5.35)

niques and endpoints are not available. The procedural outcomes

or the “core” containing potential VT isthmus elements (regions with

(eg, noninducibility, elimination of LPs or LAVA, substrate or core

bipolar voltage <0.5-1 mV and potentially important sites identified by

isolation, scar dechanneling) are acute endpoints that cannot be eas-

entrainment, activation, and pace mapping) (S9.5.5.36), confirmed by

ily randomized and/or applied to all patients with VT. The associa-

demonstrating exit block from the core, has been suggested as an in-

tion between a procedure's endpoint and favorable VT-free survival

crementally useful ablation endpoint beyond VT noninducibility. Other

might simply reflect a less complex substrate in patients for whom

methods incorporate the goal of demonstrating functional entrance

the desired endpoint can be achieved. However, success with more

block into regions of scar tissue, as demonstrated by the elimination

comprehensive ablation strategies has been consistently observed

of all previously identified LPs or local abnormal ventricular activities,

(S9.5.5.42).

either by targeting channels of conduction or by direct ablation at all

It is important to note that studies have suggested various defi-

abnormal sites (S9.5.5.13, S9.5.5.37–S9.5.5.39). These approaches

nitions for abnormal electrograms as surrogates for the VT substrate

often involve more comprehensive substrate modification than the

targeted by ablation (S9.5.5.15, S9.5.5.16, S9.5.5.31–S9.5.5.34,

initial strategy of transecting potential circuits with linear lesion sets.

S9.5.5.38, S9.5.5.39, S9.5.5.43, S9.5.5.44). Validation is challenging

Although substrate-based ablation for clinical and induced VTs

and usually limited to mappable VTs (S9.5.5.38). The specificity and

remains a probabilistic approach to VT ablation, the technique has

sensitivity of these abnormal electrograms for identifying the VT

been successfully performed after a presumed first VT episode

substrate throughout the range of observed post-MI scars recorded

1) Presence of a
circumscribed dense
scar (BV < 1.5 mV,
area < 100 cm2)
2) Recurrent unmappable VT
3) Post-MI
Exclusion: patchy scar/
multiple scars

—

32 ± 13

12
12/117
pts with
post-MI
VT

Tilz et al. (2014)
(S9.5.5.35)
Single center
observational

1) Post-MI
2) Recurrent stable
AAD refractory VT
(symptomatic or requiring ICD therapy)
Exclusion: syncope,
cardiac arrest, prior
failed ablation, renal
failure, end-s tage heart
failure

34%

Group 1
33 ± 14
Group 2
32 ± 10

118

Di Biase et al. (2015)
(S9.5.5.13)
VISTA trial
Multicenter RCT

1) Sustained VT resistant to AAD therapy
and requiring external
cardioversion or ICD
therapies
2) SHD with ischemic
or nonischemic dilated
cardiomyopathy
Exclusions:
1) VA attributable to
an acute or reversible
cause
2) Repetitive PVCs or
nonsustained VT without sustained VT

35 ± 10

70

Jais et al. (2012)
(S9.5.5.31)
Two centers
observational

Inclusion

NR

EF (%)

N

Study

Prior
CABG
(%)

VT recurrence at
12 months
Group 1: 48.3%
Group 2: 15.5%
P < 0.001
Mortality at
12 months
Group 1: 15%
Group 2: 8.6%
P = 0.21

VT recurrence 33%
Median follow-up
497 days

Group 1:
RF time
35 ± 27 min
Procedural time
4.6 ± 1.6 h
Group 2:
RF time
68 ± 27 min
(P < 0.001)
Procedural time
24.2 ± 1.3 h
(P = 0.13)
Complications 5%
RF time 53 ± 15 min
Procedure time
195 ± 64 min
No complication

Group 1:
Noninducibility
of clinical VT—
achieved in 100%
Group 2:
1) Elimination
of abnormal
potentials
2) No capture
from within the
scar (20 mA)
3) Noninducibility
of clinical VT—
achieved in 100%
1) Lack of abnormal
EGMs within area
2) No capture
within area—
achieved in 50%
3) Max. 40 RF
lesion
Noninducibility
of any VT (no
predefined endpoint)—observed
in 92%

Group 1: Clinical VT
ablation, linear lesion to transect VT
isthmus
Group 2: Extensive
substrate ablation
targeting any
abnormal potential
(=fractionated and/
or LP)

Circumferential linear
lesion along BZ
(BV < 1.5 mV) to
isolate substrate

1) Substrate mapping
(BV ≤ 1.5 mV) + Group 1
2) PES and activation
mapping/pace mapping
for clinical and stable
nonclinical VT (unstable
VT not targeted)

1) PES
2) Substrate mapping:
area of BV < 1.5 mV +
double, fractionated
or LP
3) PES after ablation

Endocardial
Epicardial when
clinical VTs were
inducible after
endocardial
ablation + no
CABG
Group 1: 11.7%
Group 2: 10.3%
3.5-mm tip

Endocardial
3.5-mm tip

|
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Combined endpoint
of VT recurrence
or death occurred
in 39 pts (55.7%);
45% of pts with
LAVA elimination
and 80% of those
without
VT recurrence
in 32 (46%); 32%
of pts with LAVA
elimination and
75% of those
without
7 cardiac deaths
(10%) over
22 months of median follow-up
RF time 23 ± 11 min
Procedure time
148 ± 73 min
Complications
6 pts (8.6%):
tamponade or
bleeding managed
conservatively (3),
RV perforation
requiring surgical
repair (1); 3 pts
died within 24 h
due to low-flow
state (2) plus
arrhythmia recurrence (1), PEA (1)
1) Complete LAVA
elimination—
achieved in 47 of
67 pts with LAVA
(70.1%)
2)
Noninducibility—
achieved in 70%,
similar if LAVA
eliminated or not

1) Ablation of LAVA
in SR
2) Ablation of tolerated VTs guided by
entrainment and
activation mapping
3) Remapping (in
stable patients)
with further
ablation if residual
LAVA or persistent
inducibility

1) PES and activation
mapping of induced
stable VTs
2) Substrate mapping
for LAVAs—sharp high-
frequency electrograms
often of low amplitude,
occurring during or after
the far-f ield ventricular
electrogram, sometimes
fractionated or multicomponent, poorly
coupled to the rest of
the myocardium

VT recurrence and
burden (follow-up)

Retrograde in 61
pts (87%)
Transseptal in 32
pts (46%);
epicardial access
in 21 pts (31%)
Dual access
encouraged
3.5-mm external
irrigated
ablation catheter;
multielectrode
mapping catheter
in 50% endocardial
procedures and in
all epicardial
procedures

RF time procedural duration
complications

Ablation strategy

Procedural
endpoint

Mapping strategy

Access mapping
catheter

TABLE 7 Select recent radiofrequency catheter ablation studies in patients post myocardial infarction with a focus on substrate-based ablation strategies
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25%

—

34 ± 11

36 ± 13

159

101
Post-MI
75

Wolf et al. (2018)
(S9.5.5.16)
One center
observational

Berruezo et al.
(2015) (S9.5.5.37)
One center
observational

1) Scar-related VT

1) Post-MI
2) First VT ablation
3) Recurrent, AAD
refractory episodes VT

1) Post-MI
2) AAD refractory VT
3) First VT ablation at
the center

28 ± 9.5
inducible
after RFCA
34 ± 9.2
endpoint
reached

160

Silberbauer et al.
(2014) (S9.5.5.15)
One center
observational

22.5%

31 ± 13

44
Post-MI
32
44/566
pts with
SHD

Tzou et al. (2015)
(S9.5.5.36)
Two centers
observational

1) SHD
2) AAD refractory VT
3) Intention to achieve
core isolation

Inclusion

—

EF (%)

Prior
CABG
(%)

N

(Continued)

Study

TA B L E 7

VT-free survival 55%
during 47 months
(33–82)
Outcome according to endpoints:
LAVA abolished vs
not abolished 63%
vs 44%
VT-free survival at
1 year 73%
RF time 36 ± 20 min
Procedure time
250 ± 78 min
Complications
7.5% (4 surgical
interventions)
Procedure-related
mortality 1.3%

RF time
24 ± 10 min only
scar dechanneling
(31 ± 18 min + additional RFCA)
Procedure time
227 ± 69 min
Complications
6.9%
No death

1) Abolition of
LAVA—achieved
in 93/146 pts
(64%)
2)
Noninducibility—
achieved in
94/110 tested pts

1) Scar dechanneling
— Achieved in 85
pts (84.2%)
— Noninducible
after 1)
55 pts (54.5%)
2) Noninducibility
—achieved in 78%

1) Ablation of mappable VT
2) Ablation of
LAVA (until local no
capture)
LAVA present at
baseline
Endocardium
141/157 pts
Epicardium 36/46
pts
1) Scar dechanneling
targeting entrance
2) Short linear lesions (eg, between
scar and mitral
annulus)
3) Ablation of VT-
related sites—performed in 45%

1) PES
2) Activation mapping
3) Substrate mapping: BV mapping
(<1.5 mV) + LAVA (=sharp
high-frequency EGMs,
possibly of low amplitude,
distinct from the far-field
EGM occurring anytime
during or after the far-
field EGM
4) PES
1) Substrate mapping: BV
(<1.5 mV) + EGMs with
delayed components:
identification of entrance
(shortest delay) of conducting channels
2) PES
3) Activation mapping +
pace-match

Endocardial
Combined endoepicardial 27%
— Epicardial access was encouraged
— Epicardial ablation 27/46 pts
3.5-mm tip (70
pts)
Multielectrode
catheters (89 pts)

|
(Continues)

VT recurrence 27%
after a median
follow-up of
21 months (11–29)
1-year VT-free
survival according
to endpoint: scar
dechanneling complete vs incomplete
(≈82% vs ≈ 65%)

VT recurrence 32%
after median 82
(16–192) days
VT recurrence
according to
endpoint 1 + 2
achieved (16.4%)
Endpoint 2
achieved (46%)
No endpoint
achieved (47.4%)
RF time endocardial
median ≈ 25 min
epicardial ≈ 6 min
Procedure time
Median
210–270 min
Complications
3.1%
In-hospital mortality
2.5%
1) Abolition of all
LP—achieved at
endocardium in
79 pts (49%), at
epicardium 12/32
pts (37%)
2) Noninducibility
of any VT—
achieved in 88%

1) Ablation mappable
VT
2) Ablation of all LP
LP present at
baseline
Endocardium
100/160 pts
Epicardium 19/32
pts

1) Substrate mapping:
BV < 1.5 mV + LP (=continuous, fragmented
bridging to components
after QRS offset/inscribing after QRS, no
voltage cutoff) + early
potentials (EP = fragmented < 1.5 mV)
Pace-match
2) PES
3) Activation mapping
4) PES after substrate
ablation

Endocardial
Combined
endoepicardial
(20%)
— Clinical findings
— Prior ablation
— Research
protocol
3.5-mm tip/4mm tip

Endocardial
Combined
endoepicardial
(27/101 pts,
among post-MI
not provided)
— Endo no
substrate/suggestive epi
— CE-MRI
— VT ECG
3.5-mm tip

VT recurrence 14%
Follow-up
17.5 ± 9 months

RF lesions
111 ± 91
Procedure time
326 ± 121 min
Complications
2.2%
No death

1) No capture of
the ventricle during pacing inside
core
2) Dissociation
of isolated
potentials—core
isolation achieved
in 70% post-MI
3) Noninducibility
—achieved in 84%

1) Circumferential linear lesion to isolate
core (=confluent
area of BV < 0.5 mV
area and regions
with BV < 1 mV harbouring VT-related
sites
2) Targeting
fractionated and LP
within core
3) Targeting VT-
related sites outside
core (2 and 3 in
59%)

1) BV mapping
2) PES
3) Activation mapping
4) Substrate mapping
Dense scar BV < 0.5 mV;
BZ BV 0.5–1.5 mV/voltage channels/fractionated/LP; pace-match,
S-QRS > 40 ms
5) PES after core
isolation

VT recurrence and
burden (follow-up)

Endocardial
Epicardial postMI 6%
3.5-mm tip
Selected patients:
multi-electrode
catheters for exit
block evaluation

RF time procedural duration
complications

Ablation strategy

Procedural
endpoint

Mapping strategy

Access mapping
catheter
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33 ± 11

33 ± 12

20

60

Porta-S ánchez et al.
(2018) (S9.5.5.34)
Multicenter
observational

de Riva et al. (2018)
(S9.5.5.33)
One center
observational

30%

—

Prior
CABG
(%)

1) Post-MI
2) Sustained VT

1) Post-MI
2) Recurrent VT

Inclusion

Endocardial
Epicardial 10%
— Endocardial
failure
— Epicardial substrate suspected
3.5-mm tip
catheter

Endocardial
3.5-mm tip 4 pts
Multielectrode
catheters 16 pts

Access mapping
catheter

VT recurrence
25% at 6-month
follow-up

VT recurrence 22%
at median followup of 16 months
(8–23)
Subgroup of
patients with EDPs
in normal-voltage
areas at baseline
(hidden substrate)
compared to
historical matched
group without EDP
mapping
VT-free survival at
1 year 89% vs 73%

RF time
30.6 ± 21.4 min
Procedure time
and complications
not reported

RF time
15 min (10–21)
Procedure time
173 min (150–205)
Complications
3.3%
One procedure-
related death

1) Noninducibility—
achieved in
80% after DEEP
ablation
— Remains 80%
after additional
ablation in those
inducible

1) Elimination of
EDPs—achieved
in all
2) Noninducibility
of targeted VT
(fast VT with
VTCL≈VERP not
targeted)
— Achieved in
67% after EDP
ablation
— Achieved in
90% after additional ablation

1) Targeting areas
with DEEP
2) Ablation of VT-
related sites discretion of operator

1) Targeting EDPs
only
2) Ablation of VT-
related sites based
on activation/pace
mapping

1) Substrate mapping: annotation of LP (=fractionated/isolated after QRS
offset) and assessment
if LP showed additional
delay of > 10 ms after RV
extrastimuli (S1 600 ms,
S2 VERP + 20 ms)
defined as DEEP
2) PES
3) Additional mapping
1) PES
2) Substrate mapping:
systematic assessment
of presumed infarct
area independent of
BV during SR and RV
extrastimuli.
Pacing (S1 500 ms,
S2 VRP + 50 ms):
EDP (evoked delayed
potentials) = low
voltage (<1.5 mV)
EGM with conduction
delay > 10 ms or block
in response to S2
3) Activation and pace
mapping

VT recurrence and
burden (follow-up)

Ablation strategy

RF time procedural duration
complications

Mapping strategy

Procedural
endpoint

Included studies: post myocardial infarction (or data for patients post myocardial infarction provided).
Abbreviations: AAD, antiarrhythmic drug; BV, bipolar voltage; BZ, border zone; CABG, coronary artery bypass grafting; CE-MRI, contrast-enhanced
magnetic resonance imaging; DC, delayed component; DEEP, decremental evoked potential; ECG, electrocardiogram; EDP, evoked delayed potential;
EF, ejection fraction; EGM, electrogram; ICD, implantable cardioverter defibrillator; LAVA, local abnormal ventricular activity; MI, myocardial
infarction; PEA, pulseless electrical activity; PES, programmed electrical stimulation; pts, patients; PVC, premature ventricular complex; RCT,
randomized controlled trial; RF, radiofrequency; RFCA, radiofrequency catheter ablation; RV, right ventricle; SHD, structural heart disease; SR, sinus
rhythm; VT, ventricular tachycardia.

EF (%)

N
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with different catheters, electrode sizes, and interelectrode spac-

series (S9.5.5.12, S9.5.5.15, S9.5.5.16) had previously undergone car-

ings remain to be determined.

diac surgery. In most patients, the presence of substantial pericardial

High-resolution mapping of post-MI reentrant VT in an animal

adhesions from surgery or postinfarct pericarditis requires the cre-

model of reperfused MI indicates that functional conduction block

ation of a surgical window in the electrophysiology lab or operating

during VT can play an important role (S9.5.5.45), and these areas

room to access the pericardial space. Even after epicardial access has

might not be detectable during sinus rhythm or pacing at slow rates.

been achieved, mapping can be particularly limited over the anterior

Targeting sites that show delayed conduction after delivering ex-

wall (S9.5.5.55, S9.5.5.56). Continued oral anticoagulation and dual

trastimuli has been shown to be beneficial, with a smaller target

antiplatelet therapy raise the concern for bleeding risks associated

area and lower VT recurrence than when other sites were targeted

with pericardial puncture (S9.5.5.16).

(S9.5.5.33, S9.5.5.34).

In experienced referral centers, percutaneous or surgical epicar-

This result might be particularly relevant for patients with small,

dial access has been considered appropriate in 9%-29% of patients

less confluent or nontransmural scars after MI, in whom parts of the

(S9.5.5.12, S9.5.5.15, S9.5.5.16, S9.5.5.55). At least 6% of post-MI pa-

VT substrate might be functional, and a systematic application of an

tients referred for VT ablation benefit from an epicardial procedure

RV short-coupled extrastimuli can be useful for identifying hidden

(S9.5.5.55). A previously failed endocardial ablation preceded most

substrate components.

of the epicardial procedures. Caution is advised, however, given the

High-d ensity multielectrode mapping with smaller electrode

often associated comorbidities and the large proportion of patients

sizes and spacings can be helpful in obtaining more complete and

with insufficient target structures that can be safely ablated in the

rapid characterization of the arrhythmogenic substrate (Section 8),

epicardium (S9.5.5.55). Furthermore, procedural failure can be re-

allowing for superior characterization of low-a mplitude local elec-

lated to reasons other than an epicardial VT origin.

trograms from thin endocardial myocardium, which can be ob-

Based on the available data, the relative contribution of first-line

scured by large far-field potentials from adjacent myocardium if

epicardial ablation to a patient's outcome remains unclear. For a large

catheters with large electrodes with distant interelectrode spac-

number of patients, accessible epicardial ablation target sites cannot

ing are used (S9.5.5.46–S9.5.5.49). Further studies are required

be identified, and these patients are exposed to additional proce-

to assess the effect of these mapping techniques on ablation

dural risks and discomfort. Considering the higher risk for procedural

outcomes.

complications with an epicardial approach (S9.5.5.57), careful pa-

Finally, imaging is of major importance for identifying scars and

tient selection is warranted. Further study is required to determine

the critical arrhythmogenic substrate within the scar. The use of var-

whether preprocedural imaging can help to identify post-MI patients

ious imaging modalities has been detailed in Section 5. Numerous

who will benefit from an epicardial approach (S9.5.5.58, S9.5.5.59).

studies have demonstrated a good correlation between CMR-
defined scars and EAM-defined scars. The same is true for CT in
which the wall thickness has been employed to identify scars in
patients post infarction. Increased tissue heterogeneity within the
scar demonstrated by CMR has helped to identify critical sites that
can be selectively targeted (S9.5.5.50), resulting in decreased VT recurrences. Likewise, CT-defined scar topography helps to identify
critical VT target sites (S9.5.5.51). Critical areas are often located in
myocardial ridges that are separated by areas of thinning (S9.5.5.51).

9.5.5 | Epicardial mapping and ablation
The role of postinfarction epicardial mapping and ablation is not
clearly defined.
Despite a predominant subendocardial substrate in most patients, reentry circuits can be confined to the subepicardial layer
(S9.5.5.3). The current incidence of epicardial substrate in patients
referred for catheter ablation is unknown. ECG features are not
reliable for predicting epicardial LV-V T exit in postinfarction VT
(S9.5.5.52). Epicardial circuits might also be interrupted from the endocardium, particularly in areas with wall thinning, and evidence of
this phenomenon is more frequently observed in post-MI patients
than in patients with DCM (S9.5.5.53). Some 42%-57% of all post-MI
patients included in multicenter studies (S9.5.5.18, S9.5.5.29,
S9.5.5.40, S9.5.5.54) and 23%-41% of patients from single-center
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9.6 | Dilated cardiomyopathy

Key Points
• Identifying the location and extent of scarring on CMR is
beneficial in procedural planning and has improved the outcomes of ablation in patients with DCM.
• The ablation strategy is similar to postinfarction VT.
• An intramural substrate is more frequently encountered in
DCM than in postinfarction patients and requires a different ablation strategy than for patients with either epicardial
or endocardial scarring.
• Epicardial ablation is beneficial if the scar is located in the
epicardium of the LV free wall.
• For intramural circuits involving the septum, epicardial ablation is not beneficial.
• In the absence of CMR, unipolar voltage mapping has been
described as a method to indicate a deeper-seated scar.

In nonischemic DCM, ablation may be considered for sustained
monomorphic VT, recurrent polymorphic VT, or VF initiated by triggering PVCs (see Section 9.9), and for frequent nonsustained VT and PVCs
that are suspected of contributing to ventricular systolic dysfunction
or interfering with effective delivery of cardiac resynchronization pacing (see Section 4.3).
The prevalence of DCM is estimated to be in the range of 37 cases
per 100 000 population (S9.6.1). Although the etiology is often clinically obscure, approximately 40% of patients have a genetic cause
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(S9.6.1). Although uncommon, sustained monomorphic VT occurs at

risk of VT recurrence (S9.6.29–S9.6.31). Another study found that

an annual rate of approximately 3%-4% in patients with an ICD, a LVEF

the presence of only rapid VTs after ablation (CL <30 ms plus the RV

≤0.35, nonsustained VT, and no prior history of sustained VAs (S9.6.2).

effective refractory period measured at a pacing CL of 400 ms) was

In the DANISH trial, fewer than 3% of the patients with class II or III

not associated with a greater risk of recurrence (S9.6.32).

heart failure symptoms and an LVEF ≤0.35 had sustained VT during a

Scar-related VTs tend to originate from scar regions along the mi-

median follow-up of 5.6 years (S9.6.3). In a series of 158 patients with

tral annulus or within the interventricular septum (S9.6.12, S9.6.20,

DCM, a mean LVEF of 0.31, and no history of sustained VT, 13% of

S9.6.22, S9.6.33). Multiple morphologies of inducible VT and poorly

the patients were found to have inducible sustained monomorphic VT

tolerated VTs are common. The VT circuit can involve the endocar-

(S9.6.4). VT due to DCM is occasionally encountered in patients with

dial, epicardial, or intramural regions of the LV. The ECG morphology

atherosclerotic coronary artery disease and is suggested by the pres-

of the VT is a useful guide to the likely target region and can inform

ence of multiple basal origin VTs and scar regions extending beyond

the initial approach. The risk, outcomes, and approach to ablation

the distribution expected from an infarct (S9.6.5).

also vary with the substrate location.

Three VT mechanisms have been identified in patients un-

VTs that originate from an LV scar in the free wall along the mitral

dergoing ablation (S9.6.6–S9.6.8), the most common of which is

annulus typically have an RBBB configuration and dominant R waves

scar-related reentry, accounting for more than 80% of sustained

in the midprecordial leads (V3, V4), with an axis directed inferiorly

monomorphic VTs. Reentry involving the bundle branches or fas-

(if the VT exit is superior) or superiorly (if the VT exit is inferiorly

cicles (see Section 9.4) is encountered in up to 19% of patients,

located) (S9.6.12, S9.6.20). A qS or QS configuration in lead I often

whereas focal VT mechanisms occur less frequently.

indicates an epicardial exit, consistent with initial forces directed

CMR with gadolinium contrast identifies areas of delayed hype-

from the epicardium to the endocardium. The QRS morphology can

renhancement consistent with myocardial fibrosis in 30%–50% of

be misleading, however, particularly for fast VTs (S9.6.14, S9.6.34).

patients with DCM, and the presence of this scarring is associated

Epicardial ablation is often helpful, although some of these VTs can

with an increased risk of sudden death and VT (S9.6.9–S9.6.11). In

be successfully ablated from the endocardium. With LV free wall

patients with monomorphic VT, CMR also identifies scar areas that

VTs, some laboratories start with mapping in the epicardium, obtain-

are a valuable guide to potential ablation target regions, given that

ing epicardial access before anticoagulation is administered. Other

the reentry circuit sites are usually associated with >25% scar trans-

laboratories always start on the endocardium to avoid the risks of

murality (S9.6.12–S9.6.18). CMR is therefore particularly helpful

epicardial access and obtain this if the endocardial approach fails. In

in planning and performing ablation procedures in these patients.

reported series from experienced centers, epicardial mapping is per-

Knowledge of the scar location has improved ablation outcomes in

formed in 29%-74% of patients (S9.6.12, S9.6.22, S9.6.35, S9.6.36).

patients with DCM (S9.6.19).

The approach to epicardial ablation is reviewed in Section 6.3.

The approaches to mapping and ablation for scar-related VTs in

Recognizing that low voltage can be recorded over epicardial fat and

DCM are similar to those for postinfarction VTs; however, intramural

avoiding the left phrenic nerve and coronary artery injury are im-

substrates that are not easily identifiable or accessible for ablation

portant considerations (S9.6.37).

are more common than in the postinfarct population and contrib-

VTs that originate from the anteroseptal region typically have a

ute to procedure failures and recurrences (S9.6.8, S9.6.12, S9.6.20,

dominant S wave in V1, with an inferior axis and prominent R waves

S9.6.21). The relevant scar area is identified from imaging and/or

by V3 to V4 (S9.6.12, S9.6.20). The frontal plane axis can be inferiorly

substrate mapping. When VT can be induced and is sustained and

or superiorly directed. If the scar extends leftward along the aortic

hemodynamically tolerated, a combination of activation mapping

root and toward the AMC region, the VT can have a dominant R wave

and entrainment mapping can be used to select the ablation region

in V1 with an inferior axis. If the scar extends inferiorly in the septum,

in or near the scar area (S9.6.20, S9.6.22). When VT is not mappable

VTs with a superiorly directed axis can be present. Ablation for VTs

and an area of low voltage (bipolar voltage <1.5 mV) can be identi-

that originate in scars at the anteroseptum has a lower success rate

fied that is consistent in location with the VT QRS morphology, a

compared with those from the inferolateral basal LV in a number of

substrate type of approach can be used in the endocardium and/

studies (S9.6.12, S9.6.20). Access from the epicardial aspect is limited

or epicardium (S9.6.23–S9.6.26). Although isolated LPs and fraction-

by the overlying RVOT, the epicardial fat pad, and the left coronary

ated potentials are encountered less frequently than in postinfarct

arteries. In the septum, ablation can be limited by proximity to the

VT scars, these electrogram targets can still be used to guide abla-

AV conduction system. Determining the risk of heart block and man-

tion (S9.6.26, S9.6.27). Pace mapping can suggest the VT exit region;

aging its consequences are important considerations. Implementation

however, as with other scar-related VTs, critical parts of the reentry

of pacing for CRT might be warranted if ablation results in AV block.

circuit where ablation may also be successful can be several centi-

Intramural VTs can occur in any location but are common

meters distant from the exit region. One study found that when a

in the periaortic region and septum (S9.6.12, S9.6.20, S9.6.33).

low-voltage area is present, extensive ablation over the region (both

Preprocedural CMR is the gold standard for identifying scarring

endocardially and epicardially) was associated with a lower risk of

and is particularly helpful in identifying intramural scars (Section 5).

VT recurrence compared with targeting only inducible VTs (S9.6.28).

Identification of intramural scars is best accomplished by a pre-

Absence of inducible VT after ablation is associated with a lower

procedural CMR. In the absence of CMR data, intramural scarring
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is suspected when the endocardial bipolar voltage is >1.5 mV (with

be controlled or if the procedure is complicated by hemodynamic

3.5-mm electrode mapping catheters) over the endocardial region

deterioration. Mechanical support has also been employed during

that is closest to the VT. If located at the LV free wall, an epicardial

ablation procedures to prevent hemodynamic deterioration and to

origin can be excluded when epicardial mapping fails to identify a

facilitate mapping (Section 6). Ablation that results in LBBB or AV

VT substrate in the overlying epicardium. The unipolar endocardial

block can lead to hemodynamic deterioration due to cardiac dys-

voltage can be helpful for identifying deeper seated scar tissue. An

synchrony that can warrant implementation of biventricular pacing.

LV unipolar voltage <8.3 mV over an area with an endocardial bipo-

Extensive ablation of areas of normal myocardium has the potential

lar voltage >1.5 mV is consistent with intramural or epicardial scars;

to further impair ventricular function, although this risk has not been

however, electrogram amplitude is also dependent on wall thick-

clearly defined. It seems prudent to avoid empiric ablation over large

ness, and there is substantial variability (S9.6.33, S9.6.38–S9.6.40).

regions that are not known to contain scars.

As indicated in Section 8.5.2, different voltage cutoff values have
been reported, and validation studies with CMR-defined scars have
demonstrated that there is a substantial overlap of unipolar low
voltage between scar zones and regions without scars. These cutoff values should therefore be used with caution in the absence of
available CMR data. Septal intramural scars are suggested by a conduction time of >40 ms when pacing is performed on the RV side of
the septum, and recording from the adjacent LV septum (S9.6.41).
Use of intracardiac ultrasound has also been suggested for detecting
scars, but data are limited (S9.6.42). The optimal approach to ablation for these VTs is not defined; however, ablation targeting the
closest overlying endocardial and epicardial sites is effective in some
patients.
Overall outcomes are largely from case series published by experienced centers, a number of which have included results from multiple procedures (S9.6.12, S9.6.20–S9.6.24, S9.6.26, S9.6.28, S9.6.31,
S9.6.36, S9.6.43). Ablation abolishes at least one inducible VT in
60%-74% of patients and all inducible VTs in 43%–72% of patients.
Programmed stimulation is not performed after ablation in 10%-15%
of patients, largely due to hemodynamic concerns. Persistent inducibility of sustained monomorphic VT is associated with increased
recurrences (S9.6.29–S9.6.31). During median/mean follow-
ups
ranging from 15 to 48 months, 31%-61% of patients experience at
least 1 VT recurrence. Approximately half of those with recurrent
VT experience fewer VT episodes than prior to ablation (S9.6.12,
S9.6.22). When directly compared in the same center, recurrent
VT is more frequent after ablation for DCM VT than for postinfarction VT (S9.6.21). Transplant-free survival ranges from 76% to
89%. Patients with large scar areas associated with larger areas of
low voltage and VTs that have LV apical exits, often associated with
scar extending from base to near the apex, have increased mortality
during follow-up (S9.6.43, S9.6.44).
Complications, including vascular access bleeding, tamponade,
and volume overload, are reported in 4%-11% of patients (S9.6.22,
S9.6.23, S9.6.31). Serious complications, including tamponade requiring surgery, phrenic nerve injury, and coronary artery injury, are
more frequent when percutaneous epicardial access is performed
(S9.6.22, S9.6.35). Thromboembolic complications appear to be rare,
but pulmonary embolism can occur. In-hospital mortality is as high
as 3% and has been reported due to uncontrollable VT, refractory
heart failure, and tamponade sequelae (S9.6.23). When LV systolic
function is severely depressed, the option of cardiac transplantation
or an LVAD is an important consideration if the arrhythmia cannot
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induced. VTs were sometimes stable and permitted activation and
entrainment mapping. Voltage mapping identified a combination of
epicardial and endocardial scars in most patients. Isolated endocardial
or epicardial scarring rarely occurred. The ablation strategy entailed
targeting late or fractionated electrograms and pace mapping and/or
substrate modification targeting low bipolar voltage (≤1.5 mV) regions.
It is worth noting that epicardial ablation was required in most patients.
During a 3-year follow-up, 30% of the patients underwent recurrent
shocks, with repeat procedures required for two patients.
A similar approach was used in another series of 22 patients with
more advanced disease (mean LVEF of 35%) (S9.7.13). Scar-related
VTs occurred most often (60%) from the LV-RV junctions, either at

9.7 | Ventricular tachycardia ablation in
hypertrophic cardiomyopathy

the basal (42%) or apical (18%) LV segment level (coinciding with the
anatomical regions frequently associated with fibrosis). Epicardial
ablation was required in almost two-thirds of the patients, and 73%
remained arrhythmia-free at 20 months. In another report of five pa-

Key Points
• Polymorphic VT and VF are the most common VAs in HCM;
monomorphic VT is less common.
• The arrhythmogenic substrate in HCM often involves the
septum but can extend to the epicardium, often necessitating combined endocardial and epicardial ablation procedures
to eliminate the VT.
• VT associated with apical aneurysms is often ablated
endocardially.

tients with the dilated phase of HCM (LVEF of approximately 35%),
VT circuits were predominantly distributed in the basal septum and
the basal anterior to anterolateral LV. In addition to the endocardial
ablation, intracoronary ethanol ablation and surgical cryoablation
were required in a number of patients (S9.7.14).
Patients with HCM and an LV apical aneurysm have a greater
risk of sudden death, embolic stroke, and progressive heart failure
than the general population with HCM and warrant special consideration (S9.7.15). The thin-walled dyskinetic or akinetic segment
can be composed of dense scars with channels of viable myocardium (resembling ischemic substrate). Both sustained monomorphic VTs and VTs with an RBBB or LBBB pattern in lead V1 can

Malignant VA contributes to sudden death in patients with HCM.

occur, the latter consistent with an exit from the septal aspect of

ICDs are therefore the mainstay of prevention. The substrate for VAs

the aneurysm. Careful imaging is important for defining the aneu-

in HCM is complex. The combination of myofibrillar disarray and fi-

rysm and ruling out thrombi prior to the procedure. Transthoracic

brosis likely generates heterogeneous conduction properties and,

contrast echocardiography, left ventriculography, and real-time

together with the vulnerability of the hypertrophied myocardium to

visualization with ICE can be helpful. Anticoagulation therapy is

supply-demand ischemia, creates a potentially arrhythmogenic milieu

a reasonable postprocedure treatment. Ablation strategies can in-

(S9.7.1–S9.7.3). Interstitial-type fibrosis (compared with replacement

clude those techniques used for ICM (S9.7.16). In a recent series,

fibrosis), postmyectomy scars, alcohol ablation, and the presence of

endocardial ablation was successful in most patients, and epicar-

an apical aneurysm can also influence arrhythmogenesis (S9.7.4). The

dial ablation was required in only 1 patient (S9.7.17). In a number

fibrotic areas visualized on CMR that characterize HCM can result in a

of cases, however, the aneurysm does not have low-voltage endo-

similar substrate to scars from ischemic disease, in which case similar

cardial or epicardial scars. When ablation is not possible or is inef-

techniques can be applied during VT ablation (S9.7.5–S9.7.8). However,

fective, surgical approaches could be successful (S9.7.18, S9.7.19).

increased myocardial thickness and intramyocardial or epicardial sites

Common themes emerge from these reports on ablation for mono-

of fibrosis limit the reach of classical mapping and ablation methods.

morphic VT in HCM. ECG characteristics might not be helpful for locating

The varying mechanisms (eg, reentrant vs triggered) and morphology

epicardial or intramural circuits (S9.7.16). Preprocedural imaging is rec-

(monomorphic vs polymorphic) of VAs encountered in HCM represent

ommended when deciding on the endocardial vs combined endocardial-

further challenges. ICD records indicate that polymorphic VT degener-

epicardial approach, as in other VT substrates (see Section 5). If unavailable,

ating to VF is the most common event (S9.7.9–S9.7.11).

epicardial access can be obtained at the beginning of the case in anticipa-

Ablation is generally performed for monomorphic VT that recurs

tion of the need for combined endocardial-epicardial ablation (S9.7.12).

despite antiarrhythmic therapy, particularly with ICD shocks. These

Intramural reentry might be difficult to target because the myocardium

VAs are only a small proportion of VAs in HCM, and the ablation ex-

is thick. Mapping methods can include a combination of voltage-based

perience is limited to case reports and small case series of highly se-

substrate mapping (using conventional voltage ranges) and activation,

lected patients. In a series of 10 patients with preserved LVEF (LVEF

entrainment, and late or fractionated potential mapping. VTs associated

of 57 ± 13%), programmed stimulation induced clinical VT in 7 patients

with apical aneurysms are often ablated endocardially. Although the ar-

(S9.7.12). A mean of 2 VTs per patient (including nonclinical VTs) were

rhythmia mechanisms for monomorphic VTs in HCM appear to be mostly

432

|

scar-related reentry, reports have also mentioned ablation of BBR, focal
RVOT (S9.7.12, S9.7.16), papillary muscle VTs, and left posterior fascicular
VT (S9.7.20). Reports have not suggested an increased incidence of major
complications compared with VT ablation in other populations, although
cardiac tamponade can be more of a concern in patients with apical aneurysms. The results of ablation are encouraging, acutely eliminating VT
in 80% of patients, with more than two-thirds of patients free of VT in
the long-term follow-up. If catheter ablation is ineffective, other methods,
including transcoronary alchohol and surgical resection and ablation, may
be considered. Methods enhancing lesion size in order to reach the deep
arrhythmia substrate will likely facilitate treatment.
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9.8 | Brugada syndrome

Key Points
• PVC-triggered VF or polymorphic VT are the most prevalent VAs that motivate device therapy in patients with
Brugada syndrome.
• Monomorphic VT is less frequent but can be caused by
BBRVT in patients with Brugada syndrome.
• The arrhythmogenic substrate is located in the RV epicardium and can be demonstrated by sodium channel blockers.
• Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the RV.

9.8.1 | Introduction
Catheter ablation for VA in Brugada syndrome may be considered
for VF, polymorphic VT, sustained monomorphic VT or PVCs triggering VF or polymorphic VT. Ablation strategies have evolved
from initially only targeting the PVC triggers for VA storms to the
current complete elimination of the arrhythmogenic substrate that
is usually located on the epicardial aspect of the RVOT (S9.8.6.1,
S9.8.6.2).
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Although quinidine can be effective for VA suppression in

by activation mapping or pace mapping has been the dominant pro-

Brugada syndrome, its use is complicated by its limited availability,

cedural strategy (S9.8.6.1). Patients with Brugada syndrome, how-

its difficult pharmacokinetics, and its adverse effects in two-thirds

ever, generally have little ambient ectopy in between phases of

of patients, leading to discontinuation in a quarter of patients in a re-

arrhythmic instability, and ablation targeting VF triggers is rarely

cent randomized double-blind trial (S9.8.6.3). The clinical indications

reported. Moreover, isoproterenol administration can suppress VF

for catheter ablation in Brugada syndrome are detailed in Section 4.

storms and prevent VF inducibility and is not likely to be useful for

The worldwide prevalence of Brugada syndrome ranges from 0.5

provoking triggering PVCs during an ablation procedure (S9.8.6.24,

to 35.5 per 1000 inhabitants (S9.8.6.4). Brugada syndrome was first

S9.8.6.25). In most reported cases, foci have been mapped to endo-

systematically described in 1992 in a series of 8 patients with VF ar-

cardial sites in the RVOT (S9.8.6.26, S9.8.6.27).

rest. Brugada syndrome is an inherited arrhythmogenic condition defined on the basis of its characteristic ECG phenotype (S9.8.6.5). An
RBBB-like pattern with ≥2 mm coved ST segment elevation in the right
precordial leads constitutes the so-called type I Brugada pattern nec-

9.8.3 | Approach to sustained monomorphic
ventricular tachycardia

essary for diagnosis (S9.8.6.6). This pattern is dynamic and can fluc-

Sustained monomorphic VT can occur but is unusual in Brugada

tuate according to variations in autonomic tone, body temperature,

syndrome. Rodriguez-Manero et al. (S9.8.6.28) observed Brugada

diurnal influences, electrolyte levels, and drug exposure, especially

syndrome in 4.2% of patients with appropriate ICD interventions,

drugs with sodium channel blocking properties (S9.8.6.7–S9.8.6.9).

with approximately half of these patients able to be pace terminated.

Additionally, the ECG pattern can be concealed unless V1 and V2 are

Most of these tachycardias were mapped to and ablated in the

recorded at the higher second and third intercostal spaces (S9.8.6.10,

RVOT, although BBR was observed in 2 of the 8 patients who under-

S9.8.6.11). Multiple conditions can present as a Brugada phenocopy

went ablation. Sustained monomorphic VT ablation is approached

and need to be ruled out before a diagnosis of Brugada syndrome can

similarly to other conditions with reentrant VTs, and CMR imaging

be reached (S9.8.6.12). The inheritance pattern for Brugada syndrome

is beneficial for assessing scarring that might be due to another dis-

is usually autosomal dominant. Although its genetic basis was initially

ease process. The effectiveness of empiric targeting of the epicardial

identified as a loss-of-function mutation in the SCN5A gene encoding

RVOT substrate when sustained monomorphic VT is not inducible is

the α-subunit of the cardiac sodium channel NaV1.5, numerous ge-

not known.

netic culprits have since been recognized (S9.8.6.13).
The mechanism generating the Brugada syndrome phenotype
has been the focus of significant research, and considerable recent
evidence has implicated depolarization abnormalities in the patho-

9.8.4 | Approach to polymorphic ventricular
tachycardia/ventricular fibrillation

genesis of Brugada syndrome (S9.8.6.14). However, repolarization

Polymorphic VT and VF causing recurrent ICD shocks or electrical

abnormalities have also been described, with disproportionate

storms are the most pressing arrhythmic indications for catheter ab-

shortening of the epicardial action potential leading to the poten-

lation in Brugada syndrome. In the absence of a triggering PVC, the

tial for phase 2 reentry and the induction of polymorphic VT or VF

arrhythmogenic substrate in the RVOT is the only possible ablation

(S9.8.6.15, S9.8.6.16). Subtle but significant cardiac ultrastructural

target. The preponderance of experience finds this substrate located

alterations, especially on the epicardial aspect of the RVOT, have also

on the epicardial aspect of the RVOT, with only 10% of patients hav-

been found in numerous patients (S9.8.6.17). Electrophysiological

ing some potential abnormal substrate identified from endocardial

and electroanatomical abnormalities have also been described in

mapping (S9.8.6.29). For this reason, catheter ablation for Brugada

this location, present both spontaneously and upon provocation

syndrome should be performed at centers with experience in the

with sodium channel blockers or the pericardial instillation of warm

specialized techniques of percutaneous pericardial access and epi-

water (S9.8.6.18–S9.8.6.20). High-frequency, low-amplitude, long-

cardial mapping (see Section 6).

duration fractionated electrograms are routinely recorded from this

Percutaneous epicardial access can be obtained in accordance

region and are the target of substrate-based ablation procedures

with the operator's usual technique. The anterior pericardial access

(S9.8.6.18). Complete elimination of all spontaneous and provoked

approach provides direct access to the epicardial RVOT, and the best

epicardial fractionation is associated with normalization of the

access to this region via a posterior pericardial access approach can

Brugada ECG phenotype and with elimination of inducible and spon-

be achieved with the catheter passing through the transverse sinus.

taneous VAs in most patients at the short-term follow-up (S9.8.6.18,

Double-wiring the initial access sheath allows for a second pericardial

S9.8.6.20–S9.8.6.23).

sheath to be placed, through which a multipolar mapping catheter can
be introduced. The ablation catheter is usually deployed through a de-

9.8.2 | Approach to triggering premature
ventricular complexes

flectable sheath to aid in obtaining optimal tissue contact.
Once the appropriate catheter set has been deployed, the relevant anatomy should be defined. Integration of a preacquired CT

For patients with recurrent PVC-triggered VF or polymorphic VT

into the EAM, particularly with the assistance of ICE, is an efficient

with ongoing spontaneous PVCs, localization of these focal triggers

means for defining anatomy (Figure 10A). Virtual epicardial (and/or
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F I G U R E 1 0 Epicardial substrate ablation in a patient with Brugada syndrome and appropriate ICD shocks for VF. Image integration
of a preacquired CT with the electroanatomical epicardial substrate map is shown in (A). Purple represents bipolar voltage >1.5 mV.
Fractionated potentials (arrows) are tagged with black dots, and a representative example is displayed. Widespread fractionated potentials
were recorded from the epicardial aspect of the RVOT extending down into the basal RV body. Ablation lesions are tagged with red dots.
Some fractionated potentials could not be ablated due to the proximity of the acute marginal branches of the right coronary artery. Panel
(B) shows the significant transient accentuation of the Brugada ECG pattern during the application of radiofrequency energy at one of
these sites. CT = computed tomography; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; PA = pulmonary artery;
RA = right atrium; RCA = right coronary artery; RFA = radiofrequency ablation; RV = right ventricle; RVOT = right ventricular outflow tract;
VF = ventricular fibrillation

endocardial RV) chamber geometry in the EAM system can also be

nerve is not usually a consideration, the proximal large subdivisions

acquired directly with a roving catheter.

of the right coronary artery are potentially at risk, particularly the

Mapping efforts are then concentrated on the region of interest in

conus branch and the RV marginal arteries (S9.8.6.32). Ablation-

the epicardial aspect of the RVOT. Multielectrode catheters with small

induced acute occlusion of the former could potentially result in

electrodes can provide better definition of high-frequency fraction-

VF, and injury to the latter risks infarction of an otherwise normally

ation than ablation catheters. Although mapping can commence in the

contractile RV. Coronary angiography prior to lesion delivery is

basal state if the Brugada syndrome ECG pattern is present at base-

therefore strongly recommended. Coronary angiography of the left

line, several studies have shown an increase in the area of arrhyth-

coronary arteries should also be performed because the disease pro-

mogenic substrate after administration of a sodium channel blocker

cess can also involve the LV epicardium.

(S9.8.6.21, S9.8.6.22, S9.8.6.30). A similar effect has been observed
All

high-
frequency,

long-
duration,

multicomponent,

An irrigated RF ablation catheter is used for epicardial lesion delivery, targeting the previously defined fractionated electrograms.

with the pericardial instillation of warm water (S9.8.6.20).
low-

Contact force sensing helps to confirm an optimal catheter contact

amplitude fractionated or isolated late electrograms are tagged on

vector toward the epicardium rather than outward toward the pari-

the substrate map (Figure 10A). Given the potential presence of

etal pericardium. Characteristic accentuation of Brugada syndrome-

significant epicardial fat, low voltage in isolation is not indicative of

type ST elevation in the right precordial leads is generally observed

underlying substrate. Caudal extension of the substrate has been as-

with RF application (Figure 10B) and usually resolves after RF delivery

sociated with the presence of concomitant inferolateral J waves and

ceases. However, acute occlusion of an RV marginal coronary artery

early repolarization syndrome (S9.8.6.31, S9.8.6.32).

needs to be ruled out if it persists. Ablation continues until all electro-

After a complete map has defined the region and extent of the

gram fractionation in the arrhythmogenic substrate region has been

arrhythmogenic Brugada syndrome substrate, an ablation strategy

eliminated, both at rest and with repeat provocation with sodium

can be devised. The most important factor in this regard is the rela-

channel blockers. When this has been achieved, the Brugada syn-

tionship of the surrounding at-risk structures. Although the phrenic

drome ECG phenotype has usually normalized (both in the standard
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and higher interspace recordings), and polymorphic VAs are no longer
inducible.

9.8.5 | Outcomes
There have been no randomized trials of catheter ablation in
Brugada syndrome, and all reported clinical outcomes are from
short-term follow-ups of largely single-center observational studies. These initial data are encouraging, with most investigators
reporting 73%-100% freedom from recurrent VT/VF during follow-up (S9.8.6.18, S9.8.6.22, S9.8.6.30, S9.8.6.33). A systematic
review of all published cases to 2018 found an overall 96.7% freedom from recurrent VT/VF (S9.8.6.29). However, given that recurrent VF was observed in several patients despite an apparently
successful procedure, catheter ablation cannot be recommended
as a replacement for ICD insertion to mitigate the risk of sudden
death in symptomatic Brugada syndrome. Additionally, most of
the reported patients had undergone ablation for symptomatic
VA, and there are no controlled outcome data to support a role
for catheter ablation in asymptomatic individuals with the Brugada
syndrome ECG phenotype.

9.8.6 | Risks
Catheter ablation for Brugada syndrome is an invasive and complex
procedure with significant potential for acute and delayed complications. These events include those related to epicardial access and
epicardial ablation and the general risks related to invasive catheter ablation, which are detailed elsewhere in this document (see
Sections 6.3 and 10.2). The most frequent reported complications are
isolated pericardial effusions and pericarditis (S9.8.6.18, S9.8.6.22,
S9.8.6.30, S9.8.6.33). No procedural deaths, strokes, MIs, or tamponades have been reported to date, but the early published worldwide
experience includes only approximately 200 cases. It should be noted
that these reports are from high-volume centers, and complication
rates with more widespread deployment could be higher.
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9.9 | Polymorphic ventricular tachycardia/
ventricular fibrillation triggers

Key Points
• Recurrent PVC-induced VF is most often triggered by PVCs
originating from Purkinje fibers, located in the RVOT, the
moderator band, or the LV.
• Patients with a single triggering PVC are better ablation
candidates; however, there are often multiple triggers.
• Patients with healed MI often require extensive ablation of
the Purkinje fiber system within or at the scar border.
• Ischemia should be ruled out as a trigger for VF prior to
ablation.

Although relatively rare, polymorphic VT and VF can be triggered by
PVCs in patients with or without structural and/or electrical heart disease (long QT syndrome, catecholaminergic polymorphic VT, Brugada
syndrome) (S9.9.1–S9.9.9). When this occurs, the clinical presentation
is often a polymorphic VT/VF storm (S9.9.4, S9.9.5, S9.9.7–S9.9.9).
The syndrome is recognized when short-coupled, unifocal PVCs (typically from the RVOT or Purkinje fiber system, including the RV and
LV papillary muscles) (S9.9.1, S9.9.2, S9.9.7) trigger polymorphic VT
or VF episodes. Ruling out acute myocardial ischemia as the cause is
important. Several considerations have emerged from a number of
small studies on catheter ablation in patients with polymorphic VT or
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VF refractory to antiarrhythmic therapy (S9.9.1–S9.9.9): (a) mapping
and ablation is facilitated when the index PVCs are frequent; procedural planning includes withdrawal of AADs where feasible and minimal sedation; (b) ablation sites are often associated with presystolic
Purkinje activation; in some instances, there can be slight variation in
PVC morphology and Purkinje potential to local ventricular activation
time, suggesting different exits from the same source (S9.9.1); (c) in
the setting of MI, successful ablation sites are related to Purkinje activation in the infarct border zone (S9.9.4–S9.9.6, S9.9.8); (d) multiple
ablation lesions are typically delivered, given the relative imprecision
of mapping and the serious consequences of failed ablation; and (e)
although acute procedural success in experienced centers is high,
late recurrence of PVC-triggered polymorphic VT/VF is observed in
5%-15% of patients, emphasizing the need for defibrillator therapy.
Multipolar mapping and ICE imaging, especially for PVCs originating
from papillary muscles, is helpful.
As discussed in Section 4.3, catheter ablation is indicated
for patients with drug-r efractory, recurrent, monomorphic PVCs
triggering polymorphic VT/VF in the absence of SHD and for patients with remote MI. In the acute phase of MI or in the early
phase following coronary revascularization, PVC-t riggered polymorphic VT/VF is initially best treated conservatively, given that
these arrhythmias often resolve spontaneously in a relatively
short period.
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9.10 | Arrhythmogenic right ventricular
cardiomyopathy
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9.10.3 | General approach for ablation
Given that ARVC affects the epicardium first, endocardial VT ablation
alone is often insufficient (S9.10.4.10, S9.10.4.16–S9.10.4.19) and can re-

Key Points
• The arrhythmogenic substrate in ARVC is located in the epicardium and can involve the endocardium in advanced stages.
• The most commonly affected areas are the subtricuspid and
RV outflow regions.
• LV involvement is not uncommon.
• Endocardial-epicardial ablation is often required and results
in higher acute success and lower recurrence rates compared with endocardial ablation alone.
• Conventional mapping and ablation techniques, including
entrainment mapping of tolerated VT, pace mapping, and
substrate ablation, are used.

sult in VT recurrence. A combined endoepicardial approach as first-line
therapy (S9.10.4.4, S9.10.4.5, S9.10.4.20, S9.10.4.21) or adjuvant epicardial ablation after unsuccessful endocardial ablation or after VT recurrence results in improved acute and long-term outcomes (S9.10.4.11,
S9.10.4.22). After combined or adjuvant epicardial ablation, VT reoccurs in 16%-29% of patients after approximately 3 years of follow-up,
with varying proportions of patients in these studies taking AADs
(S9.10.4.5, S9.10.4.11, S9.10.4.20–S9.10.4.22). Predominant LV involvement is an independent predictor of recurrence after ablation (S9.10.4.5).
Given the variable endocardium-to-epicardium disease involvement, the benefit of epicardial ablation likely varies among patients.
The presence of an epicardial arrhythmic substrate in patients with
limited or no endocardial VT substrate can be identified by endocardial unipolar voltage mapping (S9.10.4.23). Areas of endocardial

9.10.1 | Introduction to the specific disease
substrate characteristics

unipolar voltage <5.5 mV are associated with epicardial low-voltage

ARVC is a genetically determined myocardial disease characterized by

patients (S9.10.4.4, S9.10.4.5, S9.10.4.11, S9.10.4.18), and these pa-

progressive RV fibrofatty replacement, VAs, heart failure, and sudden

tients might require epicardial ablation. The low-voltage areas are

cardiac death. Fibrofatty replacement starts at the epicardium or mid-

typically adjacent to the tricuspid valve annulus and in the free wall

myocardium and extends until becoming transmural (S9.10.4.1). The

of the RVOT. In contrast, patients with advanced stage ARVC have

scar distribution predominantly affects the subtricuspid and OT regions

more extensive involvement of the RV endocardium (wider areas of

and, less frequently, the apex (S9.10.4.2–S9.10.4.4). LV involvement

low voltage in the bipolar map) and can have less arrhythmic sub-

is present in more than half of all cases and is more frequent in ad-

strate in the epicardium, which is likely due to the progressive fibro-

vanced stages (S9.10.4.5), affecting the posterolateral subepicardium

fatty replacement of the subepicardial myocardium, such that the

(S9.10.4.5, S9.10.4.6). ARVC is typically diagnosed through the estab-

surviving myocardium supporting reentry is closer to the endocar-

lished Task Force Criteria, although there is increasing evidence sup-

dium (S9.10.4.5). These patients constituted approximately 20% of

porting a role for invasive EAM to diagnose the early stages of ARVC

patients with ARVC in a recent multicenter study and can be recog-

when Task Force Criteria are inconclusive (S9.10.4.7–S9.10.4.9). In the

nized by an endocardial bipolar vs unipolar low-voltage area ratio of

early stages of the disease, VT reentry circuits are located nearly exclu-

≥0.23 (Figure 11) (S9.10.4.5).

scar regions. Isolated epicardial involvement with a completely
normal endocardial bipolar map has been observed in 26%-4 0% of

sively in the epicardium (S9.10.4.4, S9.10.4.5, S9.10.4.10, S9.10.4.11).

One strategy for guiding the selective use of epicardial map-

In more advanced disease, the VT substrate reaches the endocardium,

ping and ablation in ARVC is based on initial endocardial mapping.

and areas in the epicardium can be fibrotic and lack reentry circuits

Epicardial access is obtained for patients whose endocardial voltage

(S9.10.4.4, S9.10.4.5, S9.10.4.10, S9.10.4.11).

map shows limited or no endocardial substrate [eg, a bipolar vs unipolar low-voltage endocardial area ratio of <0.23 (S9.10.4.5)], which

9.10.2 | General management

is characteristic of early disease. Initial endocardial ablation is per-

ICDs are recommended to prevent death in patients with ARVC and

substrate characteristic of advanced disease, followed by epicardial

VAs and can also be considered in those with recognized risk factors

access for epicardial ablation if the VTs that are considered clinically

who have not yet had VT (S9.10.4.12). Neither AADs nor catheter abla-

relevant are still inducible. Alternatively, Santangeli et al (S9.10.4.22)

tion provides sufficient protection against sudden cardiac death. AADs

found that a strategy of epicardial mapping and ablation only when

(sotalol and amiodarone) are frequently used to improve symptoms and

VTs are still inducible or recur after endocardial ablation achieved

to prevent recurrent VT episodes, but have limited efficacy. Sotalol has

good long-term outcomes.

formed for patients with more extensive endocardial low-voltage

been shown to reduce VT inducibility in an electrophysiology study

Conventional mapping and ablation techniques used for other

(S9.10.4.13); however, data on its long-term efficacy are limited. Limited

scar-related VT substrates are also employed in ARVC. Ablation can

evidence suggests that amiodarone is the most effective drug for pre-

be performed during sinus rhythm, targeting the substrate based on

venting VAs (S9.10.4.14). Flecainide combined with metoprolol or sotalol

electrogram characteristics and pace mapping (see Section 8) and/or

has also been used to suppress arrhythmias (S9.10.4.15). Catheter abla-

during mappable monomorphic VTs. These ablation strategies have not

tion is commonly used to reduce the frequency of arrhythmia episodes.

been directly compared in patients with ARVC and are complementary
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F I G U R E 1 1 Right ventricular voltage maps from cases of moderate (upper row) and advanced (lower row) arrhythmogenic right
ventricular cardiomyopathy (ARVC) are shown. Purple represents a voltage > 1.5 mV in the bipolar maps (left and right) and > 5.5 mV in the
unipolar maps (center); red represents a voltage < 0.5 mV in the bipolar maps and < 3.5 mV in the unipolar maps. Moderate ARVC is defined
as having a bipolar/unipolar low-voltage area ratio of <0.23 and is associated with epicardial arrhythmogenic substrate area (ASA) (defined
by the presence of electrograms with delayed components of >10 cm2). Advanced ARVC displays a bipolar/unipolar endocardial low-voltage
area of ≥0.23, which is associated with an epicardial arrhythmogenic substrate area of ≤10 cm2 (S9.10.4.5). Adapted with permission from
Oxford University Press (S9.10.4.5)
and often combined. The procedure can be started during sinus rhythm

with RV enlargement or advanced stage disease (S9.10.4.5). The in-

with the hope of reducing radiation exposure and the need for elec-

cidence of major complications related to epicardial access has

trical cardioversion (S9.10.4.24). Complete elimination of all substrate

been reported to be as high as 8% (see Section 6.3) (S9.10.4.11,

characterized by electrograms with delayed components by targeting

S9.10.4.20–S9.10.4.22, S9.10.4.26, S9.10.4.27). Although the risk of

the conducting channel entrances has been shown to be a feasible and

coronary injury from epicardial ablation appears to be low, MI from

efficient strategy, needing only a small amount of RF delivery in some

an injury to an anomalous RV coronary branch has been reported

patients (S9.10.4.4, S9.10.4.5, S9.10.4.20). Complete substrate elimina-

(S9.10.4.28).

tion and noninducibility of any sustained monomorphic VT as procedural endpoints are associated with good long-term results.
Some VTs are catecholamine induced. A recent study found that
high-dose isoproterenol infusions could induce PVCs that had the
same morphology as sustained VTs, and focal ablation of the PVCs
eliminated these catecholamine-mediated VTs (S9.10.4.25).

9.10.4 | Risks
The additional benefit in arrhythmia control obtained with epicardial
mapping and ablation in ARVC should be carefully weighed against
the risks associated with obtaining epicardial access. The risk of inadvertent RV puncture with pericardial bleeding can be increased
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9.11 | Mapping and ablation in congenital
heart disease

Key Points
• Patients with a VT substrate after congenital heart defect
surgery include those with repaired tetralogy of Fallot, repaired VSD, and repaired d-transposition of the great arteries (D-TGA), as well as Ebstein's anomaly among other
disease processes.
• VT isthmuses are often located between anatomical barriers and surgical incisions or patch material.
• An AI can be identified and targeted during sinus rhythm.
• For tolerated VTs, entrainment mapping is the method of
choice for identifying critical components of the reentry
circuit.
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9.11.1 | Introduction
As the population of patients with repaired CHD continues to grow,

CRONIN et al.

incidence and the potential substrate for arrhythmias (S9.11.3.16).
Therefore, knowledge of the malformation and careful review of all
operation records before ablation is important.

management of recurrent VT in this population becomes increas-

AIs can be reconstructed during sinus rhythm by noncon-

ingly important (Figure 2). Monomorphic sustained VT approach-

tact mapping (S9.11.3.3) or by electroanatomical bipolar voltage

able by catheter or surgical ablation typically occurs in patients with

mapping combined with high-output pacing (10 mA, 2 ms) at low-

ventricular incisions, surgical scars, and patch materials. Accordingly,

voltage sites (<1.5 mV) to identify unexcitable tissue (S9.11.3.2,

for patients with CHD included in mapping and ablation stud-

S9.11.3.4). Noncapture despite good catheter contact is indicative

ies, repair of tetralogy of Fallot is the most commonly performed

of patch material or surgical scars. VT induction and activation

procedure, followed by VSD closure and complex D-
TGA repair

mapping for hemodynamically tolerated VT or pace mapping within

(S9.11.3.1–S9.11.3.7). As in other patients with SHD who present

anatomically defined isthmuses can be performed to confirm that

with VT, a complete evaluation of factors that promote arrhythmias

the AI is critical for sustaining VT (S9.11.3.2, S9.11.3.4, S9.11.3.6).

is necessary. Cardiac imaging to identify residual or new lesions is

Transection of the AI by connecting the adjoining anatomical

also important. Hemodynamic abnormalities resulting in increased

boundaries by linear RF lesions can be performed during sinus

wall stress and ischemia can serve as important triggers for VAs

rhythm (S9.11.3.2, S9.11.3.4, S9.11.3.6, S9.11.3.7). Demonstration

(S9.11.3.8). In particular, significant pulmonary regurgitation after

of conduction block after transection of the VT isthmus provides

prior transannular patching with subsequent RV enlargement is a

a defined procedural endpoint similar to that for achieving block in

common finding in repaired tetralogy of Fallot (S9.11.3.9) and might

the cavotricuspid isthmus for atrial flutter and is a valuable acute

require surgery or transcutaneous valve replacement. Treatment

procedural endpoint combined with noninducibility (see below)

of the underlying hemodynamic abnormalities can reduce the in-

(S9.11.3.2, S9.11.3.4, S9.11.3.6).

cidence of recurrent VAs by eliminating the triggers; however, the

Isthmus dimension and conduction properties likely determine

underlying substrate for monomorphic VT in repaired tetralogy of

the susceptibility to arrhythmias. In a study that included 24 patients

Fallot remains (S9.11.3.10). Accordingly, concomitant intraopera-

with tetralogy of Fallot, electroanatomical voltage mapping com-

tive cryoablation with (S9.11.3.9, S9.11.3.11, S9.11.3.12) or without

bined with activation mapping during sinus rhythm demonstrated

(S9.11.3.13, S9.11.3.14) intraoperative mapping has been success-

that relatively narrow and slowly conducting AIs (calculated conduc-

fully performed in select patients with tetralogy of Fallot, VT, and an

tion velocity <0.5 m/s) were the substrate for all 37 documented and

indication for reoperation.

induced VTs in patients with preserved cardiac function (S9.11.3.17).
These slowly conducting isthmuses can be identified and ablated

9.11.2 | Mapping and ablation

during sinus rhythm; inducibility of the clinical arrhythmia and hemodynamic tolerance is no longer a prerequisite for successful abla-

Most spontaneous and induced monomorphic VTs in patients with

tion in patients with AI-dependent macroreentrant VT (S9.11.3.17).

CHD referred for ablation are due to macroreentry, with a critical isth-

Isthmus 3 between the pulmonary annulus and the VSD patch or

mus defined by anatomical barriers, bordered by unexcitable tissue

septal scar is the most common cause of VT and occasionally re-

(S9.11.3.1–S9.11.3.4, S9.11.3.6, S9.11.3.7); however, focal mecha-

quires ablation from both the RV and LV sides of the septum or SV

nisms are occasionally encountered (S9.11.3.3, S9.11.3.4, S9.11.3.6).

for transection (S9.11.3.18).

The boundaries of AIs are the valve annuli and (unlike most other
acquired heart diseases) patch material and surgical incisions. Four
VT-related AIs in tetralogy of Fallot have been identified: isthmus 1,

9.11.3 | Outcome after ablation

bordered by the tricuspid annulus and the scar or patch in the an-

Four recent series have reported on ablation outcomes, combining

terior RVOT; isthmus 2, between the pulmonary annulus and the RV

activation mapping with a substrate-b ased ablation approach and

free wall incision or RVOT patch, sparing the pulmonary valve annu-

including a total of 99 patients with CHD (82 of 99 had tetral-

lus; isthmus 3, between the pulmonary annulus and the VSD patch

ogy of Fallot) (S9.11.3.3, S9.11.3.4, S9.11.3.6, S9.11.3.7). VTs were

or septal scar; and isthmus 4 (which is rarely encountered), between

typically fast, with a median CL of 295-3 00 ms, requiring a map-

the VSD patch or septal scar and the tricuspid annulus in case of an

ping and ablation approach during the underlying baseline rhythm.

inferior muscular rim (S9.11.3.2) (Figure 12). Additional AIs bordered

The definition of complete acute success (noninducibility with or

by surgical scars and valve annuli have been described after surgery

without isthmus block) differed among the studies or changed

for other CHDs, including complex D-TGA, VSD closure, and surgery

during the study period (S9.11.3.7) but was achieved in 73%-82%

for Ebstein's anomaly (S9.11.3.4, S9.11.3.6, S9.11.3.15). Substrate for-

of the patients. During a mean follow-up ranging from 33 months

mation might depend on the coincidence of pathological myocardial

to 9.5 years, VT recurred in 12%-32% of the patients after a sin-

remodeling and anatomical boundaries determined by the type and

gle procedure and in 5%-
11% after repeat ablation (S9.11.3.6,

timing of prior corrective surgery. Changes in surgical approaches over

S9.11.3.7).

the past decades (eg, a combined transatrial-transpulmonary approach

In two series of adults with CHD (most with tetralogy of Fallot),

avoiding ventriculotomies in tetralogy of Fallot) are likely to affect the

successful AI ablation (combined endpoint noninducibility and
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F I G U R E 1 2 Anatomical isthmuses (AI) in repaired tetralogy of Fallot according to the surgical approach and variation of the
malformation. RV = right ventricle; TA = tricuspid annulus; VSD = ventricular septal defect
isthmus block) was achieved in 25 of 34 patients (S9.11.3.4) and in 8

withholding ablation due to proximity to the conduction system

of 14 patients (S9.11.3.6), respectively. No patients with confirmed

and coronary arteries, myocardial hypertrophy, and the protec-

conduction block had a recurrence of monomorphic VT during

tion of portions of the AIs by patch material (S9.11.3.3, S9.11.3.5,

follow-ups of 46 ± 29 (S9.11.3.4) and 33 ± 7 months (S9.11.3.6),

S9.11.3.6, S9.11.3.18). In particular, a pulmonary homograft can

respectively. Accordingly, noninducibility with conduction block

cover parts of the infundibular septum in patients with tetralogy

across the targeted isthmus is a useful ablation procedure endpoint

of Fallot, preventing isthmus transection from an RV approach

(S9.11.3.2–S9.11.3.4, S9.11.3.6, S9.11.3.7).

(S9.11.3.18). Although a septal AI can be successfully approached

Serious procedure-related complications are rare (S9.11.3.4,

from the LV or aorta after right-sided ablation failure, proximity

S9.11.3.6, S9.11.3.7); however, high-risk ablation target sites, in-

to the coronary arteries and potential damage to the aortic valve

cluding the para-Hisian region with a risk of AV block, need to be

can increase the procedural risk (S9.11.3.18). Accordingly, sur-

considered (S9.11.3.5, S9.11.3.17). Ablation failure can result from

gical ablation concomitant with repair of residual hemodynamic
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abnormalities should be considered in these patients with spontaneous VT, especially if new patch material will prevent postsurgical access to the substrate. For these patients, a preoperative
electrophysiology study and EAM can be helpful in guiding surgical ablation (S9.11.3.17). The use of empirical intraoperative linear cryoablation without preoperative or intraoperative mapping,
transecting AI III and AI I, has been reported in patients with and
without clinical VT, with mixed results (S9.11.3.13). However, empiric linear lesions might not be sufficient. After intraoperative
isthmus ablation was performed in 31 patients who were inducible for VA prior to pulmonary valve replacement, 47% remained
inducible after surgery (S9.11.3.14). Similar to catheter ablation,
preoperative mapping, tailored cryoablation, and intraoperative
confirmation of bidirectional conduction block across linear lesions can improve outcomes.
The strong link between a slowly conducting AI and sustained
VT (S9.11.3.17, S9.11.3.18) in tetralogy of Fallot is intriguing, and
preventive ablation of these potential isthmus areas with a demonstration of conduction block may be considered, especially if future
surgical procedures might affect the accessibility of these potential
VT isthmus areas. Whether this would be beneficial for patients
with tetralogy of Fallot remains to be determined and will need to be
demonstrated by randomized studies.
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9.12 | Sarcoidosis

Key Points
• The arrhythmogenic substrate in cardiac sarcoidosis is
often intramurally located but can include the endocardium
and epicardium.
• A CMR is beneficial in planning an ablation procedure in
cardiac sarcoidosis.
• The arrhythmogenic substrate can be complex and can include areas of active inflammation and chronic scarring.
• The VT recurrence rate after ablation is high.

Cardiac sarcoidosis is a dynamic infiltrative noncaseating granulomatous disease with periods of inflammation that often culminate
in fibrosis (S9.12.1–S9.12.4). Patients with cardiac symptoms and
low LVEF fare the poorest among patients with cardiac sarcoidosis
in terms of prognosis and mortality. In contrast, patients with asymptomatic cardiac sarcoidosis and normal LVEF have a 10-year survival
rate of 89%-100%. Although only approximately 5% of patients with
systemic sarcoidosis have symptomatic cardiac involvement, autopsy
and imaging studies suggest that asymptomatic cardiac involvement
occurs in 25%–92% of patients (S9.12.4–S9.12.6). Isolated cardiac involvement has been increasingly recognized; a longitudinal study in
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patients with cardiac sarcoidosis treated with immunosuppression has
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The initial presentation was associated with AV block in 48% of cases
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for a minimum of 3 months, after which the medication may be ta-

Muser et al. (S9.12.25)

cyclophosphamide, cyclosporine, mycophenolate, and infliximab),

21

alent), along with steroid-
sparing agents (including methotrexate,

Kumar et al. (S9.12.27)

have included corticosteroids (prednisolone 1 mg/kg/d or equiv-

8

sarcoidosis-
related VT (S9.12.12, S9.12.24, S9.12.26). Regimens

Dechering et al.
(S9.12.12)

steroids or immunosuppressive therapy alone for managing cardiac

42 ± 14

S9.12.22, S9.12.26). There are limited data supporting the use of

9

AADs may be considered over ablation (S9.12.1, S9.12.4, S9.12.13,

14

When PET scanning identifies active inflammation at the time the
VT presents, acute treatment with immunosuppressive agents and

Jefic et al. (S9.12.15)

same patient (S9.12.15, S9.12.18–S9.12.27).

Naruse et al. (S9.12.24)

chronic phase. Multiple VT mechanisms can be encountered in the

35 ± 15

flammatory phase and predominantly scar-related reentry in the

8

The mechanisms of VT in patients with cardiac sarcoidosis include abnormal automaticity and triggered activity during the in-

Koplan et al. (S9.12.26)

promise for providing greater diagnostic yield (S9.12.4, S9.12.17).

LVEF, %

opsy targeting areas of abnormal bipolar or unipolar voltage has shown

N

of blind endomyocardial biopsy is <25% (S9.12.4). Endomyocardial bi-

Study

cult because granulomatous infiltration can be patchy, and the yield

Concurrent immunosuppressive therapy,
n (%)

lesions (S9.12.16). Reaching a cardiac tissue diagnosis is often diffi-

TA B L E 8

and reach the endocardium/epicardium by extension of the intramural

Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis

flammatory process of sarcoidosis are located within the myocardium

VTs induced,
mean ± SD

also originates in the epicardium, whereas the granulomas in the in-

36 ± 14

tem is rarely involved in ARVC (S9.12.13). The disease process in ARVC

NR

ARVC rarely involves the septum, and therefore the conduction sys-

8/1

to differentiate the two conditions. In contrast to cardiac sarcoidosis,

14/0

Mapping,
Endo n/
Epi n

S9.12.15). There are a number of clinically useful findings that can help

6/2

characteristics identified in intracardiac mapping (S9.12.4, S9.12.10–

Abbreviations: LVEF, left ventricular ejection fraction; N, number; NR, not reported; VT, ventricular tachycardia.

tion of epsilon waves, surface ECG characteristics, including signal-

31/8

Ablation,
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and cardiac sarcoidosis, including imaging characteristics, identifica-

11 (52)

There is substantial overlap in the clinical diagnostic criteria for ARVC

21/5

involvement can be localized to the RV (S9.12.4, S9.12.10–S9.12.15).

NR

B) (S9.12.9). Importantly, cardiac sarcoidosis can mimic ARVC, and its

NR

ing is recommended in current heart failure guidelines (COR IIa, LOE

3 (33)

process such as cardiac sarcoidosis (S9.12.8), and obtaining this imag-

4 (29)

Patients undergoing repeated
procedures, n (%)

particularly helpful in raising the suspicion of an infiltrative disease

NR

ing therapy with immunosuppressive drugs (S9.12.4). A CMR can be

14/0

ences in both acute and long-term management, specifically regard-

1 (13)

VT, consideration of cardiac sarcoidosis is important, given the differ-

8/2

VT recurrence, n (%)

are no randomized trials on this issue. For patients presenting with

6 (75)

that early recognition and treatment could be of value, although there
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studies have suggested that immunosuppression reduces the burden
of VAs (S9.12.13, S9.12.19, S9.12.24, S9.12.26), whereas others have
either failed to show a benefit or have demonstrated a worsening
of VAs (S9.12.28–S9.12.30). Data suggest that immunosuppression
could be more beneficial for VAs in early disease with preserved LVEF
(S9.12.4). Nevertheless, the current expert consensus recommendation is to consider assessing the patients for active inflammation
using PET scanning and administering therapy with immunosuppressants and AADs if active inflammation is present (S9.12.4).
Medical therapy, including immunosuppression therapy, has
failed for most patients in reports on VT ablation in cardiac sarcoidosis (Table 8) (S9.12.12, S9.12.15, S9.12.26). If urgent imaging
is unavailable or the VT persists despite empiric medical treatment,
ablation may also be considered (S9.12.4).
The ablation approach to scar-related macroreentrant VT in cardiac sarcoidosis is similar to that employed in other scar-related VTs
(see Sections 8 and 9) and is largely based on identifying the abnormal
substrate during sinus rhythm. Activation and/or entrainment mapping
during VT is often limited due to hemodynamic instability, multiple
VT morphologies, or noninducibility (S9.12.12, S9.12.15, S9.12.23–
S9.12.26). Substrate-
based ablation targets areas with abnormal
electrograms (see Section 8) and favorable pace maps (see Section 8)
(S9.12.12, S9.12.15, S9.12.23–S9.12.27). A feature common to other
nonischemic VT substrates is the predilection for involvement of the
epicardium (22%-26%) (S9.12.15, S9.12.25–S9.12.27) and midmyocardium, the latter of which can be difficult to define in the absence
of a CMR or with standard mapping techniques. Granulomatous infiltration can affect any part of the myocardium; cardiac imaging studies
with CMR, nuclear perfusion scanning, and PET scanning can therefore be helpful for locating and assessing the burden of the complex
substrate (S9.12.4, S9.12.11, S9.12.13, S9.12.25, S9.12.27). The frequent involvement of the basal septum results in a high prevalence of
right septal VTs or VTs involving the Purkinje fiber system (S9.12.24),
and the predominance of a basal substrate gives rise to peritricuspid and perimitral VTs (S9.12.15, S9.12.24). Nonstandard and investigational adjunctive ablation techniques (see Section 9.1) designed
to create larger and deeper lesions have been used to attempt the
ablation of intramural substrate when standard ablation fails, including bipolar ablation, needle-facilitated ablation, the use of half normal
saline RF electrode irrigation, and transcoronary arterial or venous
ethanol ablation (S9.12.28–S9.12.31).
A number of observational studies have investigated the utility of catheter ablation in patients with cardiac sarcoidosis (Table 8).
Outcomes have varied widely, as have the differences in patient characteristics, the concomitant use of immunosuppression, and follow-up
times (S9.12.12, S9.12.15, S9.12.24–S9.12.27, S9.12.32). In general,
freedom from any recurrent VT is achieved in 45.8% of cases for up
to 2 years of follow-up, with multiple procedures required in 12.5%-
43% of patients (S9.12.15, S9.12.24–S9.12.27, S9.12.32); however,
the overall VT burden has been reduced by 88% (S9.12.32). Major
procedural complications have been observed in up to 5% of cases
(S9.12.25, S9.12.27, S9.12.32).
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9.13.1 | Chagas disease
ChD is a chronic parasitosis affecting the heart and other organs and
is caused by the protozoan Trypanosoma cruzi. ChD is transmitted to
humans mainly through parasite-laden feces from a hematophagous
insect vector found only in the Americas, where the disease in considered endemic. The World Health Organization estimates a prevalence of ChD ranging from 1%-6% in endemic areas, with 10 million
people infected worldwide (mostly in Latin American countries), 100
million at risk of infection, and 300 000 new cases reported each
year. The World Health Organization estimates that 50 000 CCM-
related deaths occur annually, with 60%, 25%, and 15% related to
sudden cardiac death, progressive heart failure, and stroke, respectively (S9.13.3.1, S9.13.3.2).
Cardiac involvement is the most frequent and serious manifestation of chronic ChD. Although the pathogenesis of cardiac damage is
complex and not completely understood, at least 4 possible mechanisms have been suggested: cardiac parasympathetic neuronal depopulation, immune-mediated myocardial injury, parasite persistence
in cardiac tissue with secondary antigenic stimulation, and coronary
microvascular abnormalities causing myocardial ischemia. Diffuse
arteriolar dilatation found in CCM can result in a coronary steal phenomenon of blood flow from epicardial coronary arteries to dilated
arterioles, producing low perfusion pressure in the distal microvasculature supplying susceptible areas distal to the coronary branches.
The watershed areas between main coronary artery branches would
be the most susceptible to this steal phenomenon, causing low perfusion pressure, secondary ischemia, microinfarctions, and reparative
fibrosis. The most frequently observed areas of myocardial scarring
in CCM are the posterolateral LV and the LV apex in the watershed
zones between the right coronary and circumflex arteries, and the
anterior descending and posterior descending coronary arteries,
respectively. VT is typically related to an inferolateral LV aneurysm
(S9.13.3.2).

9.13.2 | Ventricular tachycardia in chagas
cardiomyopathy
Sustained VT is usually due to reentry, associated with an inferolateral LV scar in over 70% of patients. Occasionally, endocardial radiofrequency ablation can result in transmural injury, effectively
treating all portions of the myocardium involved in the arrhythmia
circuit. However, scars commonly exist intramyocardially and/or

9.13 | Chagas disease

subepicardially in an area with an associated thick layer of subendocardial myocardium. Mapping and ablation from the epicardial surface is performed in up to 40% of patients (S9.13.3.3, S9.13.3.4). A

Key Points

myocardial isthmus of surviving tissue between the inferolateral LV

• The pathogenesis of ChD is poorly understood but often

scar and the mitral valve annulus can be involved in a macroreen-

results in an inferolateral LV aneurysm.
• The arrhythmogenic substrate is located intramurally and
on the epicardial surface, often necessitating an epicardial
ablation procedure.

trant submitral circuit, as has been described for postinfarction VTs
(S9.13.3.5). BBR can occur but is unusual (S9.13.3.6).
In CCM that presents with VT storms, cardiac sympathetic denervation (CSD) can reduce VT episodes and is a potentially valuable
treatment option (S9.13.3.7).
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9.13.3 | Epicardial ablation of sustained ventricular
tachycardia in chagas heart disease

9.14.1 | Lamin cardiomyopathy

The prevalence of epicardial VT origins in patients with CCM is high

gene includes a familial form of DCM with autosomal dominant

(approximately 37%). Electrograms obtained during epicardial mapping

inheritance and a variety of clinical manifestations ranging from

from the areas giving rise to VT are similar to those observed for other

progressive heart failure, AV block to supraventricular block, and

scar-related VTs, including delayed potentials, mid-diastolic potentials,

VAs (S9.14.4.1–S9.14.4.3). Malignant VAs are particularly prevalent

and continuous electrical activity during VT. The critical isthmus of the

in these patients and can precede the development of overt DCM

reentrant circuit can be confirmed by entrainment maneuvers or in-

(S9.14.4.4). Risk factors for developing VAs include the presence

terruption of VT with RF ablation. With the progressive nature of the

of AV conduction abnormalities, the male sex, and the presence of

disease, VT recurrences are common (S9.13.3.4, S9.13.3.8).

nonmissense mutations in the LMNA gene (S9.14.4.4–S9.14.4.6). LV

The cardiac phenotype associated with mutations in the LMNA

dysfunction has also been reported as a risk factor for developing
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VAs, although malignant VAs can occur in up to one-third of cases
despite the presence of normal LV function (S9.14.4.4). Longitudinal
studies assessing the natural history of patients with LMNA DCM
have consistently described a poor long-term prognosis regardless
of the initial clinical presentation, with most patients eventually
progressing to end-s tage heart failure and the need for advanced
therapies including heart transplantation (S9.14.4.1, S9.14.4.4).
The management of recurrent VAs in patients with LMNA DCM
is challenging owing to the progressive nature of the disease, the
variable response to AAD therapy, and the predominant anteroseptal location of the underlying arrhythmogenic substrates, with a high
prevalence of intramural substrates. The role of catheter ablation in
managing recurrent VT in patients with LMNA cardiomyopathy has
been recently evaluated in a multicenter registry (S9.14.4.7). Of the 25
patients included in the registry, an anteroseptal substrate was found
in 82%, with all patients having multiple inducible VT morphologies.
Ablation was challenging, with most patients having residual VT inducible at the end of the ablation procedure. Over a relatively short-term
follow-up (median of 7 months), the mortality rate was 26%, 44% of
patients were considered for mechanical circulatory support or heart
transplantation, and the cumulative recurrence rate was 91%. Of note,
a procedure-related complication occurred in 25% of cases, including
anticipated complete heart block (in the process of ablating septal
substrate), asystole, cardiogenic shock, and thromboembolic events.
Given the overall poor success in achieving lasting VT control, the high

9.14 | Miscellaneous diseases and clinical scenarios
with ventricular tachycardia
Key Points
• Lamin cardiomyopathy often has a poor prognosis, progressing to end-stage heart failure.

risk of procedural complications, and the rapid progressive nature of
the disease, catheter ablation has only a palliative role for patients
with LMNA cardiomyopathy and recurrent drug-refractory VAs.

9.14.2 | Left ventricular noncompaction
LVNC is a rare primary cardiomyopathy likely caused by an arrest of

• VT ablation is challenging due to intramural substrates.

the normal embryogenesis of the endocardium and mesocardium,

• VT recurrence rate is high after ablations.

leading to the formation of prominent trabeculations and deep in-

• VT in patients with noncompaction tends to originate from

tertrabecular recesses within the LV wall communicating with the

regions of noncompacted myocardium where scar can be

cavity (S9.14.4.8, S9.14.4.9). The inferior and lateral walls of the LV

identified in the midapical LV.

from the mid-cavity to the apex are the most commonly involved

• VT ablation in patients with LVAD can be challenging due

regions. The clinical presentation of LVNC is highly variable, ranging

to the limitation of preprocedural imaging, and the electro-

from completely asymptomatic to end-stage heart failure, and is fre-

magnetic noise generated by the LVAD.

quently associated with VAs and thromboembolic events (S9.14.4.8,
S9.14.4.10). The substrate underlying VAs in these patients is
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complex and involves pathological myocardial changes consisting
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heart failure (S9.14.4.30, S9.14.4.31). These issues can typically

of fibrosis, disruption of cellular architecture, and noncompacted

be ruled out with a transthoracic echocardiogram, LVAD interro-

myocardium. Reentrant VAs tend to colocalize with the regions of

gation, and blood tests for hemolysis, which can be a marker of

noncompacted myocardium in the midapical LV cavity, and patients

pump thrombosis. However, most patients presenting with repeti-

can have a unique substrate distribution compared with other forms

tive sustained VAs, particularly those with a history of VAs before

of NICM, with isolated involvement of the mid to apical LV seg-

the LVAD implantation (S9.14.4.29, S9.14.4.32), have no identifi-

ments and sparing the perivalvular regions (S9.14.4.11). However,

able mechanical trigger and usually require therapy to achieve VA

significant heterogeneity in the VA substrates has been described,

suppression. Although antiarrhythmic therapies have not been

and VAs can also arise from regions remote from the noncompacted

well studied, an observational study by Raasch et al (S9.14.4.32)

myocardial segments (S9.14.4.11, S9.14.4.12). Small observational

of 61 patients undergoing LVAD implantation reported that 9 of

studies and isolated reports of patients with drug-refractory VA

15 (60%) patients in whom amiodarone was initiated after the

have shown that catheter ablation can be performed safely and can

occurrence of VAs remained free of recurrent arrhythmias; how-

achieve long-term arrhythmia control (S9.14.4.11–S9.14.4.16). Owing

ever, the follow-up duration in this subgroup was not specified.

to the high thromboembolic risk associated with LVNC, long-term

In the patients experiencing recurrent VAs despite therapy with

oral anticoagulation is usually warranted, and it is important that

amiodarone, the authors reported no convincing benefits for ad-

patients undergo a careful preprocedural imaging evaluation to rule

juvant therapy with other antiarrhythmic agents, including sotalol,

out the presence of intracavitary thrombi, which can be challenging

lidocaine, mexiletine, and procainamide. In particular, mexiletine

to identify due to the presence of dense trabeculations. Catheter

was added to amiodarone in 4 patients but was effective in only 1.

ablation can be performed on uninterrupted oral anticoagulation or

For recurrent VAs despite AAD therapy, catheter ablation should

with efforts to minimize the time off of oral anticoagulation using

be considered. Multiple observational studies and a large multicenter

periprocedural bridging with heparin (S9.14.4.11).

registry have shown that catheter ablation can be performed safely
and effectively in patients with LVADs (S9.14.4.33, S9.14.4.34), al-

9.14.3 | Congenital left ventricular aneurysms

though there are several important considerations. The preprocedural
definition of the substrate can be challenging due to significant im-

Congenital LV aneurysms and diverticula are rare and believed to be

aging artifacts from ICD devices and the LVAD cannula. LVADs that

the result of the disrupted embryogenesis of portions of the ventric-

have a magnetically levitated impeller introduce substantial electro-

ular myocardium (S9.14.4.17, S9.14.4.18). The diagnosis of congenital

magnetic noise that can render the QRS morphology of VT from the

ventricular aneurysms and diverticula is typically reached through

body surface ECG uninterpretable. The aortic valve often has minimal

noninvasive imaging studies after ruling out secondary aneurysmal

or no motion in patients with LVADs, cusp fusion can develop, and,

evolution from myocardial insults such as coronary artery disease,

in some instances, the aortic valve is surgically oversewn to abolish

inflammatory cardiomyopathies, and trauma. Congenital ventricular

aortic insufficiency. The SVs can be sources of thrombi. A transseptal

aneurysms and diverticula can be asymptomatic or can present with

approach to access the LV is usually preferred, and is the only option

thromboembolic complications, heart failure, myocardial rupture,

in some cases (S9.14.4.33–S9.14.4.35), although the resulting atrial

or malignant VAs and sudden cardiac death (S9.14.4.17–S9.14.4.19).

septal communication can potentially cause clinically significant right

Monomorphic reentrant VTs can originate from congenital ventricu-

to left shunting, with systemic oxygen desaturation in some patients

lar aneurysms or diverticula (S9.14.4.20–S9.14.4.22), and isolated

who have concomitant RV failure and increased right atrial pressure.

reports have demonstrated that catheter ablation can achieve arrhythmia control (S9.14.4.20, S9.14.4.23, S9.14.4.24).

Sacher et al (S9.14.4.33) have reported on a multicenter study of
catheter ablation in 34 patients with LVADs who underwent 39 procedures (25 with a transseptal and 14 with a retrograde aortic approach).

9.14.4 | Left ventricular assist devices

Of note, the targeted VT was related to the LVAD cannula in only 9% of
the cases, whereas the remaining VAs were associated with the under-

Patients with permanent LVADs have a high incidence of recur-

lying disease substrate. After a mean follow-up of 25 ± 15 months, 7

rent VT, with an estimated incidence of 22%-53%, with the high-

patients underwent heart transplantation, 10 died, and 13 (76%) of the

est incidence in patients with a history of sustained VT prior to

remaining 17 patients remained free from recurrent VT. These results

LVAD placement (S9.14.4.25–S9.14.4.27). Recurrent sustained

are in line with other single-center observational series (S9.14.4.34–

VT has been associated with increased mortality in a select num-

S9.14.4.39) and support the benefits of catheter ablation as an import-

ber of studies (S9.14.4.27–S9.14.4.29). Sustained VT has nega-

ant treatment option for patients with LVADs and recurrent VT.

tive hemodynamic consequences in some patients, possibly due
to the deterioration of RV function. Whenever a patient with an
LVAD presents with new-onset VA, it is important to rule out
mechanical triggers such as mechanical interaction between the
inflow cannula and the adjacent apical-s eptal myocardium, “suction events,” and mechanical pump failure resulting in worsening
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9.15 | Surgical therapy

Key Points
• Surgery-facilitated access to the epicardium via a limited
subxiphoid incision can be helpful in the case of adhesions.
• Cryoablation via thoracotomy is possible for posterolateral
substrates and via sternotomy for anterior substrates.

In some patients, standard endocardial approaches combined with
percutaneous epicardial catheter ablation remain ineffective in providing VA control due to deep intramural circuits (S9.15.1). Percutaneous
epicardial access might not be feasible for patients with prior pericarditis
or cardiac surgery, and epicardial VTs might not be easily targeted using
standard ablation approaches (S9.15.2). Alternative treatment methods
need to be considered for patients with failed endocardial and epicardial ablation procedures (S9.15.3). The threshold for a surgical approach
might be lower if a concomitant surgical procedure is indicated. For
patients with an inaccessible epicardial space, percutaneous catheter
ablation in the electrophysiology laboratory can be facilitated by a surgically created epicardial window allowing entry into the pericardial space
(S9.15.4). This approach is most straightforward in patients with an
apical or inferior VA substrate, because the area of the heart closest to
the window is most easily accessed, and pericardial adhesions can limit
extensive mapping. Surgical cryoablation can also be conducted in the
operating room utilizing a lateral thoracotomy or sternotomy (S9.15.5,
S9.15.6). Thoracotomy is the preferred approach to lateral and posterior
substrates, whereas sternotomy is often needed for anterior substrates.
Portable EAM can be utilized to help to localize the substrate, and VT
can be inducible when the patient is off the cardiopulmonary bypass.
When possible, preprocedural planning should include CT imaging of
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9.16 | Sympathetic modulation

grafts for patients with prior bypass surgery to prevent injury to these
structures. The use of surgical VT ablation has also been described in patients undergoing percutaneous LVAD implantation (S9.15.7, S9.15.8).
Recently, there has been growing concern regarding the increased rates
of LVAD thrombosis among patients who undergo both endocardial
and epicardial surgical cryoablation at the time of LVAD implantation
(S9.15.9). In highly selected patients with epicardial LVOT VAs refractory
to standard techniques due to overlying epicardial fat and/or proximity

Key Points
• Sympathetic modulation targeting the stellate ganglia by
video-assisted thoracoscopy may be considered for failed
VT ablation procedures or VF storms.
• A temporary effect can be obtained with the percutaneous
injection or infusion of local anesthetics.

to coronary arteries, open (S9.15.10) or minimally invasive (S9.15.11,
S9.15.12) approaches have been used. The full characterization of the
efficacy and safety of these approaches is pending.

The autonomic nervous system (ANS) has a central role in regulating heart rate and cardiac function and contributes to the pathogenesis
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of VA in structurally normal hearts, abnormal hearts, and channelopa-

QT syndrome when beta blockers are not effective, or when ICD

thies (S9.16.1). The ANS includes the parasympathetic component me-

therapy is contraindicated or declined (S9.16.11, S9.16.12, S9.16.16–

diated by the vagus nerve and a sympathetic component mediated by

S9.16.18). CSD is associated with a significant reduction of events in

cervicothoracic paravertebral sympathetic ganglia. The ANS undergoes

patients with high-risk long QT syndrome, with a reported 50%–80%

remodeling and becomes dysfunctional in SHD (S9.16.1). In most situ-

long-term success rate (S9.16.17–S9.16.21). A significant decrease in

ations, ANS imbalances contribute to the onset and/or maintenance of

QTc duration is usually observed after CSD (S9.16.11, S9.16.17).

VAs, especially through the activation of efferent sympathetic pathways.
Interventions that decrease sympathetic tone are often beneficial.

CSD can also be considered for patients with catecholaminergic
polymorphic VT and recurrent symptomatic VA (syncope or ICD shocks)

Sympathetic activation and vagal withdrawal are associated

while undergoing optimal drug therapy with beta blockers and flecain-

with diminished respiratory sinus arrhythmia and heart rate vari-

ide and for patients with a contraindication for beta blockers (S9.16.12,

ability.

Iodine-
123

metaiodobenzylguanidine

and

11C-
meta- S9.16.22, S9.16.23). In catecholaminergic polymorphic VT with recur-

hydroxyepinephrine imaging provide an indication of sympathetic nerve

rent VA despite optimal therapy, CSD achieved 80% event-free survival

distribution and local noradrenaline reuptake that reflects sympathetic

at 2 years and has been advocated as an alternative to an ICD (S9.16.21).

activity (S9.16.1). Although iodine-123 metaiodobenzylguanidine and

Spinal cord stimulation of T1-T5 with an external stimulator ap-

11C-
meta-
hydroxyepinephrine (S9.16.2) imaging findings are associ-

pears to modulate autonomic activity, possibly via both sympathetic

ated with VA in various settings, the clinical utility of using these findings

inhibition and an increase in vagal activity (S9.16.2). Spinal cord

for risk stratification and to guide therapy has yet to be proven (S9.16.1).

stimulation reduced VA episodes 75%-100% in a small number of pa-

Beta blockers are a first-line therapy for VA sensitive to ANS

tients with cardiomyopathy and high VA burden (S9.16.17). The spi-

influences. Beta blockers often decrease idiopathic RVOT PVCs in

nal cord stimulation mechanism is not completely understood, and

healthy individuals (S9.16.3) and reduce the rate of sudden cardiac

the long-term clinical effects and safety have not been studied in hu-

death after MI (S9.16.4, S9.16.5). Conversely, in electrical storms due

mans. Low-level stimulation of the cervical vagosympathetic trunks

to Brugada syndrome or idiopathic VF, beta-adrenergic stimulation

or carotid body can antagonize proarrhythmic sympathetic surges

by isoproterenol infusion can abolish recurrent arrhythmia (S9.16.6,

and decrease VAs in animal models, but there is no experience for

S9.16.7).

this with humans (S9.16.2).

Transient CSD achieved by high thoracic epidural anesthesia with

Renal denervation decreases both central sympathetic activity and

bupivacaine administered at the T1-T2 or T2-T3 level into the epidural

systemic catecholamine excretion, possibly mediated through either

space can be employed as a bridge to more definitive therapy (S9.16.8).

afferent or efferent renal sympathetic nerves and independent of the

An 80% reduction in VA episodes was observed in 6 of 8 patients un-

effect on blood pressure (S9.16.2, S9.16.24). In small series or isolated

dergoing thoracic epidural anesthesia, with infusion durations ranging

cases with various cardiomyopathies and refractory VA, catheter-

from 48 to 96 hours (S9.16.8). Partial denervation can be achieved

based percutaneous renal denervation was observed to reduce VAs

by percutaneous stellate ganglion block and can also quiet post-MI

and appeared safe (S9.16.25–S9.16.28). Techniques and acute pro-

electrical storms (S9.16.5). A recent meta-analysis of nonrandomized

cedural endpoints need further evaluation, and randomized trials are

studies found that temporary percutaneous stellate ganglion block

needed to assess the efficacy and safety.

was associated with a major acute reduction in the burden and supports its potential use as a bridge to more definitive therapy (S9.16.9).
Persistent CSD is achieved at open surgery (or by video-assisted
thoracoscopy) by resecting the lower third to half of the stellate ganglia
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9.17 | Endpoints of catheter ablation of ventricular
tachycardia

Key Points
• Noninducibility of VT by PES after ablation is a reasonable
endpoint and predictor for VT recurrence after VT ablation
in patients with SHD.
• Due to the limitations of programmed stimulation, endpoints other than noninducibility have been described,
including elimination of excitability, elimination of LPs or
LAVA, dechanneling, substrate homogenization, core isolation, image-guided ablation, and anatomically fixed substrate ablation.

9.17.1 | Historical perspective
In the early days of electrophysiology testing to study arrhythmias, PES was recognized as a tool for evaluating the efficacy of
treatments (at that time, drugs and surgical ablation). For both
supraventricular arrhythmia and VA, elimination of inducible sustained tachycardia following drug or surgical intervention, when
the arrhythmia had been reproducibly induced with PES prior to
intervention, correlated with successful treatment at least by the
short-term follow-up (S9.17.4.1, S9.17.4.2). PES was known to be
a somewhat unreliable assessment tool in that (a) it did not perfectly predict outcomes (sensitivity or specificity) and )b) significant
day-to-day variability in the results was demonstrable in the absence of an intervention (S9.17.4.3). In addition, varying definitions
of “noninducibility” have been used, including noninducible VA of
any type using up to triple extrastimuli from 2 RV sites and 2 drive
CLs; initiation of only “nonclinical” VTs that had morphologies and/
or CLs that had not been previously observed spontaneously; and
rendering a previously easily inducible VT no longer inducible at
that step of the PES protocol but without performing the complete
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PES protocol. Despite these shortcomings, VA noninducibility was

their own procedural endpoints (almost all combined with end-of-

regarded for over two decades as the standard means for assessing

procedure PES). A short description of these strategies is provided

the efficacy of therapeutic interventions, including catheter abla-

below (S9.17.4.11, S9.17.4.12). In many of these studies, substrate

tion (S9.17.4.4, S9.17.4.5).

ablation was combined with ablation guided by activation and entrainment mapping when a hemodynamically tolerated VT was in-

9.17.2 | Programmed electrical stimulation

ducible. For all of these approaches, data are largely limited to small
series from single centers or groups of investigators.

PES at the end of the ablation procedure is still employed and remains
a reasonable predictor of VT recurrence. In particular, patients in whom

1 Elimination of electrical excitability (S9.17.4.13): Targeting VT

relatively slow VTs (CL >300 ms) remain inducible at the end of the pro-

isthmuses between areas of electrically unexcitable scar and

cedure are more likely to experience recurrence than those in whom no

ablation to the extent that isthmus tissue cannot be stimulated

VT (or only rapid, unmappable VT) is inducible (S9.17.4.6). In a recent

with unipolar pacing output of 10 mA (the endpoint of this

study, inducible nonclinical VT that has a CL longer than the RV effec-

strategy) has been shown to result in fewer VT recurrences in

tive refractory period plus 30 ms was associated with recurrent VTs,

follow-up. This approach has the drawbacks of contact depen-

whereas faster inducible nonclinical VTs were not associated with recur-

dency and time expense, especially in cases with more extensive

rence (S9.17.4.7). A meta-analysis of post-MI VT ablation studies found

areas of ablation in which repeated cycles of stimulation and

that the absence of inducible VT was associated with a substantially

ablation can be tedious and time-consuming.

lower risk of recurrent VT compared with the inducibility of nonclinical
VT (odds ratio [OR] 0.49) and clinical VT (OR 0.10) (S9.17.4.5).

2 Elimination of LPs (S9.17.4.14): Elimination of all recordable LPs
(high-frequency electrogram components inscribed after the

The predictive capacity of immediate postablation PES was re-

end of the surface QRS complex that reflect slowed conduc-

cently challenged by Frankel et al (S9.17.4.8), who have shown that

tion or block) has been shown to improve freedom from recur-

NIPS using the patient's ICD a few days after the ablation procedure

rent VT compared with cases in which LPs were not eliminated

yielded a more accurate picture of the likelihood of VT recurrence

(S9.17.4.15). This approach is limited by sampling density and the

after ablation than the acute end-of-procedure stimulation protocol.

time required for remapping to assess the absence of LPs.

In this study, 18% of patients without inducible VT at the end of

3 Elimination of LAVAs (S9.17.4.16): LAVAs are defined as electro-

the ablation procedure had inducible clinical VT using subsequent

grams with 2 or more distinct components that might be evident

NIPS, and another 37% had inducible nonclinical VT. Each group had

in the resting rhythm or can be revealed by a stimulation wave-

shorter recurrence-free survival than those without inducible VT at

front arriving from a different direction. LAVAs thus include

delayed NIPS. Similar results were recently reported by Oloriz et al

standard LPs but also the split potentials (those with an isoelec-

(S9.17.4.9). Numerous potential causes of postablation recurrent VT

tric interval between components of at least 30 ms) that are not

episodes have been proposed, including ablation lesion healing, de-

late and even some normal-appearing electrograms for which

velopment of new circuits, withdrawal of AADs that had suppressed

stimulation might reveal previously unobserved abnormalities.

some VTs, and emergence of VTs at the periphery of ablation zones

Whereas elimination of LPs has generally been performed on the

(S9.17.4.10). The optimal management of patients found to have in-

endocardium, LAVA mapping and ablation requires endocardial

ducible VT has not yet been defined.

and (when possible) epicardial mapping and ablation. Elimination
of all LAVAs (the endpoint of this strategy) has been correlated

9.17.3 | Current ablation strategies and
assessment of results

with high rates of freedom from spontaneous recurrence of VT.
Problems with this approach include the lack of standard programmed stimulation methods to detect LAVA at sites without

For focal arrhythmias (such as nonsustained or sustained VT or

these potentials during sinus rhythm, the extent of ablation

PVCs, typically observed in individuals without SHD), activation

needed to treat all LAVAs (endocardial and epicardial ablation,

and/or pace mapping are generally adequate guides for ablation

the latter might not always be feasible), and the inability to know

(assuming the arrhythmia was present spontaneously or inducible

when all LAVAs had been ablated successfully (sampling bias).

prior to ablation). Assessment of efficacy is termination of VT, or

Additionally, the mapping catheter used can affect LAVA detec-

elimination of PVCs, and subsequent noninducibility of VT or PVCs

tion, with small, closely spaced electrodes detecting LAVA and

by catecholamine infusion or electrical stimulation that had reliably

LP more readily than standard ablation electrodes. However, this

provoked episodes prior to ablation.

might necessitate double access to the chamber in question or

For patients with SHD in whom reentry is the primary VT mecha-

repeated catheter exchanges.

nism, the effectiveness of ablation has usually been assessed by PES

4 Dechanneling: Using this method, EAM is used to identify sites

(typically through triple ventricular extrastimuli at 1 or 2 RV sites

with high-frequency delayed (not necessarily “late”) potentials in-

and 1-2 drive CLs), with or without an adjunctive catecholamine in-

scribed after a far-field component in sinus rhythm and targets

fusion. In addition to these mapping tools, a variety of substrate-

those with relatively short intervals from potential entry sites into

based strategies are currently in use for ablation for VA, each with

channels within scars that can participate in reentry. Endpoints of
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this “dechanneling” approach are the elimination of delayed po-

demonstrated a reduction in VT recurrence in patients post in-

tentials or reversal of the activation sequence of delayed poten-

farction (S9.17.4.27).

tials when recorded with multipolar catheters. VT-free outcomes
were better when complete dechanneling could be affected

As noted, most strategies also use PES to assess for VT inducibility at

(S9.17.4.17).

the end of the procedure. It is important to note that the assessment

5 Substrate homogenization (S9.17.4.18): This strategy is similar

of efficacy of these ablation strategies is predicated on the assumption

in principle to LP and LAVA ablation but more broadly targets

that ablation lesions have permanent effects, which cannot be known.

the entire region in which low-amplitude (<1.5 mV bipolar) abnormal electrograms are observed with very extensive ablation on both the endocardium and epicardium when abnormal

9.17.4 | Summary

epicardial substrate is identified. The endpoint is electrogram

The preponderance of experience for assessing the results of VT abla-

elimination (amplitude reduction to the background noise level

tion is with PES, despite its inherent limitations. Multiple methods of

or below) and noninducibility of VT. In a small randomized trial

substrate ablation have been described, each with its own procedural

of patients with prior MI and a nonrandomized series of pa-

endpoint (but almost always with PES assessment at the end of the

tients with post-MI and NICM, VT recurrence was less likely

procedure). Several observations can be made based on available data:

with extensive substrate ablation than with ablation guided by
activation and entrainment mapping targeting only the clinical

1 Some method of assessing success (prespecified endpoints) should

VT (S9.17.4.18, S9.17.4.19). However, it is not known whether

be employed at the end of any ablation procedure for treating

this technique would be superior to the targeting of clinical

VA, insofar as possible (constrained by patient safety consider-

VT(s) plus more limited substrate ablation using the other de-

ations). Scar-based reentrant VT usually incorporates PES using 3

scribed techniques. This approach necessarily requires exten-

extrastimuli at 2 drive CLs from 1 or more RV stimulation sites

sive ablation (with more fluid volume administered if irrigated

or at least as vigorous a stimulation protocol as was required to

ablation is employed) and potentially longer procedural times.

initiate arrhythmia prior to ablation, as well as achieving endpoints

The technique is not applicable to diseases that do not have
identifiable low-voltage scar regions.
6 Core isolation (S9.17.4.20, S9.17.4.21): The principle underlying
this strategy is that endocardial VT circuits can be somewhat

particular to whichever substrate-based ablation strategy is used.
2 If a “clinical” (spontaneously occurring) VT remains inducible at the
end of the procedure, the likelihood of postprocedure recurrence is
high.

“compartmentalized” by layers of midmyocardial scar tissue, such

3 Nonclinical VTs induced at the end of an ablation procedure have

that conduction is largely spread on the endocardial surface. The

a recurrence rate during follow-up lower than persistently induc-

encircling of the region with abnormal electrograms that contain

ible clinical VTs but higher than if no VT is induced at the end of

the VT circuits need only reach the midmyocardial barrier to iso-

the ablation procedure. Clinicians should carefully consider the

late the area (ie, damage need not be transmural). In the study

risks and benefits of targeting these nonclinical VTs, which entail

by Tzou et al (S9.17.4.21), core isolation was usually achievable

longer procedure time and potential risk.

and was associated with improved freedom from VT recurrence

4 It is reasonable to consider using NIPS 2-3 days after ablation to

compared with a nonrandomized reference group. This approach

refine the prognosis (see Section 10.4). If clinical VT can be initi-

is not always feasible and requires extensive ablation in some pa-

ated at that time, repeat ablation may be considered, although

tients. The extent to which these core elements reconnect with

the risks and benefits of this approach have not been defined.

healing of the ablation lesions and resolution of the edema is
unknown.
7 Imaging-guided lesion assessment: Estimating the acute extent (particularly depth) of ablation-related damage, particularly in normal
ventricular tissue, has been shown to be feasible with intracardiac
ultrasound (S9.17.4.22), CMR (S9.17.4.23), near-infrared spectroscopy (S9.17.4.24), and by elevations in the pacing threshold
(S9.17.4.25), as well as with other methods. Lesion size assessment
has promise for future applications as an indicator of the adequacy of
ablation but has not been studied in detail as a procedural endpoint.
8 Identification of a largely anatomically fixed substrate during
baseline rhythm by pace mapping (S9.17.4.26) and by locating
isolated potentials (S9.17.4.14) has been beneficial in identifying a critical isthmus. Targeting the arrhythmogenic substrate by
combining pace mapping and electrogram mapping has further
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10 | P OS TPRO C E D U R A L C A R E
10.1 | Postprocedural care: Access, anticoagulation, disposition
10.1.1 | Postprocedural care: Access
Recommendations for management of venous access sites after catheter ablation of VA
COR

LOE

Recommendations

References

I

A

1. Manual compression is effective in achieving hemostasis after
venous access for VT ablation.

S10.1.2.1–S10.1.2.3
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COR

LOE

Recommendations

References

IIa

B-R

2. Venous access closure using temporary purse-string or figure-
of-8 suture techniques can be useful in achieving faster hemostasis
and earlier ambulation and reducing pain or discomfort associated
with hemostasis compared to manual compression.

S10.1.2.1, S10.1.2.2

Recommendation-specific supportive text
1 Although little has been written on postprocedural management of
access sites specifically after catheter VT ablation, practices have
been adapted by extrapolating results from other procedures requiring femoral venous or arterial access. Manual compression has been
the standard of care for achievement of hemostasis after venous
sheath removal. In randomized studies of other electrophysiology
procedures comparing manual compression with temporary suture
closures or a vascular closure device, comparable high rates of
hemostasis had been achieved (S10.1.2.1–S10.1.2.3). Extrapolating
these results to ventricular ablation procedures, manual compression
is effective in achieving hemostasis, though time to hemostasis
can be expected to be shorter with temporary suture techniques
compared with manual compression (S10.1.2.1–S10.1.2.3).
2 The use of a temporary purse-string or figure-of-8 suture that can
be removed after achieving hemostasis has been studied after venous access in other ablation procedures, such as for AF, in which
procedures are routinely performed on uninterrupted anticoagulation and/or with large-bore catheters (S10.1.2.4–S10.1.2.8).
Compared with manual compression, temporary suture techniques
can yield faster hemostasis and ambulation times and reduce the
pain or discomfort associated with hemostasis. Two randomized
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studies have shown shorter times to hemostasis and ambulation,
with one reporting reduced rates of access complications compared with manual compression (S10.1.2.1, S10.1.2.2).
3 Vascular closure device-based methods for venous closure have
not been specifically studied for electrophysiology procedures
(S10.1.2.9–S10.1.2.11). One randomized study compared manual
compression to an extravascular closure system that delivers resorbable polyethylene glycol sealant external to the vessel at the
sheath access point in 208 patients with a 5, 6, or 7 Fr sheath in the
common femoral vein (S10.1.2.3). There were no vascular complications in either arm. Time to hemostasis was significantly shorter
in the device arm (0.12 ± 0.89 vs 7.6 ± 5.7 minutes; P < 0.001).
4 When the writing committee was surveyed regarding venous access hemostasis, all the respondents used manual compression,
approximately half (53%) used temporary figure-of-8 or pursestring sutures some of the time, and only 1 (6%) had used a vascular closure device.
5 Given that venous access complications are driven primarily by
insertion difficulties or concomitant arterial access, reduction in
venous access complication outcomes might be best achieved
with methods such as use of ultrasound at insertion, rather than
by device- or suture-based methods.

Recommendation for management of arterial access sites after catheter ablation of VA
COR

LOE

Recommendation

References

I

A

1. Achieving arterial access site hemostasis using either manual
compression or a vascular closure device is recommended.

S10.1.2.12, S10.1.2.13

Recommendation-specific supportive text
1 Arterial access after VT ablation is typically closed by manual
compression or use of vascular closure devices, with comparably high success rates in achieving hemostasis. Though
not specifically studied for VT ablation access closure, manual compression and vascular closure device use have been
extensively studied for coronary or structural intervention
procedures. Several systematic reviews and randomized trials
have demonstrated shorter time to hemostasis, with little need
for compression, shorter time to mobilization, and lower hematoma rates with use of vascular closure devices for arterial
closure compared with manual compression, with no differences in vascular injury, thrombosis, or infection (S10.1.2.12,
S10.1.2.13). Extrapolating these results to arterial closure after
VT ablation, vascular closure device use could reduce the

time to hemostasis and ambulation and reduce the risk of
hematoma, compared with manual compression. Vascular injury
rates for pseudoaneurysm, dissection, or arteriovenous fistula
might be more reflective of insertion difficulties rather than
of closure methods.
2 Use of vascular closure devices is generally avoided if the arteriotomy site is at or distal to the common femoral bifurcation, if
contamination of the sheath is suspected, or if the posterior wall
of the artery is suspected to have been punctured.
3 When the writing committee was surveyed regarding arterial access hemostasis, 42% of the respondents had used manual compression 100% of the time, 29% had used temporary figure-of-8
or purse-string sutures 1%-25% of the time, and 67% had used a
vascular closure device at least some of the time (24% had used a
vascular closure device over half the time).
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Recommendations for management of epicardial access sites after catheter ablation of VA
COR

LOE

Recommendations

I

C-EO

1. If pericardial bleeding or cardiac tamponade has occurred during epicardial VT ablation, a pericardial drain should be left in place until bleeding has resolved.

IIa

B-NR

2. The instillation of intrapericardial corticosteroids can be effective in reducing
pericarditic chest pain after epicardial VT mapping or ablation.

S10.1.2.14, S10.1.2.15

IIa

B-NR

3. To reduce pericardial pain after epicardial VT ablation, unless pericardial bleeding
or cardiac tamponade has occurred, it is reasonable to remove all pericardial access
sheaths at the end of the procedure.

S10.1.2.14, S10.1.2.15

IIb

C-EO

4. Leaving a pericardial drain in place might be reasonable in patients at high risk
for late bleeding or cardiac tamponade after epicardial VT ablation.

Recommendation-specific supportive text
1. If pericardial bleeding or cardiac tamponade has occurred during
the procedure, the pericardial drain should ideally be left in place
until there is minimal drainage output. This often requires observation in an intensive care unit and follow-up echocardiograms to
assess for residual or loculation of fluid.
2. Epicardial access for VT ablation can be associated with postprocedure pericarditic pain and acute pericarditis. The use of steroids
can reduce the incidence of postprocedure pericardial chest pain.
In an animal model, triamcinolone 2 mg/kg significantly attenuated
inflammation and postprocedure inflammatory adhesion formation after epicardial mapping and ablation (S10.1.2.16). Della Bella
et al (S10.1.2.14) compiled the epicardial VT ablation experience
of 6 European high-volume VT ablation centers. Of 218 patients,
postprocedural precordial pain occurred in 21% and was considered severe in half of these. Oral steroids were used by 1 center
routinely after 2007; 1 center routinely used intrapericardial steroids; and 4 centers did not use steroids. Dyrda et al (S10.1.2.15)
retrospectively evaluated the use of 3 therapeutic approaches on
the incidence of pericarditis and AF after epicardial mapping and
ablation for VT in 85 cases. The approach evolved over time from
no steroids to systemic oral or intravenous steroids (1 mg/kg/d for
3 days) to intrapericardial steroids (triamcinolone acetate 2 mg/kg,
injected into the pericardial space via a pigtail catheter and left in
place by capping of the pigtail). Compared with no steroids, the
incidence of pericarditic chest pain was lower with intrapericardial
steroids (21.1% vs 58.8%; P = 0.006), but not with intravenous or
oral steroids (43.4% vs 58.8%, P = 0.31). No difference was found in
the occurrence of ECG findings for pericarditis with steroid therapy
(36.8%, 30.0%, and 41.2% for intrapericardial steroids, intravenous

References

absence of bleeding or tamponade, 38% leave a pericardial drain
in place after epicardial ablation, usually for 8-24 hours (89%) or
>24 hours (11%).
3. Whether or not to leave a pericardial drain in place after epicardial ablation can be a difficult decision and is based on concerns for late cardiac tamponade. However, Della Bella et al.
(S10.1.2.14) noted that precordial pain could be due to the pigtail
left in the pericardium for continuous drainage. In the Dyrda et al
(S10.1.2.15) study the pigtail catheter was left in place <3 hours in
8% and ≥24 hours in 44%. More chest pain occurred if the pigtail
was left in place ≥24 hours (51% vs 25%; P = 0.012); however,
ECG changes were noted less frequently (19% vs 48%; P = 0.006).
4. In deciding whether to remove the pericardial drain, leaving a guidewire in the pericardial space after pericardial sheath removal and
observing several minutes with intracardiac or transthoracic echo
might be useful. This can exclude a “through and through” puncture of the RV, which will present with early significant hemorrhage
after sheath removal. A pericardial drain may be left in place after
epicardial ablation based on concerns for late cardiac tamponade.
Della Bella et al (S10.1.2.14) noted that 4 of 8 patients with cardiac
tamponade occurred late, which provided the rationale for leaving
a pericardial drain in place. In the study by Dyrda et al (S10.1.2.15),
postprocedure pericardial effusion or tamponade occurred in 13
patients, observed 18 ± 14 hours after the procedure. There were
4 cases of severe pericardial bleeding, occurring acutely in 2 and
delayed in 2. The delayed cases were given low-molecular-weight
heparin or heparin plus dual antiplatelet therapy. If the drain is left
in place, longer duration can be associated with pericarditic chest
pain (see above), and removal of the drain within 24 hours might
reduce the incidence of pericarditic chest pain.

or oral steroids, or no steroids, respectively), and a nonsignificant
reduced incidence of chest pain with ECG changes was found with
steroid use (13.2%, 10.0%, and 29.4% for intrapericardial steroids,
intravenous or oral steroids, or no steroids, respectively).
Among the writing committee members, 75% reported instilling
steroids in the pericardial space after epicardial mapping/ablation,
with 2 reporting this practice only after extensive epicardial ablation. Methylprednisolone, triamcinolone, or triamcinolone acetate
were used by 40%-50%, and 9% had used dexamethasone. Only
8% instilled lidocaine into the pericardial space after ablation. In the

10.1.2 | Atrial fibrillation after epicardial ventricular
arrhythmia ablation
The use of amiodarone might be reasonable to lower the risk of new-onset
AF after epicardial VT ablation in patients with evidence of acute pericarditis. AF is reported to occur in 4.1%-19.5% (S10.1.2.16–S10.1.2.18) of
patients after epicardial VT ablation and tends to occur more commonly
in those with signs of pericarditis. In the study by Dyrda et al (S10.1.2.15),
AF occurred in 8.3% of patients with no prior history of it. Median time
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to new-onset AF was 36 hours. Patients with pericarditic ECGs tended
to be at greater risk of AF (16.7 vs 3.6%; P = 0.091). Mahapatra et al.
(S10.1.2.18) reported a new AF incidence of 19.5%, and all had clinical symptoms of pericarditis. New AF was associated with younger
age, longer epicardial ablation time (424 ± 169 vs 867 ± 450 seconds;
P < 0.001), longer epicardial mapping time (103 ± 28 vs 135 ± 51 minutes; P = 0.02), RV puncture (9.1% vs 50.0%; P = 0.02), and pericarditis
pain score at 24 hours (1.58 ± 0.79 vs 2.25 ± 0.16; P = 0.03). Prolonged
drainage >24 hours was not associated with AF incidence (P = 0.28). The
occurrence of pericarditis renders anticoagulation decisions challenging;
however, the use of steroids was not associated with a lower incidence of
AF after epicardial VT ablation in these studies (S10.1.2.16, S10.1.2.18).
In contrast, the use of amiodarone was associated with lower rates of AF
in this population (87.9% vs 12.5%; P < 0.001 in the study by Mahapatra
et al) (S10.1.2.16, S10.1.2.18). New-onset AF tends to be paroxysmal and
self-limited after epicardial VT ablation. Amiodarone was used by only 1
writing committee member (4%) for AF prophylaxis after epicardial ablation. The writing committee did not feel there was sufficient evidence to
make a recommendation about amiodarone use in this setting.
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10.1.3 | Postprocedural care: Anticoagulation
Recommendations for anticoagulation after VA ablation procedures
COR
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Recommendations

References

IIa

C-LD

1. After less extensive endocardial VT ablation, treatment with an antiplatelet agent for a
limited period of time is reasonable.

S10.1.4.1, S10.1.4.2

IIa

C-LD

2. Heparin reversal with protamine for sheath removal after ablation is reasonable.

S10.1.4.3, S10.1.4.4

IIb

C-LD

3. After extensive endocardial VT ablation, treatment with an oral anticoagulant for a
limited period of time might be reasonable.

S10.1.4.1, S10.1.4.2

IIb

C-EO

4. The use of heparin bridging after endocardial VT ablation may be considered but can be
associated with an increased risk of periprocedural bleeding.

No

No

No

No

No

No

Not required

SMASH-V T
2007
(S10.1.4.6)

Stevenson 2008
(S10.1.4.1)

Euro-V T 2010
(S10.1.4.7)

VTACH 2010
(S10.1.4.8)

CALYPSO 2015
(S10.1.4.9)

Marchlinski
2016
(S10.1.4.10)

Postprocedure
NIPS

Not dictated
by the study
protocol

Discouraged

At 6 months and at
1, 2, and 3 y

At 3 and 6 mo

Not dictated by the study
protocol

Investigators were required to ensure that VT
detection in the ICD is
programmed at least 10
beats below the rate of the
slowest documented VT.

Per clinical conditions and physician
preference

At the discretion of
the treating physician, anticoagulation
recommended with
aspirin or warfarin
for 6–12 weeks

One transient ischemic
ST-segment elevation;
1 TIA
VF zone with a cutoff rate
of 200-220 bpm and a VT
zone with a cutoff CL of
60 ms above the slowest
documented VT and ATP
followed by shock.

Not specified

Discouraged

Every 3 mo from ICD
implantation until
completion of the
study

No major bleeding
or thromboembolic
complications

Not specified

Investigators were encouraged to program ICD
detection for slow VT for
at least 20 beats or 10 s to
allow nonsustained VT to
terminate before therapy is
triggered.

At 2, 6, and 12 mo,
with ICD interrogation where
applicable

Drug management during
follow-up was at
the discretion of
the investigator.

(Continues)

Cardiac perforation
(n = 1), pericardial effusion (n = 3)

Vascular access complications in 4.7%; no thromboembolic complications
Three months with
either 325 mg/d
aspirin or warfarin
if ablation had been
performed over an
area over 3 cm in
length.

Not specified

Echocardiogram
and neurologist
examination before
and after ablation;
office visit at 2 and
6 mo, with ICD
interrogation where
applicable

Six months, after
which time
drug therapy
was left to the
discretion of the
investigator

One pericardial effusion
without tamponade,
managed conservatively; 1 deep venous
thrombosis

Four of 146 (2.7%) stroke
or TIA, 4 (2.7%) episodes
of pericardial tamponade

Bleeding and thromboembolic events (ablation arm)

Oral anticoagulation
4-6 wk, aspirin if
fewer than 5 ablation
lesions

Not specified

Anticoagulation post
ablation

Not specified

Not specified

ICD programming

Followed in the ICD
clinic at 3, 6, 9, 12,
18, and 24 mo;
echocardiography
at 3 and 12 mo

Evaluation at 1, 3,
6, 9, 12, and 24 mo
after ablation

Follow-up

N/A

At least the first
3 mo after hospital discharge

AAD duration

|

Not dictated by the study
protocol

Discouraged

Discouraged

Drug management during
follow-up was at the discretion of the investigator.

The previously ineffective
AAD was continued for the
first 6 months, after which
time drug therapy was left
to the discretion of the
investigator.

No patient received an AAD
(other than beta blockers)
before the primary endpoint was reached.

Patients were continued on
the type of antiarrhythmic
therapy they had received
before ablation.

AAD type

Postprocedural care in prospective studies of ventricular tachycardia catheter ablation

Calkins 2000
(S10.1.4.5)

Study
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No

SMS 2017
(S10.1.4.12)

At the discretion of the
investigator

Continued preprocedure
antiarrhythmic medications

AAD type

At the discretion of the
investigator

Not specified

AAD duration

At 3, 6, 9, and
12 mo, and at 3-or
6-month intervals
until completion of
the study or until
33-month followup was reached

A 3-month office
visit, echo, ICD
check; a 6-month
office visit, ICD
check; every
6 months thereafter, an office visit,
ICD check

Follow-up

Major bleeding in 3
patients; vascular injury
in 3 patients; cardiac perforation in 2 patients

Two tamponades requiring pericardiocentesis

Aspirin (250 mg/d) or
warfarin as necessitated by the underlying heart disease

VF zone at 200-220 bpm,
detection 18 of 24 beats,
shock only; VT zone detection at least 16 consecutive
beats, ATP, and shocks.
Where VT rates were
exclusively > 220 bpm,
VT zone at 160–180 bpm
was recommended; where
VT rates were < 220 bpm,
VT zone with a CL 60 ms
above the slowest VT was
recommended

Bleeding and thromboembolic events (ablation arm)

Intravenous heparin
(without bolus) 6 h
after sheath removal,
then warfarin if
substrate-mapping
approach used or if
more than 10 min of
RF time

Anticoagulation post
ablation

VT detection at 150 bpm or
with a 10-20 bpm margin if
the patient was known to
have a slower VT. ATP was
recommended in all zones.
The protocol was modified
to recommend prolonged
arrhythmia detection duration for all patients.

ICD programming

Abbreviations: AAD, antiarrhythmic dug; ATP, antitachycardia pacing; CL, cycle length; ICD, implantable cardioverter defibrillator; NIPS, noninvasive programmed stimulation; RF, radiofrequency; TIA,
transient ischemic attack; VF, ventricular fibrillation; VT, ventricular tachycardia.

No

Postprocedure
NIPS

(Continued)

VANISH 2016
(S10.1.4.11)

Study

TA B L E 9
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along with initiation of warfarin. This was followed by 3 months
of anticoagulation, or longer if another indication was present.

1 Antiplatelet therapy for less extensive endocardial VT ablation

If a direct oral anticoagulant had been administered prior to the

appears to be safe, with no significant bleeding nor thromboem-

procedure, it was resumed as early as 48 hours after sheath re-

bolism risks. The Multicenter Thermocool Ventricular Tachycardia

moval if there was no bleeding. With this regimen, in-hospital

Ablation Trial has recommended antiplatelet therapy with aspirin

bleeding occurred in 6% and an arterial thromboembolic event

325 mg/d or anticoagulation with warfarin for 3 months after

occurred in 1 (0.6%) patient who had received bridging antico-

ablation, if ablation has been performed over an area with >3 cm

agulation. Among the 214 patients discharged, 89% were pre-

between ablation sites (S10.1.4.1). No procedure-related thrombo-

scribed systemic anticoagulation, and no definite or possible

embolic complication or stroke had been detected by neurological

thromboembolic events were documented in the first 3 months;

examination. In the study by Siontis et al (S10.1.4.2), in patients

1 patient had a major bleeding event. Of the writing commit-

with less extensive ablation, antiplatelet agents with full-dose

tee members, approximately two-thirds initiate anticoagulation

aspirin or clopidogrel plus aspirin were used at the physician's

after LV endocardial ablation in some patients, generally after

discretion instead of therapeutic anticoagulation. Among 24 pa-

more extensive lesions. The postprocedural anticoagulation

tients discharged on only antiplatelet agents (4 low-dose aspirin,

protocols in the major prospective studies of VT catheter abla-

9 full-dose aspirin, 1 clopidogrel, 10 combination of aspirin and

tion are outlined in Table 9.

clopidogrel), no definite or possible thromboembolic events and no

4 Heparin bridging to oral anticoagulation or ambulation has been

bleeding events were documented in the first 3 months. Among

practiced but can be associated with a small risk of periprocedural

the writing committee, over 90% prescribe either antiplatelets or

bleeding after VT ablation. Among patients bridged with low-mo-

anticoagulants after endocardial VA ablation, with various criteria

lecular-weight heparin to oral anticoagulation after VT ablation,

used to decide which. When antiplatelets were used (almost

Siontis et al (S10.1.4.2) reported in-hospital bleeding in 6% of the

exclusively aspirin), the most common duration was 4-6 weeks.

patients. Of the two-thirds of writing committee members who

2 Anticoagulation during left-sided VT ablation procedures is gener-

initiate anticoagulation after endocardial LV ablation, 60% initiate

ally reversed for sheath removal, typically with protamine. In a ret-

heparin until this has been established, and a further 20% if start-

rospective cohort study of 158 patients undergoing RF catheter

ing warfarin until the international normalized ratio is >2, but not if

ablation, including 11 for VAs, 116 received protamine and 42 did

starting a direct oral anticoagulant. See Section 5.5 for further dis-

not (S10.1.4.3). No significant difference in thrombotic events was

cussion of this topic, including the writing committee's practices.

observed between groups (one pulmonary embolism in the protamine group and 0 thrombotic events in the control group). Among
150 patients undergoing AF ablation, a randomized trial reported

10.1.4 | Postprocedural care: Disposition

that compared to control, protamine reversal of heparin led to

After completion of VT ablation, patients are generally monitored

a trend toward shorter duration of manual compression (20 ± 9

on telemetry in the hospital for at least 1 day, and often longer for

vs 24 ± 16 minutes; P = 0.06) and a shorter time to ambulation

VT ablation in cases of SHD or heart failure. Patients who are hemo-

(316 ± 80 vs 480 ± 92 minutes; P < 0.001), with no differences in

dynamically unstable, who require hemodynamic or ventilator sup-

vascular access complications or thromboembolic events (S10.1.4.4).

port, or who have had pericardial bleeding, cardiac tamponade, or a

3 After extensive endocardial VT ablation, use of anticoagula-

pericardial drain left in place are usually monitored and stabilized in

tion for a period of time has frequently been included as part

an intensive care unit prior to transfer to a regular telemetry floor.

of postprocedural practice, although there are no comparison

Selected right-sided ablation patients may be discharged the same

studies. In the Multicenter Thermocool Ventricular Tachycardia

day, if stable, but patients with significant comorbidities, any insta-

Ablation Trial, antiplatelet therapy with aspirin 325 mg/d or

bility, or left-sided VA ablation are typically monitored >24 hours.

anticoagulation with warfarin was administered for 3 months

Transtelephonic or CIED remote monitoring is often used to facili-

after ablation if ablation was performed over an area with

tate follow-up (see Section 10.4). Outpatient follow-up generally oc-

>3 cm between ablation sites (S10.1.4.1). No procedure-related

curs by 1-4 months after the procedure.

thromboembolic complication or stroke was detected. The an-

A survey of the writing committee showed that 42% routinely

ticoagulation regimens used in other major prospective clinical

have patients monitored in an intensive care unit after ventricular

trials are described in Table 9. Siontis et al. (S10.1.4.2) evalu-

ablation. Stable patients are kept in the hospital for 1 day (overnight)

ated an anticoagulation protocol after VT ablation of large LV

by 35%, 2 days by 52%, 3 days by 9%, and >3 days by 4% of the writ-

endocardial ablation areas (>3 cm between ablation sites) in 217

ing committee members.

patients with infarct-related VT without evidence of procedurerelated pericardial effusion. Starting 8 hours after access site
hemostasis, an infusion of low-dose, slowly escalating unfractionated heparin 600-900 U/h was administered for 6 hours,
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another hospitalization, those that require additional intervention for treatment, and/or those that result in significant injury or
death. All other complications, such as small hematomas not requiring intervention, are defined as minor. A recent meta-analysis
reported major complication rates of 8%-10% after VT ablations
(S10.2.9.4). Slightly higher complication rates have been reported
in administrative and registry real-world studies compared with
clinical trials (9.39% vs 7.97%) (S10.2.9.4). The most common
complication reported is vascular damage, followed by pericardial complications (cardiac tamponade, hemopericardium, pericarditis). Although new technologies and techniques have been
incorporated for VT ablations, the rate of complications has not
decreased, perhaps because more patients at high risk have been
scheduled for ablation (S10.2.9.2). It is also notable that in one recent study, the complication rates were independently related to
operators and to timing of the procedure, with significantly higher
complication rates when the ablation was begun after 2 pm (10% vs
5%; P < 0.0001) (S10.2.9.5).

10.2.2 | Mortality
Interpretation of mortality in the setting of VT ablations in patients
with SHD is difficult, given mortality can be a consequence of
procedure-related complications but can also be related to procedural failure (incessant or recurrent VT). Table 10 shows the incidence of in-hospital or early mortality in patients who underwent
VT ablation. Some clinical trials have shown no mortality, whereas
other studies have reported rates of in-hospital or early mortality as
high as 3% (S10.2.9.1, S10.2.9.2, S10.2.9.6–S10.2.9.10). Some of the
following predictors of in-hospital or early mortality have been reported: smoking, hypothyroidism, fluid and electrolyte disturbances,
chronic renal failure, peripheral vascular disease, lower LVEF, history
of AF, ICM, and multiple slow VTs (S10.2.9.1, S10.2.9.6, S10.2.9.7). It
is also important to note that VT ablation in low-or medium-volume
centers has been shown to be an independent predictor of mortality
in these complex ablations (S10.2.9.1).

10.2.3 | Acute periprocedural hemodynamic
decompensation and cardiogenic shock
Periprocedural AHD, defined as sustained systolic hypotension de-

10.2 | Incidence and management of complications

spite optimized doses of vasopressors or requiring mechanical HS

10.2.1 | Introduction

tions in patients with SHD (S10.2.9.10). The occurrence of AHD is

Ablation of VAs is an invasive procedure that can be performed in

recurrence of VT, and procedure failure (S10.2.9.10, S10.2.9.12–

patients with or without SHD. Despite new technologies and progress in techniques in recent years, complications are expected, especially in patients with more severe disease. In fact, the incidence
of complications related to VT ablation is higher in patients with
SHD than in idiopathic VT (S10.2.9.1–S10.2.9.3).
For the purpose of this document, major complications are
defined as those that result in prolongation of hospital stay or

and procedure discontinuation, can occur in up to 11% of VT ablaassociated with increased in-hospital and long-term mortality, higher
S10.2.9.14). Some of the following predictors of AHD have been
reported, although they were tested only in a univariate analysis:
older age, diabetes mellitus, ICM, NYHA class III/IV, VT storm, lower
EF, prolonged procedure duration, and general anesthesia. Ablation
should be carefully planned in these patients (S10.2.9.10). A score
was developed to identify higher-risk patients, who might benefit

Emboli from left ventricle,
aortic valve, or aorta;
cerebral bleeding

Catheter manipulation,
RF delivery, epicardial
perforation

3%-35%
(12–
39 mo of
follow-up)

0%-2.7%

0%-2.7%

0%-1.4%

0.4%-1.9%

0%-3%

0%-0.7%

Long-term mortality

Neurological complication (stroke,
TIA, cerebral
hemorrhage)

Pericardial
complications:
cardiac tamponade,
hemopericardium,
pericarditis

AV block

Coronary artery
damage/MI

Heart failure/pulmonary edema

Valvular injury

Catheter manipulation,
especially retrograde
crossing the aortic valve
and entrapment in the mitral valve; energy delivery
to subvalvular structures,
including papillary muscle

External irrigation, sympathetic response due to ablation, and VT induction

Ablation near coronary artery, unintended coronary
damage during catheter
manipulation in the aortic
root or crossing the aortic
valve

Energy delivery near the
conduction system

VT recurrence and progression of heart failure

VT recurrence, heart
failure, complications of
catheter ablation

0%-3%

In-hospital mortality

Mechanisms

Incidence

Acute cardiovascular
collapse, new murmurs,
progressive heart failure
symptoms

Heart failure symptoms

Acute coronary syndrome;
confirmation with coronary catheterization

Fall in blood pressure and
ECG changes

Abrupt or gradual fall in
blood pressure; arterial
line is recommended in
ablation of complex VT

Focal or global neurological deficits

Cardiac nonarrhythmic
death (heart failure) and
VT recurrence

Not applicable

Presentation

Careful catheter manipulation; ICE
can be useful for identification of
precise location of energy delivery

Urinary catheter and careful attention to fluid balance and diuresis,
optimize clinical status before
ablation, reduce irrigation volume
if possible (decrease flow rates or
use closed irrigation catheters)

Limit power near coronary arteries
and avoid energy delivery <5 mm
from coronary vessel; ICE is useful
to visualize the coronary ostium

Careful monitoring when ablation
is performed near the conduction
system; consider cryoablation

Contact force can be useful, careful
in RF delivery in perivenous foci
and RVOT

Careful anticoagulation control; ICE
can help detection of thrombus
formation, and of aortic valve calcification; TEE to assess aortic arch

Identification of patients with indication for heart transplantation

Correct electrolyte disturbances
and optimize medical status before
ablation

Prevention

Major complications of ventricular arrhythmia ablation in patients with structural heart disease

Complication

TA B L E 1 0

Echocardiography is essential in
the diagnosis; medical therapy,
including vasodilators and
dobutamine before surgery;
IABP is useful in acute mitral
regurgitation and is contraindicated in aortic regurgitation

New/increased diuretics

Percutaneous coronary
intervention

Pacemaker; upgrade to a biventricular pacing device might be
necessary

Pericardiocentesis; if necessary, surgical drainage, reversal
heparin; steroids and colchicine
in pericarditis

Thrombolytic therapy

—

—

Treatment

|
(Continues)

S10.2.9.6–S10.2.9.9

S10.2.9.6–S10.2.9.9

S10.2.9.1,
S10.2.9.6–S10.2.9.9

S10.2.9.1,
S10.2.9.6–S10.2.9.8

S10.2.9.1,
S10.2.9.6–S10.2.9.9

S10.2.9.1,
S10.2.9.6–S10.2.9.9

S10.2.9.6–S10.2.9.9

S10.2.9.1,
S10.2.9.6–S10.2.9.9

Ref.
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7%-14.7%
Overall all
complications

3.8%-11.24%
Overall major
complications with
SHD

Abbreviations: AV, atrioventricular; ECG, electrocardiogram; HS, hemodynamic support; IABP, intra-aortic balloon pump; ICE, intracardiac echocardiography; MI, myocardial infarction; pLVAD, percutaneous left ventricular assist device; RF, radiofrequency; RVOT, right ventricular outflow tract; SHD, structural heart disease; TEE, transesophageal echocardiography; TIA, transient ischemic attack; VT,
ventricular tachycardia.

S10.2.9.2, S10.2.9.7,
S10.2.9.11

S10.2.9.1,
S10.2.9.6–S10.2.9.9

S10.2.9.1,
S10.2.9.6–S10.2.9.9
Ultrasound-guided compression,
thrombin injection, and surgical
closure
Ultrasound-guided access
Groin hematomas, groin
pain, fall in hemoglobin
Access to femoral arterial
and catheter manipulation
0%-6.9%
Vascular injury:
hematomas, pseudoaneurysm, AV
fistulae

S10.2.9.6–S10.2.9.10
Mechanical HS
Close monitoring of fluid infusion
and hemodynamic status
-Optimize medical status before
ablation
-pLVAD
-Substrate mapping preferred, avoid
VT induction in higher-risk patients
Sustained hypotension despite optimized therapy
0%-11%
Acute periprocedural hemodynamic
decompensation,
cardiogenic shock

Fluid overloading, general
anesthesia, sustained VT

Incidence
Complication

TA B L E 1 0

(Continued)

Mechanisms

Presentation

Prevention

Treatment

Ref.
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from periprocedural HS. The PAAINESD score is further discussed
in Section 5.1.
Some measures can help to prevent these complications: close
monitoring of fluid balance and diuresis, careful attention to hemodynamic status, optimization of medical status before ablation,
avoidance of VT induction in higher-risk patients, preferring substrate mapping ablation, and avoidance of general anesthesia and
certain drugs that can result in myocardial depression, including
propofol. Use of a pLVAD, as discussed in Section 6.4, might be helpful in specific cases (S10.2.9.11–S10.2.9.14).
The pLVAD has been used in two scenarios: prophylactic, when
higher-risk patients are identified, and for rescue during an acute
complication. When used prophylactically, the pLVAD has been
shown to prevent AHD and has a lower 30-day mortality (4.2% vs
58%). Mathuria et al (S10.2.9.15) showed a similar 30-day mortality
among patients with prophylactic use compared to the non-pLVAD
group (4.2% vs 3.1%), although the first group showed a higher
PAAINESD score (16.5 vs 13.5; P = 0.02). Other studies have failed
to demonstrate the benefit of pLVAD, although the fact that these
devices are selected for patients with more severe disease is a bias
that is not possible to rule out (S10.2.9.11, S10.2.9.13–S10.2.9.16).
Furthermore, few randomized, prospective, controlled trials exist
to identify the appropriate utility of this device in the setting of VA
ablation.

10.2.4 | Neurological complications
Neurological complication is a rare but devastating event due to
cerebral emboli or intracerebral hemorrhage that can occur with VA
ablation, with a reported incidence of 0%-2.7% (S10.2.9.1, S10.2.9.6–
S10.2.9.9). It can occur during or shortly after the ablation procedure,
usually in the first 24 hours, although in the two subsequent weeks
following the procedure the risk is still present. Possible mechanisms
for thromboembolic complications include thrombus formation on
the catheter or on the tissue, air embolism, plaque disruption in
the aortic arch, displacement of endocardial thrombus adhered to
LV prior to ablation, char formation and/or tissue disruption during
ablation, or generation of calcific emboli while passing a catheter
through a heavily calcified aortic valve. Optimal anticoagulation during the procedure targeting ACT >300 seconds and adequate control
of RF energy delivery parameters are important practices that could
help to prevent thrombus formation during ablation. Given that air
embolism can also occur, careful attention to sheath management is
crucial. In the presence of specific neurological symptoms suggesting stroke or transient ischemic attack after ablation, brain MRI, CT,
or cerebral angiography should be performed. If stroke is confirmed,
thrombolytic therapy or endovascular mechanical or pharmacological therapy might be useful.
A possible neurological complication is asymptomatic microembolism that results from thrombus formation, gas, tissue and/or fat
dislodgement, and/or air embolism (S10.2.9.17). The long-term consequences of this phenomenon are unknown.
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10.2.5 | Pericardial complications: Cardiac
tamponade, hemopericardium, and pericarditis

CRONIN et al.

ablation procedures (S10.2.9.4). Vascular complications after VT ablation are typically related to vascular access and include hematoma,
retroperitoneal hematoma, pseudoaneurysm, arteriovenous fistula,

Pericardial complication is the second most common reported compli-

and dissection or occlusion of the artery accessed. Prior to sheath

cation of VT ablation in patients with SHD, being reported in 0%-4.5%

deployment, confirmation that the guide wire used for arterial ac-

of procedures, although it can be higher in the subgroup of procedures

cess is indeed in the lumen and not in the arterial wall is important

in which pLVAD is used (S10.2.9.1, S10.2.9.6, S10.2.9.8, S10.2.9.9,

to avoid retrograde dissection of the iliac artery and aorta. This can

S10.2.9.15, S10.2.9.16). In one study by Turagam et al. (S10.2.9.13),

be accomplished with techniques such as ultrasound or angiography.

however, the incidence of cardiac tamponade was 5% vs 1.8% when

Furthermore, longer sheaths are preferable in the setting of tortu-

HS was used in VT ablation procedures. A greater incidence of peri-

ous peripheral vessels to avoid damage of the vessel wall with the

cardial effusion is expected in epicardial compared with endocardial

catheter tip. Imaging of the aortic arch (with transesophageal echo-

approaches (S10.2.9.18). Possible mechanisms of this complication are

cardiography or CT) prior to ablation using a retrograde approach

cardiac perforation due to overheating, direct trauma due to catheter

could help to identify patients at risk for thromboembolic events in

manipulation, transseptal accident when this approach is chosen, or

the presence of mobile atheromas or thick plaque material. ICE can

accident when using a pericardial approach. The level of anticoagula-

also be beneficial to identify plaque material in the ascending aorta

tion can also influence the possibility of hemopericardium, facilitating

prior to a planned retrograde approach. Many electrophysiologists

the perpetuation of bleeding. Cardiac tamponade must be suspected

curve the ablation catheter to a “J” shape in the descending aorta

if there is a drop in blood pressure; thus, an arterial line for continu-

to minimize trauma to the aortic valve when mapping the LV with

ous blood pressure monitoring is important, and previous recordings

a retrograde approach. The catheter is then prolapsed into the LV.

of cardiac silhouette in the left anterior oblique view can be helpful.

In higher-risk patients, such as those with high body mass index,

ICE can help to prevent or quickly detect this complication, allowing

body surface area <1.6 m2, hypertension, age >70 years, baseline

earlier initiation of appropriate treatment that might prevent more

anemia, and known peripheral vascular disease, ultrasound-guided

serious and irreversible consequences. The use of ICE in this setting

percutaneous access and careful management of anticoagulation

is discussed in Section 8.6. When pericardial drainage is needed, an-

status should be strongly considered (S10.2.9.19). Reversal of hepa-

ticoagulation therapy should be reevaluated, and reversing heparin

rin with protamine before sheath removal can also be useful to pre-

effects with protamine might be necessary. Percutaneous pericar-

vent groin hematoma. There are no conclusive data demonstrating

diocentesis and placement of a pericardial drain are frequently man-

that the use of vascular closure devices decreases this complication

datory in cardiac tamponade. The aspirated pericardial blood can be

compared with manual compression (S10.2.9.20).

returned to the central vein when the cardiac tamponade is diagnosed

Large hematomas after sheath removal are the most common

during the procedure, although this approach has not been systemati-

complication and are usually self-
limited, but they can be large

cally evaluated. The ablation procedure is usually interrupted unless

enough to result in blood transfusion. When femoral arterial pseu-

bleeding stops shortly after drainage. In some cases, surgical repair

doaneurysm and arteriovenous fistulas are suspected, ultrasound

might be necessary if the bleeding is not controlled. After drainage

Doppler or CT scan are useful imaging tools for diagnosis. A CT scan

and clinical stability, a pericardial drain should be maintained during

can also be useful in patients with back pain and acute anemia after

the first 24 hours, and echocardiography should be used for further

ablation to evaluate for retroperitoneal hematoma. Percutaneous

evaluation and decisions regarding the timing of removing the peri-

thrombin injection, surgical repair of pseudoaneurysm and arterio-

cardial drain. It is also important to carefully evaluate the appropriate

venous fistula, and surgical evacuation of large hematomas are pos-

timing of reintroducing anticoagulation therapy as needed.

sible interventions for these vascular complications.

Another pericardial complication that can be found after VT ablation is pericarditis. It can be the sole complication or it might follow
pericardial drainage due to cardiac tamponade. Symptoms of chest
pain and low-
grade fever, leukocytosis, and elevated C-
reactive

10.2.7 | Myocardial ischemia, coronary
artery damage

protein levels are commonly observed; diagnosis can be confirmed

Myocardial ischemia can occur during VT ablation due to hypoten-

with ECG or echocardiogram. Pericarditis is also typically more fre-

sion after VT induction or other causes. MI was reported in 1.7% in a

quent when an epicardial approach is used. Steroid administration

large retrospective database study (S10.2.9.1). Caution is crucial es-

in the pericardial space might be useful to prevent pericarditis (see

pecially in patients with known nontreatable ischemia, possibly with

Section 10.1). Treatment with nonsteroidal anti-inflammatory drugs,

avoidance of VT induction. Coronary artery damage can also cause

colchicine, and/or steroids is useful.

myocardial ischemia. Although injury to coronary arteries is rare,
it can occur while crossing the aortic root with the catheter when

10.2.6 | Vascular injury

using the retrograde aortic approach, with ablation in the coronary
cusps, or with dislodgement of the ablation catheter in the LVOT.

The incidence of vascular injury after VT ablation ranges from 0% to

ICE, as discussed in Section 8.6, can be useful for continuous visu-

8.6% and is the most common major complication reported after VT

alization of the ablation catheter and the coronary artery ostium.

CRONIN et al.

Coronary angiography and continuous protection using a coronary
angioplasty wire can be useful when the ablation site is close to a
coronary ostium (S10.2.9.21).

10.2.8 | Valve injury
Valve injury is a rare but potentially fatal complication of VT ablation
(Table 10). The incidence of valve injury is reported in up to 0.7% of
cases (S10.2.9.6–S10.2.9.9); when using the retrograde aortic approach, it can occur while crossing the aortic valve with the ablation
catheter. Entrapment of the ablation catheter in the mitral or tricuspid
valve can also occur using transseptal or retrograde approaches. Energy
delivery direct to the valve apparatus can lead to valve injury. Ablation
of the papillary muscle could result in this complication, and it can occur
with both RF energy and cryoablation (S10.2.9.22, S10.2.9.23).
Clinical presentations of this complication include acute cardiovascular collapse, new murmurs, and symptoms of worsening congestive heart failure. It is important to note that this complication
can occur immediately after the ablation when resulting from entrapment or mechanical damage, but when resulting from direct energy delivery to the papillary muscle, symptoms can appear weeks
after the ablation procedure.
To prevent valve damage, one should be careful whenever manipulating the catheter when crossing the aortic valve and mapping
near the mitral valve. ICE is useful to continuously visualize catheter
position and its relationship with the valve apparatus and papillary
muscle (see details of ICE in Section 8.6). Surgical intervention might
be needed for removal of an entangled catheter or for repair of a damaged valve. Given the acute damage of the valve, repair instead of
valve replacement is always preferable whenever possible.

10.2.9 | Atrioventricular block
AV block is reported in up to 1.4% of the VT ablations (S10.2.9.1,
S10.2.9.6–S10.2.9.9), and it can occur when ablation is performed in the
septal region near the conduction system. It can be anticipated in patients with a known diseased conduction system, especially in patients
with previous complete bundle branch block (either right or left) and energy delivered to the basal septum (either left or right sided). If the ablation is performed during VT, monitoring of AV conduction is not possible,
and ablation during sinus rhythm might be preferable. Although many VT
ablations are performed in patients with a CIED, the need for RV pacing
could worsen LVEF, and upgrade to CRT might be required.
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10.3 | Hemodynamic deterioration and proarrhythmia
Recommendation for echocardiography after VA ablation
COR

LOE

Recommendation

Reference

I

C-LD

Echocardiography should be performed in case of hemodynamic deterioration
post-V T ablation to assess for pericardial effusion and cardiac tamponade.

S10.3.1

Recommendation-specific supportive text
1 Cardiac tamponade is a serious and potentially reversible cause
of hemodynamic deterioration after VA ablation. It can present
intraprocedure, postprocedure, or late. When suspected, immediate
transthoracic, transesophageal, or ICE should be performed to assess for the presence of a pericardial effusion or thrombus (S10.3.1).

Synopsis
Extensive ablation in viable myocardium and repeated VT episodes with hypotension that can cause myocardial ischemia can
lead to worsening of heart failure or cardiogenic shock in patients with impaired ventricular function. In patients with scar-
related VT, particularly after MI, heart failure accounts for more
than one-third of mortality during follow-u p late after ablation
and exceeds 10% per year in some studies (S10.3.2–S10.3.10).
In the Multicenter Thermocool Ventricular Tachycardia Ablation
Trial, 35% of 1-year mortality was due to heart failure (S10.3.3).
In another study, despite the lack of a difference in the EF for the

patients had early recurrent VT preceding death, although the
time course from time of first VT recurrence to death was highly
variable. Refractory VT was the cause of death in 22% of cases,
with another 39% dying of other cardiac causes (most commonly
advanced heart failure) (S10.3.14).
Nevertheless, hemodynamic deterioration and early mortality
from heart failure after ablation remain concerns, especially in patients with fragile hemodynamic status, patients with evident hemodynamic deterioration, or patients who required extensive ablation
in areas of normal ventricular myocardium or near coronary arteries.
Close monitoring of LV function and potential need for continued
hemodynamic monitoring and/or support might be necessary after
such ventricular ablation procedures.
Nontransmural and incomplete lesions can form a new or modified substrate, promoting arrhythmia after ablation; indeed, the majority of VTs recurring after ablation of postinfarction VT are new
VTs, as determined by analysis of ICD electrograms and repeat ablation procedures (S10.3.15).

entire group, 14 of 62 (22.5%) patients did have a decline in EF
when a repeat echocardiogram was performed within 7 days of
the ablation (S10.3.10). However, some observations suggest that
VT ablation might not be the sole nor major cause of the heart
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chronic kidney disease, VT storm, and unmappable VTs can pre-
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10.4 | Follow-up of patients post catheter ablation of ventricular tachycardia
Recommendation for NIPS after catheter ablation of VT
COR

LOE

Recommendation

References

IIa

B-NR

NIPS can be useful in the several days following VT catheter ablation to inform
further management, including ICD programming, predicting the risk of VT recurrence, and/or considering a repeat VT catheter ablation.

S10.4.1, S10.4.2

Recommendation-specific supportive text

therapy in 210 consecutive patients. The positive and negative
predictive values of PES for VT recurrence over 1 year of follow-

1 Some advocate for routine PES, largely NIPS, shortly after VT
catheter ablation and before discharging patients. However, there
are no data from RCTs on the clinical usefulness of such a
practice. Data on NIPS after VT catheter ablation were generated by two observational studies. In one such study, 132 patients
with SHD underwent NIPS an average of 3 days after VT catheter
ablation; 59 (44.7%) patients had no inducible VT, 49 (37.1%)
had inducible nonclinical VT, and 24 (18.2%) had inducible clinical
VT. At 1 year, patients with inducible clinical VT had a significantly lower VT-free survival than patients with no inducible VT

up were 53% and 88%, respectively, and the negative predictive
value was highest among patients with IHD and those with an
LVEF >35% (S10.4.2). However, these studies were single-center,
retrospective studies that did not include a large number of
patients and that did not subject all patients undergoing VT
catheter ablation to PES (S10.4.1, S10.4.2). As such, the routine
performance of NIPS is currently not standard of care, and decisions regarding NIPS should be individualized until more data
from prospective studies, preferably RCTs, emerge on the clinical
usefulness of NIPS post-VT catheter ablation.

(<30% vs >80%; P < 0.001). The authors concluded that when
patients with VT and SHD have no VT or have only inducible

Summary

nonclinical VT at the end of ablation or if they are too unstable

Close follow-up of patients after VT catheter ablation is critically

to undergo final programmed stimulation during ablation, NIPS

important because complications can be detected and addressed

can be useful in the subsequent several days to further define

during this period, and decisions regarding postprocedure manage-

the risk of VT recurrence, and if clinical VT is inducible during

ment are made. These decisions relate to whether to perform NIPS,

NIPS, to consider repeating VT catheter ablation due to the

whether to maintain the patient on an AAD, and how to best pro-

high risk of recurrence during follow-up (S10.4.1). In another

gram and follow ICDs in patients with such devices.

study, 218 PESs (186 noninvasive and 32 invasive) were per-

Another important decision after VT catheter ablation is whether

formed an average of 6 days after ablation on beta-blocker

to maintain a patient on an AAD, and if so, what medication to choose
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and for what duration. No RCTs have specifically addressed these issues, and RCTs of VT catheter ablation implemented different protocols related to postprocedure use of AADs (Table 9). In 3 clinical

S10.4.5.

trials of VT catheter ablation, preablation AADs (mostly amiodarone)
were continued either for 3-6 months or for an unspecified period

S10.4.6.

of time (S10.4.3–S10.4.6). In 3 other clinical trials of VT ablation, the
use of AADs post-VT catheter ablation was either discouraged or left
to the discretion of the treating physician (S10.4.7–S10.4.9). In the
SMASH-VT trial, no patient received an AAD (other than beta block-

S10.4.7.

ers) before the primary endpoint was reached (S10.4.10). Given this
variability in the use of AADs post-VT ablation in prior RCTs, there is
no standard of care for their use in this scenario; as such, decisions in
this regard should be individualized based on patient characteristics

S10.4.8.

and findings of the PES at the end of the VT catheter ablation (or
later), keeping in mind the toxicities of these medications and their
potential detrimental effects on survival (S10.4.11). In particular,

S10.4.9.

given its toxicities, many favor discontinuing amiodarone after ablation. In fact, amiodarone use had decreased in several prospective
cohort studies of VT ablation (S10.4.4, S10.4.6, S10.4.9), and dose
reduction or discontinuation had been feasible in patients who were

S10.4.10.

not inducible post ablation in 1 single-center experience (S10.4.12).
Data on the best programming parameters of ICDs post-
VT

S10.4.11.

catheter ablation are scarce, given that studies of optimal ICD
programming were conducted largely in patients with no prior VT
(S10.4.13–S10.4.15). In a few clinical trials of VT catheter ablation, information on ICD programming was not provided (S10.4.3,
S10.4.4, S10.4.10). In the clinical trials that provided information on
ICD programming, programming instructions to the sites were vari-

S10.4.12.

able (Table 9). However, based on current practice, ICDs may be programmed with a 10-20 bpm margin if the patient has slower VT and,
where appropriate, with ATP and prolonged arrhythmia detection

S10.4.13.

durations and higher detection rates for VF. Although not specific
to post-V T catheter ablation programming, the HRS document on
optimal programming of ICDs can be a useful resource (S10.4.15).

S10.4.14.

Given the risk of VT recurrence after VT ablation, it is imperative to
follow ICDs closely, preferably with remote monitoring that allows
earlier detection and treatment of VT recurrences (S10.4.16).
S10.4.15.
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Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm.
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10.5 | Assessing the outcomes of catheter ablation
10.5.1 | Introduction
Important outcomes of clinical trials for VA catheter ablation include
procedure-related complications and mortality, recurrent VA, long-
term mortality, and quality of life. It is also important to recognize
that outcomes are also impacted by the many factors following
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F I G U R E 1 3 Factors influencing
outcomes post VA ablation.
ICD = implantable cardioverter
defibrillator; LVAD = left ventricular assist
device; VA = ventricular arrhythmia;
VT = ventricular tachycardia

ablation that have the potential to influence the frequency and nature of arrhythmia recurrences (Figure 13).

ICDs (S10.5.7.5–S10.5.7.7). This type of analysis can be challenging.
The number of VT episodes before and after ablation can be influenced by programmed ICD detection criteria and AAD management.

10.5.2 | Recurrent arrhythmias

It is also difficult to know how to assign a “frequency” to preablation incessant VT or VT storm for comparison with single VT recur-

Recurrence of any sustained VT is an important endpoint for patients

rences post ablation. Prior ICD interrogations are not always available

who have ICDs. In patients with SHD and ICDs, the QRS morphology

to confirm the arrhythmia burden. The VT burden that has clinical

of recurrent VT compared with preablation VT is frequently difficult

relevance has not been defined and likely would vary depending on

to assess and is not usually reported in clinical trials. The ECG mor-

other patient factors. Further work on methods by which arrhythmia

phology of spontaneous VTs terminated by ICDs is often unknown,

burden can best be assessed and compared in patients undergoing

and the QRS morphology of VTs can be altered by changes in the ar-

VT ablation is needed.

rhythmia substrate and AAD therapy after ablation. Any spontaneous
sustained VT might be of clinical significance, whether it was observed
previously or not. Clinical trials assessing the effect of catheter abla-

10.5.4 | Ventricular tachycardia storm

tion on recurrent sustained VT have reported the time from the abla-

VT storm has been defined as 3 or more separate episodes of sus-

tion procedure to the first recurrence of VT in Kaplan–Meier curves

tained VT in a 24-hour period, and it has been associated with poorer

(S10.5.7.1–S10.5.7.4). These curves provide important information

outcomes (S10.5.7.8). Prevention of VT storm is an important goal.

and are widely understood. They fail, however, to capture other po-

Again, ICD programming has an important influence on detection

tential benefits of the procedure, including reduction in VT burden,

and counting of these events.

prevention of VT storm, conversion of symptomatic episodes causing
ICD shocks to asymptomatic episodes terminated by ATP, and reductions in medications.

10.5.5 | Hospitalizations

For patients with nonsustained VAs and PVCs, outcome as-

Hospitalizations for cardiovascular disease and recurrent VA are

sessment is determined by ambulatory monitoring of a duration

also potentially important outcomes. Recurrent arrhythmias can be

sufficient to detect recurrences, based on the frequency of the ar-

precipitated by intercurrent illness. Whether a patient requires hos-

rhythmia prior to treatment, and considering the goals of therapy.

pitalization for a recurrence is sometimes a subjective assessment.

10.5.3 | Arrhythmia burden

10.5.6 | Patient-reported outcomes

Several studies have reported arrhythmia burden using the patient as

Assessing the impact of therapies on quality of life and measur-

their own reference during a specified time prior to ablation and com-

ing patient-reported outcomes is endorsed by the AHA and the

paring the arrhythmia frequency after ablation in patients who have

European Society of Cardiology (S10.5.7.9, S10.5.7.10). In the United

470

|

States, the Food and Drug Administration has also recently implemented the Medical Device Development Tools program in which
patient-reported outcome tools can be submitted for evaluation and
potential certification allowing their use for clinical outcome assessment in trials of medical devices (S10.5.7.11).
Assessment of the impact of ablation on quality of life is likely to
reflect not only the outcome of ablation therapy, but also the severity
of the arrhythmia's impact on the patient prior to ablation. For example, a recent trial of left ventricular assist devices (LVADs) found that
LVADs improved health status in patients with heart failure who had
low self-reported quality of life, but not in those with acceptable quality of life at the time of LVAD implantation (S10.5.7.12). The measure
of quality of life prior to ablation is potentially useful information for
defining who benefits from ablation.
Although a number of validated tools are available, the interpretation of findings can also be challenging. The VANISH trial assessed quality of life using 4 validated instruments (Short Form 36
Health Survey, the Implantable Cardioverter Defibrillator Concerns
Questionnaire, the Hospital Anxiety and Depression Scale, and the
EuroQol five dimensions questionnaire) (S10.5.7.13). Among 16 different measures of quality of life at 6 months and 1 year that were
compared with baseline, persistent improvements were observed in
some (energy and fatigue), transient improvements that were no longer present at 1 year in others (eg, social functioning), and no improvement was found in yet others (eg, general health perceptions scale).
How to integrate multiple measures to assess net benefit of the procedure could be a challenge.

10.5.7 | Mortality
Assessing mortality after ablation is important. Although mortality is
relatively high in many VA ablation populations, and VA recurrence
has been associated with increased mortality, no trial has yet shown
a mortality benefit from catheter ablation. Efforts to enroll a sufficient number of patients will be key to conclusively establishing
the impact of ablation on mortality in a randomized trial (S10.5.7.4,
S10.5.7.14). Recently, risk scores for predicting mortality in patients
with SHD undergoing VT ablation have been developed, and await
further validation (S10.5.7.15, S10.5.7.16).
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11 | TR A I N I N G A N D I N S TIT U TI O N A L R EQ U I R E M E NT S A N D CO M PE TE N C I E S
11.1 | Training requirements and competencies for catheter ablation of ventricular arrhythmias
Recommendation for training requirements and competencies for catheter ablation of VA
COR

LOE

Recommendation

I

C-EO

For clinical cardiac electrophysiologists who perform catheter ablation of VAs, appropriate advanced
training and continued lifelong learning is recommended.

Recommendation-specific supportive text

Accreditation Council of Graduate Medical Education and American
Board of Medical Specialties. These 6 core competency domains include

1 Catheter ablation of VAs requires advanced skills in clinical
cardiac electrophysiology. Physicians performing these procedures
should be trained at electrophysiology programs with expertise
in complex VA ablations and should meet the general and advanced training requirements for clinical cardiac electrophysiologists during training or with an experienced mentor if novel procedures and approaches have developed after training.

Medical Knowledge, Patient Care and Procedural Skills, Systems-Based
Practices, Practice-Based Learning and Improvement, Professionalism,
and Interpersonal and Communications Skills (S11.1.8.8).

11.1.2 | Medical knowledge
A detailed understanding of cardiac anatomy is required, including the
conduction system, the coronary arterial and venous systems, and
anatomical variations due to underlying heart disease. Knowledge

11.1.1 | Training requirements
For adult electrophysiologists in the United States, these training competencies are outlined in the 2015 ACC COCATS 4: Task Force 11: Training in
Arrhythmia Diagnosis and Management, Cardiac Pacing, and Electrophysiology
report, the 2015 ACC/AHA/HRS Advanced Training Statement on Clinical
Cardiology Electrophysiology, and the 2009 EHRA/HRS Expert Consensus
on Catheter Ablation of Ventricular Arrhythmias (S11.1.8.1–S11.1.8.3). For
pediatric electrophysiologists in the United States, these training competencies are outlined in the 2015 SPCTD/ACC/AAP/AHA Task Force 4:
Pediatric Cardiology Fellowship Training in Electrophysiology and the 2013
Recommendations for Advanced Fellowship Training in Clinical Pediatric and
Congenital Electrophysiology: A Report from the Training and Credentialing
Committee of the Pediatric and Congenital Electrophysiology Society (S11.1.8.4,
S11.1.8.5). Although these requirements mainly reflect fellowship training in
the United States, other countries have requirements that are similar, including the Working Group of Pacing, Electrophysiology of the French Society
of Cardiology (S11.1.8.6). Training requirements vary from country to country, but irrespective of local differences, appropriate advanced training and
continued lifelong learning are strongly recommended for all clinical cardiac
electrophysiologists who perform catheter ablation for VAs.
As the field of catheter ablation for VAs continues to evolve
with introduction of new approaches, technology, and application in
higher-risk and more complex patients (ie, adults with VADs and CHD),
trainees and practicing operators specializing in these ablations are
expected to continue to maintain their core and specialized competencies as outlined in the 2017 ACC/HRS Lifelong Learning Statement
of Clinical Cardiac Electrophysiology Specialists (S11.1.8.7). These procedures should be performed by select qualified cardiac electrophysiologists with a practice focus on VAs at programs with expertise.
Physicians performing catheter ablation for VAs should achieve
proficiency in 6 core competency domains promulgated by the

is necessary of the mechanisms and pathophysiology of VAs, with a
particular focus on the relationship between these arrhythmias and
acquired, inherited, or SHD; sympathetic and parasympathetic tone;
and drugs. This understanding, along with proficiency in electrocardiographic interpretation, helps guide appropriate mapping and ablation approaches. In addition, knowledge of patient-specific factors
such as disease type, severity, and comorbidities; procedural risks;
and alternative therapies such as AADs, surgery, or device therapy
should be used to guide appropriate patient selection.

11.1.3 | Patient care and procedural skills
A comprehensive and structured approach to the clinical evaluation
and management of patients with VAs undergoing catheter ablation
is necessary across all settings (inpatient and outpatient) and time
points (preprocedural planning, periprocedural and intraprocedural
care, and postprocedural follow-up). Trainees should demonstrate
and maintain these proficiencies as pertains to their practice area of
focus. A clear understanding of the various approaches and systems
used (mapping, ablation, and imaging) and proficient demonstration of the skills to perform VA ablations are required. Additional
advanced technical skills are needed for those seeking to perform
epicardial ablations or ablations in CHD. Given patients undergoing
complex VA ablations often have underlying medical conditions and
comorbidities, recognition of the potential need for a multidisciplinary approach and coordination with other specialists (anesthesiologists, surgeons, interventional cardiologists, cardiologists, heart
failure specialists, and/or intensivists) will ensure optimal procedural
outcomes.
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11.1.4 | Systems-based practice
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recommendations have emphasized the importance of awareness
of the principles of radiation safety and their implementation

Complications can occur in catheter ablation procedures for VAs that

on a day-by-d ay basis while using radiation for medical imaging

can range from minimal to fatal. These can include vascular injury,

(S11.1.8.9, S11.1.8.10).

thromboembolic events, cardiac tamponade, malignant VA including
electrical storm, acute MI, and hemodynamic instability or collapse. A
careful understanding of the potential procedural complications that
might arise from either the patient's underlying medical conditions or
the electrophysiology procedure itself is necessary. When appropriate,
the use of a multidisciplinary team for the management of high-risk
patients should be in place for prevention, prompt detection, timely
intervention, and optimal management of complications. Functional
systems should be in place to promptly care for patients in case of
unanticipated complications.

11.1.5 | Practice-based learning and improvement
All trainees should continue to participate in lifelong learning to
maintain and enhance skills and knowledge through self-assessment,
regular literature review, updated practice guidelines, consensus
document and appropriate use criteria, and attending appropriate
scholarly meetings with a focus on VAs.

11.1.6 | Professionalism
On the basis of personal expertise and technical skills, practicing
clinical cardiac electrophysiologists and trainees should practice
within their scope as pertains to the specialized field of catheter ablation for VAs.

11.1.7 | Interpersonal and communications skills
Catheter ablation for VAs can be challenging due to increased procedural risk and complexity necessitating additional technical expertise.
Practicing clinical cardiac electrophysiologists and trainees should
engage patients, families, and interprofessional teams in a shared
decision-making approach. These physicians must develop the skills
to communicate and counsel effectively regarding the diagnosis, risks,
and benefits of catheter ablation, and alternative management options.

11.1.8 | Ionizing radiation
Awareness is rising of the detrimental effects on patients, the
electrophysiology staff, and the operator of ionizing radiation
during imaging. The use of low-frame rate fluoroscopy equipment, pre-and intraprocedural imaging with ICE, as well as 3D
EAM, all contribute to reduce radiation exposure. Appropriate
education of all personnel involved in the procedure on the
risks and benefits of radiation is key for safer imaging. Societal
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11.2 | Institutional requirements for catheter ablation of ventricular tachycardia
Recommendations for institutional requirements for catheter ablation of VT
COR

LOE

Recommendations

I

C-EO

1. Patients with certain underlying medical conditions and comorbidities undergoing complex VA ablations who
are deemed to have increased procedural risk should undergo procedures in a hospital-based electrophysiology
laboratory.

I

C-EO

2. Onsite interventional cardiology expertise is recommended for electrophysiology procedures requiring coronary
imaging to delineate coronary anatomy for epicardial ablation, aortography to delineate coronary ostia for SV VT
ablation, and need for placement of HS devices.

I

C-EO

3. Onsite cardiothoracic surgical backup is recommended for electrophysiology procedures requiring pericardial
access due to the potential need for emergent sternotomy and cardiopulmonary bypass.

I

C-EO

4. Availability of anesthesia personnel is recommended for all patients undergoing catheter ablation of VAs.

Recommendation-specific supportive text
1 High-risk patients include those with advanced heart failure, severe
ventricular dysfunction, severe valvular dysfunction, prosthetic
heart valves, CHD, inherited arrhythmia disorders, recent MI, recent stroke, chronic kidney disease, severe obstructive pulmonary
disease, pulmonary hypertension, severe/morbid obesity, active
oral anticoagulation, and advanced or pediatric age groups. Due
to the potential risks associated with catheter ablation in close
proximity to the coronary arteries and epicardial ablation, these
procedures should be performed in a hospital-based electrophysiology lab with immediate availability of interventional cardiology
or cardiothoracic surgical support (S11.2.1).
2 Interventional procedures, including coronary angiography, aortography, and deployment of percutaneous HS devices (pLVAD,
IABP), requires advanced skills and should be performed by appropriately trained personnel.
3 Epicardial ablation and mapping requires pericardial access
that carries the risk of ventricular laceration or perforation.
Inadvertent injury to the ventricle can result in life-threatening
tamponade and hemodynamic collapse, which might require
emergent surgical intervention via sternotomy. Immediate surgical intervention is critical and dependent on designated surgical backup (in-room or onsite with a clear notification protocol
in place) and immediate access to an emergency surgical tray
(S11.2.1).
4 Due to procedural complexities and patient factors, including underlying medical conditions and comorbidities, the use of anesthesia services (anesthesiologist, nurse anesthetist, or equivalent
trained personnel) provides optimal periprocedural patient care
and additional expertise in the setting of life-threatening complications (S11.2.1).
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11.3 | Ventricular tachycardia network and
ventricular tachycardia unit
VT ablation is a domain of specialized centers with high operational expertise. Within these centers, logistics for optimizing patient flow and
referral are crucial. Therefore, many tertiary referral centers for VT
ablation have established their network of regional referring centers
to improve patient admission and early VT ablation. Few studies have
documented their experience with this concept (S11.3.1, S11.3.2).
Conceptionally, “VT networks” centralize around highly experienced centers capable of all techniques associated with VT and
electrical storm ablation, including epicardial ablation and HS.
Discussion with a multidisciplinary team and immediate transfer
should be possible. Electrophysiology staff should be available
on a 24/7 basis. Although acute ablation, defined as ablation for
rhythm stabilization within 8 hours after onset, is rare, there is
a potential need for catheter ablation on a 24/7 basis (S11.3.1–
S11.3.3). However, very few electrophysiology labs worldwide
have this capacity.
Dedicated VT units have been established in some tertiary
referral centers to expedite the transfer and management of
patients with VT in a specialized intensive care unit. The optimal technical set-u p of a dedicated VT unit has not been defined, but 12-lead ECG monitoring, online device telemetry,
and intensive care unit facilities are helpful. The organization
of VT units and networks would likely vary substantially across
different countries according to the local health care delivery organization and resources. The ability to provide 24/7
catheter ablation might be useful for effective early rhythm
stabilization, specifically in unstable patients with recurrent
VA; however, comparisons with standards of care, including
pharmacological suppression, HS, and neuromodulation, have
not been made (S11.3.1, S11.3.2). Less than half of the writing committee members’ institutions have a formal capacity
to perform VA ablations outside of regular working hours (necessitating personnel to be called into the hospital overnight
or on weekends), although two-t hirds had performed such a
procedure after hours in exceptional circumstances, almost
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all between <1 and 5 times per year. Opinions were divided

this area are significant, and include patient and provider biases

about whether a formal on-c all schedule for VA ablation was

and preferences (particularly for randomized trials of procedures

necessary.

compared to pharmacotherapy), challenges to standardization of
procedural techniques and endpoints, as well as trial funding and
reimbursement (S12.1.4.11).
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12.1.2 | Ongoing randomized controlled trials
Several randomized trials comparing catheter ablation with medical
therapy are ongoing. The PARTITA trial (NCT01547208) is enrolling and following 586 patients with ICD implantation, and randomly
allocating 176 who present with first ICD shocks to early catheter ablation vs withholding ablation until electrical storm occurs,
with a primary composite endpoint of heart failure hospitalization
and death from any cause. The PAUSE-SCD trial (NCT02848781)
is enrolling 120 patients with ICM or NICM and randomly allocat-

12 | FU T U R E D I R EC TI O N S

ing them to ICD implant followed by catheter ablation or medical

12.1 | Clinical trials of catheter ablation of
ventricular tachycardia

therapy with a composite endpoint of recurrent VT, cardiovascular re-hospitalization, and all-cause mortality. The IMPRESS TRIAL
(NCT03531502) is enrolling 75 patients with cardiomyopathy who
experienced a first ICD shock and is performing a NIPS procedure

12.1.1 | Introduction

with a noninvasive mapping system (Cardioinsight, Medtronic). If the

The development of high-quality randomized trial evidence to es-

eter ablation guided by noninvasive mapping or standard medical

tablish an optimal therapy for VT has been challenging, despite

therapy with a primary endpoint of ICD shocks. The PREVENTIVE

the clinical importance of the question. Relatively few RCTs have

VT Trial (NCT03421834) is a randomized trial of 60 patients with

been published comparing catheter ablation with noninterven-

a subset of ICM (chronic total occlusion of infarct-
related area).

tional therapies. Recent consensus and guideline documents have

Patients will be randomized to ICD alone or ICD plus catheter ab-

consistently stressed the importance of further research in the

lation, with an endpoint of time to first ICD therapy or VT-related

field (S12.1.4.1–S12.1.4.3), particularly the need for prospective

hospitalization. The VANISH2 trial (NCT02830360) is enrolling 366

randomized trials. Important clinical questions remain regard-

patients with prior MI who present with sustained monomorphic VT

ing optimal techniques for catheter ablation, its optimal role and

and is randomizing them to receive either catheter ablation or AAD

timing in ischemic and nonischemic cardiomyopathies, as well as

therapy, with a primary composite endpoint of death, appropriate

the relative merits of catheter ablation in comparison with anti-

shock, or VT storm.

NIPS procedure is positive, then patients will be randomized to cath-

arrhythmic or other pharmacological therapy. Published randomized trials completed thus far have included patients with ICM.
Three trials compared catheter ablation to standard care in the
setting of initial presentations with VAs (S12.1.4.4), with presen-

12.1.3 | Endpoints for prospective clinical trials of
ventricular tachycardia ablation

tations with tolerated VT (S12.1.4.5), and with nontolerated VT

Although observational studies have demonstrated an association

(S12.1.4.6). One trial compared ablation to more aggressive AAD

between recurrent VAs and mortality (S12.1.4.12–S12.1.4.15), no

therapy for patients with VT despite first-
line AAD treatment

prospective study thus far has demonstrated a significant beneficial

(S12.1.4.7). At least 8 trials of catheter ablation for VT have been

effect of VT ablation on survival. Successful completion of a pro-

initiated but were terminated because of insufficient enrollment

spective trial of VT ablation with a primary outcome of mortality is

(STAR-V T, NCT02130765; VeTAMed, NCT01798277; INTERVENE,

challenging due to competing mortality risks in patients with VT. In

NCT02301390; AVATAR, NCT02114528; ASPIRE, NCT01557842;

the VANISH trial, there was no clear effect of ablation on mortality

CEASE-
V T,

NCT01045668;

in comparison with escalated AAD therapy (S12.1.4.7, S12.1.4.16),

CALYPSO, NCT01576042), of which only CALYPSO has published

likely because arrhythmia was an infrequent cause of death in the

results available. Trials comparing various methods of VT ablation

trial, and because additional interventions were undertaken when

or treatment have been reported [VISTA (S12.1.4.8); Ultra High

patients experienced clinical deterioration or recurrent arrhythmia.

Density mapping, NCT02083016 (S12.1.4.9)] or are listed as on-

For randomized trials enrolling patients with low-
frequency VT

going on trial registry sites [MAGNETIC VT (S12.1.4.10); Impress,

events, the use of time-to-event endpoints (rather than measures

NCT01097330;

BERLIN-
V T,

NCT03531502; ZFOVA zero fluoro trial, NCT03041519; Ripple

of arrhythmia burden) has traditionally been preferred, given cli-

Mapping, NCT02216760]. Barriers to completion of research in

nicians and patients might not tolerate large burdens of recurrent
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arrhythmia events without considering treatment alternatives to assigned therapy. For randomized trials specifically enrolling patients
with high VT burden, the use of reduction in VT burden provides
a meaningful endpoint for both patient satisfaction and scientific
inquiry.

12.1.4 | Future clinical studies
Further research is required to identify optimal methods for arrhythmia suppression and to understand the influences of each method
on arrhythmia outcomes, as well as on cardiac function, symptoms,
quality of life (S12.1.4.17), cost-effectiveness (S12.1.4.18, S12.1.4.19),
and long-term outcomes. The best first-line therapy for VT, beyond
the use of ICDs, remains undetermined, as does the most appropriate time to intervene. Ablation outcomes in nonischemic cardiomyopathies, specific disease states, and patient subgroups also require
further study. Developing, funding, and executing patient-centered,
prospective, and randomized trials are strongly encouraged to move
the field of VT ablation forward in ways that promote patient health
and minimize confounding biases.
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12.2 | Future directions in the treatment of patients
with ventricular arrhythmias
12.2.1 | Introduction
Awareness of the importance of VAs as a frequent and potentially modifiable cause of death has led to increased development
of novel methods to improve VT mapping (both inside and outside the body), VT treatment (inside and outside the body), and
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identification of an individual patient's status, along the spectrum

with Brugada syndrome (S12.2.4.11), long QT syndrome (S12.2.4.12),

of cardiac illness.

and early repolarization syndrome (S12.2.4.13).

12.2.2 | Advances in mapping

12.2.3 | Advances in ablation

Cardiac mapping has made an important advance with the develop-

A better understanding of biophysical properties of RF energy to

ment of tools that employ multiple small, closely spaced electrodes.

create ablative heat in both normal and abnormal ventricular myo-

These tools provide higher resolution mapping during sustained VT

cardium has driven important innovations. A change in the catheter

and sinus rhythm (see Section 8.1).

irrigant to half normal saline alters the local ionic content, which cre-

Outside of catheter mapping, tools have been created to take

ates a larger ablation lesion (S12.2.4.14). In prospective clinical use,

advantage of coronary vasculature access to intramyocardial struc-

this approach has translated into high rates of successful ablations in

tures. The most common example involves mapping the perforator

patients who failed traditional ablation (S12.2.4.15), although direct

veins (S12.2.4.1) facilitated by the use of electrically protected wires

comparisons with conventional irrigant are lacking. Caution should

into septal perforating branches (S12.2.4.2), the use of cold saline

be exercised, given the authors reported a 12% rate of steam pop

(S12.2.4.3), and the use of dual site pace mapping (S12.2.4.4) to iden-

with this technique.

tify intramural VA origins.

Alternate forms of delivering RF energy have been developed.

Advances in cardiac imaging are enabling a more comprehen-

The most prominent of such technologies is a catheter with a

sive understanding of the 3D nature of cardiac scarring and the

needle that can be deployed into ventricular myocardium to both

dynamic nature of ventricular electrophysiology. Preprocedural

map and ablate (S12.2.4.16). Clinical trials in patients with VA are

imaging with CMR and CT is increasingly being used to identify

underway (NCT01791543; NCT03204981). Advantages include

abnormal myocardium, but its value as a stand-
alone ablation

more precise intramyocardial mapping, injection of dye to assess

guide has not yet been proven. Studies are underway to address

location of potential ablation using fluoroscopy, and deeper ab-

this possibility.

lation lesions than standard catheter ablation. Disadvantages in-

The synthesis of cardiac imaging with detailed cardiac mapping

clude the difficulty ensuring safe use and unpredictable energy

is furthering the understanding of the relationship between the VT

distribution. A warm saline-infused needle ablation catheter, ca-

circuit and myocardial scarring. Important observations have been

pable of creating large lesions, is currently being studied in pa-

made from mapping several surfaces of the heart simultaneously

tients with ICM and VT (NCT02994446) (S12.2.4.17). Alternative

(S12.2.4.5). Additional observations can be made by comparing

methods for RF delivery to larger areas are under development,

maps and electrograms in sinus rhythm, RV pacing, LV pacing and

including expandable catheter tips that form spheres or round lat-

sustained VT (S12.2.4.6). However, these detailed maps are time-

tice structures.

consuming to create, potentially exposing patients to additional

Beyond RF energy to create thermal ablation, alternative en-

procedural risk. The translation of these observations into tangible

ergies have been studied to control VT. These alternatives include

value for the operator or for improved patient outcomes remains to

localized intracoronary alcohol injection, locally applied pulsed field

be proven and is an area of active investigation.

direct current electroporation, and noninvasive focused stereotac-

Entirely noninvasive electrophysiological mapping has been

tic radiation. Coronary ethanol infusion has been performed in both

developed with ECGI. This technology combines body surface uni-

an antegrade (S12.2.4.18) and retrograde fashion (S12.2.4.19) on

polar electrograms obtained from a vest of electrodes with patient-

patients for the treatment of refractory VT. Electroporation using

specific heart-torso geometry. Local ECGs are reconstructed on the

localized direct current is a technology in rapid development with

surface of the heart geometry, requiring a single beat of arrhyth-

significant advantages of speed (seconds) and a tissue-selective ab-

mia. ECGI has been shown to localize the site of VT origin (S12.2.4.7,

lation effect in preclinical models. Its safety and efficacy in humans

S12.2.4.8), ventricular scar locations (S12.2.4.9), and risk assessment

has yet to be established. Stereotactic radioablation is a noninvasive

for future VT events in a small cohort of patients with IHD and

and rapid (minutes) method for delivery of photons (X-rays), pro-

ICDs (S12.2.4.10). Compared with catheter-based mapping, nonin-

tons, or heavy ions (carbon) into selected cardiac tissue. The use of

vasive ECGI mapping of VT does not provide similar local bipolar

noninvasive photon ablation in humans was first reported in 2015

electrogram detail and ECGI does not image during ventricular di-

(S12.2.4.20). The development of an entirely noninvasive process

astole. Unipolar ECG reconstructions on the ventricular surface can

for mapping and ablating VT, combining ECGI, cardiac imaging, and

infer activation patterns from deeper structures, such as septum or

stereotactic cardiac ablation, represents a promising new option in

papillary muscles, but further refinement is needed to reliably map

the field (S12.2.4.21).

these structures. Advantages include the ability to map both ventri-

Outside of a direct ablative effect on the diseased myocardium,

cles simultaneously in a single beat, obtaining an immediate sense

modulation of the nervous system can alter the likelihood that VT will

of VT entrance and exit locations, as well as mapping unstable VT/

occur. Neuromodulation is largely designed to decrease sympathetic

VF. Outside of the electrophysiology lab, ECGI offers possibilities

tone and enhance parasympathetic tone. There are many locations

for clinical VT risk stratification, such as was recently demonstrated

at which to manipulate the nervous system, including cervical vagal
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stimulation, transcutaneous auricular vagal stimulation, baroreceptor activation therapy, spinal cord stimulation, ganglionated plexus
ablation, renal sympathetic denervation, and left CSD.

12.2.4 | Advances in patient evaluation
As we progress into a future where artificial intelligence becomes increasingly used for predictive analytics, the field of VT ablation is ripe
for such advances. In silico multiscale cardiac modeling of patients
with ICM has provided an exciting possibility for the development of
a patient-specific a priori ablation strategy (S12.2.4.22). Beyond this
approach, the use of predictive tools can further help physicians to
identify the right patients, the proper timing of the procedure, and
the expected outcomes with various forms of ablation techniques to
ultimately offer the right patient the right ablation at the right cardiac
location at the right time in the course of the disease.
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